amiodarone has been researched along with Atrial Fibrillation in 1592 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the use of amiodarone for the treatment of atrial fibrillation has increased, reports of its use for the restoration of sinus rhythm have been conflicting." | 10.20 | Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation. ( Kochiadakis, GE; Vardas, PE, 2003) |
| "Although amiodarone is the most effective antiarrhythmic agent for maintaining sinus rhythm in patients with atrial fibrillation, it is generally used as the drug of the last resort in the United States." | 10.17 | Low-dose amiodarone should not be the first-line treatment for atrial fibrillation. ( Sung, RJ, 1994) |
| "This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo." | 9.69 | Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. ( Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M, 2023) |
| "In this double-blind, placebo-controlled trial, patients at high risk of postoperative atrial fibrillation scheduled to undergo major thoracic surgery were randomized to N-acetylcysteine plus amiodarone or placebo plus amiodarone." | 9.51 | Amiodarone with or without N-Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial. ( Amar, D; Chung, MK; Desiderio, D; Fischer, GW; Isbell, JM; Jones, DR; Meyers, BF; Milne, GL; Molena, D; Park, BJ; Pedoto, A; Roistacher, N; Rusch, VW; Tan, KS; Zhang, H, 2022) |
| "This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes." | 9.51 | Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. ( Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M, 2022) |
| "Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL)." | 9.51 | Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial. ( Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J, 2022) |
| "The ARTEMIS atrial fibrillation (AF) Loading and Long-term studies evaluated switching patients with paroxysmal/persistent AF from amiodarone to dronedarone." | 9.34 | Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. ( Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J, 2020) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 9.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "The objective of this study was to assess the safety and efficacy of local epicardial application of amiodarone-releasing hydrogel for prevention of postoperative atrial fibrillation (POAF) in patients after coronary artery bypass grafting." | 9.34 | Epicardial Application of Hydrogel with Amiodarone for Prevention of Postoperative Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting. ( Bockeria, LA; Bockeria, OL; Kanametov, TN; Sanakoev, MK; Shvartz, VA; Sokolskaya, MA; Zhuginisov, DS, 2020) |
| "The Short-term AMIOdarone treatment after CATheter ablation for atrial fibrillation (AMIO-CAT) trial randomized patients to 8 weeks of oral amiodarone or placebo following AF ablation." | 9.30 | QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Hansen, J; Johannessen, A; Pehrson, S; Svendsen, JH, 2019) |
| "Adjunctive short-term amiodarone therapy improves the success rate after catheter ablation of persistent atrial fibrillation during long-term follow-up." | 9.27 | Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. ( Gramley, F; Kettering, K, 2018) |
| "Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF)." | 9.27 | Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients. ( Aidonidis, I; Dipla, K; Hatziefthimiou, A; Hevas, A; Simopoulos, V; Skoularigis, I; Tsilimingas, N, 2018) |
| "Pharmacological treatment during ablation of persistent atrial fibrillation (AF) is common, but utility of irrigated catheter application of amiodarone during ablation of persistent AF remains unclear." | 9.24 | Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation. ( Chen, Y; He, L; Huang, X; Huang, Y; Liu, S; Peng, J; Shee, V; Xu, D; Zhao, H, 2017) |
| "Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm." | 9.24 | Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy. ( Aidonidis, I; Daskalopoulou, SS; Giamouzis, G; Hatziefthimiou, A; Skoularigis, I; Triposkiadis, F; Tsanaxidis, N, 2017) |
| "Prophylactic topical application of amiodarone may be effective and safe for preventing post-operative new-onset atrial fibrillation." | 9.22 | Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence. ( Baranchuk, A; Chen, X; El-Diasty, M; Fernandez, AL; Ross-White, A; Sartor, C; Zhang, S, 2022) |
| "Whether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with heart failure is unknown." | 9.22 | Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. ( Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Haissaguerre, M; Hao, S; Hongo, R; Horton, R; Jais, P; Lakkireddy, D; Mohanty, P; Mohanty, S; Narducci, ML; Natale, A; Neuzil, P; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, J; Santangeli, P; Schweikert, R; Themistoclakis, S; Tondo, C; Trivedi, C, 2016) |
| "We aimed to evaluate the impact of 8weeks of amiodarone treatment on thyroid function in patients with atrial fibrillation (AF) undergoing catheter ablation in a randomised, double-blind clinical trial." | 9.22 | Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Feldt-Rasmussen, U; Hansen, J; Johannesen, A; Pehrson, S; Svendsen, JH, 2016) |
| "The impact of amiodarone on ablation outcome in longstanding persistent atrial fibrillation (LSPAF) patients is not known yet." | 9.20 | Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). ( Al-Ahmad, A; Bai, R; Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Gallinghouse, JG; Hongo, R; Horton, R; Hranitzky, PM; Lakkireddy, D; Mohanty, P; Mohanty, S; Natale, A; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, JE; Santangeli, P; Themistoclakis, S; Tondo, C; Trivedi, C; Zagrodzky, J, 2015) |
| "The multichannel blocker dronedarone is currently indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF), with careful monitoring of cardiac, hepatic and renal function." | 9.20 | One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care. ( Benninger, G; Bosch, RF; Goette, A; Paar, WD; Pittrow, D; von Stritzky, B, 2015) |
| "In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE)." | 9.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "This study examined the influence of preoperative administration of amiodarone and metoprolol in preventing postoperative atrial fibrillation (AF) after coronary artery bypass grafting (CABG) surgery." | 9.20 | Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation: After Coronary Bypass Surgery? ( Erkut, B; Onk, OA, 2015) |
| " We investigated its ability to shorten the time to conversion of postoperative atrial fibrillation (POAF) when added to amiodarone after coronary artery bypass graft (CABG) surgery." | 9.19 | Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. ( Aidonidis, I; Chryssagis, K; Daskalopoulos, ME; Daskalopoulou, SS; Lenos, A; Molyvdas, PA; Simopoulos, V; Skoularingis, I; Tagarakis, GI; Tsilimingas, NB, 2014) |
| "Our aim was to estimate the costs and health benefits of routinely administered postoperative amiodarone as a prophylactic agent in reducing the risk of atrial fibrillation in patients undergoing surgery for lung cancer." | 9.19 | Amiodarone is a cost-neutral way of preventing atrial fibrillation after surgery for lung cancer. ( Christensen, TD; Pilegaard, HK; Riber, LP, 2014) |
| " 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF." | 9.19 | Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. ( Bonato, R; Chiale, PA; Elizari, MV; Galperin, J; Lago, M; Ledesma, R; Piasentin, J; Sanchez, J; Spada, P; Vazquez Blanco, M, 2014) |
| "Amiodarone is used commonly for pharmacological cardioversion of atrial fibrillation (AF), but it is limited by moderate efficacy and delayed action." | 9.19 | Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. ( Fragakis, N; Katritsis, D; Koskinas, KC; Skeberis, V; Vassilikos, V, 2014) |
| "Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF)." | 9.19 | Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. ( Al-Khatib, SM; Allen-LaPointe, N; Anstrom, KJ; Daubert, JP; DeWald, T; Horton, JR; Lokhnygina, Y; Peterson, ED; Piccini, JP; Shaw, LK; Steinberg, BA; Thomas, K; Wojdyla, DM, 2014) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 9.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction." | 9.19 | Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014) |
| "Short-term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of atrial tachyarrhythmias at the 6-month follow-up, but it more than halved atrial arrhythmia related hospitalization and cardioversion rates during the blanking period." | 9.19 | Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). ( Chen, X; Darkner, S; Hansen, J; Johannessen, A; Nielsen, JB; Pehrson, S; Svendsen, JH, 2014) |
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 9.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "The ATHENA trial randomized 4628 patients with atrial fibrillation (AF) or atrial flutter, aged ≥ 70 years with risk factors or ≥ 75 years without risk factors, to receive 400 mg dronedarone twice daily or placebo in addition to standard therapy." | 9.17 | Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial. ( Berg, J; Connolly, S; Lindgren, P; Sauriol, L, 2013) |
| "In a matched-cohort design, 18 patients taking amiodarone before atrial fibrillation (AF) ablation (amiodarone group) were matched for age, sex and type of AF with 18 patients who had undergone AF ablation without taking amiodarone (no-amiodarone group)." | 9.17 | Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation. ( Chen, PS; Joung, B; Lee, MH; Lin, SF; Mun, HS; Pak, HN; Shen, C, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop long after amiodarone withdrawal." | 9.17 | Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Tanaka, Y; Yagishita, A, 2013) |
| "The patients in the amiodarone prophylaxis group had a reduction in the risk of atrial fibrillation of 23% (12 to 31); number needed to treat was 4." | 9.16 | Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. ( Christensen, TD; Hoejsgaard, A; Jensen, HK; Pilegaard, HK; Riber, LP, 2012) |
| "To report our experience using single high dose oral amiodarone for the cardioversion of recent onset atrial fibrillation to sinus rhythm in patient presenting with symptoms within 48 h." | 9.16 | Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation. ( Nadarasa, K; Williams, MJ, 2012) |
| "Ranolazine, an antianginal agent with antiarrhythmic properties, prevents atrial fibrillation (AF) in patients with acute coronary syndrome." | 9.16 | Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. ( Fragakis, N; Geleris, P; Katritsis, DG; Koskinas, KC; Pagourelias, ED; Zografos, T, 2012) |
| "Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter." | 9.16 | Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. ( Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M, 2012) |
| "This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF)." | 9.15 | A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. ( Beatch, G; Camm, AJ; Capucci, A; Hohnloser, SH; Mangal, B; Torp-Pedersen, C; Van Gelder, IC, 2011) |
| "Dronedarone has been shown to reduce cardiovascular hospitalizations or death in patients with atrial fibrillation (AF) and additional risk factors." | 9.15 | Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. ( Connolly, SJ; Duray, GZ; Hohnloser, SH; Torp-Pedersen, C, 2011) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 9.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| " The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone." | 9.15 | Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C, 2011) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 9.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation." | 9.14 | Effect of dronedarone on cardiovascular events in atrial fibrillation. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization." | 9.14 | Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. ( Lam, KF; Lau, CP; Lee, WL; Siu, CW; Tse, HF, 2009) |
| "Amiodarone is effective in preventing atrial fibrillation (AF)." | 9.14 | Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion. ( Kanic, V; Naji, F; Sabovic, M; Suran, D; Vokac, D, 2009) |
| "To compare the efficacy of combined amiodarone and irbesartan use versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation (AF) post valve replacement and cardioversion." | 9.14 | [Comparison of amiodarone plus irbesartan regimen versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation post valve replacement and cardioversion]. ( Chen, LJ; Deng, XJ; Ding, P; Li, L; Yuan, YQ; Zhang, H, 2009) |
| " Overall atrial fibrillation occurred more frequently in the perioperative intravenous amiodarone group compared with the placebo group (59." | 9.14 | Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery. ( Beaulieu, Y; Carrier, M; Couture, P; Denault, AY; Lambert, J; Levesque, S; O'Meara, E; Pagé, P; Roy, D; Talajic, M; Tardif, JC, 2010) |
| "Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy." | 9.14 | A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. ( Hammoud, ZT; Kesler, KA; Rieger, KM; Tisdale, JE; Wall, DS; Wroblewski, HA; Young, JV, 2010) |
| "We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF)." | 9.14 | A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. ( Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J, 2010) |
| "Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF)." | 9.14 | Dronedarone in patients with congestive heart failure: insights from ATHENA. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2010) |
| "The intraoperative use of amiodarone in patients with atrial fibrillation (AF) undergoing valvular heart surgery was unclear." | 9.14 | The effect of amiodarone on cardiac rhythm after cardiopulmonary bypass in patients with atrial fibrillation. ( Jie, S; Xiaohu, L; Xiaoyang, T; Yanning, Q; Yu, C; Zhengnian, D, 2010) |
| "To evaluate the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate in patients with atrial fibrillation (AF) during anesthesia period." | 9.14 | [A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period]. ( Shen, SL; Zhao, YC, 2010) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 9.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "The purpose of this study was to examine the relationship between long-term efficacy of amiodarone therapy (100-200 mg/day) combined with angiotensin converting enzyme inhibitor (ACEI; enalapril 5 mg/day) administration, and the development of structural atrial remodeling in patients with paroxysmal atrial fibrillation (AF)." | 9.13 | Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. ( Komatsu, T; Kunugida, F; Nakamura, M; Orii, M; Ozawa, M; Sato, Y; Tachibana, H, 2008) |
| "Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF." | 9.13 | Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. ( Alings, A; Davy, JM; Herold, M; Hoglund, C; Radzik, D; Timmermans, A; Van Kempen, L, 2008) |
| "To investigate the effect of combination of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation." | 9.13 | [Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation]. ( Cao, DJ; Mu, CY; Tang, RB; Tong, F, 2008) |
| "Amiodarone effectively suppresses atrial fibrillation but causes many adverse events." | 9.13 | Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. ( Ahmed, S; Bosker, HA; Crijns, HJ; Hillege, HL; Links, TP; Lok, DJ; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ; Wiesfeld, AC, 2008) |
| "The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) is the largest single antiarrhythmic drug trial ever conducted." | 9.13 | Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria ( Connolly, SJ; Crijns, HJ; Hohnloser, SH; Page, RL; Seiz, W; Torp-Petersen, C, 2008) |
| "In the AFIST III (Atrial Fibrillation Suppressions Trial III), anterior fat pad (AFP) retention did not decrease the incidence of postoperative atrial fibrillation (POAF), but prophylaxis with amiodarone did." | 9.13 | Impact of amiodarone on the ability of anterior fat pad retention to prevent postcoronary arterial bypass grafting atrial fibrillation incidence: a substudy of the AFIST III (Atrial Fibrillation Suppression Trial III). ( Coleman, CI; Dale, K; Gallagher, R; Henyan, N; Kluger, J; Reinhart, K; Sander, S; White, CM, 2008) |
| "The purpose of this study was to estimate the costs and health benefits of routinely administered postoperative amiodarone as prevention of atrial fibrillation for patients undergoing coronary artery bypass grafting (CABG) for stable angina." | 9.13 | Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery. ( Christensen, TD; Hjortdal, VE; Kristiansen, IS; Zebis, LR, 2008) |
| "Amiodarone, given as intravenous bolus has not yet been studied in patients with atrial fibrillation and a high ventricular rate." | 9.12 | Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. ( Hofmann, R; Kammler, J; Kypta, A; Leisch, F; Steinwender, C, 2006) |
| "To evaluate the effects and adverse reactions of amiodarone and sotalol in treatment of atrial fibrillation." | 9.12 | [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study]. ( Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006) |
| "The purpose of the present study was to evaluate the clinical efficacy of perindopril or losartan in combination with low-dose amiodarone on maintenance of sinus rhythm in patients with idiopathic paroxysmal atrial fibrillation (PAF)." | 9.12 | [Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation]. ( Dai, Y; Lan, XB; Ling, ZY; Liu, ZC; Luo, KL; Su, L; Wu, JJ; Yang, XY; Yin, YH, 2006) |
| "The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF." | 9.12 | Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. ( Dai, Y; Dalal, D; Dong, J; Lan, X; Ling, Z; Liu, D; Liu, Z; Luo, K; She, Q; Su, L; Woo, K; Wu, J; Yin, Y, 2006) |
| "To observe the clinical effect of the combined use of amiodarone and Wenxin Granule (WXG) in auricular fibrillation (AF) conversion and its safety." | 9.12 | [Clinical observation on effect and safety of combined use of wenxin granule and amiodarone for conversion of auricular fibrillation]. ( Huang, SE; Wang, M; Yu, YB, 2006) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 9.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "To investigate whether oral amiodarone administered before surgery for a short period in high dose would reduce the incidence of postoperative atrial fibrillation or atrial flutter and reduces the length of hospital stay." | 9.12 | High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter. ( Alcalde, RV; Bodanese, LC; Castro, I; Feier, F; Goldani, MA; Guaragna, JC; Noer, R; Petracco, JB; Sussenbach, E, 2006) |
| "Aim of the study was to investigate mechanisms of amiodarone action on atrial and ventricular rhythm during persistent atrial fibrillation (PAF), and to assess efficacy of amiodarone as monotherapy or in combination with digoxin." | 9.12 | [On the possibility of amiodarone use in some cases of persistent atrial fibrillation]. ( Blagova, OV; Nedostup, AV, 2006) |
| "The patients in amiodarone prophylaxis experienced a reduction in risk of atrial fibrillation of 14% (95% confidence interval [CI], 5." | 9.12 | Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. ( Christensen, TD; Folkersen, L; Hjortdal, VE; Mikkelsen, MM; Sørensen, HT; Thomsen, HF; Zebis, LR, 2007) |
| "Postoperative intravenous amiodarone prophylaxis followed by oral amiodarone significantly reduces the incidence of atrial fibrillation after off-pump coronary artery bypass grafting and the ventricular rate during atrial fibrillation." | 9.12 | Intravenous and oral amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass surgery. ( Ata, Y; Ozkan, H; Ozyazicioglu, A; Turk, T; Vural, H; Yavuz, S, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects." | 9.12 | Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. ( Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN, 2007) |
| "This is a substudy of a prospective randomized controlled trial (SAFE-Trial) in which amiodarone, sotalol, and placebo for persistent atrial fibrillation were evaluated." | 9.12 | Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. ( Batcher, EL; Hershman, JM; Reda, DJ; Singh, BN; Singh, SN; Tang, XC, 2007) |
| "Amiodarone and sotalol are commonly used for the maintenance of sinus rhythm, but the efficacy of these agents administered as high-dose infusions for rapid conversion of atrial fibrillation is unknown." | 9.11 | Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. ( Cooper, MJ; Crampton, R; Eipper, V; Guy, D; Kijvanit, P; Ross, DL; Thomas, SP; Wallace, E, 2004) |
| "To compare the efficacy and safety of amiodarone and propafenone when used for the prevention of atrial fibrillation (AF) and maintenance of normal sinus rhythm in patients with refractory AF." | 9.11 | Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. ( Hamilos, MI; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE; Zacharis, EA, 2004) |
| "This was a substudy of a clinical trial evaluating the efficacy of an amiodarone regimen or an atrial-septal pacing strategy on the occurrence of postoperative atrial fibrillation." | 9.11 | Indicators of atrial fibrillation risk in cardiac surgery patients on prophylactic amiodarone. ( Caron, MF; Coleman, CI; Kalus, JS; Kluger, J; Takata, H; White, CM, 2004) |
| "To compare the cost-effectiveness of intravenous plus oral amiodarone, atrial septal pacing, and both strategies combined to prevent atrial fibrillation after open heart surgery." | 9.11 | Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery. ( Caron, MF; Coleman, CI; Horowitz, S; Kalus, JS; Karapanos, A; Kluger, J; Reddy, P; White, CM, 2004) |
| "We studied the use of perioperative IV and oral administration of amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (CABG)." | 9.11 | Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. ( Hollander, G; Kerstein, J; Lichstein, E; Majid, M; Qamar, M; Shani, J; Soodan, A, 2004) |
| "This prospective, randomized, double-blind, placebo-controlled study compared the efficacy and safety of amiodarone and sotalol in the prevention of atrial fibrillation (AF) following open heart surgery." | 9.11 | Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial. ( Arcidi, JM; Hilleman, DE; Lenz, TL; Mohiuddin, SM; Mooss, AN; Packard, KA; Rovang, KS; Sugimoto, JT; Wurdeman, RL, 2004) |
| "This study was designed to assess the effects of a perioperative dosing regimen of amiodarone administration, high thoracic epidural anesthesia (TEA), or a combination of the 2 regimens on atrial fibrillation (AF) after coronary artery bypass grafting (CABG)." | 9.11 | Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting. ( Aldershvile, J; Eliasen, K; Hviid, LB; Krogsgaard, K; Nygård, E; Pedersen, FM; Ravn, J; Svendsen, JH; Sørensen, LH; Thomassen, L, 2004) |
| "The prophylactic effect of amiodarone on atrial fibrillation after coronary bypass grafting with extracorporeal circulation was compared with that of diltiazem in two groups of 60 patients each." | 9.11 | Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery. ( Bougioukas, G; Didilis, V; Konstantinou, F; Mikroulis, D; Tsakiridis, K; Vretzakis, G, 2005) |
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 9.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "To assess the prophylactic effect of postoperative oral amiodarone on the incidence and severity of atrial fibrillation (AF) after coronary artery surgery." | 9.10 | Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. ( Haddad, F; Hayek, G; Madi-Jebara, S; Rahbani, P; Yazigi, A; Zeid, HA, 2002) |
| "In clinical practice the use of intravenous amiodarone has been proposed for the conversion of recurrent atrial fibrillation in patients already under chronic treatment with the same drug." | 9.10 | Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable? ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 9.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "Within the first 4 hrs, atrial fibrillation was converted in nine of 20 patients (45%) in group ibutilide and in ten of 20 patients (50%) in group amiodarone (not significant)." | 9.10 | Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. ( Bernard, EO; Candinas, R; Germann, R; Scharf, C; Schmid, ER; Schmidlin, D, 2003) |
| "Amiodarone is effective in preventing the recurrence of atrial fibrillation (AF) after cardioversion (CV)." | 9.10 | Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation. ( Armstrong, KL; Fitzpatrick, AP; Fynn, SP; Garratt, CJ; Hobbs, WJ; Todd, DM, 2003) |
| "The purpose of this study was to evaluate the safety and efficacy of postoperative administration of prophylactic amiodarone in the prevention of new-onset postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting." | 9.10 | Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. ( Apaydin, A; Atay, Y; Ayik, F; Buket, S; Calkavur, T; Islamoglu, F; Nalbantgil, S; Posacioglu, H; Yagdi, T, 2003) |
| "To assess the effects of amiodarone and diltiazem on atrial fibrillation (AF) induced atrial electrical remodeling and their clinical implications." | 9.10 | Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. ( Dermitzaki, DN; Kallergis, EM; Kambouraki, DC; Kanoupakis, EM; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "The study was undertaken to assess the efficacy of intravenous amiodarone in cardioversion of recent-onset paroxysmal atrial fibrillation (AF)." | 9.10 | Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. ( Budaj, A; Ceremuzyński, L; Cybulski, J; Danielewicz, H; Kawka-Urbanek, T; Kułakowski, P; Maciejewicz, J, 2003) |
| "This pilot study aimed to compare right atrial pacing, intravenous amiodarone and oral beta-blockers in the prevention, time to onset, duration and effect on hospital stay of postoperative atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG) at our center." | 9.10 | Effect of right atrial pacing, intravenous amiodarone and beta blockers for suppression of atrial fibrillation after coronary artery bypass surgery: a pilot study. ( Cardona, F; Cox, RA; Pérez, CM; Seide, H, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 9.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| "The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers." | 9.10 | Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). ( Antman, EM; Atwood, JE; Ezekowitz, MD; Falk, RH; Fletcher, RD; Fye, CL; Jacobson, AK; Lewis, HD; Lopez, B; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2003) |
| "The effect of a hybrid intravenous and oral prophylactic amiodarone regimen on postcardiothoracic surgery (CTS) atrial fibrillation (AF) is unknown." | 9.10 | Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). ( Caron, MF; Gallagher, R; Kalus, JS; Kluger, J; Reddy, P; Rose, H; Song, J; White, CM, 2003) |
| "Amiodarone, used in conjunction with percutaneous balloon mitral commissurotomy, can safely convert rheumatic atrial fibrillation in 38% of patients compared with 0% in those without it." | 9.10 | Conversion of rheumatic atrial fibrillation by amiodarone after percutaneous balloon mitral commissurotomy. ( Hsueh, CW; Lai, HC; Lee, WL; Liu, TJ; Ting, CT; Wang, KY, 2003) |
| "This study aimed to assess whether enalapril could improve cardioversion outcome and facilitate sinus rhythm maintenance after conversion of chronic atrial fibrillation (AF)." | 9.10 | Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. ( Chan, KC; Chen, CY; Chen, SA; Lin, CS; Lin, MC; Tsai, CF; Tsai, TP; Ueng, KC; Wu, DJ; Yu, WC, 2003) |
| "To determine if the additional costs of oral amiodarone in patients undergoing open heart surgery would be offset by reductions in the frequency of atrial fibrillation." | 9.10 | An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. ( Dunn, AB; Giri, S; Kluger, J; Reddy, P; Tsikouris, JP; White, CM, 2002) |
| "This prospective randomized study aims at evaluation and comparison of the prophylactic effects of amiodarone versus digoxin and metoprolol combination in postcoronary bypass atrial fibrillation." | 9.10 | Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation. ( Catav, Z; Gunaydin, S; Kandemir, O; Tokmakoglu, H; Yorgancioglu, C; Zorlutuna, Y, 2002) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 9.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "The efficacy and safety of amiodarone in the conversion of persistent atrial fibrillation (AF) were investigated in a prospective, randomized, controlled study." | 9.09 | Efficacy of amiodarone for the termination of persistent atrial fibrillation. ( Chlouverakis, GI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Solomou, MC; Vardas, PE, 1999) |
| "The effects of a 6-week treatment with amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease have been studied." | 9.09 | Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. ( Adamus, J; Anker, SD; Banasiak, W; Coats, AJ; Fuglewicz, A; Kalka, D; Molenda, W; Ponikowski, P; Reczuch, K; Telichowski, A, 1999) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 9.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| ") amiodarone would prevent atrial fibrillation and decrease hospital stay after open heart surgery." | 9.09 | Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. ( Dudek, A; Gottlieb, SO; Guarnieri, T; Lowry, DR; Nolan, S, 1999) |
| "Spontaneous conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm occurs commonly and is not affected by low-dose amiodarone treatment." | 9.09 | Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. ( Blatt, A; Cotter, G; Golik, A; Kaluski, E; Koren, M; Litinski, I; Metzkor-Cotter, E; Moshkovitz, Y; Peleg, E; Simantov, R; Vered, Z; Zaidenstein, R, 1999) |
| "Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg." | 9.09 | Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. ( Aschieri, D; Capucci, A; Piepoli, MF; Rosi, A; Villani, GQ, 2000) |
| "The efficacy of amiodarone has been proved in long-term maintenance of sinus rhythm (SR) in patients with paroxysmal atrial fibrillation (AF)." | 9.09 | Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. ( Juvonen, J; Lilja, M; Linnaluoto, M; Niemelä, M; Peuhkurinen, K; Ylitalo, A, 2000) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 9.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "To investigate the efficacy and safety of amiodarone administered as the drug of first choice in the conversion of atrial fibrillation, regardless of its duration." | 9.09 | Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Simantirakis, EN; Tsatsakis, AM; Vardas, PE, 2000) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 9.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "Intraoperative prophylactic use of amiodarone does not prevent new onset of atrial fibrillation in patients undergoing coronary artery bypass grafting and had no effect on outcome." | 9.09 | Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations. ( Dörge, H; Messmer, BJ; Schoberer, M; Schoendube, FA; Stellbrink, C; Voss, M, 2000) |
| "Atrial fibrillation occurred in 9 (12%) of the amiodarone group patients and in 26 (34%) of the control group patients during hospitalization (p < 0." | 9.09 | Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. ( Chang, CM; Chen, SA; Cheng, JJ; Hung, CR; Lee, RJ; Lee, SH; Lu, MJ, 2000) |
| "This study compared the efficacy and safety of intravenous dofetilide with amiodarone and placebo in converting atrial fibrillation or flutter to sinus rhythm." | 9.09 | Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. ( Alboni, P; Bianconi, L; Castro, A; Dinelli, M; Pappalardo, A; Richiardi, E; Santini, M, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 9.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "The efficacy of diltiazem or amiodarone pretreatment (oral, 1 month before and 1 month after conversion) on direct-current conversion of persistent atrial fibrillation was assessed in 120 patients, randomly assigned to 3 matched groups: A (n = 44, diltiazem); B (n = 46, amiodarone), and C (n = 30, digoxin)." | 9.09 | Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. ( Capucci, A; Piepoli, MF; Terracciano, C; Villani, GQ, 2000) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 9.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "Our aims were to examine whether the administration of amiodarone or magnesium sulphate after coronary artery bypass graft surgery (CABG) could reduce the occurrence of atrial fibrillation, and to identify the risk factors associated with atrial fibrillation after CABG." | 9.09 | Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. ( Adamec, R; Perneger, TV; Romand, JA; Suter, PM; Treggiari-Venzi, MM; Waeber, JL, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "Beta-blockers and amiodarone reduce the frequency of atrial fibrillation after open-heart surgery but the effectiveness of oral amiodarone in older patients already receiving beta-blockers is unknown." | 9.09 | Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. ( Dunn, AB; Felton, K; Freeman-Bosco, L; Giri, S; Kluger, J; Reddy, P; Tsikouris, JP; White, CM; Wilcox, HA, 2001) |
| "Various regimens have been proposed for the prevention of postoperative atrial fibrillation, including the use of intravenous and oral amiodarone." | 9.09 | Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. ( Babić, R; Bojić, M; Borzanović, M; Bosković, SD; Jovanović, T; Kovacević, S; Maras, D; Marinković, J; Nastasić, S; Nesković, AN; Otasević, P; Popović, AD; Popović, Z; Vuk, L, 2001) |
| "The efficacy and safety of low-dose amiodarone (Cordarone; Wyeth-Ayerst, Philadelphia, PA) was assessed in 62 symptomatic patients with paroxysmal atrial fibrillation who were resistant to at least two types of IA drugs." | 9.09 | Efficacy of low-dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type IA antiarrhythmic drugs. ( Faitel, K; Kerin, IA; Kerin, NZ; Quinones, L; Stomel, RJ, 2000) |
| "Of the 100 patients recruited for the Amiodarone arm of the study, 12 were excluded for a variety of reasons detailed in the discussion with atrial fibrillation occurring in 28 (a rate of 32%)." | 9.09 | Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery. ( Harahsheh, BS; Sawalha, WA, 2001) |
| "Both amiodarone and beta-blockers have been shown to decrease the incidence of atrial fibrillation after cardiovascular surgery." | 9.09 | Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery. ( Greenberg, MD; Katz, NM; Kilborn, MJ; Solomon, AJ, 2001) |
| "We sought to assess the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial." | 9.09 | Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. ( Chiale, PA; Elizari, MV; Galperín, J; Ledesma, R; Molina, RT; Scapín, AO; Vázquez Blanco, M, 2001) |
| " A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats." | 9.08 | Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ( Chang, MS; Chen, CY; Chiang, HT; Hou, ZY; Lin, SL; Tu, MS; Woosley, RL, 1995) |
| "In a randomized, double-blind, controlled study of 98 patients with atrial fibrillation (AF) (present for > or = 30 minutes, < or = 72 hours, and a ventricular response of > or = 100 beats/min), intravenous flecainide (2 mg/kg, maximum 150 mg) was compared with intravenous amiodarone (7 mg/kg) and placebo." | 9.08 | Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. ( Dobb, GJ; Donovan, KD; Hockings, BE; Lee, KY; Power, BM, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 9.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 9.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "This study was designed to determine the efficacy of intravenous amiodarone in the management of recent-onset atrial fibrillation." | 9.08 | Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. ( Arnau, JM; Artaza, MA; Ballester, R; Galve, E; García-Dorado, D; Rius, T; Soler-Soler, J, 1996) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 9.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P=0." | 9.08 | Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. ( Bitar, C; Bolling, SF; Daoud, EG; Deeb, GM; Goyal, R; Man, KC; Meissner, MD; Morady, F; Pagani, FD; Strickberger, SA, 1997) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 9.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "The efficacy and safety of intravenous propafenone, amiodarone, or placebo were compared in the treatment of atrial fibrillation (AF) of recent onset (duration < or = 48 hours)." | 9.08 | Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. ( Igoumenidis, NE; Kochiadakis, GE; Marketou, ME; Mezilis, NE; Parthenakis, FI; Simantirakis, EN; Vardas, PE, 1998) |
| "In a multicenter, double-blind, placebo-controlled study, the long-term effects of amiodarone on morbidity and mortality in patients with congestive heart failure (CHF) and atrial fibrillation (AF) were evaluated during a 4-year period." | 9.08 | Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Departmen ( Deedwania, PC; Ellenbogen, K; Fisher, S; Fletcher, R; Singh, BN; Singh, SN, 1998) |
| "The effectiveness of propafenone versus amiodarone for conversion to sinus rhythm of paroxysmal atrial fibrillation was compared." | 9.07 | [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. ( Alfano, C; Rossini, E; Treglia, A, 1994) |
| "An open, multi-centre study was carried out to assess the effectiveness and tolerability of amiodarone at a lower dose than routinely used in the clinical and symptomatic treatment of older patients with atrial fibrillation who were resistant to other therapy or in whom other therapy was either poorly tolerated or contraindicated." | 9.07 | Amiodarone dosage in older patients with atrial fibrillation: an open, multi-centre study. ( Sandler, M, 1992) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 9.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "The efficacy and the safety of amiodarone therapy in 82 patients with recurrent tachyarrhythmias, refractory to conventional antiarrhythmics, were evaluated by a multicenter trial." | 9.07 | Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias. ( Kato, K, 1992) |
| "To study efficacy and safety of low-dose amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation or flutter." | 9.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 9.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| "Two intravenous amiodarone dosing schedules in 28 patients with atrial fibrillation arisen less than 10 days before, were evaluated." | 9.07 | [Amiodarone and its infusion velocity in recent-onset atrial fibrillation]. ( Bonino, ML; Ramus, GV; Tonda, L; Veglio, F, 1991) |
| "The effectiveness of amiodarone and quinidine in converting atrial fibrillation of recent onset (less than three weeks) to sinus rhythm was compared in a randomized, open-label study." | 9.06 | [Comparison of amiodarone and quinidine in the conversion to sinusal rhythm of atrial fibrillation of recent onset]. ( De Ponti, C; Gibelli, G; Negrini, M, 1990) |
| "This study was designed to assess the clinical efficacy of oral flecainide for the prevention of paroxysmal attacks of atrial fibrillation (AF)." | 9.06 | Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. ( Chouty, F; Coumel, P, 1988) |
| "Thirty-eight patients were studied to evaluate amiodarone hydrochloride in the treatment of refractory atrial fibrillation." | 9.06 | Amiodarone in the management of refractory atrial fibrillation. ( Benaderet, D; Blevins, RD; Faitel, K; Frumin, H; Jarandilla, R; Kerin, NZ; Rubenfire, M, 1987) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 9.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 9.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "Clinicians frequently pre-treat patients with amiodarone to increase the efficacy of electrical cardioversion for atrial fibrillation (AF)." | 9.01 | Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. ( Amit, G; Belley-Côté, EP; Chu, VA; Healey, JS; Koziarz, A; McIntyre, WF; Mendoza, PA; Um, KJ; Whitlock, RP, 2019) |
| "Recent evidence from relatively small randomized controlled trials would seem to support a useful role of ranolazine for the prevention and treatment of atrial fibrillation (AF)." | 8.98 | Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. ( Ariano, C; Cioppa, C; De Vecchis, R; Giasi, A, 2018) |
| "We performed a systematic review of MEDLINE, the Cochrane Central Register of Clinical Trials, and Embase, limiting our search to randomized controlled trials of patients with atrial fibrillation that have compared DOACs versus warfarin for prophylaxis of stroke or systemic embolism, to analyze the impact on stroke or systemic embolism, major bleeding, and intracranial bleeding risk in patients with concomitant use of amiodarone." | 8.98 | Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. ( Briceno, D; Di Biase, L; Ferrick, K; Fisher, J; Gross, JN; Kim, S; Krumerman, A; Lupercio, F; Maraboto, C; Peltzer, B; Romero, J; Villablanca, P, 2018) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 8.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| " The question addressed was whether the administration of amiodarone is safe in patients undergoing lung resection either for prophylaxis or treatment of de novo postoperative atrial fibrillation (POAF)." | 8.95 | In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation? ( Billè, A; Harling, L; Kolokotroni, SM; Toufektzian, L, 2017) |
| "To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF." | 8.95 | Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation. ( Nguyen, E; White, CM, 2017) |
| "Despite probably being the most effective prophylactic drug for postoperative atrial fibrillation (POAF), amiodarone is reserved as a second-line agent because of its potential systemic side effects." | 8.93 | Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation. ( Chu, FV; Habbab, LM, 2016) |
| "The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial flutter, as part of the Institute's single technology appraisal (STA) process." | 8.88 | Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2012) |
| "Dronedarone is a benzofuran derivative approved by the Food and Drug Administration to decrease the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) and associated cardiovascular risk factors who are in sinus rhythm or will undergo cardioversion." | 8.88 | Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. ( Aikat, S; Chatterjee, S; Ghosh, J; Lichstein, E; Mukherjee, D, 2012) |
| "Current guidelines recommend beta-blocker as the first-line preventive treatment of atrial fibrillation (AF) after cardiac surgery; if beta-blocker therapy is contraindicated, then amiodarone is recommended." | 8.88 | Meta-analysis of amiodarone versus β-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. ( Gao, D; Gao, Y; Lu, Y; Wang, C; Zhang, C; Zhang, Y; Zhu, J, 2012) |
| "The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations." | 8.88 | Drug safety evaluation of dronedarone in atrial fibrillation. ( De Ferrari, GM; Dusi, V, 2012) |
| "Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial." | 8.88 | Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. ( Salam, AM, 2012) |
| "The readers will gain an understanding of the findings of recent trials performed with dronedarone, which will provide important information for this relatively new antiarrhythmic drug, used for the treatment of atrial fibrillation." | 8.87 | Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. ( Lip, GY; Pamukcu, B, 2011) |
| "We present three patients treated with amiodarone for atrial fibrillation who developed AIT at least 36 months after beginning the treatment." | 8.87 | [Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases]. ( Arias, N; Boix, E; González, VL; Moreno-Pérez, Ó; Picó, AM; Revert, P; Sánchez-Ortiga, R; Serrano, J, 2011) |
| "We performed a systematic review and meta-analysis on the effect of dronedarone on the occurrence of stroke or transient ischemic attack (TIA) in patients with paroxysmal or persistent AF." | 8.87 | Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. ( Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C, 2011) |
| "To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation." | 8.86 | Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. ( Duray, GZ; Ehrlich, JR; Hohnloser, SH, 2010) |
| "Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hospitalization driven by atrial fibrillation/flutter." | 8.86 | Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? ( Cingolani, E; Diamond, GA; Kaul, S; Singh, D, 2010) |
| "Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL)." | 8.86 | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF)." | 8.86 | Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. ( Langdorf, MI; Lotfipour, S; Simonian, SM; Wall, C, 2010) |
| "Vernakalant is a promising novel antiarrhythmic intravenous drug for the rapid conversion of atrial fibrillation to sinus rhythm." | 8.86 | [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm]. ( Eschenhagen, T; Hirt, MN, 2010) |
| "Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter." | 8.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. ( Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report on the clinical effectiveness and cost-effectiveness of dronedarone for the treatment of atrial fibrillation (AF) or atrial flutter based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 8.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2010) |
| " Dronedarone, the first noniodinated amiodarone congener, has been developed largely to obtain the antiarrhythmic efficacy in the control of atrial fibrillation without the known adverse side effects of dronedarone." | 8.86 | A new agent for atrial fibrillation: electrophysiological properties of dronedarone. ( Cingolani, E; Singh, BN, 2010) |
| "To assess whether amiodarone, as part of a strategy to achieve sinus rhythm, is safe and effective compared with a placebo or rate control drug in patients with persistent atrial fibrillation (AF) of more than 30 days' duration." | 8.85 | Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. ( Doyle, JF; Ho, KM, 2009) |
| "We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF)." | 8.85 | Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. ( Califf, RM; Hasselblad, V; Kong, DF; Peterson, ED; Piccini, JP; Washam, JB, 2009) |
| "To investigate a possible dose-response relationship between amiodarone and reduction in incidence of postoperative atrial fibrillation, and to determine whether pre- or postoperative initiation of amiodarone is superior." | 8.84 | Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. ( Buckley, MS; Copeland, JG; Hilleman, DE; Nolan, PE; Slack, MK; Tisdale, JE, 2007) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation." | 8.84 | Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. ( Dale, KM; White, CM, 2007) |
| "A meta-analysis was conducted to assess the safety of amiodarone in the prevention of postoperative atrial fibrillation." | 8.83 | Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. ( Coleman, CI; Gillespie, EL; Kluger, J; Patel, AA; White, CM, 2006) |
| "Amiodarone has been proposed to decrease atrial fibrillation after cardiac surgery." | 8.83 | Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Bagshaw, SM; Exner, DV; Galbraith, PD; Ghali, WA; Mitchell, LB; Sauve, R, 2006) |
| "This meta-analysis compared amiodarone with placebo and class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF), defined as lasting less than seven days." | 8.82 | Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. ( Burri, H; Chevalier, P; Cucherat, M; Durand-Dubief, A; Kirkorian, G; Touboul, P, 2003) |
| "Although clinicians sometimes choose amiodarone to convert atrial fibrillation (AF) to sinus rhythm, no current and comprehensive systematic review has summarized its effectiveness." | 8.82 | Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. ( Ena, J; Guyatt, GH; Letelier, LM; Udol, K; Weaver, B, 2003) |
| "The efficacy and safety of amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 8.82 | Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Gowda, RM; Khan, IA; Mehta, NJ, 2003) |
| "A short cut review was carried out to establish whether amiodarone is better than flecainide at restoring sinus rhythm in patients with atrial fibrillation." | 8.82 | Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation. ( Argall, J; Crawford, I, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 8.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "To evaluate efficacy and safety of intravenous amiodarone for conversion of recent-onset atrial fibrillation." | 8.81 | Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. ( Hilleman, DE; Spinler, SA, 2002) |
| "Amiodarone in low to moderate doses is generally safe in controlling arrhythmias in patients with congestive heart failure (CHF)." | 8.80 | The current role of amiodarone in patients with congestive heart failure. ( Bello, D; Massie, BM, 1998) |
| "Oral amiodarone may be used in the prevention of recurrences of paroxysmal atrial fibrillation (AF) or in chronic AF following electrical cardioversion or for pharmacological cardioversion of AF." | 8.80 | Amiodarone in atrial fibrillation. ( Levy, S, 1998) |
| "Amiodarone is the most important drug in the treatment of ventricular arrhythmias and is widely used for atrial fibrillation." | 8.80 | [Amiodarone-induced thyrotoxicosis]. ( Cron, TA; Kaufmann, C; Meier, C; Oberholzer, M; Osswald, S; Staub, JJ, 2000) |
| "To discuss the role of amiodarone for the maintenance of normal sinus rhythm in patients with atrial fibrillation (AF) and review the clinical trial data evaluating the efficacy and safety of amiodarone in patients with AF." | 8.79 | Amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. ( Howard, PA, 1995) |
| " The search was conducted by intersecting "quinidine," "warfarin," or "amiodarone" with "atrial fibrillation." | 8.79 | Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis. ( Gornbein, JA; Middlekauff, HR; Stevenson, WG, 1995) |
| "To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease." | 8.79 | Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. ( Hohnloser, SH; Klingenheben, T; Singh, BN, 1994) |
| "Five recent randomized controlled trials of warfarin in atrial fibrillation, 6 randomized controlled trials of quinidine, and 13 longitudinal studies of low-dose amiodarone were used." | 8.79 | Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. ( Birkmeyer, JD; Disch, DL; Greenberg, ML; Holzberger, PT; Malenka, DJ, 1994) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 8.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| "Concerns about proarrhythmia risk and inefficacy associated with class I antiarrhythmic drugs have revived interest in low-dose amiodarone (maintenance dose 200-400 mg/day) for suppression of atrial fibrillation." | 8.78 | Low-dose amiodarone for atrial fibrillation. ( Middlekauff, HR; Stevenson, WG; Wiener, I, 1993) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 8.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 8.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "The association between amiodarone treatment for postoperative atrial fibrillation (POAF) after surgical aortic valve replacement (SAVR) and both the return to normal sinus rhythm (NSR) and anticoagulation use at discharge has not been extensively studied." | 8.31 | Postoperative Atrial Fibrillation After Surgical Aortic Valve Replacement: Amiodarone and Warfarin Use. ( Beaulieu-Jones, BR; Haime, M; Lin, B; Phillips, AM; Quin, JA, 2023) |
| "Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation." | 8.31 | Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation. ( Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M, 2023) |
| "To evaluate the effectiveness and safety of dronedarone compared with other commonly used antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrences." | 8.12 | International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF). ( Abenhaim, L; Botto, GL; Breithardt, G; de Abajo, FJ; Grimaldi-Bensouda, L; Khachatryan, A; Kirchhof, P; Merino, JL; Stambler, B, 2022) |
| "Compared to co-administration of amiodarone and rivaroxaban, co-administration of dronedarone and rivaroxaban increases the risk of CRNMB but it does not increase the risk of major hemorrhages in blanking period after AF ablation." | 8.12 | Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation. ( Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q, 2022) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 8.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Amiodarone is commonly used in atrial fibrillation (AF)." | 8.12 | Amiodarone is associated with increased short-term mortality in elderly atrial fibrillation patients with preserved ejection fraction. ( Di Biase, L; Li, W; Tiwari, N; Wang, YC, 2022) |
| "We analyzed changes in physicians' use of dronedarone after the PALLAS trial (Palbociclib Collaborative Adjuvant Study; November 2011) showed that dronedarone increased the risk of death from cardiovascular events among patients with permanent atrial fibrillation." | 8.02 | Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. ( Desai, NR; Everhart, A; Jena, A; Karaca-Mandic, P; Ross, JS; Shah, N; Smith, LB; Stecher, C, 2021) |
| "Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM) has not been studied." | 8.02 | Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. ( Akhavein, R; Al-Rashdan, L; Elman, MR; Fischer, KL; Heitner, SB; Lin, LQ; Mannello, M; Masri, A; Nazer, B; Shalen, EF; Song, HK, 2021) |
| "It was reported that intravenous amiodarone might induce ventricular fibrillation for acute treatment in patients with atrial fibrillation (AF) and Wolff-Parkinson-White (WPW) syndrome." | 8.02 | The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome. ( Ren, J; Shao, X; Wang, J; Wu, S; Yang, Y; Zhang, H; Zhu, J, 2021) |
| "Intravenous amiodarone infusion is effective and widely used treatment for pharmacological cardioversion of recent-onset atrial fibrillation (Af)." | 8.02 | Frontal plane QRS-T angle in the monitoring of intravenous amiodarone infusion for pharmacological cardioversion of acute atrial fibrillation. ( Eyuboglu, M, 2021) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 8.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "The authors present a case of a 55-year-old gentleman with a medical history of atrial fibrillation on amiodarone who presented with weight loss, palpitations and exertional dyspnoea." | 8.02 | Amiodarone-induced type 2 thyrotoxicosis. ( Abela, A; Fava, S; Mifsud, S; Portelli, D, 2021) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 8.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "The study's goal was to compare the efficacy and safety of dofetilide (DOF) versus amiodarone (AMIO) in patients with atrial fibrillation (AF)." | 8.02 | Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation. ( Batul, A; Bogun, F; Chugh, A; Chung, E; Crawford, T; Cunnane, R; Ghanbari, H; Ghannam, M; Jongnarangsin, K; Latchamsetty, R; Liang, J; Morady, F; Oral, H; Pelosi, F; Saeed, M; Shantha, G, 2021) |
| "Using nationwide registers, we included all Danish patients with atrial fibrillation (AF) treated with amiodarone from 1996 to 2014." | 7.96 | Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. ( D'Souza, M; Dalgaard, F; Hansen, ML; Hilmar Gislason, G; Pallisgaard, JL; Piccini, J; Rasmussen, PV; Ruwald, MH; Torp-Pedersen, C, 2020) |
| "Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects." | 7.96 | Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. ( Fonarow, GC; Freeman, JV; Gersh, BJ; Holmes, DN; Kowey, PR; Mahaffey, KW; Naccarelli, GV; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Shrader, P; Singer, DE; Thomas, L; Washam, JB, 2020) |
| "Combination use of digoxin and other medications might lead to worse outcomes in patients with atrial fibrillation (AF)." | 7.96 | Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation. ( Chang, CH; Chen, JJ; Chen, PC; Chiang, FT; Chiang, JY; Chu, FY; Hwang, JJ; Lin, JL; Lin, LY; Wu, CK; Yang, YH, 2020) |
| "Amiodarone is a widely used drug in the emergency department (ED) for control of atrial fibrillation, but it has a delayed onset of action and slow metabolism, leading to longer length of ED stay." | 7.96 | Impact of emergency department management of atrial fibrillation with amiodarone on length of stay. A propensity score analysis based on the URGFAICS registry. ( Arranz, M; Cabello, I; Esquerrà, A; Frances, P; Guzman, J; Jacob, J; Mòdol, JM; Moreno-Pena, A; Santos, J; Yuguero, O, 2020) |
| "This study aimed to describe a case of optic neuropathy after substitution of amiodarone with dronedarone for treatment of atrial fibrillation." | 7.96 | Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation. ( Maharshak, I; Paul, M; Steiner, H, 2020) |
| "Post hoc analysis of the landmark atrial fibrillation follow-up investigation of rhythm management trial revealed that amiodarone was associated with higher risks of mortality, intensive care unit admission, and non-cardiovascular death." | 7.96 | Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry. ( Dong, JZ; Du, X; He, L; Hou, XX; Ma, CS; Wang, GH, 2020) |
| "One of the drugs that are widely used in the treatment of atrial fibrillation is amiodarone." | 7.91 | TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY. ( Cerovec, D; Ciglenečki, N; Lakušić, N; Slivnjak, V, 2019) |
| "This study aims to examine the effects of amiodarone in restoring sinus rhythm in patients with new-onset atrial fibrillation during thoracic operations." | 7.91 | Transient new-onset atrial fibrillation during general thoracic operations and its treatment with amiodarone: a retrospective analysis in a single centre. ( Chen, M; Ji, C; Wu, D; Wu, J; Xu, M, 2019) |
| "A 63-year-old man underwent cardioversion of atrial fibrillation with intravenous amiodarone through an antecubital fossa cannula." | 7.91 | Focal myositis and contracture secondary to amiodarone extravasation from a peripheral cannula. ( Cordato, D; Ledingham, D, 2019) |
| "The purpose of this study was to evaluate whether rapid switching from amiodarone to dofetilide is safe in atrial fibrillation patients with an ICD." | 7.91 | Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator. ( Atkins, D; Bommana, S; Carroll, H; Gopinathannair, R; Jeffrey, C; Lakkireddy, D; Natale, A; Newton, D; Nydegger, C; Sharma, SP; Turagam, M, 2019) |
| "The aim of the study was to examine the safety and efficacy of dronedarone in patients with a history of atrial fibrillation and amiodarone-induced hyperthyroidism." | 7.88 | Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study. ( Babu Dasari, J; Battaini, F; Bernardini, S; De Lorenzo, A; Intorcia, A; Merra, G; Morgagni, R; Perrone, MA; Romeo, F; Sergi, D, 2018) |
| " Amiodarone, an antiarrhythmic associated with significant adverse effects with long-term use, is commonly used for new-onset atrial fibrillation in critical illness (NAFCI)." | 7.85 | Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness. ( Alpert, J; Bloom, J; Dongtai, W; Huckleberry, Y; Kopp, B; Leelathanalerk, A, 2017) |
| "Iodine-induced thyrotoxicosis, which raises several diagnostic and therapeutical challenges, is often overlooked." | 7.83 | Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly. ( Cascio, C; Foppiani, L; Lo Pinto, G, 2016) |
| "The authors assessed the efficacy and safety of landiolol, an ultra-short-acting beta-blocker, with those of amiodarone in the restoration of sinus rhythm for postoperative atrial fibrillation (POAF) in intensive care unit (ICU) patients." | 7.83 | Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients. ( Fujino, Y; Ohta, N; Shibata, SC; Uchiyama, A, 2016) |
| "Although oral amiodarone (AMD) has been used for the management of atrial fibrillation (AF), serious complications such as interstitial pneumonia (IP) occur very occasionally." | 7.83 | Obesity Is Associated With the Development of Interstitial Pneumonia Under Long-Term Administration of Amiodarone in Refractory Atrial Fibrillation Patients. ( Fujino, T; Fukunaga, S; Ikeda, T; Kinoshita, T; Kitahara, K; Kobayashi, K; Koike, H; Koike, M; Sato, H; Shinohara, M; Suzuki, T; Yuzawa, H, 2016) |
| "The aim of this study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant atrial fibrillation (AF) and mortality after HTX." | 7.83 | Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. ( Akhavanpoor, M; Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleissner, CA; Helmschrott, M; Katus, HA; Rivinius, R; Ruhparwar, A; Schmack, B; Schweizer, PA; Thomas, D, 2016) |
| "Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown." | 7.83 | Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. ( Aissaoui, N; Alazard, M; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Le-Heuzey, JY; Salem, JE; Urien, S, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 7.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "Sotalol and amiodarone are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation (POAF)." | 7.83 | Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. ( Brophy, JM; Johnson, SM, 2016) |
| "Amiodarone is an antiarrhythmic drug that is frequently used to control atrial fibrillation (AF)." | 7.83 | Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis. ( Cai, S; Feng, W; Sun, L; Wang, M; Zhao, Q, 2016) |
| "In this study, our aim is to examine the role of the neutrophil to lymphocyte ratio (NLR) in the predictions of recurrence under long-term follow-up in patients whose sinus rhythms (SRs) were restored with amiodarone in acute atrial fibrillation (AF)." | 7.81 | Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone. ( Karapınar, H; Karavelioğlu, Y; Kurt, R; Memiç, K; Sarak, T; Yilmaz, A; Yüksel, M, 2015) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 7.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "Median trough plasma concentration of dabigatran in our study was observed to be similar to median trough plasma concentration of dabigatran at a dose of 150 mg bid without concomitant dronedarone in earlier studies with low reported rate of bleeding and thrombosis." | 7.81 | Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. ( Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015) |
| "Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm." | 7.81 | Acute severe back pain radiating to the whole body during intravenous administration of amiodarone. ( Shen, H; Yan, Y, 2015) |
| "Intravenous amiodarone can cause severe and refractory hypotension." | 7.81 | Amiodarone-Induced Life-Threatening Refractory Hypotension. ( Doshi, D; Jayawardana, R, 2015) |
| "Amiodarone is often prescribed in the management of atrial fibrillation (AF) but is known to cause significant end-organ toxicities." | 7.81 | Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. ( Adelstein, E; Alam, MB; Jain, SK; Khattak, F; Leef, G; Munir, MB; Patel, D; Qin, D; Rattan, R; Saba, S, 2015) |
| "There are limited data on mortality outcomes associated with use of amiodarone in atrial fibrillation and flutter (AF)." | 7.81 | Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. ( Fan, J; Frayne, SM; Heidenreich, PA; Kaiser, DW; Perino, AC; Phibbs, CS; Schmitt, S; Than, CT; Turakhia, MP; Ullal, AJ, 2015) |
| " Two weeks after amiodarone initiation (200 mg/d) hemoptysis occurred and computed tomography revealed unilateral pulmonary infiltrates with ground-glass opacities limited to the lower lobe of the left lung." | 7.81 | [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease]. ( Elikowski, W; Małek, M; Skowroński, M; Skrzywanek, P; Wróblewski, D; Zawilska, K, 2015) |
| "This study aimed to assess safety and cardiovascular outcomes of dronedarone in patients with paroxysmal or persistent atrial fibrillation (AF) with coronary heart disease (CHD)." | 7.80 | Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. ( Connolly, SJ; Crijns, HJ; Hohnloser, SH; Naditch-Brûlé, L; Page, RL; Pisters, R; Torp-Pedersen, C, 2014) |
| " We analyzed 3 guidelines from medical specialty societies about dronedarone hydrochloride, an antiarrhythmic drug related to amiodarone hydrochloride, for treatment of patients with atrial fibrillation." | 7.80 | Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. ( Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P, 2014) |
| "The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/flutter (AF/AFL)." | 7.80 | Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. ( Jhaveri, M; Kim, MH; Koren, A; Lin, J, 2014) |
| "Pulmonary opacities have many causes we are presenting a case of pulmonary opacity in a patient of breathlessness; who was on amiodarone for atrial fibrillation (AF)." | 7.80 | Amiodarone induced pulmonary toxicity in a case of atrial fibrillation. ( Deodhar, KY; Patil, AS; Ranpise, SM; Sirsikar, SS, 2014) |
| " He was diagnosed with atrial fibrillation 2 years previously and started on amiodarone and warfarin." | 7.80 | Amiodarone-induced thyrotoxicosis: type 1 or type 2? ( Khan, A; Puttanna, A; Raskauskiene, D, 2014) |
| "We present the case of intentional caffeine poisoning after ingestion of tablets containing guarana extract, complicated by atrial fibrillation." | 7.80 | Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose. ( Biedroń, W; Ciszowski, K; Gomólka, E, 2014) |
| "Many patients with atrial fibrillation (AF) receive amiodarone." | 7.79 | Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study. ( Lebedev, AD; Lebedev, DS; Mikhaylov, EN; Orshanskaya, VS; Szili-Torok, T, 2013) |
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 7.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 7.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "In clinical trials, dronedarone lowers ventricular rate during atrial fibrillation (AF)." | 7.79 | Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation. ( Belardinelli, L; Kanas, AF; Machado, AD; Nearing, BD; Pagotto, VP; Sobrado, LF; Sobrado, MF; Varone, BB; Verrier, RL; Zeng, D, 2013) |
| "Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF)." | 7.79 | Efficacy and tolerability of dronedarone for patients with atrial fibrillation. ( Goldberger, JJ; Teme, T, 2013) |
| " Amiodarone, the drug of choice for arrhythmia treatment in such patients, can cause a number of complications, including amiodarone induced thyrotoxicosis (AIT)." | 7.79 | Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome. ( Czarnywojtek, A; Fichna, M; Florek, E; Greberska, W; Guzik, P; Kwiecinska, B; Lodyga, M; Ruchała, M; Waśko, R; Woliński, K; Zgorzalewicz-Stachowiak, M, 2013) |
| "The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 7.79 | Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. ( Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M, 2013) |
| "To examine whether low-dose ranolazine and/or dronedarone can protect against vulnerability to atrial fibrillation (AF) and ventricular tachyarrhythmias." | 7.79 | Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ( Belardinelli, L; Kanas, AF; Nearing, BD; Pagotto, VP; Sobrado, MF; Verrier, RL; Zeng, D, 2013) |
| "Our study showed that during the intra- and postoperative periods, both amiodarone and magnesium sulfate are effective at preventing the incidence of atrial fibrillation following lung resection surgery in comparison to the control group." | 7.79 | A comparative study between amiodarone and magnesium sulfate as antiarrhythmic agents for prophylaxis against atrial fibrillation following lobectomy. ( Abdel Azeem, MS; Al-Agaty, AE; Ali, WG; Khalil, MA, 2013) |
| " Here we describe a Caucasian woman who developed a bronchiolitis obliterans organizing pneumonia (BOOP)-like interstitial pneumonia after PTU administration for amiodarone-induced thyrotoxicosis." | 7.78 | Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis. ( Brigante, G; Diazzi, C; Rochira, V; Rossi, G, 2012) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 7.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "Nurses noted that the rate of phlebitis was high when intravenous amiodarone was infused via a peripheral site." | 7.78 | Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone. ( Boyce, BA; Yee, BH, 2012) |
| "Amiodarone is a potent anti-atrial fibrillation (AF) agent; however, its systemic administration induces serious side effects such as interstitial pneumonia." | 7.77 | Topical application of a biodegradable disc with amiodarone for atrial fibrillation. ( Hyon, SH; Ikeda, T; Marui, A; Minakata, K; Miwa, S; Nakajima, N; Saito, N; Sakata, R; Shimamoto, T; Takeda, T; Uehara, K, 2011) |
| "We investigated the effect of amiodarone on prevention of post-operative atrial fibrillation (POAF) after cardiac surgery." | 7.77 | [Prophylactic use of amiodarone against postoperative atrial fibrillation after cardiac surgery]. ( Araki, E; Osawa, H; Sakurada, T; Sasaki, J, 2011) |
| "Amiodarone is recognized as the most effective therapy for maintaining sinus rhythm (SR) post cardioversion in patients with atrial fibrillation (AF)." | 7.77 | Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. ( Hachiya, H; Higuchi, K; Hirao, K; Inaba, O; Isobe, M; Kawabata, M; Tanaka, Y; Yagishita, A, 2011) |
| "Amiodarone (AM)-induced thyrotoxicosis (AIT) is a condition with uncertainties from the diagnostic and therapeutic standpoints." | 7.77 | Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis. ( Braga, DC; Carvalho, D; Fernandes, H; Matos, MJ; Pereira, J; Souto, SB, 2011) |
| "The aim of this work was to analyze the prevalence of level function disorder in patients with atrial fibrillation taking constantly amiodarone." | 7.77 | [Abnormal liver function during therapy with amiodarone in patients with persistent atrial fibrillation]. ( Buniatian, ND; Korsun, LV; Sviridenko, AV; Uteshev, DB; Voronkina, MV, 2011) |
| " Food and Drug Administration for the treatment of patients with atrial fibrillation (AF) as a safe alternative to amiodarone." | 7.76 | Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A, 2010) |
| "To describe a challenging patient case in which dronedarone was selected for a patient with atrial fibrillation and heart failure; the drug may have been associated with worsening heart failure, leading to acute renal and hepatic failure." | 7.76 | Worsening heart failure in the setting of dronedarone initiation. ( Coons, JC; Plauger, KM; Seybert, AL; Sokos, GG, 2010) |
| "To observe the therapeutic efficacy and safety of amiodarone combined with Shenmai Injection (参麦注射液) on atrial fibrillation." | 7.76 | Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection (参麦注射液). ( Chen, ZM; Deng, M; Ma, W; Sui, XQ; Xu, Y; Zhu, SB, 2010) |
| "The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF)." | 7.76 | Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Sicouri, S, 2010) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone plus angiotensin II receptor blockers (ARBs) and catheter ablation may improve sinus rhythm maintenance of paroxysmal atrial fibrillation (AF), their clinical efficacies have not been compared." | 7.75 | Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. ( Lan, X; Ling, Z; Liu, Z; Su, L; Wu, J; Yang, X; Yin, Y; Zrenner, B, 2009) |
| "Patients with persistent or paroxysmal atrial fibrillation and at least 1 risk factor for cardiovascular hospitalization were randomized to receive dronedarone (400 mg BID) or double-blind matching placebo and followed up for a minimum of 1 year to a common termination at 30 months." | 7.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter." | 7.75 | Dronedarone (Multaq) for atrial fibrillation. ( , 2009) |
| " During amiodarone infusion a torsade de pointes occurred, which was immediately converted to sinus rhythm by synchronized cardioversion." | 7.75 | "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. ( Benazzi, B; Bernardi, M; Berzigotti, A; Bracci, E; Di Micoli, A; Trevisani, F; Zambruni, A; Zappoli, P; Zoli, M, 2009) |
| "Several studies demonstrated the efficacy of amiodarone pretreatment in achieving bet-ter outcomes after electrical cardioversion of atrial fibrillation." | 7.74 | [Effects of pretreatment with amiodarone infusion in patients with persistent atrial fibrillation submitted to external electrical cardioversion: a single center experience]. ( Bielli, M; Dellavesa, P; Franchetti Pardo, N; Maffè, S; Nicali, R; Paffoni, P; Paino, AM; Parravicini, U; Perucca, A; Signorotti, F; Zanetta, M; Zenone, F, 2008) |
| "Although amiodarone is one of the most effective pharmacologic agents used in clinical management of atrial fibrillation (AF), little is known about its differential effects in atrial and ventricular myocardium." | 7.74 | Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. ( Antzelevitch, C; Burashnikov, A; Carlsson, L; Di Diego, JM; Ferreiro, M; Sicouri, S, 2008) |
| "We describe the effects of iopanoic acid on daily levels of free triiodothyronine (FT(3)) and free thyroxine (FT(4)) in a patient with progressive type II amiodarone-induced thyrotoxicosis (AIT) who was undergoing thyroidectomy." | 7.74 | Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. ( Falciglia, M; Matrka, L; Nikiforov, Y; Steward, D, 2008) |
| "Special attention should be paid to patients on treatment with amiodarone and/or a diagnosis of atrial fibrillation as they may have an increased risk of fracture." | 7.74 | Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. ( Mosekilde, L; Rejnmark, L; Vestergaard, P, 2007) |
| " Amiodarone is also used for the cardioversion of atrial fibrillation and prolongs the QT interval but rarely causes torsades de pointes." | 7.74 | The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm. ( Bonios, M; Exarchos, P; Kogias, J; Melexopoulou, C; Sideris, S; Tsatiris, K, 2007) |
| "To evaluate the usefulness of Doppler parameters in the differentiation between the two types of amiodarone-associated thyrotoxicosis (AAT)." | 7.74 | Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. ( Cerri, GG; Chammas, MC; Farage, L; Jorge, PT; Macedo, TA; Santos, VA; Souza, LP; Watanabe, T, 2007) |
| "Epididymitis, as an unusual side-effect of amiodarone use, in a patient with dilated cardiomyopathy is reported along with a pertinent literature review." | 7.74 | Amiodarone-induced epididymitis: a case report and review of the literature. ( Ikonomidis, I; Kremastinos, D; Lekakis, I; Nikolaou, M; Tsiodras, S, 2007) |
| "To assess if prophylaxis with moderate doses of amiodarone in the postoperative period of cardiac surgery (coronary artery bypass grafting and/or valve surgery), reduces the incidence of atrial fibrillation in patients with high risk for developing this arrhythmia." | 7.74 | Prevention of atrial fibrillation with moderate doses of amiodarone in the postoperative period of cardiac surgery is safe and effective in patients with high risk for developing this arrhythmia. ( Alves, RJ; Brito, Gd; Geovanini, GR; Glauser, VA; Miguel, GA; Nakiri, K, 2007) |
| "This study was designed to compare clinical efficacy of segmental pulmonary vein ablation (SPVI), amiodarone or amiodarone plus losartan on sinus rhythm maintenance in patients with lone paroxysmal atrial fibrillation (PAF)." | 7.74 | [Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study]. ( Chen, YQ; Lan, XB; Ling, ZY; Liu, D; Liu, ZC; Luo, KL; She, Q; Su, L; Wu, JJ; Yang, XY; Yin, YH; Zrenner, B, 2007) |
| "Postoperative atrial fibrillation following cardiothoracic surgery is common and frequently managed with intravenous (IV) amiodarone." | 7.74 | The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations. ( Boyd, SY; Duffy, B; Roth, JE; Rubal, BJ; Slim, AM, 2007) |
| "Amiodarone is recommended for the cardioversion of atrial fibrillation and prevention of paroxysmal atrial fibrillation in patients with structural heart disease, coronary artery disease or left ventricular dysfunction." | 7.74 | Ataxia caused by amiodarone in older people. ( Hindle, JV; Ibrahim, A; Ramaraj, R, 2008) |
| "In the Atrial Fibrillation Follow-up Investigation of Rhythm Management study, preexisting pulmonary disease did not preclude the use of amiodarone." | 7.73 | Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. ( Greene, HL; Kostis, J; Olshansky, B; Rubin, A; Sami, M; Shorofsky, S; Slee, A, 2005) |
| "The factors controlling the preventive effect of long-term amiodarone therapy were evaluated in patients with paroxysmal atrial fibrillation." | 7.73 | [Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles]. ( Horiuchi, D; Komatsu, T; Nakamura, S; Okumura, K; Suzuki, O; Yomogida, K, 2005) |
| "To evaluate the effect of prophylactic amiodarone on length of stay (LOS), postoperative stroke, and postoperative atrial fibrillation (POAF)." | 7.73 | Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gillespie, EL; Ismaili, A; Kardas, M; Kluger, J; Perkerson, KA; Takata, H; White, CM, 2005) |
| "Ibutilide and amiodarone are used for the pharmacological conversion of atrial fibrillation (AF) or flutter (AFl), but their efficacy is rather moderate." | 7.73 | Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. ( Dilaveris, P; Gialafos, E; Giannopoulos, G; Stefanadis, C; Synetos, A, 2005) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 7.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 7.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "Amiodarone has long been the anti-arrhythmic drug of choice for the treatment of atrial fibrillation." | 7.73 | [Amiodarone: treatment or cause of atrial fibrillation?]. ( Allali, G; Falconnet, C, 2005) |
| "To assess the safety and efficacy of amiodarone used after unsuccessful direct current (DC) cardioversion of persistent atrial fibrillation (AF)." | 7.73 | Amiodarone after unsuccessful direct-current cardioversion of persistent atrial fibrillation. ( Jasik, M; Kiliszek, M; Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kapłon, B, 2005) |
| "By exclusion, it was determined that the subepithelial depositions and cystic formations were secondary to an acute amiodarone dosage increase by a new practitioner." | 7.73 | Acute onset of halos and glare: bilateral corneal epithelial edema with cystic eruptions--atypical presentation of amiodarone keratopathy. ( Dovie, JM; Gurwood, AS, 2006) |
| "To determine whether prophylactic amiodarone, dosed according to Atrial Fibrillation Suppression Trial (AFIST) I and II regimens, is a cost-effective strategy for prevention of postoperative atrial fibrillation." | 7.73 | Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gallagher, R; Gillespie, EL; Kluger, J; Rancourt, JA; White, CM, 2006) |
| "Amiodarone is one of the most efficient and safe antiarrhythmic drugs in the treatment of atrial fibrillation (AF)." | 7.73 | "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. ( Bitzen, A; Lewalter, T; Lüderitz, B; Schrickel, JW; Schwab, JO; Yang, A, 2006) |
| "Amiodarone may still be safely prescribed for Chinese patients who have baseline liver dysfunction." | 7.73 | Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. ( Chan, WW; Fung, JW; Ho, SS; Hui, HH; Kum, LC; Sanderson, JE; Wong, GW; Yu, CM, 2006) |
| "Amiodarone prophylaxis (AMP) reduces the prevalence of postoperative atrial fibrillation (POAF) after cardiac surgery." | 7.73 | Risk-stratified evaluation of amiodarone to prevent atrial fibrillation after cardiac surgery. ( Barnes, BJ; Gorton, ME; Grauer, DW; Howard, PA; Kirkland, EA; Kramer, JB; Muehlebach, GF; Reed, WA, 2006) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 7.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "Two patients presented with atrial fibrillation which was refractory to amiodarone but successfully treated with bepridil." | 7.73 | [Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports]. ( Hadano, Y; Iwami, T; Kimura, M; Matsuzaki, M; Miyazaki, Y; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2006) |
| "The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker." | 7.72 | Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. ( Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2003) |
| "The study analyzed the role of different variables that determine long-term sinus rhythm maintenance in patients with persistent atrial fibrillation who are treated with amiodarone." | 7.72 | Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. ( Blanco, MV; Bonato, R; Chiale, PA; Elizari, MV; Galperín, J; Lago, M; Ledesma, R; Molina, RT; Scapín, AO, 2003) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 7.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy." | 7.72 | [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131]. ( Arlot, S; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 7.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "Amiodarone, given as a single intravenous bolus through a peripheral vein rapidly reduced ventricular rate and was well tolerated in patients with atrial fibrillation, even in the presence of congestive heart failure and cardiogenic shock." | 7.72 | Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. ( Hofmann, R; Kammler, J; Kypta, A; Leisch, F; Steinwender, C; Wimmer, G, 2004) |
| "To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed." | 7.71 | Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. ( Heidland, UE; Heintzen, MP; Hennersdorf, MG; Perings, C; Perings, SM; Strauer, BE; Zühlke, C, 2002) |
| "This study evaluated the cost-effectiveness of administering prophylactic intravenous (IV) amiodarone therapy to patients undergoing cardiac surgery according to their predicted risk of postoperative atrial fibrillation." | 7.71 | Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation. ( Mahoney, EM; Thompson, TD; Veledar, E; Weintraub, WS; Williams, J, 2002) |
| "Low-dose amiodarone was safe and effective in restoring and maintaining SR in patients with AF and rheumatic heart disease." | 7.71 | Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone. ( Kapoor, A; Kumar, S; Pandey, CM; Singh, RK; Sinha, N, 2002) |
| "To determine the safety of amiodarone therapy, we conducted a retrospective analysis of elderly patients hospitalized with AMI who experienced atrial fibrillation and had survived to hospital discharge (n = 17,597)." | 7.71 | Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. ( Gersh, BJ; Kilborn, MJ; Oetgen, WJ; Rathore, SS; Solomon, AJ, 2002) |
| "Association of autonomic status and efficacy of therapy with amiodarone was studied in 90 patients with paroxysmal atrial fibrillation of ischemic (n=45, mean age 62 years) and nonischemic (n=45, mean age 38 years) origin." | 7.71 | [Effect of amiodarone on autonomic status and its efficacy in the treatment of different variants of paroxysmal atrial fibrillation]. ( Guseva, IA; Shabalin, AV; Shaposhnikova, IuS, 2002) |
| "To study the efficacy and safety of low-dose amiodarone (AD) for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases." | 7.71 | [Efficacy and safety of low dose amiodarone for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases]. ( Chen, H; Yang, Y, 2001) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 7.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 7.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| "The medical records, including radiographic imaging, pathology and operative reports, of 2 postpubertal boys who had sterile epididymitis after prolonged therapy with amiodarone were reviewed." | 7.70 | Amiodarone induced epididymitis in children. ( Diamond, DA; Hutcheson, J; Peters, CA, 1998) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 7.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "We examined the efficacy and safety of intravenous amiodarone in 20 unselected patients with recent-onset atrial fibrillation who were admitted to a general internal medicine department during a 6-month period." | 7.70 | Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. ( Gur, H; Kreiss, Y; Sidi, Y, 1999) |
| "The cost-effectiveness of amiodarone prophylaxis of atrial fibrillation (AF) in patients undergoing coronary artery bypass grafting (CABG) was determined." | 7.70 | Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. ( Chow, MS; Dunn, A; Freeman-Bosco, L; Reddy, P; Richerson, M; White, CM, 1999) |
| "Among 92 consecutive patients with typical atrial flutter who underwent isthmus ablation 28 patients had atrial flutter without a history of previous atrial fibrillation (group I), 10 patients had atrial flutter following the initiation of amiodarone therapy for paroxysmal atrial fibrillation (group II) and 54 patients had atrial flutter and atrial fibrillation (group III)." | 7.70 | Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. ( Dorwarth, U; Gerth, A; Hoffmann, E; Reithmann, C; Remp, T; Spitzlberger, G; Steinbeck, G, 2000) |
| "Little information exists about the early outcomes of initiating amiodarone for atrial fibrillation in patients with advanced heart failure." | 7.70 | Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. ( Drazner, MH; Stevenson, LW; Stevenson, WG; Weinfeld, MS, 2000) |
| " An 81-year-old man known for paroxysmal atrial fibrillation and chronic renal insufficiency, treated with 6 mg budesonide for collagenous colitis, developed Cushing's syndrome under co-administration of amiodarone." | 7.70 | Cushing's syndrome in an 81-year-old patient treated with budesonide and amiodarone. ( Ahle, GB; Blum, AL; Dorta, G; Martinek, J; Oneta, CM, 2000) |
| "Ninety-one percent of patients with atrial fibrillation (AF) resisting electrical cardioversion because of immediate reinitiation of AF after the shock maintain long-term sinus rhythm with amiodarone and repeat cardioversion." | 7.70 | Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. ( Crijns, HJ; Schoonderwoerd, BA; Van Gelder, IC; Van Noord, T, 2000) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 7.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "A 70-year-old woman suffering from atrial fibrillation was treated with amiodarone, but developed acute respiratory failure necessitating mechanical ventilation for four weeks." | 7.69 | [Respiratory insufficiency due to pulmonary toxicity of amiodarone]. ( Jukema, GJ; Kerkhof, SC; Strack van Schijndel, RJ; ter Maaten, JC, 1995) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 7.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "We describe a case of hepatotoxicity, pancreatitis and inappropriate ADH secretion syndrome developed in a patient receiving chronic amiodarone treatment, not related to other causes." | 7.69 | [Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone]. ( Calvo Elipe, A; Gilsanz Fernández, C; Gorgojo Martínez, JJ; Guerrero Vega, E; Muñoz Ruiz, AI; Vera López, E, 1996) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 7.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "We investigated whether amiodarone delivered into the pericardial sac exerted an effect on atrial and ventricular refractoriness, impulse generation, and conduction and on induced atrial fibrillation." | 7.69 | Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. ( Ayers, GM; Ben-David, J; Besch, HR; Rho, TH; Zipes, DP, 1996) |
| "Amiodarone is effective for long-term maintenance of sinus rhythm after electrical cardioversion of refractory atrial fibrillation or flutter." | 7.69 | Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. ( Crijns, HJ; de Kam, PJ; Gosselink, AT; Lie, KI; Tieleman, RG; van den Berg, MP; van Gelder, IC; van Gilst, WH, 1997) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 7.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| "A case of amiodarone pulmonary toxicity (APT) occurring within days of the start of therapy and presenting with hemoptysis is reported." | 7.69 | Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. ( Goldstein, I; Heller, I; Isakov, A; Segev, D; Topilsky, M, 1997) |
| "To report our experience using high dose oral amiodarone (1,800 mg/day) for the reversion of atrial fibrillation to sinus rhythm in patients submitted to cardiac surgery." | 7.69 | [Use of high-dose oral amiodarone for the reversion of atrial fibrillation during the postoperative period of cardiac surgery]. ( Bodanese, LC; Brauner, FB; Brunini, TM; Guaragna, JC; Linhatti, JL; Martins, V; Pires, RC, 1997) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 7.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone." | 7.68 | Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. ( Essop, MR; Röthlisberger, C; Sareli, P; Skoularigis, J; Skudicky, D; Wisenbaugh, T, 1993) |
| "To compare the efficacy and safety of intravenous (IV) amiodarone and procainamide for the treatment of atrial tachyarrhythmias (AT) in the critically ill." | 7.68 | Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. ( Chapman, MJ; Cunningham, DN; Moran, JL; O'Fathartaigh, MS; Peisach, AR, 1993) |
| "The effectiveness and safety of quinidine in the conversion of chronic atrial fibrillation after administration of amiodarone was assessed in 15 patients." | 7.68 | The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. ( Ansari-Leesar, M; Cohen, A; Faitel, K; Frumin, H; Kerin, NZ; Narala, C, 1993) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Fifty-two consecutive patients with atrial fibrillation underwent 86 episodes of attempted cardioversion with oral amiodarone, intravenous amiodarone or DC cardioversion." | 7.68 | A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. ( Horner, SM, 1992) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 7.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "The safety and efficacy of short intravenous therapy with amiodarone were evaluated in 44 patients (24 males, 20 females), aged 21-84 years, with supraventricular tachyarrhythmias newly arisen in less than 24 hours." | 7.68 | Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. ( Burzio, P; Latini, R; Marchisio, U; Veglio, F; Vietti-Ramus, G, 1992) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 7.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "To shorten the delay in the onset of antiarrhythmic effect when using amiodarone for the conversion of refractory atrial tachyarrhythmias to sinus rhythm, 19 patients were given oral amiodarone according to a high-dose loading protocol." | 7.68 | Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. ( Mostow, ND; Noon, D; Rakita, L; Vrobel, TR, 1990) |
| "Twenty-seven patients with atrial fibrillation without any concomitant conduction abnormality have been treated with oral amiodarone in a daily maintenance dose of 200 mg." | 7.67 | Amiodarone in atrial fibrillation. ( Blomström, P; Edvardsson, N; Olsson, SB, 1984) |
| "Forty patients with atrial fibrillation (AF), 23 patients with ventricular extrasystoles (VES), and 11 patients with various arrhythmias (VA) were treated with amiodarone (0." | 7.67 | Amiodarone--application and clinical pharmacology in atrial fibrillation and other arrhythmias. ( Anastasiou-Nana, M; Levis, GM; Moulopoulos, SD, 1984) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 7.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "The clinical and electrophysiologic effects of oral amiodarone were evaluated in 10 patients with a history of spontaneous atrial fibrillation and a rapid ventricular response, complicating the Wolff-Parkinson-White syndrome." | 7.67 | Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. ( Feld, GK; Klitzner, T; Nademanee, K; Singh, BN; Stevenson, W; Weiss, J, 1988) |
| "We treated a 78-year-old patient with hyperthyroidism and atrial fibrillation with amiodarone 1200 mg/day for 3 days and methimazole 60 mg/day." | 7.67 | Treatment of atrial fibrillation associated with hyperthyroidism by amiodarone and methimazole. ( Cauchie, P; Decaux, G; Unger, J, 1988) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 7.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| "We observed a dangerous increase of ventricular rate following the intravenous administration of amiodarone in a patient with atrial fibrillation and rapid ventricular response associated with the Wolff-Parkinson-White syndrome." | 7.67 | Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. ( Gmeiner, R; Leisch, F; Schützenberger, W, 1987) |
| "In 65 patients a single oral dose of amiodarone (30 mg/kg) produced an antiarrhythmic effect on supraventricular or ventricular arrhythmias within 3 to 8 hours and lasted for 17 to 19 hours." | 7.67 | Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. ( Cheymol, G; Coumel, P; Escoubet, B; Jaillon, P; Lagier, G; Leclercq, JF; Maison-Blanche, P; Menasche, P; Piwnica, A; Poirier, JM, 1985) |
| "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias." | 7.67 | Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. ( Clarke, B; Honey, M; Ward, DE, 1985) |
| "We report two patients who developed symptomatic life-threatening ventricular tachyarrhythmias with changing QRS axes (resembling torsades de pointes), during treatment of their supraventricular tachycardias with oral amiodarone." | 7.67 | Life-threatening ventricular arrhythmias provoked by amiodarone treatment. ( Eydt, J; Kumana, CR; Tanser, P, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 7.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "The efficacy of amiodarone was assessed in 38 patients with atrial fibrillation resistant to quinidine and an effort made to identify factors correlated with amiodarone response." | 7.67 | Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. ( Brady, PM; Brown, R; Greenspan, AM; Horowitz, LN; Kay, HR; Mintz, GS; Morganroth, J; Spielman, SR, 1985) |
| "Amiodarone was administered to 121 patients (82 males, 39 females; average age 59 years) with refractory atrial tachyarrhythmias." | 7.66 | Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. ( Graboys, TB; Lown, B; Podrid, PJ, 1983) |
| "Amiodarone was used in 30 patients with tachyarrhythmias refractory to treatment with several antiarrhythmic agents." | 7.66 | Amiodarone in long term management of refractory cardiac tachyarrhythmias. ( Lowe, JB; Lubbe, WF; Mercer, CJ; Roche, AH, 1981) |
| "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes)." | 7.66 | Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide. ( Benhorin, J; Gottlieb, S; Keren, A; Stern, S; Tzivoni, D, 1982) |
| "Oral amiodarone has been used to treat 21 patients with various supraventricular arrhythmias; 13 had Wolff-Parkinson-White syndrome, which was complicated by atrial fibrillation and re-entry atrioventricular tachycardia in four, and re-entry tachycardia alone in the other nine." | 7.66 | Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. ( Krikler, DM; Rowland, E, 1980) |
| "The effect of amiodarone in the Wolff-Parkinson-White syndrome was studied with programmed electrical stimulation of the heart in 15 patients." | 7.65 | Effect of amiodarone in the Wolff-Parkinson-White syndrome. ( Bär, FW; Dohmen, HJ; Düren, DR; Durrer, D; Lie, KI; Wellens, HJ; Wesdorp, JC, 1976) |
| "Landiolol is a new-generation beta-blocker with fast onset and short half-life." | 7.30 | Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial. ( Besnier, E; Briant, AR; Caspersen, E; Denisenko, A; Descamps, R; Fellahi, JL; Fischer, MO; Gaudard, P; Guinot, PG; Hanouz, JL; Lorne, E; Mahjoub, Y; Mongardon, N; Moussa, MD; Oilleau, JF; Parienti, JJ; Paul, LPS; Rozec, B; Tomadesso, C, 2023) |
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 7.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events." | 7.11 | Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. ( Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022) |
| " The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age." | 7.11 | Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. ( Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP, 2022) |
| "Dronedarone was associated with a statistically significantly lower risk of all-cause death versus sotalol (hazard ratio [HR] = 0." | 7.01 | Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. ( Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP, 2023) |
| "Amiodarone is an antiarrhythmic drug with a significant adverse effect profile, including neurotoxicity." | 7.01 | Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports. ( Dumic, I; Kaur, A; Kaur, P; Khaliq, W; Singh, A; Sinha, A, 2023) |
| "Neiguan point acupuncture combined with amiodarone is superior to amiodarone alone in reducing early recurrences of patients with persistent AF after PVI." | 6.90 | Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation. ( Bao, M; Dong, L; Fu, H; He, B; Huang, C; Huang, H; Liu, H; Liu, X; Liu, Y; Lu, Z; Wu, G; Yang, B; Yang, M; Yin, J; Yu, S; Zhao, Q, 2019) |
| "Amiodarone was discontinued in 18 patients randomized to amiodarone for side effects, bradycardia, or noncompliance." | 6.82 | Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. ( Ad, N; Holmes, SD; Miller, CE; Pritchard, G; Shuman, DJ, 2016) |
| "Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13-19 h)." | 6.80 | A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers. ( Boddy, A; DiMarco, JP; Ellenbogen, KA; Ezekowitz, MD; Geba, GP; Kaszala, K; Koren, A; P, GG, 2015) |
| "Bradycardia was observed less in the study group (76 ± 29) than in the control group (93 ± 18; P < ." | 6.79 | Effectiveness of biatrial epicardial application of amiodarone-releasing adhesive hydrogel to prevent postoperative atrial fibrillation. ( Feng, XD; Wang, W; Wang, XN; Yuan, XH, 2014) |
| "Bepridil was superior to amiodarone in achieving sinus conversion and in maintaining sinus rhythm after cardioversion in patients with persistent AF." | 6.77 | Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial. ( Daida, H; Nakazato, Y; Yamase, M, 2012) |
| "The primary end-point was recurrence of AF." | 6.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "Treatment with bisoprolol resulted in a trend to lower ventricular response rate in AF cases." | 6.74 | Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial. ( Ashoush, R; El Rassi, I; Haddad, F; Hayeck, G; Jebara, V; Madi-Jebara, S; Sleilaty, G; Yazigi, A, 2009) |
| "amiodarone was more effective than biatrial pacing in prevention of post operative AF and we recommend use of this drug in high risk patients." | 6.74 | Biatrial pacing vs. intravenous amiodarone in prevention of atrial fibrillation after coronary artery bypass surgery. ( Akbarzadeh, F; Golmohammadi, A; Kazemi-Arbat, B; Pourafkari, L, 2009) |
| "Amiodarone is a drug frequently used for cardioversion." | 6.73 | Does stopping amiodarone after successfully treating atrial fibrillation occurring after cardiac surgery increase the risk of recurrence? ( Attaran, S; Desai, J; El-Gamel, A; John, L; Sherwood, R, 2008) |
| "Amiodarone was employed as the anti-arrhythmic drug during the first 18 months, and diltiazem in the second half of the study." | 6.73 | Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem. ( Ampollini, L; Bettati, S; Bobbio, A; Caporale, D; Carbognani, P; Internullo, E; Rossini, E; Rusca, M, 2007) |
| "Amiodarone is a potent antiarrhythmic drug." | 6.73 | Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. ( Bassiakos, S; Bassiakou, E; Michalakis, K; Moutzouris, DA; Papadimitriou, L; Vlachos, IS; Xanthos, T, 2007) |
| "Amiodarone was given as 600 mg oral single dose one day before and from days 2 through 7 after surgery." | 6.72 | Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study. ( Budeus, M; Erbel, R; Feindt, P; Felix, O; Gams, E; Hennersdorf, M; Lehmann, N; Perings, C; Perings, S; Reimert, K; Röhlen, S; Sack, S; Schnitzler, S; Wieneke, H, 2006) |
| " Four patients (11%) in group A but none in group B experienced significant adverse effects that necessitated withdrawal of amiodarone." | 6.72 | Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. ( Chang, MH; Chang, TC; Chen, CY; Chou, P; Fu, CY; Jong, GP; Ma, TC; Tien, LY, 2006) |
| "Amiodarone was associated with adverse effects in 46." | 6.71 | A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. ( Bhuripanyo, K; Kangkagate, C; Krittayaphong, R; Pooranawattanakul, S; Punlee, K; Raungrattanaamporn, O; Sriratanasathavorn, C, 2003) |
| "Amiodarone treated patients had a lower incidence of AF (22." | 6.71 | Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). ( Kluger, J; White, CM, 2003) |
| "Amiodarone pre-treatment before electrical DCCV for persistent AF allows chemical conversion in one-fifth of patients without altering the efficacy of subsequent DC conversion." | 6.71 | A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. ( Batin, P; Birchall, A; Brooksby, WP; Channer, KS; Grant, S; Muthusamy, R; Rhoden, WE; Saeed, BT; Steeds, RP; Walters, SJ; West, JN; Wilson, I; Yeo, WW, 2004) |
| "Amiodarone was administered as the third antiarrhythmic agent to patients who had AF recurrence on the first two antiarrhythmic agents (propafenone, sotalol or disopyramide)." | 6.71 | Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study. ( Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kaplon, B, 2005) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 6.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| "If immediate recurrences of AF occurred 2 more times, the alternative study drug was administered, and cardioversion was repeated." | 6.70 | Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. ( Chugh, A; Greenstein, R; Hassan, S; Knight, BP; Lai, SW; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Scharf, C; Strickberger, SA; Tada, H, 2002) |
| "amiodarone treatment or oral digoxin/quinidine treatment in a randomized unblinded single crossover study." | 6.68 | The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. ( Faitel, K; Kerin, NZ; Naini, M, 1996) |
| " Consecutive patients were treated with P replacing previous therapy with amiodarone (A) withdrawn on account of adverse side effects occurring on average after 1." | 6.67 | [Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects]. ( Foscoli, M; Giofrè, R; Labriola, E; Lolli, C; Tarquinii, M; Toschi, GP, 1993) |
| "0005) regarding total digoxine dosage and length of treatment." | 6.65 | [Short-term therapy of atrial fibrillation with an association of digitalis and amiodarone (author's transl)]. ( Bueno, J; del Río, A; Ferreira, JI; Ramos, F; Ruiz, C, 1980) |
| "Dronedarone, a derivative of amiodarone with structural modifications, was designed to have similar electrophysiological properties with a less toxic profile." | 6.55 | Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation. ( Aronow, WS; Khan, MH; Rochlani, Y, 2017) |
| "Dronedarone was found to have divergent safety profiles in randomized controlled trials (RCT) in term of cardiac death and overall mortality." | 6.55 | Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. ( Biffi, M; Boriani, G; Diemberger, I; Lorenzetti, S; Martignani, C; Massaro, G; Reggiani, MLB; Ziacchi, M, 2017) |
| "Dronedarone is a non-iodinated benzofuran derivative with antiarrhythmic properties." | 6.50 | An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. ( Connolly, SJ; Halperin, JL; Hohnloser, SH; John Camm, A; Radzik, D, 2014) |
| "Dronedarone is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added." | 6.50 | The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. ( Kowey, PR; Naccarelli, GV, 2014) |
| "Dronedarone is a recent antiarrhythmic drug that has been developed for treatment of AF, with electrophysiological properties similar to amiodarone but with a lower incidence of side effects." | 6.50 | Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation. ( Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C, 2014) |
| "Dronedarone has been evaluated in several large clinical trials, which have shown reduced mortality and hospitalization rates in patients with non-permanent AF." | 6.49 | Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. ( Adlan, AM; Lip, GY, 2013) |
| "Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter." | 6.48 | Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. ( Fischer, GW; Trigo, P, 2012) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 6.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Dronedarone is a new anti-arrhythmic drug that has been developed to provide rhythm and rate control in AF patients with fewer side effects compared with amiodarone." | 6.47 | Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. ( Becker, R; Katus, HA; Schweizer, PA; Thomas, D, 2011) |
| "Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by Swissmedic for management of patients with atrial fibrillation or atrial flutter." | 6.47 | Dronedarone for the management of atrial fibrillation. ( Brenner, R; Delacrétaz, E, 2011) |
| "Dronedarone is a new benzofuran derivative that has been developed as an antiarrhythmic agent on the basis of the amiodarone molecular structure with the intent of maintaining the same pharmacological effects while reducing thyroid and pulmonary toxicity." | 6.47 | Dronedarone for atrial fibrillation therapy. ( Lombardi, F; Marzocchi, M, 2011) |
| "Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events." | 6.47 | The management of patients with atrial fibrillation and dronedarone's place in therapy. ( Boiangiu, C; Cohen, M, 2011) |
| "Dronedarone is a benzofuran derivative; specifically N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methane-sulfonamide and its production process has been patented." | 6.46 | Dronedarone--a new alternative for management of atrial fibrillation. ( Garg, RK; Hundal, M, 2010) |
| "Dronedarone has been recently approved for clinical use by the Food and Drug Administration and by the European Medicines Agency." | 6.46 | Dronedarone: an emerging therapy for atrial fibrillation. ( Rosei, EA; Salvetti, M, 2010) |
| "Diagnosis of thyrotoxicosis is easy, based on the finding of increased free thyroid hormone concentrations and suppressed TSH levels." | 6.46 | Approach to the patient with amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Martino, E, 2010) |
| "Dronedarone is an amiodarone analogue without iodine moiety in its structure, and is similar to amiodarone with regard to its structural and electrophysiological properties." | 6.45 | Dronedarone: a promising alternative for the management of atrial fibrillation. ( Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB, 2009) |
| "Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile." | 6.45 | Dronedarone for atrial fibrillation: a new therapeutic agent. ( Arora, BL; Arora, RR; Bhuriya, R; Patel, DD; Patel, PD; Singh, PP, 2009) |
| "Dronedarone." | 6.44 | Dronedarone: a new treatment for atrial fibrillation. ( Kowey, PR; Laughlin, JC, 2008) |
| "Amiodarone is an iodinated compound, and the possibility that its molecule may be modified with or without elimination of the iodine is being tested." | 6.44 | Amiodarone as paradigm for developing new drugs for atrial fibrillation. ( Singh, BN, 2008) |
| " Inconsistent prescribing practices, variable dosage regimens, and a lack of consensus regarding the appropriate use of amiodarone prompted the need for developing practice guidelines." | 6.44 | Amiodarone for atrial fibrillation following cardiac surgery: development of clinical practice guidelines at a university hospital. ( Khanderia, U; Prager, R; Wagner, D; Walker, PC; Woodcock, B, 2008) |
| "Amiodarone and early CVN was more effective than nonamiodarone therapies with regard to restoring NSR for patients in whom AF developed after elective CABG." | 6.43 | Selective use of amiodarone and early cardioversion for postoperative atrial fibrillation. ( Holmes, EC; Samuels, FL; Samuels, LE, 2005) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 6.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "Amiodarone has a lower incidence of proarrhythmia and heart failure exacerbation compared with class I drugs." | 6.38 | Low-dose amiodarone for atrial fibrillation: time for a prospective study? ( Middlekauff, HR; Saxon, LA; Stevenson, WG; Wiener, I, 1992) |
| "Although the use of amiodarone for the treatment of atrial fibrillation has increased, reports of its use for the restoration of sinus rhythm have been conflicting." | 6.20 | Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation. ( Kochiadakis, GE; Vardas, PE, 2003) |
| "Although amiodarone is the most effective antiarrhythmic agent for maintaining sinus rhythm in patients with atrial fibrillation, it is generally used as the drug of the last resort in the United States." | 6.17 | Low-dose amiodarone should not be the first-line treatment for atrial fibrillation. ( Sung, RJ, 1994) |
| "Amiodarone has superior efficacy relative to other AADs." | 5.91 | Relationship between amiodarone response prior to ablation and 1-year outcomes of catheter ablation for atrial fibrillation. ( Akhtar, T; Berger, R; Brilliant, J; Calkins, H; Marine, J; Milstein, J; Sampognaro, JR; Spragg, D; Yadav, R, 2023) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 5.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 5.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo." | 5.69 | Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. ( Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M, 2023) |
| "51 ± 38." | 5.62 | Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone. ( Celik, A; Eyuboglu, M, 2021) |
| " This study aims to summarize the randomized controlled trials (RCTs) of amiodarone combined with beta blockers to maintain sinus rhythm in AF, and to determine an effective and safe intervention for the prevention of AF recurrence through network meta-analysis (NMA)." | 5.56 | The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis. ( Hu, Y; Jia, Q; Shi, J; Shi, S; Yuan, G, 2020) |
| "In this double-blind, placebo-controlled trial, patients at high risk of postoperative atrial fibrillation scheduled to undergo major thoracic surgery were randomized to N-acetylcysteine plus amiodarone or placebo plus amiodarone." | 5.51 | Amiodarone with or without N-Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial. ( Amar, D; Chung, MK; Desiderio, D; Fischer, GW; Isbell, JM; Jones, DR; Meyers, BF; Milne, GL; Molena, D; Park, BJ; Pedoto, A; Roistacher, N; Rusch, VW; Tan, KS; Zhang, H, 2022) |
| "This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes." | 5.51 | Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. ( Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M, 2022) |
| "Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL)." | 5.51 | Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial. ( Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J, 2022) |
| "However, late recurrences are more common compared to paroxAF." | 5.51 | Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy. ( Benák, A; Bencsik, G; Herczeg, A; Kohári, M; Makai, A; Pap, R; Sághy, L, 2019) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 5.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| "Amiodarone is an effective medication for AF but has limited clinical utility because of off-target tissue toxicity." | 5.48 | Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation. ( Bhatia, NK; Campbell, PF; Cesar, L; Deppen, JN; García, AJ; Garcia, JR; Kumar, G; Langberg, JJ; Levit, RD; Robinson, B; Schneider, F; Shin, EY; Wang, L; Xu, K, 2018) |
| "Aripiprazole is an atypical antipsychotic drug with a polypharmacological mechanism of action and a favorable tolerability profile." | 5.48 | Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. ( Anastasia, A; D'Urso, G; de Bartolomeis, A; Patti, S; Toscano, E, 2018) |
| "Dronedarone has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs." | 5.46 | Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation. ( Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S, 2017) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 5.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 5.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Dronedarone is a benzofuran derivative of amiodarone newly approved in 2009 for the treatment of AF." | 5.40 | Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation. ( Kim, J; Lee, EJ, 2014) |
| " However, the use of RAI in euthyroid patients requiring chronic administration of amiodarone (AM) where other antiarrhythmic drugs may lack efficacy is still controversial." | 5.40 | Results of preventive radioiodine therapy in euthyroid patients with history of hyperthyroidism prior to administration of amiodarone with permanent atrial fibrillation--a preliminary study. ( Czarnywojtek, A; Czepczyński, R; Królicki, L; Kwiecińska, B; Miechowicz, I; Płazińska, MT; Ruchała, M; Woliński, K; Zgorzalewicz-Stachowiak, M, 2014) |
| "Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s." | 5.38 | A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012) |
| "Amiodarone is a highly effective antiarrhythmic drug." | 5.37 | Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema. ( Bolognese, L; Brandini, R; Caremani, M; Fabiani, I; Grotti, S; Salvadori, C; Tacconi, D, 2011) |
| " No difference was found in the risk of adverse events between the 2 therapies." | 5.37 | Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. ( Miles, RH; Murdock, DK; Passman, R, 2011) |
| " Adverse events (AEs) associated with AADs may influence patient compliance and compromise the management of atrial fibrillation (AF)." | 5.37 | One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. ( Jhaveri, M; Kim, MH; Klingman, D; Lin, J; Smith, PJ, 2011) |
| "When landiolol was administered, enough attention should be paid to the patients whose left ventricular function was low." | 5.36 | [Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?]. ( Abe, T; Fukuda, T; Haruna, T; Inoko, M; Ito, H; Miyamoto, S; Nakane, E; Nohara, R; Sasaki, K; Uehara, K; Ueyama, K, 2010) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 5.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| "Dronedarone will cause a small increase in creatinine concentrations, without a change in glomerular filtration rate (GFR)." | 5.36 | Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ( Dorian, P, 2010) |
| "Amiodarone is a last resort, mainly because of its numerous adverse effects." | 5.36 | Dronedarone. atrial fibrillation: too many questions about long-term adverse effects. ( , 2010) |
| "Dronedarone is a new antiarrhythmic drug that may offer advantages for rhythm control, given its relative safety (although not in patients with decompensated heart failure), efficacy and tolerability." | 5.36 | Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study. ( Lip, GY; Pamukcu, B, 2010) |
| "Amiodarone is a highly effective antiarrhythmic agent used in life-threatening ventricular and supraventricular arrhythmias." | 5.35 | Amiodarone induced pneumonitis and hyperthyroidism: case report. ( Ambroziak, U; Bareła, AD; Chazan, R; Grabczak, EM; Opuchlik, A; Potulska, A; Wiwała, J; Zielonka, TM, 2008) |
| "Amiodarone does not cause elevation of GSTA1-1 as a marker of subclinical liver injury in haemodynamically stable intensive care unit patients with atrial fibrillation." | 5.35 | No elevation of glutathione S-transferase-a1-1 by amiodarone loading in intensive care unit patients with atrial fibrillation. ( Hilkens, M; Peters, WH; Pickkers, P; van der Hoeven, JG, 2009) |
| "The ARTEMIS atrial fibrillation (AF) Loading and Long-term studies evaluated switching patients with paroxysmal/persistent AF from amiodarone to dronedarone." | 5.34 | Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. ( Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J, 2020) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 5.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "The objective of this study was to assess the safety and efficacy of local epicardial application of amiodarone-releasing hydrogel for prevention of postoperative atrial fibrillation (POAF) in patients after coronary artery bypass grafting." | 5.34 | Epicardial Application of Hydrogel with Amiodarone for Prevention of Postoperative Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting. ( Bockeria, LA; Bockeria, OL; Kanametov, TN; Sanakoev, MK; Shvartz, VA; Sokolskaya, MA; Zhuginisov, DS, 2020) |
| "amiodarone treatment protocol for horses." | 5.34 | Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation. ( Baert, K; Croubels, S; De Backer, P; De Clercq, D; Deprez, P; Tavernier, R; van Loon, G, 2007) |
| "Amiodarone is effective in treating persistent atrial fibrillation compared with other antiarrhythmic drugs." | 5.33 | Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. ( Ashikaga, K; Furukawa, K; Iwasa, A; Kimura, M; Kobayashi, T; Motomura, S; Okumura, K; Owada, S; Sasaki, S, 2006) |
| "Amiodarone is a class III antiarrhythmic agent that is effective in treating different types of cardiac dysrhythmias." | 5.31 | Bone marrow granulomas possibly associated with amiodarone. ( McIntyre, WW; Ranelli, PL; Sun, TJ; Yamreudeewong, W, 2000) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 5.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| " The required dosage of amiodarone was lower in the D + AM group than in the AM group (603 +/- 563 mg versus 1058 +/- 680 mg, p = 0." | 5.31 | Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. ( Anastasiou-Nana, MI; Kontoyannis, DA; Kontoyannis, SA; Nanas, JN; Zaga, AK, 2001) |
| "The Short-term AMIOdarone treatment after CATheter ablation for atrial fibrillation (AMIO-CAT) trial randomized patients to 8 weeks of oral amiodarone or placebo following AF ablation." | 5.30 | QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Hansen, J; Johannessen, A; Pehrson, S; Svendsen, JH, 2019) |
| "Adjunctive short-term amiodarone therapy improves the success rate after catheter ablation of persistent atrial fibrillation during long-term follow-up." | 5.27 | Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. ( Gramley, F; Kettering, K, 2018) |
| "Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF)." | 5.27 | Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients. ( Aidonidis, I; Dipla, K; Hatziefthimiou, A; Hevas, A; Simopoulos, V; Skoularigis, I; Tsilimingas, N, 2018) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Thus, the safety of amiodarone in the WPW syndrome should be established by electrophysiologic studies and induction of AF, because amiodarone is not protective in all patients with WPW." | 5.27 | Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. ( Fromer, MA; Kappenberger, LJ; Shenasa, M; Steinbrunn, W, 1984) |
| "During AF in WPW syndrome, the ventricular rate is related to the duration of the anterograde refractory period of the accessory pathway." | 5.27 | Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome. ( Abdollah, H; Brugada, P; Wellens, HJ, 1983) |
| "amiodarone was administered (repeated boluses of 3 mg/kg in 3 min, or 30 min-infusions of 5 to 7." | 5.27 | Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. ( Faniel, R; Schoenfeld, P, 1983) |
| "Amiodarone was used in the treatment of 21 patients with supraventricular or ventricular arrhythmias which were refractory to conventional antiarrhythmic drugs, individually or in combination." | 5.27 | Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. ( Best, JF; Dunn, M; Lynch, L; Rinkenberger, R, 1986) |
| "Amiodarone i." | 5.26 | [Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias]. ( Bianchi, C; Bonifazi, C; Coppetti, S; Distante, S; Ferrari, O; Ricevuti, A; Rinaldo, R; Rizzi, M; Tavecchi, L; Zampaglione, G; Ziletti, G, 1981) |
| "Pharmacological treatment during ablation of persistent atrial fibrillation (AF) is common, but utility of irrigated catheter application of amiodarone during ablation of persistent AF remains unclear." | 5.24 | Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation. ( Chen, Y; He, L; Huang, X; Huang, Y; Liu, S; Peng, J; Shee, V; Xu, D; Zhao, H, 2017) |
| "Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm." | 5.24 | Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy. ( Aidonidis, I; Daskalopoulou, SS; Giamouzis, G; Hatziefthimiou, A; Skoularigis, I; Triposkiadis, F; Tsanaxidis, N, 2017) |
| "Our study provides evidence confirming the protective role of amiodarone, b-blockers, atrial pacing and posterior pericardiotomy against POAF as well as highlights the risk of untreated hypertension." | 5.22 | Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses. ( Aggeli, C; Alfredsson, J; Charitakis, E; Charitos, EI; Dragioti, E; Foukarakis, E; Karlsson, LO; Korela, D; Stratinaki, M; Tsartsalis, D; Tsioufis, C; Vanky, F; Walfridsson, H, 2022) |
| "Prophylactic topical application of amiodarone may be effective and safe for preventing post-operative new-onset atrial fibrillation." | 5.22 | Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence. ( Baranchuk, A; Chen, X; El-Diasty, M; Fernandez, AL; Ross-White, A; Sartor, C; Zhang, S, 2022) |
| "Epicardial application of amiodarone-releasing adhesive hydrogel is a less-invasive, well-tolerated, quick, and effective therapeutic option for preventing postoperative atrial fibrillation with minimal risk of extracardiac adverse side effects." | 5.22 | Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation. ( Feng, XD; Mei, YQ; Wang, W; Yuan, XH, 2016) |
| "Whether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with heart failure is unknown." | 5.22 | Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. ( Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Haissaguerre, M; Hao, S; Hongo, R; Horton, R; Jais, P; Lakkireddy, D; Mohanty, P; Mohanty, S; Narducci, ML; Natale, A; Neuzil, P; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, J; Santangeli, P; Schweikert, R; Themistoclakis, S; Tondo, C; Trivedi, C, 2016) |
| "We aimed to evaluate the impact of 8weeks of amiodarone treatment on thyroid function in patients with atrial fibrillation (AF) undergoing catheter ablation in a randomised, double-blind clinical trial." | 5.22 | Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Feldt-Rasmussen, U; Hansen, J; Johannesen, A; Pehrson, S; Svendsen, JH, 2016) |
| "The impact of amiodarone on ablation outcome in longstanding persistent atrial fibrillation (LSPAF) patients is not known yet." | 5.20 | Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). ( Al-Ahmad, A; Bai, R; Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Gallinghouse, JG; Hongo, R; Horton, R; Hranitzky, PM; Lakkireddy, D; Mohanty, P; Mohanty, S; Natale, A; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, JE; Santangeli, P; Themistoclakis, S; Tondo, C; Trivedi, C; Zagrodzky, J, 2015) |
| "The multichannel blocker dronedarone is currently indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF), with careful monitoring of cardiac, hepatic and renal function." | 5.20 | One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care. ( Benninger, G; Bosch, RF; Goette, A; Paar, WD; Pittrow, D; von Stritzky, B, 2015) |
| "In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE)." | 5.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "This study examined the influence of preoperative administration of amiodarone and metoprolol in preventing postoperative atrial fibrillation (AF) after coronary artery bypass grafting (CABG) surgery." | 5.20 | Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation: After Coronary Bypass Surgery? ( Erkut, B; Onk, OA, 2015) |
| " We investigated its ability to shorten the time to conversion of postoperative atrial fibrillation (POAF) when added to amiodarone after coronary artery bypass graft (CABG) surgery." | 5.19 | Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. ( Aidonidis, I; Chryssagis, K; Daskalopoulos, ME; Daskalopoulou, SS; Lenos, A; Molyvdas, PA; Simopoulos, V; Skoularingis, I; Tagarakis, GI; Tsilimingas, NB, 2014) |
| "Our aim was to estimate the costs and health benefits of routinely administered postoperative amiodarone as a prophylactic agent in reducing the risk of atrial fibrillation in patients undergoing surgery for lung cancer." | 5.19 | Amiodarone is a cost-neutral way of preventing atrial fibrillation after surgery for lung cancer. ( Christensen, TD; Pilegaard, HK; Riber, LP, 2014) |
| " 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF." | 5.19 | Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. ( Bonato, R; Chiale, PA; Elizari, MV; Galperin, J; Lago, M; Ledesma, R; Piasentin, J; Sanchez, J; Spada, P; Vazquez Blanco, M, 2014) |
| "Amiodarone is used commonly for pharmacological cardioversion of atrial fibrillation (AF), but it is limited by moderate efficacy and delayed action." | 5.19 | Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. ( Fragakis, N; Katritsis, D; Koskinas, KC; Skeberis, V; Vassilikos, V, 2014) |
| "Patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial (N = 14,264) were stratified by AAD use at baseline: amiodarone, other AAD, or no AAD." | 5.19 | Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Passman, R; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA, 2014) |
| "Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF)." | 5.19 | Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. ( Al-Khatib, SM; Allen-LaPointe, N; Anstrom, KJ; Daubert, JP; DeWald, T; Horton, JR; Lokhnygina, Y; Peterson, ED; Piccini, JP; Shaw, LK; Steinberg, BA; Thomas, K; Wojdyla, DM, 2014) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 5.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction." | 5.19 | Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014) |
| "Short-term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of atrial tachyarrhythmias at the 6-month follow-up, but it more than halved atrial arrhythmia related hospitalization and cardioversion rates during the blanking period." | 5.19 | Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). ( Chen, X; Darkner, S; Hansen, J; Johannessen, A; Nielsen, JB; Pehrson, S; Svendsen, JH, 2014) |
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 5.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "In PALLAS, there was a strong effect of concurrent digoxin use on the adverse effect of dronedarone on cardiovascular death, but not on occurrence of heart failure." | 5.19 | Interaction between digoxin and dronedarone in the PALLAS trial. ( Camm, AJ; Connolly, SJ; Gao, P; Halperin, JL; Hohnloser, SH; Radzik, D, 2014) |
| "The ATHENA trial randomized 4628 patients with atrial fibrillation (AF) or atrial flutter, aged ≥ 70 years with risk factors or ≥ 75 years without risk factors, to receive 400 mg dronedarone twice daily or placebo in addition to standard therapy." | 5.17 | Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial. ( Berg, J; Connolly, S; Lindgren, P; Sauriol, L, 2013) |
| "In a matched-cohort design, 18 patients taking amiodarone before atrial fibrillation (AF) ablation (amiodarone group) were matched for age, sex and type of AF with 18 patients who had undergone AF ablation without taking amiodarone (no-amiodarone group)." | 5.17 | Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation. ( Chen, PS; Joung, B; Lee, MH; Lin, SF; Mun, HS; Pak, HN; Shen, C, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop long after amiodarone withdrawal." | 5.17 | Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Tanaka, Y; Yagishita, A, 2013) |
| "The patients in the amiodarone prophylaxis group had a reduction in the risk of atrial fibrillation of 23% (12 to 31); number needed to treat was 4." | 5.16 | Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. ( Christensen, TD; Hoejsgaard, A; Jensen, HK; Pilegaard, HK; Riber, LP, 2012) |
| "To report our experience using single high dose oral amiodarone for the cardioversion of recent onset atrial fibrillation to sinus rhythm in patient presenting with symptoms within 48 h." | 5.16 | Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation. ( Nadarasa, K; Williams, MJ, 2012) |
| "Ranolazine, an antianginal agent with antiarrhythmic properties, prevents atrial fibrillation (AF) in patients with acute coronary syndrome." | 5.16 | Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. ( Fragakis, N; Geleris, P; Katritsis, DG; Koskinas, KC; Pagourelias, ED; Zografos, T, 2012) |
| "Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter." | 5.16 | Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. ( Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M, 2012) |
| "This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF)." | 5.15 | A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. ( Beatch, G; Camm, AJ; Capucci, A; Hohnloser, SH; Mangal, B; Torp-Pedersen, C; Van Gelder, IC, 2011) |
| "Dronedarone has been shown to reduce cardiovascular hospitalizations or death in patients with atrial fibrillation (AF) and additional risk factors." | 5.15 | Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. ( Connolly, SJ; Duray, GZ; Hohnloser, SH; Torp-Pedersen, C, 2011) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 5.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| " The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone." | 5.15 | Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C, 2011) |
| "We conducted a randomized, double-blind, placebo-controlled, parallel-arm trial in patients with persistent atrial fibrillation, with at least 1 relapse after cardioversion, and treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor." | 5.15 | n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. ( Campia, U; Cesana, BM; Dei Cas, L; Gheorghiade, M; Manerba, A; Milesi, G; Nodari, S; Triggiani, M, 2011) |
| "In this study, we randomly compared single oral doses of flecainide, amiodarone and propafenone versus placebo for the conversion of recent atrial fibrillation (AF) (within 48 hours)." | 5.15 | Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs. ( Balla, I; Kondili, A; Petrela, E, 2011) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 5.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation." | 5.14 | Effect of dronedarone on cardiovascular events in atrial fibrillation. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization." | 5.14 | Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. ( Lam, KF; Lau, CP; Lee, WL; Siu, CW; Tse, HF, 2009) |
| "Amiodarone is effective in preventing atrial fibrillation (AF)." | 5.14 | Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion. ( Kanic, V; Naji, F; Sabovic, M; Suran, D; Vokac, D, 2009) |
| "To compare the efficacy of combined amiodarone and irbesartan use versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation (AF) post valve replacement and cardioversion." | 5.14 | [Comparison of amiodarone plus irbesartan regimen versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation post valve replacement and cardioversion]. ( Chen, LJ; Deng, XJ; Ding, P; Li, L; Yuan, YQ; Zhang, H, 2009) |
| " Overall atrial fibrillation occurred more frequently in the perioperative intravenous amiodarone group compared with the placebo group (59." | 5.14 | Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery. ( Beaulieu, Y; Carrier, M; Couture, P; Denault, AY; Lambert, J; Levesque, S; O'Meara, E; Pagé, P; Roy, D; Talajic, M; Tardif, JC, 2010) |
| "Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy." | 5.14 | A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. ( Hammoud, ZT; Kesler, KA; Rieger, KM; Tisdale, JE; Wall, DS; Wroblewski, HA; Young, JV, 2010) |
| "We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF)." | 5.14 | A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. ( Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J, 2010) |
| "Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF)." | 5.14 | Dronedarone in patients with congestive heart failure: insights from ATHENA. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2010) |
| "Patients received intravenous flecainide, propafenone, or amiodarone on presentation and a second dose after 6 hours if atrial fibrillation persisted." | 5.14 | Management of patients with acute atrial fibrillation in the ED. ( Abbate, R; Conti, A; Del Taglia, B; Gensini, GF; Grifoni, S; Mariannini, Y; Michelucci, A; Padeletti, L; Pepe, G; Vanni, S, 2010) |
| "The intraoperative use of amiodarone in patients with atrial fibrillation (AF) undergoing valvular heart surgery was unclear." | 5.14 | The effect of amiodarone on cardiac rhythm after cardiopulmonary bypass in patients with atrial fibrillation. ( Jie, S; Xiaohu, L; Xiaoyang, T; Yanning, Q; Yu, C; Zhengnian, D, 2010) |
| "To evaluate the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate in patients with atrial fibrillation (AF) during anesthesia period." | 5.14 | [A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period]. ( Shen, SL; Zhao, YC, 2010) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 5.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "The purpose of this study was to examine the relationship between long-term efficacy of amiodarone therapy (100-200 mg/day) combined with angiotensin converting enzyme inhibitor (ACEI; enalapril 5 mg/day) administration, and the development of structural atrial remodeling in patients with paroxysmal atrial fibrillation (AF)." | 5.13 | Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. ( Komatsu, T; Kunugida, F; Nakamura, M; Orii, M; Ozawa, M; Sato, Y; Tachibana, H, 2008) |
| "Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF." | 5.13 | Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. ( Alings, A; Davy, JM; Herold, M; Hoglund, C; Radzik, D; Timmermans, A; Van Kempen, L, 2008) |
| "To investigate the effect of combination of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation." | 5.13 | [Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation]. ( Cao, DJ; Mu, CY; Tang, RB; Tong, F, 2008) |
| "Amiodarone effectively suppresses atrial fibrillation but causes many adverse events." | 5.13 | Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. ( Ahmed, S; Bosker, HA; Crijns, HJ; Hillege, HL; Links, TP; Lok, DJ; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ; Wiesfeld, AC, 2008) |
| "The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) is the largest single antiarrhythmic drug trial ever conducted." | 5.13 | Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria ( Connolly, SJ; Crijns, HJ; Hohnloser, SH; Page, RL; Seiz, W; Torp-Petersen, C, 2008) |
| "In the AFIST III (Atrial Fibrillation Suppressions Trial III), anterior fat pad (AFP) retention did not decrease the incidence of postoperative atrial fibrillation (POAF), but prophylaxis with amiodarone did." | 5.13 | Impact of amiodarone on the ability of anterior fat pad retention to prevent postcoronary arterial bypass grafting atrial fibrillation incidence: a substudy of the AFIST III (Atrial Fibrillation Suppression Trial III). ( Coleman, CI; Dale, K; Gallagher, R; Henyan, N; Kluger, J; Reinhart, K; Sander, S; White, CM, 2008) |
| "The purpose of this study was to estimate the costs and health benefits of routinely administered postoperative amiodarone as prevention of atrial fibrillation for patients undergoing coronary artery bypass grafting (CABG) for stable angina." | 5.13 | Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery. ( Christensen, TD; Hjortdal, VE; Kristiansen, IS; Zebis, LR, 2008) |
| "A total of 55 patients with AF and/or CHF (New York Heart Association functional class > or =III) who had ICDs were divided into 3 groups [amiodarone (n=24), sotalol (n=12), beta-blocker (n=19)] and the cumulative rates of inappropriate shocks were compared." | 5.13 | Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. ( Choi, KJ; Kim, HY; Kim, J; Kim, YH; Lee, CH; Nam, GB; Park, HG; Park, KM, 2008) |
| "Amiodarone, given as intravenous bolus has not yet been studied in patients with atrial fibrillation and a high ventricular rate." | 5.12 | Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. ( Hofmann, R; Kammler, J; Kypta, A; Leisch, F; Steinwender, C, 2006) |
| "A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation." | 5.12 | Circumferential pulmonary-vein ablation for chronic atrial fibrillation. ( Agricola, E; Augello, G; Bates, ER; Bogun, F; Chugh, A; Good, E; Lehmann, MH; Morady, F; Oral, H; Pappone, C; Pelosi, F; Sala, S; Santinelli, V; Vicedomini, G, 2006) |
| "To evaluate the effects and adverse reactions of amiodarone and sotalol in treatment of atrial fibrillation." | 5.12 | [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study]. ( Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006) |
| "The purpose of the present study was to evaluate the clinical efficacy of perindopril or losartan in combination with low-dose amiodarone on maintenance of sinus rhythm in patients with idiopathic paroxysmal atrial fibrillation (PAF)." | 5.12 | [Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation]. ( Dai, Y; Lan, XB; Ling, ZY; Liu, ZC; Luo, KL; Su, L; Wu, JJ; Yang, XY; Yin, YH, 2006) |
| "The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF." | 5.12 | Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. ( Dai, Y; Dalal, D; Dong, J; Lan, X; Ling, Z; Liu, D; Liu, Z; Luo, K; She, Q; Su, L; Woo, K; Wu, J; Yin, Y, 2006) |
| "To observe the clinical effect of the combined use of amiodarone and Wenxin Granule (WXG) in auricular fibrillation (AF) conversion and its safety." | 5.12 | [Clinical observation on effect and safety of combined use of wenxin granule and amiodarone for conversion of auricular fibrillation]. ( Huang, SE; Wang, M; Yu, YB, 2006) |
| "To investigate the curative effects of irbesartan, amiodarone and Wenxin Granule (WG), applied alone or in combination, on sinus rhythm maintenance in patients with auricular fibrillation (AF) after conversion." | 5.12 | [Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion]. ( Shen, SH; Xie, PY, 2006) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 5.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "To investigate whether oral amiodarone administered before surgery for a short period in high dose would reduce the incidence of postoperative atrial fibrillation or atrial flutter and reduces the length of hospital stay." | 5.12 | High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter. ( Alcalde, RV; Bodanese, LC; Castro, I; Feier, F; Goldani, MA; Guaragna, JC; Noer, R; Petracco, JB; Sussenbach, E, 2006) |
| "Aim of the study was to investigate mechanisms of amiodarone action on atrial and ventricular rhythm during persistent atrial fibrillation (PAF), and to assess efficacy of amiodarone as monotherapy or in combination with digoxin." | 5.12 | [On the possibility of amiodarone use in some cases of persistent atrial fibrillation]. ( Blagova, OV; Nedostup, AV, 2006) |
| "The patients in amiodarone prophylaxis experienced a reduction in risk of atrial fibrillation of 14% (95% confidence interval [CI], 5." | 5.12 | Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. ( Christensen, TD; Folkersen, L; Hjortdal, VE; Mikkelsen, MM; Sørensen, HT; Thomsen, HF; Zebis, LR, 2007) |
| "Postoperative intravenous amiodarone prophylaxis followed by oral amiodarone significantly reduces the incidence of atrial fibrillation after off-pump coronary artery bypass grafting and the ventricular rate during atrial fibrillation." | 5.12 | Intravenous and oral amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass surgery. ( Ata, Y; Ozkan, H; Ozyazicioglu, A; Turk, T; Vural, H; Yavuz, S, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We conducted a prospective clinical trial of 111 consecutive patients admitted to our ICU after cardiac surgery (basically, coronary artery bypass graft and/or valve surgery) and who received short-term prophylactic amiodarone treatment if they were considered at high risk of developing atrial fibrillation." | 5.12 | Is short-term amiodarone use post cardiac surgery a cause of acute respiratory failure? ( Carrió, ML; Castells, E; Farrero, E; Fortià, C; Javierre, C; Ricart, A; Rodríguez, D; Ventura, JL, 2007) |
| "Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects." | 5.12 | Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. ( Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN, 2007) |
| "This is a substudy of a prospective randomized controlled trial (SAFE-Trial) in which amiodarone, sotalol, and placebo for persistent atrial fibrillation were evaluated." | 5.12 | Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. ( Batcher, EL; Hershman, JM; Reda, DJ; Singh, BN; Singh, SN; Tang, XC, 2007) |
| "The QT/RR relationship was obtained in 45 subjects without heart disease (20 men, 25 women); 20 were taken as controls, and 30 were under antiarrhythmic prophylaxis for lone atrial fibrillation (15 with amiodarone, 15 with flecainide)." | 5.12 | Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide. ( Facchini, M; Malfatto, G; Zaza, A, 2007) |
| "Determination of neurophysiological features of the disease course in patients with paroxysmal atrial fibrillation (AF); pathogenetic validation of use and assessment of therapeutic efficacy of clonazepam (an atypical agonist of benzodiazepine receptors) in combined antiarrhythmic therapy." | 5.12 | [New facts about pathogenesis of atrial fibrillation: correlation between changes in bioelectric brain activity and recurrence of atrial fibrillation paroxysms]. ( Fedorova, VI; Gordeev, SA; Nedostup, AV; Vasiukov, SS, 2007) |
| "Amiodarone and sotalol are commonly used for the maintenance of sinus rhythm, but the efficacy of these agents administered as high-dose infusions for rapid conversion of atrial fibrillation is unknown." | 5.11 | Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. ( Cooper, MJ; Crampton, R; Eipper, V; Guy, D; Kijvanit, P; Ross, DL; Thomas, SP; Wallace, E, 2004) |
| "To compare the efficacy and safety of amiodarone and propafenone when used for the prevention of atrial fibrillation (AF) and maintenance of normal sinus rhythm in patients with refractory AF." | 5.11 | Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. ( Hamilos, MI; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE; Zacharis, EA, 2004) |
| "This was a substudy of a clinical trial evaluating the efficacy of an amiodarone regimen or an atrial-septal pacing strategy on the occurrence of postoperative atrial fibrillation." | 5.11 | Indicators of atrial fibrillation risk in cardiac surgery patients on prophylactic amiodarone. ( Caron, MF; Coleman, CI; Kalus, JS; Kluger, J; Takata, H; White, CM, 2004) |
| "Atrial fibrillation (AF) frequently occurs after cardiac surgical procedures, and beta-blockers, sotalol, and amiodarone may reduce the frequency of AF after open heart surgery." | 5.11 | A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. ( Auer, J; Berent, R; Eber, B; Hartl, P; Lamm, G; Lassnig, E; Lehner, E; Ng, CK; Puschmann, R; Schwarz, C; Strasser, U; Weber, T, 2004) |
| " Furthermore, combination of BVP and oral administration of amiodarone significantly prevented recurrence of ventricular tachycardia and paroxysmal atrial fibrillation, and maintained sinus rhythm for a long period." | 5.11 | Effect of biventricular pacing therapy in patients with dilated cardiomyopathy with severe congestive heart failure. ( Baba, H; Goto, K; Kawagoe, J; Noma, M; Origuchi, H; Sakamoto, M; Sese, A; Takemoto, M; Yamamoto, H; Yoshimura, H, 2004) |
| "We prospectively studied 144 patients with chronic rheumatic atrial fibrillation in a double-blind protocol in which rhythm control (group I), comprising 48 patients each with amiodarone (group Ia) and placebo (group Ib), were compared with each other and with patients in a ventricular rate control group (group II) in which the effects by diltiazem were determined (n = 48, open-label)." | 5.11 | Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. ( Goyal, V; Gupta, A; Karnad, D; Kulkarni, H; Lokhandwala, Y; Naik, A; Singh, BN; Vora, A, 2004) |
| "To compare the cost-effectiveness of intravenous plus oral amiodarone, atrial septal pacing, and both strategies combined to prevent atrial fibrillation after open heart surgery." | 5.11 | Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery. ( Caron, MF; Coleman, CI; Horowitz, S; Kalus, JS; Karapanos, A; Kluger, J; Reddy, P; White, CM, 2004) |
| "We studied the use of perioperative IV and oral administration of amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (CABG)." | 5.11 | Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. ( Hollander, G; Kerstein, J; Lichstein, E; Majid, M; Qamar, M; Shani, J; Soodan, A, 2004) |
| "This prospective, randomized, double-blind, placebo-controlled study compared the efficacy and safety of amiodarone and sotalol in the prevention of atrial fibrillation (AF) following open heart surgery." | 5.11 | Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial. ( Arcidi, JM; Hilleman, DE; Lenz, TL; Mohiuddin, SM; Mooss, AN; Packard, KA; Rovang, KS; Sugimoto, JT; Wurdeman, RL, 2004) |
| "This study was designed to assess the effects of a perioperative dosing regimen of amiodarone administration, high thoracic epidural anesthesia (TEA), or a combination of the 2 regimens on atrial fibrillation (AF) after coronary artery bypass grafting (CABG)." | 5.11 | Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting. ( Aldershvile, J; Eliasen, K; Hviid, LB; Krogsgaard, K; Nygård, E; Pedersen, FM; Ravn, J; Svendsen, JH; Sørensen, LH; Thomassen, L, 2004) |
| "The prophylactic effect of amiodarone on atrial fibrillation after coronary bypass grafting with extracorporeal circulation was compared with that of diltiazem in two groups of 60 patients each." | 5.11 | Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery. ( Bougioukas, G; Didilis, V; Konstantinou, F; Mikroulis, D; Tsakiridis, K; Vretzakis, G, 2005) |
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 5.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "This study compares the ability of two oral amiodarone regimens to reduce the risk of atrial fibrillation (AF) as compared with the placebo among elderly open heart surgery (OHS) patients receiving beta blockade." | 5.10 | A comparison of two individual amiodarone regimens to placebo in open heart surgery patients. ( Dunn, A; Felton, K; Giri, S; Kluger, J; Reddy, P; Tsikouris, JP; White, CM, 2002) |
| "Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone." | 5.10 | Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002) |
| "There was a strong trend towards lower mortality associated with the use of class I antiarrhythmic agents or sotalol in managing patients with atrial fibrillation after acute myocardial infarction." | 5.10 | Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. ( Califf, RM; Criger, DA; Ohman, EM; Topol, EJ; White, HD; Wilcox, RG; Wong, CK, 2002) |
| "To assess the prophylactic effect of postoperative oral amiodarone on the incidence and severity of atrial fibrillation (AF) after coronary artery surgery." | 5.10 | Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. ( Haddad, F; Hayek, G; Madi-Jebara, S; Rahbani, P; Yazigi, A; Zeid, HA, 2002) |
| "In clinical practice the use of intravenous amiodarone has been proposed for the conversion of recurrent atrial fibrillation in patients already under chronic treatment with the same drug." | 5.10 | Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable? ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 5.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "Within the first 4 hrs, atrial fibrillation was converted in nine of 20 patients (45%) in group ibutilide and in ten of 20 patients (50%) in group amiodarone (not significant)." | 5.10 | Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. ( Bernard, EO; Candinas, R; Germann, R; Scharf, C; Schmid, ER; Schmidlin, D, 2003) |
| "Amiodarone is effective in preventing the recurrence of atrial fibrillation (AF) after cardioversion (CV)." | 5.10 | Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation. ( Armstrong, KL; Fitzpatrick, AP; Fynn, SP; Garratt, CJ; Hobbs, WJ; Todd, DM, 2003) |
| "The purpose of this study was to evaluate the safety and efficacy of postoperative administration of prophylactic amiodarone in the prevention of new-onset postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting." | 5.10 | Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. ( Apaydin, A; Atay, Y; Ayik, F; Buket, S; Calkavur, T; Islamoglu, F; Nalbantgil, S; Posacioglu, H; Yagdi, T, 2003) |
| "To assess the effects of amiodarone and diltiazem on atrial fibrillation (AF) induced atrial electrical remodeling and their clinical implications." | 5.10 | Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. ( Dermitzaki, DN; Kallergis, EM; Kambouraki, DC; Kanoupakis, EM; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "The study was undertaken to assess the efficacy of intravenous amiodarone in cardioversion of recent-onset paroxysmal atrial fibrillation (AF)." | 5.10 | Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. ( Budaj, A; Ceremuzyński, L; Cybulski, J; Danielewicz, H; Kawka-Urbanek, T; Kułakowski, P; Maciejewicz, J, 2003) |
| "This pilot study aimed to compare right atrial pacing, intravenous amiodarone and oral beta-blockers in the prevention, time to onset, duration and effect on hospital stay of postoperative atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG) at our center." | 5.10 | Effect of right atrial pacing, intravenous amiodarone and beta blockers for suppression of atrial fibrillation after coronary artery bypass surgery: a pilot study. ( Cardona, F; Cox, RA; Pérez, CM; Seide, H, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 5.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| "The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers." | 5.10 | Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). ( Antman, EM; Atwood, JE; Ezekowitz, MD; Falk, RH; Fletcher, RD; Fye, CL; Jacobson, AK; Lewis, HD; Lopez, B; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2003) |
| "The effect of a hybrid intravenous and oral prophylactic amiodarone regimen on postcardiothoracic surgery (CTS) atrial fibrillation (AF) is unknown." | 5.10 | Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). ( Caron, MF; Gallagher, R; Kalus, JS; Kluger, J; Reddy, P; Rose, H; Song, J; White, CM, 2003) |
| "Amiodarone, used in conjunction with percutaneous balloon mitral commissurotomy, can safely convert rheumatic atrial fibrillation in 38% of patients compared with 0% in those without it." | 5.10 | Conversion of rheumatic atrial fibrillation by amiodarone after percutaneous balloon mitral commissurotomy. ( Hsueh, CW; Lai, HC; Lee, WL; Liu, TJ; Ting, CT; Wang, KY, 2003) |
| "This study aimed to assess whether enalapril could improve cardioversion outcome and facilitate sinus rhythm maintenance after conversion of chronic atrial fibrillation (AF)." | 5.10 | Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. ( Chan, KC; Chen, CY; Chen, SA; Lin, CS; Lin, MC; Tsai, CF; Tsai, TP; Ueng, KC; Wu, DJ; Yu, WC, 2003) |
| "To determine if the additional costs of oral amiodarone in patients undergoing open heart surgery would be offset by reductions in the frequency of atrial fibrillation." | 5.10 | An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. ( Dunn, AB; Giri, S; Kluger, J; Reddy, P; Tsikouris, JP; White, CM, 2002) |
| "This prospective randomized study aims at evaluation and comparison of the prophylactic effects of amiodarone versus digoxin and metoprolol combination in postcoronary bypass atrial fibrillation." | 5.10 | Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation. ( Catav, Z; Gunaydin, S; Kandemir, O; Tokmakoglu, H; Yorgancioglu, C; Zorlutuna, Y, 2002) |
| "In this multicentre randomized controlled trial, 68 patients affected by severely symptomatic paroxysmal atrial fibrillation were assigned, after successful atrioventricular junction ablation and pacing treatment, to antiarrhythmic drug therapy with amiodarone, propafenone, flecainide or sotalol and were compared with 69 patients assigned, after successful AV junction ablation and pacing treatment, to no antiarrhythmic drug therapy." | 5.10 | An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. ( Alboni, P; Bongiorni, MG; Botto, GL; Brignole, M; Bruna, C; Gasparini, M; Menozzi, C; Ometto, R; Verlato, R; Vincenti, A, 2002) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 5.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "The efficacy and safety of amiodarone in the conversion of persistent atrial fibrillation (AF) were investigated in a prospective, randomized, controlled study." | 5.09 | Efficacy of amiodarone for the termination of persistent atrial fibrillation. ( Chlouverakis, GI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Solomou, MC; Vardas, PE, 1999) |
| "The effects of a 6-week treatment with amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease have been studied." | 5.09 | Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. ( Adamus, J; Anker, SD; Banasiak, W; Coats, AJ; Fuglewicz, A; Kalka, D; Molenda, W; Ponikowski, P; Reczuch, K; Telichowski, A, 1999) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 5.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| ") amiodarone would prevent atrial fibrillation and decrease hospital stay after open heart surgery." | 5.09 | Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. ( Dudek, A; Gottlieb, SO; Guarnieri, T; Lowry, DR; Nolan, S, 1999) |
| "Spontaneous conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm occurs commonly and is not affected by low-dose amiodarone treatment." | 5.09 | Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. ( Blatt, A; Cotter, G; Golik, A; Kaluski, E; Koren, M; Litinski, I; Metzkor-Cotter, E; Moshkovitz, Y; Peleg, E; Simantov, R; Vered, Z; Zaidenstein, R, 1999) |
| "Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg." | 5.09 | Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. ( Aschieri, D; Capucci, A; Piepoli, MF; Rosi, A; Villani, GQ, 2000) |
| "The efficacy of amiodarone has been proved in long-term maintenance of sinus rhythm (SR) in patients with paroxysmal atrial fibrillation (AF)." | 5.09 | Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. ( Juvonen, J; Lilja, M; Linnaluoto, M; Niemelä, M; Peuhkurinen, K; Ylitalo, A, 2000) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 5.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "To investigate the efficacy and safety of amiodarone administered as the drug of first choice in the conversion of atrial fibrillation, regardless of its duration." | 5.09 | Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Simantirakis, EN; Tsatsakis, AM; Vardas, PE, 2000) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 5.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "Intraoperative prophylactic use of amiodarone does not prevent new onset of atrial fibrillation in patients undergoing coronary artery bypass grafting and had no effect on outcome." | 5.09 | Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations. ( Dörge, H; Messmer, BJ; Schoberer, M; Schoendube, FA; Stellbrink, C; Voss, M, 2000) |
| "Atrial fibrillation occurred in 9 (12%) of the amiodarone group patients and in 26 (34%) of the control group patients during hospitalization (p < 0." | 5.09 | Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. ( Chang, CM; Chen, SA; Cheng, JJ; Hung, CR; Lee, RJ; Lee, SH; Lu, MJ, 2000) |
| "This study compared the efficacy and safety of intravenous dofetilide with amiodarone and placebo in converting atrial fibrillation or flutter to sinus rhythm." | 5.09 | Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. ( Alboni, P; Bianconi, L; Castro, A; Dinelli, M; Pappalardo, A; Richiardi, E; Santini, M, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 5.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "The efficacy of diltiazem or amiodarone pretreatment (oral, 1 month before and 1 month after conversion) on direct-current conversion of persistent atrial fibrillation was assessed in 120 patients, randomly assigned to 3 matched groups: A (n = 44, diltiazem); B (n = 46, amiodarone), and C (n = 30, digoxin)." | 5.09 | Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. ( Capucci, A; Piepoli, MF; Terracciano, C; Villani, GQ, 2000) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 5.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "Our aims were to examine whether the administration of amiodarone or magnesium sulphate after coronary artery bypass graft surgery (CABG) could reduce the occurrence of atrial fibrillation, and to identify the risk factors associated with atrial fibrillation after CABG." | 5.09 | Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. ( Adamec, R; Perneger, TV; Romand, JA; Suter, PM; Treggiari-Venzi, MM; Waeber, JL, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "Beta-blockers and amiodarone reduce the frequency of atrial fibrillation after open-heart surgery but the effectiveness of oral amiodarone in older patients already receiving beta-blockers is unknown." | 5.09 | Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. ( Dunn, AB; Felton, K; Freeman-Bosco, L; Giri, S; Kluger, J; Reddy, P; Tsikouris, JP; White, CM; Wilcox, HA, 2001) |
| "Various regimens have been proposed for the prevention of postoperative atrial fibrillation, including the use of intravenous and oral amiodarone." | 5.09 | Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. ( Babić, R; Bojić, M; Borzanović, M; Bosković, SD; Jovanović, T; Kovacević, S; Maras, D; Marinković, J; Nastasić, S; Nesković, AN; Otasević, P; Popović, AD; Popović, Z; Vuk, L, 2001) |
| "The efficacy and safety of low-dose amiodarone (Cordarone; Wyeth-Ayerst, Philadelphia, PA) was assessed in 62 symptomatic patients with paroxysmal atrial fibrillation who were resistant to at least two types of IA drugs." | 5.09 | Efficacy of low-dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type IA antiarrhythmic drugs. ( Faitel, K; Kerin, IA; Kerin, NZ; Quinones, L; Stomel, RJ, 2000) |
| "Of the 100 patients recruited for the Amiodarone arm of the study, 12 were excluded for a variety of reasons detailed in the discussion with atrial fibrillation occurring in 28 (a rate of 32%)." | 5.09 | Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery. ( Harahsheh, BS; Sawalha, WA, 2001) |
| "Both amiodarone and beta-blockers have been shown to decrease the incidence of atrial fibrillation after cardiovascular surgery." | 5.09 | Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery. ( Greenberg, MD; Katz, NM; Kilborn, MJ; Solomon, AJ, 2001) |
| "We sought to assess the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial." | 5.09 | Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. ( Chiale, PA; Elizari, MV; Galperín, J; Ledesma, R; Molina, RT; Scapín, AO; Vázquez Blanco, M, 2001) |
| " A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats." | 5.08 | Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ( Chang, MS; Chen, CY; Chiang, HT; Hou, ZY; Lin, SL; Tu, MS; Woosley, RL, 1995) |
| "In a randomized, double-blind, controlled study of 98 patients with atrial fibrillation (AF) (present for > or = 30 minutes, < or = 72 hours, and a ventricular response of > or = 100 beats/min), intravenous flecainide (2 mg/kg, maximum 150 mg) was compared with intravenous amiodarone (7 mg/kg) and placebo." | 5.08 | Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. ( Dobb, GJ; Donovan, KD; Hockings, BE; Lee, KY; Power, BM, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 5.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 5.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "This study was designed to determine the efficacy of intravenous amiodarone in the management of recent-onset atrial fibrillation." | 5.08 | Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. ( Arnau, JM; Artaza, MA; Ballester, R; Galve, E; García-Dorado, D; Rius, T; Soler-Soler, J, 1996) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 5.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P=0." | 5.08 | Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. ( Bitar, C; Bolling, SF; Daoud, EG; Deeb, GM; Goyal, R; Man, KC; Meissner, MD; Morady, F; Pagani, FD; Strickberger, SA, 1997) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 5.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "The efficacy and safety of intravenous propafenone, amiodarone, or placebo were compared in the treatment of atrial fibrillation (AF) of recent onset (duration < or = 48 hours)." | 5.08 | Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. ( Igoumenidis, NE; Kochiadakis, GE; Marketou, ME; Mezilis, NE; Parthenakis, FI; Simantirakis, EN; Vardas, PE, 1998) |
| "In a multicenter, double-blind, placebo-controlled study, the long-term effects of amiodarone on morbidity and mortality in patients with congestive heart failure (CHF) and atrial fibrillation (AF) were evaluated during a 4-year period." | 5.08 | Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Departmen ( Deedwania, PC; Ellenbogen, K; Fisher, S; Fletcher, R; Singh, BN; Singh, SN, 1998) |
| "To evaluate differences between amiodarone, procainamide and quinidine in the time delay necessary to convert acute atrial fibrillation (AF) to sinus rhythm." | 5.07 | [Acute atrial fibrillation in the emergency room. Which is the best drug for a rapid sinus rhythm conversion?]. ( Amato, RV; Bellotti, G; César, LA; D'Avila, AL; Ferreira, JF; Pamplona, D; Pfeferman, E; Scanavacca, M; Serrano, CV; Sosa, EA, 1994) |
| "The effectiveness of propafenone versus amiodarone for conversion to sinus rhythm of paroxysmal atrial fibrillation was compared." | 5.07 | [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. ( Alfano, C; Rossini, E; Treglia, A, 1994) |
| " We set out to compare the relative efficacy of amiodarone and digoxin in the management of atrial fibrillation and flutter in the early postoperative period." | 5.07 | A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery. ( Cochrane, AD; Davis, BB; Marasco, S; McConaghy, L; Rosenfeldt, FL; Salamonsen, R; Siddins, M, 1994) |
| "An evaluation of amiodarone as prophylactic treatment for supraventricular tachyarrhythmias after pulmonary surgery was stopped because of a high incidence of the adult respiratory distress syndrome (ARDS) after a pneumonectomy." | 5.07 | Amiodarone and the development of ARDS after lung surgery. ( Coolen, L; Demedts, MG; Deneffe, GJ; Lacquet, LM; Malysse, I; Van Mieghem, W, 1994) |
| "An open, multi-centre study was carried out to assess the effectiveness and tolerability of amiodarone at a lower dose than routinely used in the clinical and symptomatic treatment of older patients with atrial fibrillation who were resistant to other therapy or in whom other therapy was either poorly tolerated or contraindicated." | 5.07 | Amiodarone dosage in older patients with atrial fibrillation: an open, multi-centre study. ( Sandler, M, 1992) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 5.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "The efficacy and the safety of amiodarone therapy in 82 patients with recurrent tachyarrhythmias, refractory to conventional antiarrhythmics, were evaluated by a multicenter trial." | 5.07 | Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias. ( Kato, K, 1992) |
| "To study efficacy and safety of low-dose amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation or flutter." | 5.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 5.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| "Two intravenous amiodarone dosing schedules in 28 patients with atrial fibrillation arisen less than 10 days before, were evaluated." | 5.07 | [Amiodarone and its infusion velocity in recent-onset atrial fibrillation]. ( Bonino, ML; Ramus, GV; Tonda, L; Veglio, F, 1991) |
| "The effectiveness of amiodarone and quinidine in converting atrial fibrillation of recent onset (less than three weeks) to sinus rhythm was compared in a randomized, open-label study." | 5.06 | [Comparison of amiodarone and quinidine in the conversion to sinusal rhythm of atrial fibrillation of recent onset]. ( De Ponti, C; Gibelli, G; Negrini, M, 1990) |
| "This study was designed to assess the clinical efficacy of oral flecainide for the prevention of paroxysmal attacks of atrial fibrillation (AF)." | 5.06 | Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. ( Chouty, F; Coumel, P, 1988) |
| "Thirty-eight patients were studied to evaluate amiodarone hydrochloride in the treatment of refractory atrial fibrillation." | 5.06 | Amiodarone in the management of refractory atrial fibrillation. ( Benaderet, D; Blevins, RD; Faitel, K; Frumin, H; Jarandilla, R; Kerin, NZ; Rubenfire, M, 1987) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 5.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 5.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "Clinicians frequently pre-treat patients with amiodarone to increase the efficacy of electrical cardioversion for atrial fibrillation (AF)." | 5.01 | Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. ( Amit, G; Belley-Côté, EP; Chu, VA; Healey, JS; Koziarz, A; McIntyre, WF; Mendoza, PA; Um, KJ; Whitlock, RP, 2019) |
| "Recent evidence from relatively small randomized controlled trials would seem to support a useful role of ranolazine for the prevention and treatment of atrial fibrillation (AF)." | 4.98 | Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. ( Ariano, C; Cioppa, C; De Vecchis, R; Giasi, A, 2018) |
| "We performed a systematic review of MEDLINE, the Cochrane Central Register of Clinical Trials, and Embase, limiting our search to randomized controlled trials of patients with atrial fibrillation that have compared DOACs versus warfarin for prophylaxis of stroke or systemic embolism, to analyze the impact on stroke or systemic embolism, major bleeding, and intracranial bleeding risk in patients with concomitant use of amiodarone." | 4.98 | Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. ( Briceno, D; Di Biase, L; Ferrick, K; Fisher, J; Gross, JN; Kim, S; Krumerman, A; Lupercio, F; Maraboto, C; Peltzer, B; Romero, J; Villablanca, P, 2018) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 4.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| " The question addressed was whether the administration of amiodarone is safe in patients undergoing lung resection either for prophylaxis or treatment of de novo postoperative atrial fibrillation (POAF)." | 4.95 | In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation? ( Billè, A; Harling, L; Kolokotroni, SM; Toufektzian, L, 2017) |
| "To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF." | 4.95 | Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation. ( Nguyen, E; White, CM, 2017) |
| "Despite probably being the most effective prophylactic drug for postoperative atrial fibrillation (POAF), amiodarone is reserved as a second-line agent because of its potential systemic side effects." | 4.93 | Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation. ( Chu, FV; Habbab, LM, 2016) |
| "Amiodarone remains the mostly frequently used antiarrhythmic in clinical practice and is most often used to maintain normal sinus rhythm in patients with atrial fibrillation who have failed a rate control strategy." | 4.93 | Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. ( Brown, RE; Dixon, DL; Dunn, SP; Kelly, MS; McLlarky, TR, 2016) |
| "This article provides a contemporary review of the current role of amiodarone and dronedarone in patients with atrial fibrillation who need to undergo rhythm control therapy for relief of symptoms." | 4.93 | Amiodarone and dronedarone: An update. ( Hohnloser, SH; Vamos, M, 2016) |
| "Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF)." | 4.93 | Dronedarone: Basic Pharmacology and Clinical Use. ( Andrade, JG; Nattel, S; Tadros, R, 2016) |
| " β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate." | 4.93 | Rate control in atrial fibrillation. ( Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC, 2016) |
| "Amiodarone is an antiarrhythmic agent among the I most powerful and the most frequently used for the control of recurrent ventricular tachycardia and the secondary prevention of recurrent atrial fibrillation." | 4.90 | [Amiodarone and the thyroid]. ( Beckers, A; Benoit, A; Betea, D; Brescia, L; Delvenne, P; Hamoir, E, 2014) |
| "The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial flutter, as part of the Institute's single technology appraisal (STA) process." | 4.88 | Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2012) |
| "An 88-year-old female, living independently in the community, developed duodenal and gastric ulcers from using overthe-counter naproxen sodium for pain related to a shoulder fracture and arthritis of the knees." | 4.88 | Gastrointestinal bleeding and possible hypothyroidism. ( Marshall, LL, 2012) |
| " Amiodarone-induced hypothyroidism (AIH) does not pose relevant problems, is easily controlled by L-thyroxine replacement, and does not require amiodarone withdrawal." | 4.88 | Amiodarone and the thyroid: a 2012 update. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Martino, E; Tomisti, L, 2012) |
| "Dronedarone is a benzofuran derivative approved by the Food and Drug Administration to decrease the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) and associated cardiovascular risk factors who are in sinus rhythm or will undergo cardioversion." | 4.88 | Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. ( Aikat, S; Chatterjee, S; Ghosh, J; Lichstein, E; Mukherjee, D, 2012) |
| "Current guidelines recommend beta-blocker as the first-line preventive treatment of atrial fibrillation (AF) after cardiac surgery; if beta-blocker therapy is contraindicated, then amiodarone is recommended." | 4.88 | Meta-analysis of amiodarone versus β-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. ( Gao, D; Gao, Y; Lu, Y; Wang, C; Zhang, C; Zhang, Y; Zhu, J, 2012) |
| " Other agents such as Vernakalant and Ranolazine are in development that promise to be more atrial selective in their action, thereby potentially avoiding pro-arrhythmia and heart failure side effects." | 4.88 | Novel anti-arrhythmic medications in the treatment of atrial fibrillation. ( Saklani, P; Skanes, A, 2012) |
| "Reports published with the following search terms were searched:, thyroid, hypothyroidism, hyperthyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, levothyroxine, triiodothyronine, antithyroid drugs, radioiodine, deiodinases, clinical symptoms, heart rate, HF, systolic function, diastolic function, systemic vascular resistance, endothelial function, amiodarone and atrial fibrillation." | 4.88 | Mechanisms in endocrinology: Heart failure and thyroid dysfunction. ( Biondi, B, 2012) |
| "The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations." | 4.88 | Drug safety evaluation of dronedarone in atrial fibrillation. ( De Ferrari, GM; Dusi, V, 2012) |
| "Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial." | 4.88 | Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. ( Salam, AM, 2012) |
| "The readers will gain an understanding of the findings of recent trials performed with dronedarone, which will provide important information for this relatively new antiarrhythmic drug, used for the treatment of atrial fibrillation." | 4.87 | Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. ( Lip, GY; Pamukcu, B, 2011) |
| "We present three patients treated with amiodarone for atrial fibrillation who developed AIT at least 36 months after beginning the treatment." | 4.87 | [Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases]. ( Arias, N; Boix, E; González, VL; Moreno-Pérez, Ó; Picó, AM; Revert, P; Sánchez-Ortiga, R; Serrano, J, 2011) |
| "We performed a systematic review and meta-analysis on the effect of dronedarone on the occurrence of stroke or transient ischemic attack (TIA) in patients with paroxysmal or persistent AF." | 4.87 | Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. ( Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C, 2011) |
| "To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation." | 4.86 | Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. ( Duray, GZ; Ehrlich, JR; Hohnloser, SH, 2010) |
| "Dronedarone is developed for treatment of atrial fibrillation (AF) or flutter (AFL)." | 4.86 | Efficacy and safety of dronedarone: a review of randomized trials. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "Dronedarone is an oral Class III antiarrhythmic agent which was recently approved by the US Food and Drug Administration for use in nonpermanent atrial fibrillation." | 4.86 | Dronedarone: a safety comparison to amiodarone. ( Clem, JR; Farver, DK; Fischer, JR; Johnson, TJ, 2010) |
| "Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hospitalization driven by atrial fibrillation/flutter." | 4.86 | Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? ( Cingolani, E; Diamond, GA; Kaul, S; Singh, D, 2010) |
| "Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL)." | 4.86 | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF)." | 4.86 | Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. ( Langdorf, MI; Lotfipour, S; Simonian, SM; Wall, C, 2010) |
| "Vernakalant is a promising novel antiarrhythmic intravenous drug for the rapid conversion of atrial fibrillation to sinus rhythm." | 4.86 | [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm]. ( Eschenhagen, T; Hirt, MN, 2010) |
| " However, dronedarone, a novel antiarrhythmic drug, has been shown to decrease stroke risk by 34% (p = 0." | 4.86 | Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. ( Crijns, H; Röther, J, 2010) |
| "Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter." | 4.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. ( Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D, 2010) |
| "Approved in July 2009, dronedarone is a new antiarrhythmic agent indicated to reduce the risk of hospitalization for cardiac events in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 4.86 | Dronedarone: an alternative to amiodarone? ( Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report on the clinical effectiveness and cost-effectiveness of dronedarone for the treatment of atrial fibrillation (AF) or atrial flutter based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 4.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2010) |
| " Dronedarone, the first noniodinated amiodarone congener, has been developed largely to obtain the antiarrhythmic efficacy in the control of atrial fibrillation without the known adverse side effects of dronedarone." | 4.86 | A new agent for atrial fibrillation: electrophysiological properties of dronedarone. ( Cingolani, E; Singh, BN, 2010) |
| "Dronedarone is a new antiarrhythmic agent, approved in January 2010 for the therapy of atrial fibrillation and for rate control in tachyarrhythmic atrial fibrillation." | 4.86 | [Dronedarone]. ( Gonska, BD, 2010) |
| "Decades after its registration, amiodarone is still regarded as the most effective antiarrhythmic drug available for the treatment of tachyarrhythmias." | 4.86 | [Current role of amiodarone in antiarrhythmic therapy]. ( Sohns, C; Zabel, M, 2010) |
| "Efforts to develop atrial-selective antiarrhythmics are bearing fruit, but such compounds will need to exhibit equal or superior safety and efficacy compared with multichannel blockers such as dronedarone for atrial fibrillation suppression in order to prove their worth." | 4.85 | Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? ( Ehrlich, JR; Nattel, S, 2009) |
| "To assess whether amiodarone, as part of a strategy to achieve sinus rhythm, is safe and effective compared with a placebo or rate control drug in patients with persistent atrial fibrillation (AF) of more than 30 days' duration." | 4.85 | Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. ( Doyle, JF; Ho, KM, 2009) |
| "Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm for patients with atrial fibrillation." | 4.85 | Dronedarone. ( Kowey, PR; Patel, C; Yan, GX, 2009) |
| "We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF)." | 4.85 | Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. ( Califf, RM; Hasselblad, V; Kong, DF; Peterson, ED; Piccini, JP; Washam, JB, 2009) |
| "To investigate a possible dose-response relationship between amiodarone and reduction in incidence of postoperative atrial fibrillation, and to determine whether pre- or postoperative initiation of amiodarone is superior." | 4.84 | Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. ( Buckley, MS; Copeland, JG; Hilleman, DE; Nolan, PE; Slack, MK; Tisdale, JE, 2007) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation." | 4.84 | Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. ( Dale, KM; White, CM, 2007) |
| "A meta-analysis was conducted to assess the safety of amiodarone in the prevention of postoperative atrial fibrillation." | 4.83 | Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. ( Coleman, CI; Gillespie, EL; Kluger, J; Patel, AA; White, CM, 2006) |
| "sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the potential treatment and prevention of atrial fibrillation." | 4.83 | Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent. ( Le Grand, B; Sablayrolles, S, 2006) |
| "Amiodarone has been proposed to decrease atrial fibrillation after cardiac surgery." | 4.83 | Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Bagshaw, SM; Exner, DV; Galbraith, PD; Ghali, WA; Mitchell, LB; Sauve, R, 2006) |
| "This meta-analysis compared amiodarone with placebo and class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF), defined as lasting less than seven days." | 4.82 | Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. ( Burri, H; Chevalier, P; Cucherat, M; Durand-Dubief, A; Kirkorian, G; Touboul, P, 2003) |
| "Although clinicians sometimes choose amiodarone to convert atrial fibrillation (AF) to sinus rhythm, no current and comprehensive systematic review has summarized its effectiveness." | 4.82 | Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. ( Ena, J; Guyatt, GH; Letelier, LM; Udol, K; Weaver, B, 2003) |
| "The efficacy and safety of amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 4.82 | Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Gowda, RM; Khan, IA; Mehta, NJ, 2003) |
| "A short cut review was carried out to establish whether amiodarone is better than flecainide at restoring sinus rhythm in patients with atrial fibrillation." | 4.82 | Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation. ( Argall, J; Crawford, I, 2004) |
| " Most recently, the introduction of dofetilide has widened the therapeutic options in patients with severe heart disease, and the Canadian Trial of Atrial Fibrillation indicated the superior efficacy of amiodarone at low doses." | 4.82 | Antiarrhythmic drug therapy of atrial fibrillation. ( Mounsey, JP; VerNooy, RA, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 4.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| " Amiodarone can effectively prevent and control postoperative atrial and ventricular fibrillation." | 4.82 | Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. ( Drewe, J; Krähenbühl, S; Pargger, H; Rätz Bravo, AE; Schlienger, RG; Ummenhofer, W, 2005) |
| "Two previous meta-analyses of amiodarone for prevention of postoperative atrial fibrillation (POAF) after cardiothoracic surgery did not evaluate total hospital cost, concluded that data on stroke are incomplete, and did not evaluate the effect of clinical heterogeneity between trials." | 4.82 | Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis. ( Coleman, CI; Gillespie, EL; Gryskiewicz, KA; Kluger, J; Sander, S; White, CM, 2005) |
| " Trials that assessed whether amiodarone prophylaxis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality." | 4.82 | Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. ( Aasbo, JD; Kim, MH; Krishnan, K; Lawrence, AT; Trohman, RG, 2005) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular rhythm disturbances." | 4.81 | Amiodarone: an emergency medicine perspective. ( Taylor, SE, 2002) |
| "To evaluate efficacy and safety of intravenous amiodarone for conversion of recent-onset atrial fibrillation." | 4.81 | Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. ( Hilleman, DE; Spinler, SA, 2002) |
| "Amiodarone in low to moderate doses is generally safe in controlling arrhythmias in patients with congestive heart failure (CHF)." | 4.80 | The current role of amiodarone in patients with congestive heart failure. ( Bello, D; Massie, BM, 1998) |
| "Oral amiodarone may be used in the prevention of recurrences of paroxysmal atrial fibrillation (AF) or in chronic AF following electrical cardioversion or for pharmacological cardioversion of AF." | 4.80 | Amiodarone in atrial fibrillation. ( Levy, S, 1998) |
| "Amiodarone is the most important drug in the treatment of ventricular arrhythmias and is widely used for atrial fibrillation." | 4.80 | [Amiodarone-induced thyrotoxicosis]. ( Cron, TA; Kaufmann, C; Meier, C; Oberholzer, M; Osswald, S; Staub, JJ, 2000) |
| "In summary, the Class III antiarrhythmic agents amiodarone and sotalol are effective in restoring sinus rhythm in patients with chronic atrial fibrillation with a higher effectiveness of amiodarone." | 4.79 | Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation. ( Hohnloser, SH, 1994) |
| "To discuss the role of amiodarone for the maintenance of normal sinus rhythm in patients with atrial fibrillation (AF) and review the clinical trial data evaluating the efficacy and safety of amiodarone in patients with AF." | 4.79 | Amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. ( Howard, PA, 1995) |
| " The search was conducted by intersecting "quinidine," "warfarin," or "amiodarone" with "atrial fibrillation." | 4.79 | Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis. ( Gornbein, JA; Middlekauff, HR; Stevenson, WG, 1995) |
| "To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease." | 4.79 | Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. ( Hohnloser, SH; Klingenheben, T; Singh, BN, 1994) |
| "Five recent randomized controlled trials of warfarin in atrial fibrillation, 6 randomized controlled trials of quinidine, and 13 longitudinal studies of low-dose amiodarone were used." | 4.79 | Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. ( Birkmeyer, JD; Disch, DL; Greenberg, ML; Holzberger, PT; Malenka, DJ, 1994) |
| "In the absence of randomized, controlled trials of low-dose amiodarone in atrial fibrillation or a randomized, controlled trial of ventricular rate control versus antifibrillatory therapy, a Markov decision analysis is useful in comparing different therapeutic strategies for atrial fibrillation." | 4.79 | Therapeutic strategies for atrial fibrillation. The value of decision analysis. ( Disch, DL; Greenberg, ML; Malenka, DJ, 1996) |
| " Therefore, an initiative of the German Working Group on Electrophysiology of the Deutsche Gesellschaft für Kardiologie--Herz- und Kreislaufforschung is urgently needed which will compare these strategies in a prospective controlled trial (pharmacologic intervention in atrial fibrillation PIAF: Reestablishment of sinus rhythm by the drug amiodarone, in addition DC-defibrillation if necessary; rate control with the calcium antagonist diltiazem)." | 4.79 | [Drug therapy of atrial fibrillation: control of heart rate versus establishing sinus rhythm]. ( Steinbeck, G, 1996) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 4.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| " In patients with successful DC conversion of chronic atrial fibrillation, sotalol proved to be as effective as quinidine in maintaining sinus rhythm but was better tolerated and provided beneficial rate control during atrial fibrillation in those patients who relapsed." | 4.78 | Comparison of class I and class III action in atrial fibrillation. ( Edvardsson, N, 1993) |
| "Concerns about proarrhythmia risk and inefficacy associated with class I antiarrhythmic drugs have revived interest in low-dose amiodarone (maintenance dose 200-400 mg/day) for suppression of atrial fibrillation." | 4.78 | Low-dose amiodarone for atrial fibrillation. ( Middlekauff, HR; Stevenson, WG; Wiener, I, 1993) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "A 45-year-old man had severe blue-gray cutaneous discoloration during amiodarone therapy for atrial fibrillation." | 4.78 | Reversibility of blue-gray cutaneous discoloration from amiodarone. ( Blackshear, JL; Randle, HW, 1991) |
| "Amiodarone, an investigational drug in the United States, has had considerable use in this country and worldwide in the treatment of cardiac arrhythmias." | 4.76 | Clinical use and pharmacology of amiodarone. ( Heger, JJ; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 4.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "Atrial fibrillation (AF) guidelines recommend amiodarone as the preferred antiarrhythmic medication (AAM) in patients with left ventricular hypertrophy (LVH), due to potential pro-arrhythmic risk with other AAM." | 4.31 | Mortality associated with antiarrhythmic medication for atrial fibrillation among patients with left ventricular hypertrophy. ( Adabag, S; Agdamag, AC; Angsubhakorn, N; Chen, LY; Gravely, A; Westanmo, A, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 4.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "The association between amiodarone treatment for postoperative atrial fibrillation (POAF) after surgical aortic valve replacement (SAVR) and both the return to normal sinus rhythm (NSR) and anticoagulation use at discharge has not been extensively studied." | 4.31 | Postoperative Atrial Fibrillation After Surgical Aortic Valve Replacement: Amiodarone and Warfarin Use. ( Beaulieu-Jones, BR; Haime, M; Lin, B; Phillips, AM; Quin, JA, 2023) |
| "Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation." | 4.31 | Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation. ( Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M, 2023) |
| "To evaluate the effectiveness and safety of dronedarone compared with other commonly used antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrences." | 4.12 | International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF). ( Abenhaim, L; Botto, GL; Breithardt, G; de Abajo, FJ; Grimaldi-Bensouda, L; Khachatryan, A; Kirchhof, P; Merino, JL; Stambler, B, 2022) |
| "Compared to co-administration of amiodarone and rivaroxaban, co-administration of dronedarone and rivaroxaban increases the risk of CRNMB but it does not increase the risk of major hemorrhages in blanking period after AF ablation." | 4.12 | Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation. ( Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q, 2022) |
| "Amiodarone is a class III antiarrhythmic drug effective in the treatment of ventricular arrhythmias and atrial fibrillation." | 4.12 | [Amiodarone: some toxicity considerations]. ( Bridevaux, PO; Fournier, J; Gobin, N; Savchuk, H, 2022) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 4.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Amiodarone is commonly used in atrial fibrillation (AF)." | 4.12 | Amiodarone is associated with increased short-term mortality in elderly atrial fibrillation patients with preserved ejection fraction. ( Di Biase, L; Li, W; Tiwari, N; Wang, YC, 2022) |
| "We analyzed changes in physicians' use of dronedarone after the PALLAS trial (Palbociclib Collaborative Adjuvant Study; November 2011) showed that dronedarone increased the risk of death from cardiovascular events among patients with permanent atrial fibrillation." | 4.02 | Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. ( Desai, NR; Everhart, A; Jena, A; Karaca-Mandic, P; Ross, JS; Shah, N; Smith, LB; Stecher, C, 2021) |
| "Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM) has not been studied." | 4.02 | Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. ( Akhavein, R; Al-Rashdan, L; Elman, MR; Fischer, KL; Heitner, SB; Lin, LQ; Mannello, M; Masri, A; Nazer, B; Shalen, EF; Song, HK, 2021) |
| "Previous clinical studies have shown that ranolazine (RAN) added to amiodarone (AMIO) might accelerate the termination of recent-onset atrial fibrillation." | 4.02 | Ranolazine depresses conduction of rapid atrial depolarizations in a beating rabbit heart model. ( Aidonidis, I; Dipla, K; Hatziefthimiou, A; Molyvdas, PA; Simopoulos, V; Stamatiou, R; Stravela, S, 2021) |
| "It was reported that intravenous amiodarone might induce ventricular fibrillation for acute treatment in patients with atrial fibrillation (AF) and Wolff-Parkinson-White (WPW) syndrome." | 4.02 | The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome. ( Ren, J; Shao, X; Wang, J; Wu, S; Yang, Y; Zhang, H; Zhu, J, 2021) |
| "Intravenous amiodarone infusion is effective and widely used treatment for pharmacological cardioversion of recent-onset atrial fibrillation (Af)." | 4.02 | Frontal plane QRS-T angle in the monitoring of intravenous amiodarone infusion for pharmacological cardioversion of acute atrial fibrillation. ( Eyuboglu, M, 2021) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 4.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "The authors present a case of a 55-year-old gentleman with a medical history of atrial fibrillation on amiodarone who presented with weight loss, palpitations and exertional dyspnoea." | 4.02 | Amiodarone-induced type 2 thyrotoxicosis. ( Abela, A; Fava, S; Mifsud, S; Portelli, D, 2021) |
| " Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP)." | 4.02 | Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy. ( Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M, 2021) |
| "The study's goal was to compare the efficacy and safety of dofetilide (DOF) versus amiodarone (AMIO) in patients with atrial fibrillation (AF)." | 4.02 | Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation. ( Batul, A; Bogun, F; Chugh, A; Chung, E; Crawford, T; Cunnane, R; Ghanbari, H; Ghannam, M; Jongnarangsin, K; Latchamsetty, R; Liang, J; Morady, F; Oral, H; Pelosi, F; Saeed, M; Shantha, G, 2021) |
| "The combination of antiarrhythmic agents, amiodarone or dronedarone, with the anticoagulant rivaroxaban is used clinically in the management of atrial fibrillation for rhythm control and secondary stroke prevention respectively." | 4.02 | Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents. ( Chan, ECY; Chin, SY; Tan, HL; Tang, LWT, 2021) |
| "The aim of this study was to evaluate the efficacy of the multichannel-blocker dronedarone for postoperative new onset atrial fibrillation (POAF) as compared to amiodarone." | 4.02 | Treatment of Postoperative New Onset Atrial Fibrillation with Repolarization Delaying Agents after Heart Surgery. ( Boeken, U; Dalyanoĝlu, H; Lichtenberg, A; Makimoto, H; Sipahi, FN; Sugimura, Y; Yilmaz, E, 2021) |
| "Using nationwide registers, we included all Danish patients with atrial fibrillation (AF) treated with amiodarone from 1996 to 2014." | 3.96 | Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. ( D'Souza, M; Dalgaard, F; Hansen, ML; Hilmar Gislason, G; Pallisgaard, JL; Piccini, J; Rasmussen, PV; Ruwald, MH; Torp-Pedersen, C, 2020) |
| "Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects." | 3.96 | Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. ( Fonarow, GC; Freeman, JV; Gersh, BJ; Holmes, DN; Kowey, PR; Mahaffey, KW; Naccarelli, GV; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Shrader, P; Singer, DE; Thomas, L; Washam, JB, 2020) |
| "Amiodarone inhibits warfarin metabolism and is associated with major bleeding during warfarin therapy." | 3.96 | The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. ( Brown, JR; Hennessy, S; Miano, TA; Shashaty, MGS; Yang, W; Zuppa, A, 2020) |
| "Combination use of digoxin and other medications might lead to worse outcomes in patients with atrial fibrillation (AF)." | 3.96 | Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation. ( Chang, CH; Chen, JJ; Chen, PC; Chiang, FT; Chiang, JY; Chu, FY; Hwang, JJ; Lin, JL; Lin, LY; Wu, CK; Yang, YH, 2020) |
| "Amiodarone is a widely used drug in the emergency department (ED) for control of atrial fibrillation, but it has a delayed onset of action and slow metabolism, leading to longer length of ED stay." | 3.96 | Impact of emergency department management of atrial fibrillation with amiodarone on length of stay. A propensity score analysis based on the URGFAICS registry. ( Arranz, M; Cabello, I; Esquerrà, A; Frances, P; Guzman, J; Jacob, J; Mòdol, JM; Moreno-Pena, A; Santos, J; Yuguero, O, 2020) |
| "This study aimed to describe a case of optic neuropathy after substitution of amiodarone with dronedarone for treatment of atrial fibrillation." | 3.96 | Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation. ( Maharshak, I; Paul, M; Steiner, H, 2020) |
| "Post hoc analysis of the landmark atrial fibrillation follow-up investigation of rhythm management trial revealed that amiodarone was associated with higher risks of mortality, intensive care unit admission, and non-cardiovascular death." | 3.96 | Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry. ( Dong, JZ; Du, X; He, L; Hou, XX; Ma, CS; Wang, GH, 2020) |
| "One of the drugs that are widely used in the treatment of atrial fibrillation is amiodarone." | 3.91 | TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY. ( Cerovec, D; Ciglenečki, N; Lakušić, N; Slivnjak, V, 2019) |
| "This study aims to examine the effects of amiodarone in restoring sinus rhythm in patients with new-onset atrial fibrillation during thoracic operations." | 3.91 | Transient new-onset atrial fibrillation during general thoracic operations and its treatment with amiodarone: a retrospective analysis in a single centre. ( Chen, M; Ji, C; Wu, D; Wu, J; Xu, M, 2019) |
| "A 63-year-old man underwent cardioversion of atrial fibrillation with intravenous amiodarone through an antecubital fossa cannula." | 3.91 | Focal myositis and contracture secondary to amiodarone extravasation from a peripheral cannula. ( Cordato, D; Ledingham, D, 2019) |
| "The purpose of this study was to evaluate whether rapid switching from amiodarone to dofetilide is safe in atrial fibrillation patients with an ICD." | 3.91 | Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator. ( Atkins, D; Bommana, S; Carroll, H; Gopinathannair, R; Jeffrey, C; Lakkireddy, D; Natale, A; Newton, D; Nydegger, C; Sharma, SP; Turagam, M, 2019) |
| "Providing IV and PO overlap of amiodarone for a median of 4 hours did not decrease the rate of early tachyarrhythmia recurrence." | 3.91 | Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients. ( Aberle, C; Altshuler, D; Arnouk, S; Merchan, C; Papadopoulos, J; Piper, GL, 2019) |
| " Repeat CT chest after 2 weeks for recurrent cough showed a small PE, treated with oral prednisone for suspected postablation pericarditis, with complete resolution of cough." | 3.88 | Cough as the sole manifestation of pericardial effusion. ( Abdullah, O; Fong, HK; Gautam, S, 2018) |
| "The aim of this study was to assess ventricular repolarization wave variations during the amiodarone treatment course for patients with ventricular arrhythmias and atrial fibrillation." | 3.88 | Ventricular repolarization wave variations during the amiodarone treatment course. ( Ge, Q; Gu, D; Zhao, H, 2018) |
| "The aim of the study was to examine the safety and efficacy of dronedarone in patients with a history of atrial fibrillation and amiodarone-induced hyperthyroidism." | 3.88 | Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study. ( Babu Dasari, J; Battaini, F; Bernardini, S; De Lorenzo, A; Intorcia, A; Merra, G; Morgagni, R; Perrone, MA; Romeo, F; Sergi, D, 2018) |
| "In this study, metoprolol was the most commonly used agent for atrial fibrillation with RVR." | 3.85 | Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data. ( Celi, LA; Chahin, A; Chen, KP; Cooper, AZ; Ghassemi, MM; Moskowitz, A, 2017) |
| " Amiodarone, an antiarrhythmic associated with significant adverse effects with long-term use, is commonly used for new-onset atrial fibrillation in critical illness (NAFCI)." | 3.85 | Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness. ( Alpert, J; Bloom, J; Dongtai, W; Huckleberry, Y; Kopp, B; Leelathanalerk, A, 2017) |
| "Administration of acute or chronic pretransplant amiodarone was not related to an increased occurrence of bradycardia, requirement for permanent pacemaker implantation, or mortality after HTX." | 3.85 | Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. ( Bruckner, T; Darche, FF; Doesch, AO; Helmschrott, M; Katus, HA; Rivinius, R; Ruhparwar, A; Thomas, D, 2017) |
| " Dronedarone is an antiarrhythmic agent that was recently approved for the treatment of atrial fibrillation." | 3.85 | Dronedarone produces early regression of myocardial remodelling in structural heart disease. ( Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML, 2017) |
| "Clinical trials have reported a low time in therapeutic range (TTR) in patients with atrial fibrillation treated with both warfarin andamiodarone." | 3.83 | The effect of the amiodarone-warfarin interaction on anticoagulation quality in a single, high-quality anticoagulation center. ( Ege, EJ; Flaker, G; Koerber, SM; Petroski, GF; Riggs, KW; White, RD, 2016) |
| " We identified factors associated with IV AF treatments (?-blockers [BBs], calcium channel blockers [CCBs], digoxin, or amiodarone) during sepsis." | 3.83 | Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study. ( Benjamin, EJ; Evans, SR; Walkey, AJ; Winter, MR, 2016) |
| "Iodine-induced thyrotoxicosis, which raises several diagnostic and therapeutical challenges, is often overlooked." | 3.83 | Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly. ( Cascio, C; Foppiani, L; Lo Pinto, G, 2016) |
| "The authors assessed the efficacy and safety of landiolol, an ultra-short-acting beta-blocker, with those of amiodarone in the restoration of sinus rhythm for postoperative atrial fibrillation (POAF) in intensive care unit (ICU) patients." | 3.83 | Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients. ( Fujino, Y; Ohta, N; Shibata, SC; Uchiyama, A, 2016) |
| "Although oral amiodarone (AMD) has been used for the management of atrial fibrillation (AF), serious complications such as interstitial pneumonia (IP) occur very occasionally." | 3.83 | Obesity Is Associated With the Development of Interstitial Pneumonia Under Long-Term Administration of Amiodarone in Refractory Atrial Fibrillation Patients. ( Fujino, T; Fukunaga, S; Ikeda, T; Kinoshita, T; Kitahara, K; Kobayashi, K; Koike, H; Koike, M; Sato, H; Shinohara, M; Suzuki, T; Yuzawa, H, 2016) |
| "The aim of this study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant atrial fibrillation (AF) and mortality after HTX." | 3.83 | Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. ( Akhavanpoor, M; Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleissner, CA; Helmschrott, M; Katus, HA; Rivinius, R; Ruhparwar, A; Schmack, B; Schweizer, PA; Thomas, D, 2016) |
| "Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown." | 3.83 | Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. ( Aissaoui, N; Alazard, M; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Le-Heuzey, JY; Salem, JE; Urien, S, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 3.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "Sotalol and amiodarone are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation (POAF)." | 3.83 | Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. ( Brophy, JM; Johnson, SM, 2016) |
| "Amiodarone is an antiarrhythmic drug that is frequently used to control atrial fibrillation (AF)." | 3.83 | Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis. ( Cai, S; Feng, W; Sun, L; Wang, M; Zhao, Q, 2016) |
| "In this study, our aim is to examine the role of the neutrophil to lymphocyte ratio (NLR) in the predictions of recurrence under long-term follow-up in patients whose sinus rhythms (SRs) were restored with amiodarone in acute atrial fibrillation (AF)." | 3.81 | Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone. ( Karapınar, H; Karavelioğlu, Y; Kurt, R; Memiç, K; Sarak, T; Yilmaz, A; Yüksel, M, 2015) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 3.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "A 77-year-old female patient with symptomatic atrial fibrillation with fast ventricular rate despite conventional antiarrhythmic therapy was treated with dronedarone." | 3.81 | Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug. ( Figulla, HR; Franz, M; Gecks, T; Jung, C; Kühnert, H; Prochnau, D; Schliemann, S, 2015) |
| "Median trough plasma concentration of dabigatran in our study was observed to be similar to median trough plasma concentration of dabigatran at a dose of 150 mg bid without concomitant dronedarone in earlier studies with low reported rate of bleeding and thrombosis." | 3.81 | Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. ( Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015) |
| "Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm." | 3.81 | Acute severe back pain radiating to the whole body during intravenous administration of amiodarone. ( Shen, H; Yan, Y, 2015) |
| "Intravenous amiodarone can cause severe and refractory hypotension." | 3.81 | Amiodarone-Induced Life-Threatening Refractory Hypotension. ( Doshi, D; Jayawardana, R, 2015) |
| "Amiodarone is often prescribed in the management of atrial fibrillation (AF) but is known to cause significant end-organ toxicities." | 3.81 | Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. ( Adelstein, E; Alam, MB; Jain, SK; Khattak, F; Leef, G; Munir, MB; Patel, D; Qin, D; Rattan, R; Saba, S, 2015) |
| "There are limited data on mortality outcomes associated with use of amiodarone in atrial fibrillation and flutter (AF)." | 3.81 | Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. ( Fan, J; Frayne, SM; Heidenreich, PA; Kaiser, DW; Perino, AC; Phibbs, CS; Schmitt, S; Than, CT; Turakhia, MP; Ullal, AJ, 2015) |
| " Two weeks after amiodarone initiation (200 mg/d) hemoptysis occurred and computed tomography revealed unilateral pulmonary infiltrates with ground-glass opacities limited to the lower lobe of the left lung." | 3.81 | [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease]. ( Elikowski, W; Małek, M; Skowroński, M; Skrzywanek, P; Wróblewski, D; Zawilska, K, 2015) |
| "This study aimed to assess safety and cardiovascular outcomes of dronedarone in patients with paroxysmal or persistent atrial fibrillation (AF) with coronary heart disease (CHD)." | 3.80 | Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. ( Connolly, SJ; Crijns, HJ; Hohnloser, SH; Naditch-Brûlé, L; Page, RL; Pisters, R; Torp-Pedersen, C, 2014) |
| "A dronedarone utilization study using US MarketScan and InVision Data Mart databases was conducted to estimate the prevalence of the following: (1) dronedarone use in contraindicated patients with worsening heart failure (HF) or hospitalization for HF within 1 month before dronedarone prescription; (2) concomitant prescribing of contraindicated drugs; and (3) recommended creatinine testing after dronedarone initiation among dronedarone users." | 3.80 | Assessment of dronedarone utilization using US claims databases. ( Caubel, P; Dai, W; Juhaeri, J; Koren, A; Tcherny-Lessenot, S; Thammakhoune, J; Wu, C; Wu, J, 2014) |
| " We analyzed 3 guidelines from medical specialty societies about dronedarone hydrochloride, an antiarrhythmic drug related to amiodarone hydrochloride, for treatment of patients with atrial fibrillation." | 3.80 | Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. ( Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P, 2014) |
| "The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/flutter (AF/AFL)." | 3.80 | Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. ( Jhaveri, M; Kim, MH; Koren, A; Lin, J, 2014) |
| "There has been concern about the safety of dronedarone, especially for patients with heart failure and permanent atrial fibrillation (AF)." | 3.80 | Safety of dronedarone in routine clinical care. ( Friberg, L, 2014) |
| "Despite sparse clinical data, current atrial fibrillation (AF) guidelines favor amiodarone as a drug of choice for patients with left ventricular hypertrophy (LVH)." | 3.80 | Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. ( Chung, MK; Chung, R; Houghtaling, PL; Lindsay, BD; Niebauer, MJ; Tchou, M; Tchou, PJ, 2014) |
| "We investigated the effect of amiodarone (AMD) administered intravenously for the treatment of post-operative atrial fibrillation( POAF) after cardiac surgery." | 3.80 | [Therapeutic use of amiodarone against postoperative fibrillation after cardiac surgery]. ( Araki, E; Kawaharada, N; Muraki, S; Nakashima, S; Osawa, H; Sakurada, T; Sasaki, J, 2014) |
| " More specifically, this Mini-Hot-Topic symposium has reviewed for you: (1) the evidence supporting the new novel oral anticoagulants (NOACs) as first-line therapy for prevention of stroke and systemic embolism in patients with "nonvalvular" atrial fibrillation (NVAF); (2) the winding path taken by dronedarone in reaching its current place in our antiarrhythmic armamentarium - in which it still has a role; and (3) the contrasting decisions made with respect to the marketing of vernakalant in Europe versus the United States." | 3.80 | Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come? ( Reiffel, JA, 2014) |
| "We evaluated the association of respiratory complications and amiodarone use in patients with atrial fibrillation (AF) after major lung resection." | 3.80 | Use of amiodarone after major lung resection. ( Berry, MF; D'Amico, TA; Onaitis, MW, 2014) |
| "Pulmonary opacities have many causes we are presenting a case of pulmonary opacity in a patient of breathlessness; who was on amiodarone for atrial fibrillation (AF)." | 3.80 | Amiodarone induced pulmonary toxicity in a case of atrial fibrillation. ( Deodhar, KY; Patil, AS; Ranpise, SM; Sirsikar, SS, 2014) |
| " He was diagnosed with atrial fibrillation 2 years previously and started on amiodarone and warfarin." | 3.80 | Amiodarone-induced thyrotoxicosis: type 1 or type 2? ( Khan, A; Puttanna, A; Raskauskiene, D, 2014) |
| "The clinical efficacy in preventing the recurrence of atrial fibrillation (AF) is higher for amiodarone than for dronedarone." | 3.80 | In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology. ( Barthel, P; Dössel, O; Loewe, A; Lutz, Y; Schmidt, G; Scholz, EP; Seemann, G; Sinnecker, D; Wilhelms, M, 2014) |
| "Patients underwent amiodarone treatment for various reasons, most often atrial fibrillation, for more than 2 years, and those that received a cumulative dose > 100 g were enrolled." | 3.80 | The diagnostic utility of chest computed tomography scoring for the assessment of amiodarone-induced pulmonary toxicity. ( Kang, IS; Kim, KJ; Kim, Y; Park, SH, 2014) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| "We present the case of intentional caffeine poisoning after ingestion of tablets containing guarana extract, complicated by atrial fibrillation." | 3.80 | Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose. ( Biedroń, W; Ciszowski, K; Gomólka, E, 2014) |
| "Many patients with atrial fibrillation (AF) receive amiodarone." | 3.79 | Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study. ( Lebedev, AD; Lebedev, DS; Mikhaylov, EN; Orshanskaya, VS; Szili-Torok, T, 2013) |
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 3.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 3.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "Dronedarone, a non-iodinated derivative of amiodarone, has been approved for use as a second-line agent for atrial fibrillation (AF)." | 3.79 | The dronedarone shared-care clinical model and database: a coordinated paradigm to optimize management of evolving clinical recommendations. ( Cinnamond, N; Connolly, M; Damani, L; Hussey, S; Menown, IB, 2013) |
| "Dronedarone was introduced in 2009 as a new antiarrhythmic agent and since then has been increasingly prescribed in atrial fibrillation or flutter." | 3.79 | Severe toxic hepatitis associated with dronedarone. ( Jahn, S; Lackner, C; Stauber, RE; Zollner, G, 2013) |
| "In clinical trials, dronedarone lowers ventricular rate during atrial fibrillation (AF)." | 3.79 | Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation. ( Belardinelli, L; Kanas, AF; Machado, AD; Nearing, BD; Pagotto, VP; Sobrado, LF; Sobrado, MF; Varone, BB; Verrier, RL; Zeng, D, 2013) |
| "Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF)." | 3.79 | Efficacy and tolerability of dronedarone for patients with atrial fibrillation. ( Goldberger, JJ; Teme, T, 2013) |
| " Amiodarone, the drug of choice for arrhythmia treatment in such patients, can cause a number of complications, including amiodarone induced thyrotoxicosis (AIT)." | 3.79 | Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome. ( Czarnywojtek, A; Fichna, M; Florek, E; Greberska, W; Guzik, P; Kwiecinska, B; Lodyga, M; Ruchała, M; Waśko, R; Woliński, K; Zgorzalewicz-Stachowiak, M, 2013) |
| "The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 3.79 | Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. ( Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M, 2013) |
| "Dronedarone is a new antiarrhythmic agent that has only recently been approved for the therapy of atrial fibrillation (AF)." | 3.79 | Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). ( Boenigk, H; Braun-Dullaeus, RC; Esperer, HD; Genz, C; Herold, J; Kluba, K; Said, SM; Schmeisser, A; Wiedemann, AK, 2013) |
| "Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF)." | 3.79 | Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine. ( Duncker, D; Gardiwal, A; Klein, G; König, T; Lüsebrink, U; Oswald, H; Schreyer, H, 2013) |
| "To examine whether low-dose ranolazine and/or dronedarone can protect against vulnerability to atrial fibrillation (AF) and ventricular tachyarrhythmias." | 3.79 | Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ( Belardinelli, L; Kanas, AF; Nearing, BD; Pagotto, VP; Sobrado, MF; Verrier, RL; Zeng, D, 2013) |
| "Our study showed that during the intra- and postoperative periods, both amiodarone and magnesium sulfate are effective at preventing the incidence of atrial fibrillation following lung resection surgery in comparison to the control group." | 3.79 | A comparative study between amiodarone and magnesium sulfate as antiarrhythmic agents for prophylaxis against atrial fibrillation following lobectomy. ( Abdel Azeem, MS; Al-Agaty, AE; Ali, WG; Khalil, MA, 2013) |
| "Multiple studies have shown that amiodarone is effective in treating atrial fibrillation (AF), but is associated with a relatively high incidence of side effects; however, due to amiodarone's long elimination half-life (20-100 days), physicians may hesitate to start other drugs until it has fully cleared." | 3.79 | Effects of dronedarone started rapidly after amiodarone discontinuation. ( Aliot, E; Capucci, A; Connolly, S; Crijns, H; Hohnloser, S; Immordino, L; Kowey, P; Radzik, D; Roy, D, 2013) |
| "Amiodarone is a widely used antiarrythmic drug for various atrial and ventricular arrhythmias." | 3.78 | Amiodarone-induced T-U fusion. ( Omar, HR, 2012) |
| " Here we describe a Caucasian woman who developed a bronchiolitis obliterans organizing pneumonia (BOOP)-like interstitial pneumonia after PTU administration for amiodarone-induced thyrotoxicosis." | 3.78 | Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis. ( Brigante, G; Diazzi, C; Rochira, V; Rossi, G, 2012) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 3.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "Several key reports from the American Heart Association meeting, held in Orlando (FL, USA) in November 2011, are presented related to anti-thrombotic therapy in acute coronary syndrome and the use of dronedarone in permanent atrial fibrillation is discussed in this brief (and selective) overview of this meeting." | 3.78 | Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. ( Lip, GY; Shantsila, A, 2012) |
| "According to the update of the Finnish guidelines for management of patients with atrial fibrillation (AF) dronedarone should be used only in patients with non-permanent AF as a second line medication." | 3.78 | [Update on current care guidelines: atrial fibrillation]. ( , 2012) |
| " He had been on amiodarone for atrial fibrillation and developed hemorrhagic manifestations due to factor V inhibitors within a few months of initiating amiodarone therapy." | 3.78 | A rare case of factor V inhibitor in a patient on amiodarone therapy. ( Lipshitz, J; Patel, D; Shreenivas, AV, 2012) |
| "Dronedarone is currently used for the treatment of paroxysmal and persistent atrial fibrillation (AF)." | 3.78 | Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. ( Becker, R; Katus, HA; Schmidt, C; Schweizer, PA; Thomas, D; Wiedmann, F, 2012) |
| "Nurses noted that the rate of phlebitis was high when intravenous amiodarone was infused via a peripheral site." | 3.78 | Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone. ( Boyce, BA; Yee, BH, 2012) |
| "We enrolled 52 patients with atrial fibrillation and valve disease divided in 2 groups: group 1 (26 patients) underwent intraoperative radiofrequency ablation and was followed by a team of skilled cardiologists who treated recurrences with amiodarone and electrical cardioversion; group 2 (26 patients) was treated with intraoperative radiofrequency ablation but patients were thereafter treated by their local hospital or personal cardiologist." | 3.78 | Role of an aggressive rhythm control strategy on sinus rhythm maintenance following intra-operative radiofrequency ablation of atrial fibrillation in patients undergoing surgical correction of valvular disease. ( Buja, G; Gerosa, G; Leoni, L; Nalli, C; Sponga, S; Voisine, P, 2012) |
| "Amiodarone is a commonly used medication in the treatment of atrial fibrillation (AF) of recent onset." | 3.77 | A formula for the stratified selection of patients with paroxysmal atrial fibrillation in the emergency setting: a retrospective pilot study. ( Ekmektzoglou, KA; Koudouna, E; Perrea, DN; Stroumpoulis, K; Tsitsilonis, S; Vlachos, IS; Xanthos, T, 2011) |
| "Amiodarone is a potent anti-atrial fibrillation (AF) agent; however, its systemic administration induces serious side effects such as interstitial pneumonia." | 3.77 | Topical application of a biodegradable disc with amiodarone for atrial fibrillation. ( Hyon, SH; Ikeda, T; Marui, A; Minakata, K; Miwa, S; Nakajima, N; Saito, N; Sakata, R; Shimamoto, T; Takeda, T; Uehara, K, 2011) |
| "We investigated the effect of amiodarone on prevention of post-operative atrial fibrillation (POAF) after cardiac surgery." | 3.77 | [Prophylactic use of amiodarone against postoperative atrial fibrillation after cardiac surgery]. ( Araki, E; Osawa, H; Sakurada, T; Sasaki, J, 2011) |
| "Amiodarone is recognized as the most effective therapy for maintaining sinus rhythm (SR) post cardioversion in patients with atrial fibrillation (AF)." | 3.77 | Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. ( Hachiya, H; Higuchi, K; Hirao, K; Inaba, O; Isobe, M; Kawabata, M; Tanaka, Y; Yagishita, A, 2011) |
| "Amiodarone (AM)-induced thyrotoxicosis (AIT) is a condition with uncertainties from the diagnostic and therapeutic standpoints." | 3.77 | Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis. ( Braga, DC; Carvalho, D; Fernandes, H; Matos, MJ; Pereira, J; Souto, SB, 2011) |
| " Patient had atrial fibrillation on 3rd post-operative day requiring loading dose of amiodarone followed by maintenance dose to control the arrhythmia." | 3.77 | Ultra-short course of low-dose amiodarone-induced post-operative fatal pulmonary toxicity. ( Nair, SG; Patel, V; Viswam, D, 2011) |
| "The aim of this work was to analyze the prevalence of level function disorder in patients with atrial fibrillation taking constantly amiodarone." | 3.77 | [Abnormal liver function during therapy with amiodarone in patients with persistent atrial fibrillation]. ( Buniatian, ND; Korsun, LV; Sviridenko, AV; Uteshev, DB; Voronkina, MV, 2011) |
| "Amiodarone is commonly used in the treatment of refractory paroxysmal atrial fibrillation." | 3.76 | Hepatic dysfunction and neurotoxicity in a patient receiving long-term low-dose amiodarone therapy. ( Arkun, A; Birkhahn, RH; Grau, T; Van Deusen, SK, 2010) |
| "The combination of chronic amiodarone and acute ranolazine produces a synergistic use-dependent depression of I(Na)-dependent parameters in isolated canine atria, leading to a potent effect of the drug combination to prevent the induction of atrial fibrillation." | 3.76 | Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A; Sicouri, S, 2010) |
| "Clinical studies have demonstrated the efficacy of oral and intravenous amiodarone therapy to prevent postoperative atrial fibrillation." | 3.76 | Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch. ( Boerakker, MJ; Bolderman, RW; Bruin, P; Dias, AA; Hermans, JJ; Maessen, JG; van der Veen, FH, 2010) |
| " Food and Drug Administration for the treatment of patients with atrial fibrillation (AF) as a safe alternative to amiodarone." | 3.76 | Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A, 2010) |
| "The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0." | 3.76 | Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. ( Johnston, SS; Lin, J; Naccarelli, GV; Patel, PP; Schulman, KL, 2010) |
| " Patients with symptomatic new-onset atrial fibrillation or lasting >15 minutes were treated with amiodarone and with DC shock in prolonged cases." | 3.76 | Atrial fibrillation after cardiac surgery: incidence, risk factors, and economic burden. ( Braconi, L; Carone, E; Gelsomino, S; Gensini, GF; Ghilli, L; La Meir, M; Maessen, J; Mattesini, A; Padeletti, L; Puggelli, F; Rossi, A; Rosso, G; Rostagno, C; Stefàno, PL, 2010) |
| "To describe a challenging patient case in which dronedarone was selected for a patient with atrial fibrillation and heart failure; the drug may have been associated with worsening heart failure, leading to acute renal and hepatic failure." | 3.76 | Worsening heart failure in the setting of dronedarone initiation. ( Coons, JC; Plauger, KM; Seybert, AL; Sokos, GG, 2010) |
| "To observe the therapeutic efficacy and safety of amiodarone combined with Shenmai Injection (参麦注射液) on atrial fibrillation." | 3.76 | Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection (参麦注射液). ( Chen, ZM; Deng, M; Ma, W; Sui, XQ; Xu, Y; Zhu, SB, 2010) |
| "The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF)." | 3.76 | Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Sicouri, S, 2010) |
| "We report for the first time a case of an acute disabling low-back pain episode during intravenous administration of amiodarone in a patient with atrial fibrillation." | 3.76 | Acute disabling low-back pain during intravenous administration of amiodarone: could intravenous to oral switch therapy be a safe strategy? ( García-Alberola, A; Manzano-Fernández, S; Moreno-Flores, V; Sánchez, M, 2010) |
| "The objective of the current report is to describe the case of a previously asymptomatic patient receiving amitriptyline who developed extrapyramidal symptoms within 1 month of initiating concomitant treatment with amiodarone for atrial fibrillation." | 3.76 | Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. ( Pawar, PS; Woo, DA, 2010) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone plus angiotensin II receptor blockers (ARBs) and catheter ablation may improve sinus rhythm maintenance of paroxysmal atrial fibrillation (AF), their clinical efficacies have not been compared." | 3.75 | Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. ( Lan, X; Ling, Z; Liu, Z; Su, L; Wu, J; Yang, X; Yin, Y; Zrenner, B, 2009) |
| "Evidence from multiple trials demonstrates the efficacy of prophylactic beta-blocker, amiodarone, and corticosteroid administration in reducing the incidence of postoperative atrial fibrillation." | 3.75 | Current use of prophylactic strategies for postoperative atrial fibrillation: a survey of Canadian cardiac surgeons. ( Green, MS; Hendry, P; Lam, BK; Price, J; Rubens, FD; Tee, R, 2009) |
| "Patients with persistent or paroxysmal atrial fibrillation and at least 1 risk factor for cardiovascular hospitalization were randomized to receive dronedarone (400 mg BID) or double-blind matching placebo and followed up for a minimum of 1 year to a common termination at 30 months." | 3.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter." | 3.75 | Dronedarone (Multaq) for atrial fibrillation. ( , 2009) |
| " During amiodarone infusion a torsade de pointes occurred, which was immediately converted to sinus rhythm by synchronized cardioversion." | 3.75 | "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. ( Benazzi, B; Bernardi, M; Berzigotti, A; Bracci, E; Di Micoli, A; Trevisani, F; Zambruni, A; Zappoli, P; Zoli, M, 2009) |
| "Several studies demonstrated the efficacy of amiodarone pretreatment in achieving bet-ter outcomes after electrical cardioversion of atrial fibrillation." | 3.74 | [Effects of pretreatment with amiodarone infusion in patients with persistent atrial fibrillation submitted to external electrical cardioversion: a single center experience]. ( Bielli, M; Dellavesa, P; Franchetti Pardo, N; Maffè, S; Nicali, R; Paffoni, P; Paino, AM; Parravicini, U; Perucca, A; Signorotti, F; Zanetta, M; Zenone, F, 2008) |
| " The ATHENA study showed that dronedarone reduced the incidence of the composite outcome of cardiovascular hospitalisation or death, in patients with atrial fibrillation or flutter, 29% of whom had a history of heart failure, compared with placebo." | 3.74 | Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. ( Clark, AL; Cleland, JG; Coletta, AP; Cullington, D, 2008) |
| "Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone." | 3.74 | Amiodarone pulmonary toxicity after lung transplantation. ( Arrossi, A; Budev, M; Diaz-Guzman, E; Kanne, JP; Mireles-Cabodevila, E, 2008) |
| "Although amiodarone is one of the most effective pharmacologic agents used in clinical management of atrial fibrillation (AF), little is known about its differential effects in atrial and ventricular myocardium." | 3.74 | Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. ( Antzelevitch, C; Burashnikov, A; Carlsson, L; Di Diego, JM; Ferreiro, M; Sicouri, S, 2008) |
| "We describe the effects of iopanoic acid on daily levels of free triiodothyronine (FT(3)) and free thyroxine (FT(4)) in a patient with progressive type II amiodarone-induced thyrotoxicosis (AIT) who was undergoing thyroidectomy." | 3.74 | Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. ( Falciglia, M; Matrka, L; Nikiforov, Y; Steward, D, 2008) |
| "Special attention should be paid to patients on treatment with amiodarone and/or a diagnosis of atrial fibrillation as they may have an increased risk of fracture." | 3.74 | Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. ( Mosekilde, L; Rejnmark, L; Vestergaard, P, 2007) |
| " Amiodarone is also used for the cardioversion of atrial fibrillation and prolongs the QT interval but rarely causes torsades de pointes." | 3.74 | The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm. ( Bonios, M; Exarchos, P; Kogias, J; Melexopoulou, C; Sideris, S; Tsatiris, K, 2007) |
| "To evaluate the usefulness of Doppler parameters in the differentiation between the two types of amiodarone-associated thyrotoxicosis (AAT)." | 3.74 | Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. ( Cerri, GG; Chammas, MC; Farage, L; Jorge, PT; Macedo, TA; Santos, VA; Souza, LP; Watanabe, T, 2007) |
| "Amiodarone has been advocated as an effective "long-term" therapy for atrial rhythm control in patients with atrial fibrillation (AF)." | 3.74 | Amiodarone therapy for atrial rhythm control: insights gained from a single center experience. ( Chandhok, S; Schwartzman, D, 2007) |
| "The aim of the article was to assess the efficacy of treatment of atrial fibrillation (AE) and congestive heart failure (CHF) with Enalapril in combination with Cordaron." | 3.74 | [Dynamics of echocardiographic changes and the tactic of optimal therapy in patients with atrial fibrillation with chronical heart failure]. ( Abuladze, GV; Dzhashi, IA; Dzhindzholiia, NA; Gudzhedzhiani, LA; Narsiia, EV, 2007) |
| "Epididymitis, as an unusual side-effect of amiodarone use, in a patient with dilated cardiomyopathy is reported along with a pertinent literature review." | 3.74 | Amiodarone-induced epididymitis: a case report and review of the literature. ( Ikonomidis, I; Kremastinos, D; Lekakis, I; Nikolaou, M; Tsiodras, S, 2007) |
| "To assess if prophylaxis with moderate doses of amiodarone in the postoperative period of cardiac surgery (coronary artery bypass grafting and/or valve surgery), reduces the incidence of atrial fibrillation in patients with high risk for developing this arrhythmia." | 3.74 | Prevention of atrial fibrillation with moderate doses of amiodarone in the postoperative period of cardiac surgery is safe and effective in patients with high risk for developing this arrhythmia. ( Alves, RJ; Brito, Gd; Geovanini, GR; Glauser, VA; Miguel, GA; Nakiri, K, 2007) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "This study was designed to compare clinical efficacy of segmental pulmonary vein ablation (SPVI), amiodarone or amiodarone plus losartan on sinus rhythm maintenance in patients with lone paroxysmal atrial fibrillation (PAF)." | 3.74 | [Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study]. ( Chen, YQ; Lan, XB; Ling, ZY; Liu, D; Liu, ZC; Luo, KL; She, Q; Su, L; Wu, JJ; Yang, XY; Yin, YH; Zrenner, B, 2007) |
| "To present an unusual case of atrial fibrillation due to electric shocks by the torpedo ray (electric ray)." | 3.74 | Atrial fibrillation in a commercial diver. ( Hussaini, S; Taimur, Z, 2008) |
| "Pharmacotherapy of atrial fibrillation has changed towards increased beta-blocker use with a coincident decrease in the use of other rate-limiting drugs and sotalol." | 3.74 | Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. ( Abildstrom, SZ; Folke, F; Friberg, J; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Madsen, M; Poulsen, HE; Rasmussen, S; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2008) |
| "Postoperative atrial fibrillation following cardiothoracic surgery is common and frequently managed with intravenous (IV) amiodarone." | 3.74 | The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations. ( Boyd, SY; Duffy, B; Roth, JE; Rubal, BJ; Slim, AM, 2007) |
| "Amiodarone is recommended for the cardioversion of atrial fibrillation and prevention of paroxysmal atrial fibrillation in patients with structural heart disease, coronary artery disease or left ventricular dysfunction." | 3.74 | Ataxia caused by amiodarone in older people. ( Hindle, JV; Ibrahim, A; Ramaraj, R, 2008) |
| "In the Atrial Fibrillation Follow-up Investigation of Rhythm Management study, preexisting pulmonary disease did not preclude the use of amiodarone." | 3.73 | Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. ( Greene, HL; Kostis, J; Olshansky, B; Rubin, A; Sami, M; Shorofsky, S; Slee, A, 2005) |
| "The factors controlling the preventive effect of long-term amiodarone therapy were evaluated in patients with paroxysmal atrial fibrillation." | 3.73 | [Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles]. ( Horiuchi, D; Komatsu, T; Nakamura, S; Okumura, K; Suzuki, O; Yomogida, K, 2005) |
| "To evaluate the effect of prophylactic amiodarone on length of stay (LOS), postoperative stroke, and postoperative atrial fibrillation (POAF)." | 3.73 | Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gillespie, EL; Ismaili, A; Kardas, M; Kluger, J; Perkerson, KA; Takata, H; White, CM, 2005) |
| "This report documents the occurrence of torsades de pointes (TdP) caused by marked QT interval prolongation in the case of a 71-year-old woman receiving both metronidazole and amiodarone for the treatment of pseudomembranous colitis and paroxysmal atrial fibrillation." | 3.73 | QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. ( Efraimidis, M; Kardaras, F; Kounas, SP; Letsas, KP; Sideris, A, 2005) |
| "In 37 patients with long-lasting persistent atrial fibrillation (mean duration 21 +/- 36 months) with (n = 19) or without (n = 18) amiodarone pretreatment as antiarrhythmic prophylaxis, maximum and minimum P wave duration and P wave dispersion were measured 1 min after internal cardioversion." | 3.73 | P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. ( Biffi, M; Boriani, G; Branzi, A; Camanini, C; Corazza, I; Diemberger, I; Martignani, C; Valzania, C; Zannoli, R, 2005) |
| " Because of ischemic cardiomyopathy with paroxysmal atrial fibrillation as well as recurrent ventricular tachycardias and fibrillation he was treated with phenprocoumon and amiodarone (200 mg per day) for 2 years." | 3.73 | [Severe intrahepatic cholestasis in a 66-year old male patient with medically treated atrial fibrillation]. ( Brennenstuhl, M; Gundling, F; Nerlich, A; Schepp, W; Schmidt, O; Tillmann, HL, 2005) |
| "Ibutilide and amiodarone are used for the pharmacological conversion of atrial fibrillation (AF) or flutter (AFl), but their efficacy is rather moderate." | 3.73 | Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. ( Dilaveris, P; Gialafos, E; Giannopoulos, G; Stefanadis, C; Synetos, A, 2005) |
| "To assess the effects of metoprolol and amiodarone on atrial and ventricular activity during atrial fibrillation (AF) in post-surgical patients, and to develop and use a mathematical model of the atrioventricular (AV) node during AF that incorporates parameters describing the properties of the AV node to evaluate the physiological basis of the drug effects." | 3.73 | Effects of antiarrhythmic drug therapy on atrioventricular nodal function during atrial fibrillation in humans. ( Glass, L; Mangin, L; Pagé, P; Vinet, A, 2005) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 3.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 3.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "Amiodarone has long been the anti-arrhythmic drug of choice for the treatment of atrial fibrillation." | 3.73 | [Amiodarone: treatment or cause of atrial fibrillation?]. ( Allali, G; Falconnet, C, 2005) |
| "To assess the safety and efficacy of amiodarone used after unsuccessful direct current (DC) cardioversion of persistent atrial fibrillation (AF)." | 3.73 | Amiodarone after unsuccessful direct-current cardioversion of persistent atrial fibrillation. ( Jasik, M; Kiliszek, M; Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kapłon, B, 2005) |
| "By exclusion, it was determined that the subepithelial depositions and cystic formations were secondary to an acute amiodarone dosage increase by a new practitioner." | 3.73 | Acute onset of halos and glare: bilateral corneal epithelial edema with cystic eruptions--atypical presentation of amiodarone keratopathy. ( Dovie, JM; Gurwood, AS, 2006) |
| "In this report we discuss a patient with predominant right heart failure and pulmonary hypertension, caused by thyrotoxicosis due to Graves disease, which deteriorated to asystole, due to amiodarone administration for rapid atrial fibrillation." | 3.73 | Pulmonary hypertension and predominant right heart failure in thyrotoxicosis. ( Goldin, Y; Justo, D; Nimrod, A; Paran, Y, 2006) |
| "To determine whether prophylactic amiodarone, dosed according to Atrial Fibrillation Suppression Trial (AFIST) I and II regimens, is a cost-effective strategy for prevention of postoperative atrial fibrillation." | 3.73 | Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gallagher, R; Gillespie, EL; Kluger, J; Rancourt, JA; White, CM, 2006) |
| "Amiodarone and cedilanid may be the proper drugs for the treatment of paroxysmal atrial fibrillation in the elderly." | 3.73 | Drug therapy of paroxysmal atrial fibrillation in the elderly over 75 years old. ( Cao, J; Chen, DY; Zhu, BP, 2006) |
| "Amiodarone is one of the most efficient and safe antiarrhythmic drugs in the treatment of atrial fibrillation (AF)." | 3.73 | "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. ( Bitzen, A; Lewalter, T; Lüderitz, B; Schrickel, JW; Schwab, JO; Yang, A, 2006) |
| "The present study implies that initiation of amiodarone therapy in pts with structural heart disease and AF that are concomitantly treated with beta-blockers and digitalis may have an increased risk of amiodarone-associated pro-arrhythmia." | 3.73 | Pro-arrhythmic effects of amiodarone and concomitant rate-control medication. ( Bielik, H; Bitzen, A; Lewalter, T; Lüderitz, B; Schrickel, JW; Schwab, JO; Yang, A, 2006) |
| "Amiodarone may still be safely prescribed for Chinese patients who have baseline liver dysfunction." | 3.73 | Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. ( Chan, WW; Fung, JW; Ho, SS; Hui, HH; Kum, LC; Sanderson, JE; Wong, GW; Yu, CM, 2006) |
| "Amiodarone prophylaxis (AMP) reduces the prevalence of postoperative atrial fibrillation (POAF) after cardiac surgery." | 3.73 | Risk-stratified evaluation of amiodarone to prevent atrial fibrillation after cardiac surgery. ( Barnes, BJ; Gorton, ME; Grauer, DW; Howard, PA; Kirkland, EA; Kramer, JB; Muehlebach, GF; Reed, WA, 2006) |
| "Consecutive patients with persistent atrial fibrillation of at least 1 months' duration were included prospectively in a cardioversion protocol that involved standard antiarrhythmic pretreatment, with amiodarone being offered first, and follow-up." | 3.73 | [Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation]. ( Ferrero, A; García-Civera, R; Llácer, A; Martínez-Brotóns, AM; Morell, S; Plancha, E; Roselló, A; Ruiz-Granell, R, 2006) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 3.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "An 80-year-old man, who had been taking the antiarrhythmic drug amiodarone for chronic atrial fibrillation since October 2004, developed dyspnea and fever in June 2005, and was admitted to our hospital." | 3.73 | [A case of drug-induced pneumonitis due to amiodarone]. ( Hayashi, N; Hirose, M; Horiguchi, T; Itou, T; Kobayashi, K; Kondo, R; Ouhira, D; Shiga, M; Torigoe, H, 2006) |
| "Two patients presented with atrial fibrillation which was refractory to amiodarone but successfully treated with bepridil." | 3.73 | [Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports]. ( Hadano, Y; Iwami, T; Kimura, M; Matsuzaki, M; Miyazaki, Y; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2006) |
| "The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker." | 3.72 | Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. ( Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2003) |
| "The basis of the unique effectiveness of amiodarone for atrial fibrillation (AF) is poorly understood." | 3.72 | Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. ( Nattel, S; Schram, G; Shinagawa, K; Shiroshita-Takeshita, A, 2003) |
| "Authors describe a case of drug interaction between amiodarone and warfarin in 66-year-old man with recurrent atrial fibrillation." | 3.72 | [Long-term drug interaction of warfarin with amiodarone]. ( Hirmerová, J; Mádr, T; Suchý, D, 2003) |
| "Eleven patients developed amiodarone- induced thyrotoxicosis (AIT), ten developed amiodarone-induced hypothyroidism (AIH) and one patient first developed AIT, followed by AIH." | 3.72 | Differential diagnosis and clinical course of amiodarone-induced thyroid dysfunction. ( Acu, B; Alyan, O; Arda, K; Demirkan, D; Ozdemir, O; Soylu, M, 2003) |
| "The study analyzed the role of different variables that determine long-term sinus rhythm maintenance in patients with persistent atrial fibrillation who are treated with amiodarone." | 3.72 | Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. ( Blanco, MV; Bonato, R; Chiale, PA; Elizari, MV; Galperín, J; Lago, M; Ledesma, R; Molina, RT; Scapín, AO, 2003) |
| " We present a case of acute atrial fibrillation, with a rapid ventricular rate, successfully treated with intravenous amiodarone, in a 62-year-old man with dengue hemorrhagic fever, who had no structural heart disease." | 3.72 | Acute atrial fibrillation during dengue hemorrhagic fever. ( Braga de Paiva, JM; Faria Honório, J; Ferreira Júnior, JA; Horta Veloso, H; Junqueira Bellei, NC; Vicenzo de Paola, AA, 2003) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 3.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "A 76-year-old man underwent an emergency laparotoray for a ruptured abdominal aortic ancurysm After a few days he presented ischemia of the left side of the colon and subsequently atrial fibrillation developed that was treated with Amiodarone." | 3.72 | A complication of amiodarone infusion. ( Andreoni, P; Caspani, ML; Chiumello, D; Gattinoni, L; Rossi, F, 2004) |
| "To analyze action of digoxin and some non-digitalis drugs (beta-blockers, verapamil, amiodarone, d,l-sotalol) and their combinations on electrical activity of atria, frequency and structure of ventricular rhythm in patients with permanent atrial fibrillation." | 3.72 | [Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach]. ( Blagova, OV; Bogdanova, EA; Nedostup, AV; Platonova, AA, 2004) |
| "Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy." | 3.72 | [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131]. ( Arlot, S; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 3.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "Bradyarrhythmia requiring permanent pacemaker insertion has been associated with amiodarone use but the effect of amiodarone dose has not been investigated." | 3.72 | Effect of amiodarone dose on the risk of permanent pacemaker insertion. ( Abrahamowicz, M; Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2004) |
| "Amiodarone, given as a single intravenous bolus through a peripheral vein rapidly reduced ventricular rate and was well tolerated in patients with atrial fibrillation, even in the presence of congestive heart failure and cardiogenic shock." | 3.72 | Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. ( Hofmann, R; Kammler, J; Kypta, A; Leisch, F; Steinwender, C; Wimmer, G, 2004) |
| "To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed." | 3.71 | Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. ( Heidland, UE; Heintzen, MP; Hennersdorf, MG; Perings, C; Perings, SM; Strauer, BE; Zühlke, C, 2002) |
| "This study evaluated the cost-effectiveness of administering prophylactic intravenous (IV) amiodarone therapy to patients undergoing cardiac surgery according to their predicted risk of postoperative atrial fibrillation." | 3.71 | Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation. ( Mahoney, EM; Thompson, TD; Veledar, E; Weintraub, WS; Williams, J, 2002) |
| "Low-dose amiodarone was safe and effective in restoring and maintaining SR in patients with AF and rheumatic heart disease." | 3.71 | Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone. ( Kapoor, A; Kumar, S; Pandey, CM; Singh, RK; Sinha, N, 2002) |
| "To determine the safety of amiodarone therapy, we conducted a retrospective analysis of elderly patients hospitalized with AMI who experienced atrial fibrillation and had survived to hospital discharge (n = 17,597)." | 3.71 | Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. ( Gersh, BJ; Kilborn, MJ; Oetgen, WJ; Rathore, SS; Solomon, AJ, 2002) |
| "Association of autonomic status and efficacy of therapy with amiodarone was studied in 90 patients with paroxysmal atrial fibrillation of ischemic (n=45, mean age 62 years) and nonischemic (n=45, mean age 38 years) origin." | 3.71 | [Effect of amiodarone on autonomic status and its efficacy in the treatment of different variants of paroxysmal atrial fibrillation]. ( Guseva, IA; Shabalin, AV; Shaposhnikova, IuS, 2002) |
| "To study the efficacy and safety of low-dose amiodarone (AD) for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases." | 3.71 | [Efficacy and safety of low dose amiodarone for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases]. ( Chen, H; Yang, Y, 2001) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 3.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 3.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| "The medical records, including radiographic imaging, pathology and operative reports, of 2 postpubertal boys who had sterile epididymitis after prolonged therapy with amiodarone were reviewed." | 3.70 | Amiodarone induced epididymitis in children. ( Diamond, DA; Hutcheson, J; Peters, CA, 1998) |
| " There was no statistically significant in age, height, body surface area, duration of atrial fibrillation, amiodarone therapy, ejection fraction, or underlying heart disease." | 3.70 | Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation. ( Clem, KL; Love, CJ; Mehdirad, AA; Nelson, SD; Schaal, SF, 1999) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 3.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "We examined the efficacy and safety of intravenous amiodarone in 20 unselected patients with recent-onset atrial fibrillation who were admitted to a general internal medicine department during a 6-month period." | 3.70 | Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. ( Gur, H; Kreiss, Y; Sidi, Y, 1999) |
| "The cost-effectiveness of amiodarone prophylaxis of atrial fibrillation (AF) in patients undergoing coronary artery bypass grafting (CABG) was determined." | 3.70 | Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. ( Chow, MS; Dunn, A; Freeman-Bosco, L; Reddy, P; Richerson, M; White, CM, 1999) |
| "Among 92 consecutive patients with typical atrial flutter who underwent isthmus ablation 28 patients had atrial flutter without a history of previous atrial fibrillation (group I), 10 patients had atrial flutter following the initiation of amiodarone therapy for paroxysmal atrial fibrillation (group II) and 54 patients had atrial flutter and atrial fibrillation (group III)." | 3.70 | Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. ( Dorwarth, U; Gerth, A; Hoffmann, E; Reithmann, C; Remp, T; Spitzlberger, G; Steinbeck, G, 2000) |
| "Little information exists about the early outcomes of initiating amiodarone for atrial fibrillation in patients with advanced heart failure." | 3.70 | Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. ( Drazner, MH; Stevenson, LW; Stevenson, WG; Weinfeld, MS, 2000) |
| " An 81-year-old man known for paroxysmal atrial fibrillation and chronic renal insufficiency, treated with 6 mg budesonide for collagenous colitis, developed Cushing's syndrome under co-administration of amiodarone." | 3.70 | Cushing's syndrome in an 81-year-old patient treated with budesonide and amiodarone. ( Ahle, GB; Blum, AL; Dorta, G; Martinek, J; Oneta, CM, 2000) |
| "Ninety-one percent of patients with atrial fibrillation (AF) resisting electrical cardioversion because of immediate reinitiation of AF after the shock maintain long-term sinus rhythm with amiodarone and repeat cardioversion." | 3.70 | Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. ( Crijns, HJ; Schoonderwoerd, BA; Van Gelder, IC; Van Noord, T, 2000) |
| "Dronedarone (SR33589), an amiodarone-like noniodinated antiarrhythmic agent, is undergoing clinical trials in atrial fibrillation." | 3.70 | Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. ( Gautier, P; Guillemare, E; Marion, A; Nisato, D, 2000) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 3.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "A 70-year-old woman suffering from atrial fibrillation was treated with amiodarone, but developed acute respiratory failure necessitating mechanical ventilation for four weeks." | 3.69 | [Respiratory insufficiency due to pulmonary toxicity of amiodarone]. ( Jukema, GJ; Kerkhof, SC; Strack van Schijndel, RJ; ter Maaten, JC, 1995) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 3.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "We describe a case of hepatotoxicity, pancreatitis and inappropriate ADH secretion syndrome developed in a patient receiving chronic amiodarone treatment, not related to other causes." | 3.69 | [Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone]. ( Calvo Elipe, A; Gilsanz Fernández, C; Gorgojo Martínez, JJ; Guerrero Vega, E; Muñoz Ruiz, AI; Vera López, E, 1996) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 3.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "We investigated whether amiodarone delivered into the pericardial sac exerted an effect on atrial and ventricular refractoriness, impulse generation, and conduction and on induced atrial fibrillation." | 3.69 | Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. ( Ayers, GM; Ben-David, J; Besch, HR; Rho, TH; Zipes, DP, 1996) |
| "It is well known that amiodarone is effective for the treatment of atrial fibrillation." | 3.69 | Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells. ( Hara, Y; Nakaya, H; Tamagawa, M; Watanabe, Y, 1996) |
| "Amiodarone is effective for long-term maintenance of sinus rhythm after electrical cardioversion of refractory atrial fibrillation or flutter." | 3.69 | Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. ( Crijns, HJ; de Kam, PJ; Gosselink, AT; Lie, KI; Tieleman, RG; van den Berg, MP; van Gelder, IC; van Gilst, WH, 1997) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 3.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| "A case of amiodarone pulmonary toxicity (APT) occurring within days of the start of therapy and presenting with hemoptysis is reported." | 3.69 | Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. ( Goldstein, I; Heller, I; Isakov, A; Segev, D; Topilsky, M, 1997) |
| "To report our experience using high dose oral amiodarone (1,800 mg/day) for the reversion of atrial fibrillation to sinus rhythm in patients submitted to cardiac surgery." | 3.69 | [Use of high-dose oral amiodarone for the reversion of atrial fibrillation during the postoperative period of cardiac surgery]. ( Bodanese, LC; Brauner, FB; Brunini, TM; Guaragna, JC; Linhatti, JL; Martins, V; Pires, RC, 1997) |
| "Cyc-A, similar to or slightly stronger than amiodarone (Ami), decreased incidences of atrial fibrillation elicited by CaCl2-acetylcholine in mice and increased doses of aconitine, ouabain, or adrenaline to elicit atrial fibrillation in isolated guinea pig atria." | 3.69 | Effects of cycloprotobuxine-A on atrial fibrillation. ( Sheng, BH; Tan, YH; Wang, YX; Zheng, YM, 1997) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 3.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone." | 3.68 | Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. ( Essop, MR; Röthlisberger, C; Sareli, P; Skoularigis, J; Skudicky, D; Wisenbaugh, T, 1993) |
| " The patient was discharged with digitalis, nitrates, aspirin and amiodarone for prophylactic treatment of paroxystic atrial fibrillation." | 3.68 | [Ventricular fibrillation during stress test on a treadmill. Apropos of a case]. ( Baroffio, R; Croce, A; Tisi, G, 1993) |
| "To compare the efficacy and safety of intravenous (IV) amiodarone and procainamide for the treatment of atrial tachyarrhythmias (AT) in the critically ill." | 3.68 | Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. ( Chapman, MJ; Cunningham, DN; Moran, JL; O'Fathartaigh, MS; Peisach, AR, 1993) |
| "The effectiveness and safety of quinidine in the conversion of chronic atrial fibrillation after administration of amiodarone was assessed in 15 patients." | 3.68 | The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. ( Ansari-Leesar, M; Cohen, A; Faitel, K; Frumin, H; Kerin, NZ; Narala, C, 1993) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Fifty-two consecutive patients with atrial fibrillation underwent 86 episodes of attempted cardioversion with oral amiodarone, intravenous amiodarone or DC cardioversion." | 3.68 | A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. ( Horner, SM, 1992) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 3.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "The safety and efficacy of short intravenous therapy with amiodarone were evaluated in 44 patients (24 males, 20 females), aged 21-84 years, with supraventricular tachyarrhythmias newly arisen in less than 24 hours." | 3.68 | Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. ( Burzio, P; Latini, R; Marchisio, U; Veglio, F; Vietti-Ramus, G, 1992) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 3.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "The authors suggest a new method of choice of the drug (quinidine or cordarone) for the maintenance antiarrhythmic therapy after sinus rhythm recovery in patients with permanent atrial fibrillation, in patients with rheumatic heart disease and coronary heart disease." | 3.68 | [A method of choosing maintenance anti-arrhythmia therapy after sinus rhythm restoration in patients with a permanent form of atrial fibrillation]. ( Alekseevskaia, MA; Maevskaia, IV; Nedostup, AV, 1991) |
| "To shorten the delay in the onset of antiarrhythmic effect when using amiodarone for the conversion of refractory atrial tachyarrhythmias to sinus rhythm, 19 patients were given oral amiodarone according to a high-dose loading protocol." | 3.68 | Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. ( Mostow, ND; Noon, D; Rakita, L; Vrobel, TR, 1990) |
| "Twenty-seven patients with atrial fibrillation without any concomitant conduction abnormality have been treated with oral amiodarone in a daily maintenance dose of 200 mg." | 3.67 | Amiodarone in atrial fibrillation. ( Blomström, P; Edvardsson, N; Olsson, SB, 1984) |
| "Fifty-three patients with hypertrophic cardiomyopathy who had serious arrhythmias (45 patients), refractory chest pain (5 patients) or a high risk of sudden death (3 patients) received amiodarone for 6 to 96 months (median 18) after completion of a loading and an initial maintenance period." | 3.67 | Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. ( Goodwin, JF; Harris, L; Kleinebenne, A; Krikler, DM; McKenna, WJ; Oakley, CM; Rowland, E, 1984) |
| "Forty patients with atrial fibrillation (AF), 23 patients with ventricular extrasystoles (VES), and 11 patients with various arrhythmias (VA) were treated with amiodarone (0." | 3.67 | Amiodarone--application and clinical pharmacology in atrial fibrillation and other arrhythmias. ( Anastasiou-Nana, M; Levis, GM; Moulopoulos, SD, 1984) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 3.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "In order to assess the long-term efficacy of amiodarone, we followed 187 survivors of cardiac arrest and 316 patients with nonsustained or sustained ventricular tachycardia and compared the results of amiodarone therapy with the results of conventional therapy." | 3.67 | Long-term results of amiodarone therapy. ( Herre, JM; Sauve, MJ; Scheinman, MM, 1987) |
| "The clinical and electrophysiologic effects of oral amiodarone were evaluated in 10 patients with a history of spontaneous atrial fibrillation and a rapid ventricular response, complicating the Wolff-Parkinson-White syndrome." | 3.67 | Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. ( Feld, GK; Klitzner, T; Nademanee, K; Singh, BN; Stevenson, W; Weiss, J, 1988) |
| "We treated a 78-year-old patient with hyperthyroidism and atrial fibrillation with amiodarone 1200 mg/day for 3 days and methimazole 60 mg/day." | 3.67 | Treatment of atrial fibrillation associated with hyperthyroidism by amiodarone and methimazole. ( Cauchie, P; Decaux, G; Unger, J, 1988) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 3.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| "We observed a dangerous increase of ventricular rate following the intravenous administration of amiodarone in a patient with atrial fibrillation and rapid ventricular response associated with the Wolff-Parkinson-White syndrome." | 3.67 | Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. ( Gmeiner, R; Leisch, F; Schützenberger, W, 1987) |
| "In 65 patients a single oral dose of amiodarone (30 mg/kg) produced an antiarrhythmic effect on supraventricular or ventricular arrhythmias within 3 to 8 hours and lasted for 17 to 19 hours." | 3.67 | Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. ( Cheymol, G; Coumel, P; Escoubet, B; Jaillon, P; Lagier, G; Leclercq, JF; Maison-Blanche, P; Menasche, P; Piwnica, A; Poirier, JM, 1985) |
| "This study was performed to ascertain whether intravenous amiodarone would revert supraventricular tachycardias to sinus rhythm, and if so, whether this effect depended upon the underlying mechanism of the arrhythmia." | 3.67 | Intravenous amiodarone in the acute termination of supraventricular arrhythmias. ( Crick, JC; Curry, P; Davies, DW; Holt, P, 1985) |
| "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias." | 3.67 | Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. ( Clarke, B; Honey, M; Ward, DE, 1985) |
| "We report two patients who developed symptomatic life-threatening ventricular tachyarrhythmias with changing QRS axes (resembling torsades de pointes), during treatment of their supraventricular tachycardias with oral amiodarone." | 3.67 | Life-threatening ventricular arrhythmias provoked by amiodarone treatment. ( Eydt, J; Kumana, CR; Tanser, P, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 3.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "The efficacy of amiodarone was assessed in 38 patients with atrial fibrillation resistant to quinidine and an effort made to identify factors correlated with amiodarone response." | 3.67 | Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. ( Brady, PM; Brown, R; Greenspan, AM; Horowitz, LN; Kay, HR; Mintz, GS; Morganroth, J; Spielman, SR, 1985) |
| "Our use of amiodarone in 200 patients during an 8-year period confirms our previous experience which indicated that the drug was close to being the ideal antiarrhythmic agent in children's arrhythmias." | 3.66 | The use of amiodarone in children. ( Coumel, P; Do Ngoc, D; Lucet, V, 1983) |
| "Amiodarone was administered to 121 patients (82 males, 39 females; average age 59 years) with refractory atrial tachyarrhythmias." | 3.66 | Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. ( Graboys, TB; Lown, B; Podrid, PJ, 1983) |
| "Arrhythmias may be controlled in most patients with recurrent supraventricular tachycardia or atrial fibrillation with small to moderate maintenance doses of amiodarone (100 to 400 mg/day)." | 3.66 | Ten years of experience with amiodarone. ( Chiale, PA; Elizari, MV; Haedo, A; Lázzari, JO; Rosenbaum, MB, 1983) |
| "Amiodarone has proved to be a valuable drug in atrial fibrillation associated with the Wolff-Parkinson-White syndrome." | 3.66 | Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. ( Evans, T; Sheinman, BD, 1982) |
| "An esophageal lead was used to perform decremental atrial pacing and elective induction of atrial fibrillation (AF) in 5 patients with the Wolff-Parkinson-White (W-P-W) syndrome before and after amiodarone therapy." | 3.66 | Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy. ( Coltorti, F; Condorelli, M; Critelli, G; Grassi, G; Monda, V; Perticone, F, 1983) |
| "Amiodarone was used in 30 patients with tachyarrhythmias refractory to treatment with several antiarrhythmic agents." | 3.66 | Amiodarone in long term management of refractory cardiac tachyarrhythmias. ( Lowe, JB; Lubbe, WF; Mercer, CJ; Roche, AH, 1981) |
| "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes)." | 3.66 | Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide. ( Benhorin, J; Gottlieb, S; Keren, A; Stern, S; Tzivoni, D, 1982) |
| "Oral amiodarone has been used to treat 21 patients with various supraventricular arrhythmias; 13 had Wolff-Parkinson-White syndrome, which was complicated by atrial fibrillation and re-entry atrioventricular tachycardia in four, and re-entry tachycardia alone in the other nine." | 3.66 | Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. ( Krikler, DM; Rowland, E, 1980) |
| "The effect of amiodarone in the Wolff-Parkinson-White syndrome was studied with programmed electrical stimulation of the heart in 15 patients." | 3.65 | Effect of amiodarone in the Wolff-Parkinson-White syndrome. ( Bär, FW; Dohmen, HJ; Düren, DR; Durrer, D; Lie, KI; Wellens, HJ; Wesdorp, JC, 1976) |
| "Landiolol is a new-generation beta-blocker with fast onset and short half-life." | 3.30 | Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial. ( Besnier, E; Briant, AR; Caspersen, E; Denisenko, A; Descamps, R; Fellahi, JL; Fischer, MO; Gaudard, P; Guinot, PG; Hanouz, JL; Lorne, E; Mahjoub, Y; Mongardon, N; Moussa, MD; Oilleau, JF; Parienti, JJ; Paul, LPS; Rozec, B; Tomadesso, C, 2023) |
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 3.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events." | 3.11 | Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. ( Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022) |
| " The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age." | 3.11 | Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. ( Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP, 2022) |
| "Dronedarone was associated with a statistically significantly lower risk of all-cause death versus sotalol (hazard ratio [HR] = 0." | 3.01 | Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. ( Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP, 2023) |
| "Amiodarone is an antiarrhythmic drug with a significant adverse effect profile, including neurotoxicity." | 3.01 | Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports. ( Dumic, I; Kaur, A; Kaur, P; Khaliq, W; Singh, A; Sinha, A, 2023) |
| "Neiguan point acupuncture combined with amiodarone is superior to amiodarone alone in reducing early recurrences of patients with persistent AF after PVI." | 2.90 | Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation. ( Bao, M; Dong, L; Fu, H; He, B; Huang, C; Huang, H; Liu, H; Liu, X; Liu, Y; Lu, Z; Wu, G; Yang, B; Yang, M; Yin, J; Yu, S; Zhao, Q, 2019) |
| "Amiodarone was the most commonly reported intervention with cardioversion rates ranging from 18% to 96% followed by β-antagonists with cardioversion rates from 40% to 92%." | 2.82 | Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. ( Blackwood, B; Chean, CS; Duarte, R; Hill, R; Johnston, BW; McAuley, DF; Welters, ID, 2022) |
| "Amiodarone was discontinued in 18 patients randomized to amiodarone for side effects, bradycardia, or noncompliance." | 2.82 | Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. ( Ad, N; Holmes, SD; Miller, CE; Pritchard, G; Shuman, DJ, 2016) |
| "Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13-19 h)." | 2.80 | A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers. ( Boddy, A; DiMarco, JP; Ellenbogen, KA; Ezekowitz, MD; Geba, GP; Kaszala, K; Koren, A; P, GG, 2015) |
| "Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation." | 2.79 | Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. ( Balsam, P; Kiliszek, M; Kochanowski, J; Koźluk, E; Lodziński, P; Opolski, G; Piątkowska, A; Piątkowski, R; Scisło, P, 2014) |
| "Bradycardia was observed less in the study group (76 ± 29) than in the control group (93 ± 18; P < ." | 2.79 | Effectiveness of biatrial epicardial application of amiodarone-releasing adhesive hydrogel to prevent postoperative atrial fibrillation. ( Feng, XD; Wang, W; Wang, XN; Yuan, XH, 2014) |
| " The budiodarone dose-response was statistically significant (p < 0." | 2.77 | A randomized trial of budiodarone in paroxysmal atrial fibrillation. ( Bandman, O; Canafax, D; Ellis, DJ; Ezekowitz, MD; Hohnloser, SH; Lubinski, A; Milner, PG; Nagarakanti, R; Thibault, B; Ziola, M, 2012) |
| "Bepridil was superior to amiodarone in achieving sinus conversion and in maintaining sinus rhythm after cardioversion in patients with persistent AF." | 2.77 | Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial. ( Daida, H; Nakazato, Y; Yamase, M, 2012) |
| "Amiodarone and diuretic treatment affected the rate of AF recurrence." | 2.75 | Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. ( Barlera, S; Cosmi, F; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lombardi, F; Maggioni, AP; Zeni, P, 2010) |
| "The primary end-point was recurrence of AF." | 2.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "Treatment with bisoprolol resulted in a trend to lower ventricular response rate in AF cases." | 2.74 | Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial. ( Ashoush, R; El Rassi, I; Haddad, F; Hayeck, G; Jebara, V; Madi-Jebara, S; Sleilaty, G; Yazigi, A, 2009) |
| "Sotalol was superior to placebo in step 4 (OR: 2." | 2.74 | Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. ( Reda, D; Singh, BN; Singh, SN; Tang, XC, 2009) |
| "amiodarone was more effective than biatrial pacing in prevention of post operative AF and we recommend use of this drug in high risk patients." | 2.74 | Biatrial pacing vs. intravenous amiodarone in prevention of atrial fibrillation after coronary artery bypass surgery. ( Akbarzadeh, F; Golmohammadi, A; Kazemi-Arbat, B; Pourafkari, L, 2009) |
| "Propafenone was given to Group 1 (G1); sotalol to Group 2 (G2); amiodarone to Group 3 (G3) and diltiazem to Group 4 (G4) at doses of 300 mg/day, 80 mg/day, 400 mg/day and 180 mg/day orally respectively." | 2.73 | [The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery]. ( Aytekin, S; Aytekin, V; Men, EE; Tuğcu, A; Yildirimtürk, O, 2008) |
| "In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy." | 2.73 | Rhythm control versus rate control for atrial fibrillation and heart failure. ( Arnold, JM; Bourassa, MG; Buxton, AE; Camm, AJ; Connolly, SJ; Dorian, P; Dubuc, M; Ducharme, A; Guerra, PG; Hohnloser, SH; Lambert, J; Le Heuzey, JY; Lee, KL; Nattel, S; O'Hara, G; Pedersen, OD; Rouleau, JL; Roy, D; Singh, BN; Stevenson, LW; Stevenson, WG; Talajic, M; Thibault, B; Waldo, AL; Wyse, DG, 2008) |
| "Amiodarone is a drug frequently used for cardioversion." | 2.73 | Does stopping amiodarone after successfully treating atrial fibrillation occurring after cardiac surgery increase the risk of recurrence? ( Attaran, S; Desai, J; El-Gamel, A; John, L; Sherwood, R, 2008) |
| "Amiodarone was employed as the anti-arrhythmic drug during the first 18 months, and diltiazem in the second half of the study." | 2.73 | Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem. ( Ampollini, L; Bettati, S; Bobbio, A; Caporale, D; Carbognani, P; Internullo, E; Rossini, E; Rusca, M, 2007) |
| "Amiodarone is a potent antiarrhythmic drug." | 2.73 | Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. ( Bassiakos, S; Bassiakou, E; Michalakis, K; Moutzouris, DA; Papadimitriou, L; Vlachos, IS; Xanthos, T, 2007) |
| "In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo." | 2.73 | Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). ( Anderson, J; Bardy, GH; Freudenberger, RS; Halperin, JL; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, J, 2007) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Amiodarone is a slower acting alternative." | 2.72 | Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. ( Alhazzani, W; Baranchuk, A; Belley-Côté, EP; Benz, AP; Conen, D; Dalmia, S; Devereaux, PJ; Healey, JS; Ibrahim, OA; McIntyre, WF; Um, KJ; Wang, CN; Whitlock, RP, 2021) |
| "Amiodarone 200 mg/day was started the day after PBMV." | 2.72 | One-year outcome of cardioversion of atrial fibrillation in patients with mitral stenosis after percutaneous balloon mitral valvuloplasty. ( Chotinaiwatarakul, C; Jakrapanichakul, D; Kangkagate, C; Kitrattana, B; Krittayaphong, R; Panchavinnin, P; Phankingthongkum, R; Sriratanasathavorn, C; Tresukosol, D, 2006) |
| "Amiodarone was given as 600 mg oral single dose one day before and from days 2 through 7 after surgery." | 2.72 | Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study. ( Budeus, M; Erbel, R; Feindt, P; Felix, O; Gams, E; Hennersdorf, M; Lehmann, N; Perings, C; Perings, S; Reimert, K; Röhlen, S; Sack, S; Schnitzler, S; Wieneke, H, 2006) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "And amiodarone was given from the third day before the surgery and lasted for 3 months thereafter." | 2.72 | [The clinical study of circumferential ablation around orifice of pulmonary vein by radiofrequency energy with chronic atrial fibrillation undergoing rheumatic valvular heart surgery]. ( Bai, BJ; Du, RY; Wang, CG; Wang, JZ; Xin, LP; Zhong, ZH, 2006) |
| " Four patients (11%) in group A but none in group B experienced significant adverse effects that necessitated withdrawal of amiodarone." | 2.72 | Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. ( Chang, MH; Chang, TC; Chen, CY; Chou, P; Fu, CY; Jong, GP; Ma, TC; Tien, LY, 2006) |
| "Amiodarone was used for 212 patients (51." | 2.71 | Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2003) |
| "Amiodarone was more effective at one year than either sotalol or class I agents for the strategy of maintenance of sinus rhythm without cardioversion." | 2.71 | Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. ( , 2003) |
| "Amiodarone was associated with adverse effects in 46." | 2.71 | A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. ( Bhuripanyo, K; Kangkagate, C; Krittayaphong, R; Pooranawattanakul, S; Punlee, K; Raungrattanaamporn, O; Sriratanasathavorn, C, 2003) |
| "Amiodarone treated patients had a lower incidence of AF (22." | 2.71 | Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). ( Kluger, J; White, CM, 2003) |
| "Amiodarone pre-treatment before electrical DCCV for persistent AF allows chemical conversion in one-fifth of patients without altering the efficacy of subsequent DC conversion." | 2.71 | A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. ( Batin, P; Birchall, A; Brooksby, WP; Channer, KS; Grant, S; Muthusamy, R; Rhoden, WE; Saeed, BT; Steeds, RP; Walters, SJ; West, JN; Wilson, I; Yeo, WW, 2004) |
| " Amiodarone is both safe and effective in establishing sinus rhythm." | 2.71 | Is amiodarone a safe antiarrhythmic to use in supraventricular tachyarrhythmias after lung cancer surgery? ( Barbetakis, N; Vassiliadis, M, 2004) |
| "The amiodarone dosage was lowered to 200 mg/day in the sixth postoperative week." | 2.71 | Effects of late regain of sinus rhythm on pulmonary artery pressure and functional status in patients with mitral valve replacement surgery and atrial fibrillation. ( Demircioglu, F; Ersel, F; Gölbasi, I; Kabukcu, M; Yanik, E, 2004) |
| "Many patients with paroxysmal atrial fibrillation (AF) become refractory to antiarrhythmic drugs (AADs)." | 2.71 | Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation. ( Block, JE; Calkins, H; Cher, D; Kocheril, AG; Sharma, AD; Stubbs, HA, 2005) |
| "Amiodarone was administered as the third antiarrhythmic agent to patients who had AF recurrence on the first two antiarrhythmic agents (propafenone, sotalol or disopyramide)." | 2.71 | Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study. ( Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kaplon, B, 2005) |
| "Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "Forty patients with paroxysmal atrial fibrillation (20 females, 20 males), aged 60-83 (mean 72." | 2.71 | Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation. ( Wysokiński, A; Zapolski, T, 2005) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 2.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| "If immediate recurrences of AF occurred 2 more times, the alternative study drug was administered, and cardioversion was repeated." | 2.70 | Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. ( Chugh, A; Greenstein, R; Hassan, S; Knight, BP; Lai, SW; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Scharf, C; Strickberger, SA; Tada, H, 2002) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "amiodarone was not different from placebo until 8 hours when it was associated with 57% of conversions; (3) conversion to sinus rhythm at 8 hours was observed in 37% of the placebo treated patients." | 2.69 | Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. ( Biffi, M; Boriani, G; Botto, G; Branzi, A; Broffoni, T; Capucci, A; Magnani, B; Ongari, M; Rubino, I; Sanguinetti, M; Trisolino, G, 1998) |
| "Twenty-five patients with persistent atrial fibrillation underwent internal defibrillation, using biphasic R wave synchronous shocks between two catheters in the high right atrium and the coronary sinus." | 2.69 | Limited internal shocks for atrial fibrillation refractory to external cardioversion. ( Adam, JF; Blommaert, D; De Roy, L; Jamart, J; Mucumbitsi, J, 1999) |
| "Amiodarone has been the only drug so far reported to give a combination of high efficacy and low frequency of serious side effects such as ventricular tachycardia and shock." | 2.69 | Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia? ( Møller, S; Nielsen, KD, 2000) |
| "amiodarone treatment or oral digoxin/quinidine treatment in a randomized unblinded single crossover study." | 2.68 | The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. ( Faitel, K; Kerin, NZ; Naini, M, 1996) |
| " Consecutive patients were treated with P replacing previous therapy with amiodarone (A) withdrawn on account of adverse side effects occurring on average after 1." | 2.67 | [Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects]. ( Foscoli, M; Giofrè, R; Labriola, E; Lolli, C; Tarquinii, M; Toschi, GP, 1993) |
| "Amiodarone was given after surgery in a loading bolus of 300 mg for 2 hours followed by 1200 mg every 24 hours for 2 days and 900 mg every 24 hours for the next 2 days." | 2.67 | Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. ( Dammbacher, T; Fraedrich, G; Hohnloser, SH; Jähnchen, E; Just, H; Meinertz, T; Steiert, K; Zehender, M, 1991) |
| "Amiodarone was the most commonly studied agent (10 studies), followed by beta-blockers (8), calcium channel blockers (6) and magnesium (3)." | 2.66 | Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review. ( Bedford, J; O'Bryan, LJ; Petrinic, T; Redfern, OC; Watkinson, PJ; Young, JD, 2020) |
| "0005) regarding total digoxine dosage and length of treatment." | 2.65 | [Short-term therapy of atrial fibrillation with an association of digitalis and amiodarone (author's transl)]. ( Bueno, J; del Río, A; Ferreira, JI; Ramos, F; Ruiz, C, 1980) |
| "Dronedarone, a derivative of amiodarone with structural modifications, was designed to have similar electrophysiological properties with a less toxic profile." | 2.55 | Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation. ( Aronow, WS; Khan, MH; Rochlani, Y, 2017) |
| "Dronedarone was found to have divergent safety profiles in randomized controlled trials (RCT) in term of cardiac death and overall mortality." | 2.55 | Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. ( Biffi, M; Boriani, G; Diemberger, I; Lorenzetti, S; Martignani, C; Massaro, G; Reggiani, MLB; Ziacchi, M, 2017) |
| "Dronedarone is a non-iodinated benzofuran derivative with antiarrhythmic properties." | 2.50 | An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. ( Connolly, SJ; Halperin, JL; Hohnloser, SH; John Camm, A; Radzik, D, 2014) |
| "Dronedarone is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added." | 2.50 | The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. ( Kowey, PR; Naccarelli, GV, 2014) |
| "Dronedarone is a recent antiarrhythmic drug that has been developed for treatment of AF, with electrophysiological properties similar to amiodarone but with a lower incidence of side effects." | 2.50 | Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation. ( Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C, 2014) |
| "Dronedarone has been evaluated in several large clinical trials, which have shown reduced mortality and hospitalization rates in patients with non-permanent AF." | 2.49 | Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. ( Adlan, AM; Lip, GY, 2013) |
| "Amiodarone is a structural analogue of thyroid hormone, and some of its anti-arrhythmic actions and toxicity are attributable to its interaction with nuclear receptors of thyroid hormones." | 2.48 | [Amiodarone and thyroid dysfunction]. ( Bruno, OD; Rizzo, LF, 2012) |
| "Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter." | 2.48 | Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. ( Fischer, GW; Trigo, P, 2012) |
| "Thyrotoxicosis is a common disorder, especially in women." | 2.48 | Thyrotoxicosis. ( Boelaert, K; Franklyn, JA, 2012) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 2.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Dronedarone is a new anti-arrhythmic drug that has been developed to provide rhythm and rate control in AF patients with fewer side effects compared with amiodarone." | 2.47 | Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. ( Becker, R; Katus, HA; Schweizer, PA; Thomas, D, 2011) |
| "Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by Swissmedic for management of patients with atrial fibrillation or atrial flutter." | 2.47 | Dronedarone for the management of atrial fibrillation. ( Brenner, R; Delacrétaz, E, 2011) |
| "Dronedarone is an amiodarone-like benzofuran which lacks the iodine moiety and presents a methane sulfonyl group that decreases its lipophilicity, thus shortening the half-life and decreasing tissue accumulation." | 2.47 | Dronedarone. ( Caballero, R; Delpón, E; López-Farré, A; Tamargo, J, 2011) |
| "Dronedarone is a new benzofuran derivative that has been developed as an antiarrhythmic agent on the basis of the amiodarone molecular structure with the intent of maintaining the same pharmacological effects while reducing thyroid and pulmonary toxicity." | 2.47 | Dronedarone for atrial fibrillation therapy. ( Lombardi, F; Marzocchi, M, 2011) |
| "Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events." | 2.47 | The management of patients with atrial fibrillation and dronedarone's place in therapy. ( Boiangiu, C; Cohen, M, 2011) |
| "Dronedarone is a benzofuran derivative; specifically N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methane-sulfonamide and its production process has been patented." | 2.46 | Dronedarone--a new alternative for management of atrial fibrillation. ( Garg, RK; Hundal, M, 2010) |
| "Dronedarone is a derivative of amiodarone indicated for the treatment of AF." | 2.46 | Dronedarone: current evidence and future questions. ( Gleason, PP; Kjesbo, NK; Schafer, JA, 2010) |
| "Dronedarone is a benzofuran derivative structurally similar to amiodarone but non-iodinated." | 2.46 | [Clinical pharmacology and electrophysiological properties of dronedarone]. ( Goette, A; Hohnloser, S; Kirch, W; Lewalter, T; Pittrow, D, 2010) |
| "Dronedarone has been recently approved for clinical use by the Food and Drug Administration and by the European Medicines Agency." | 2.46 | Dronedarone: an emerging therapy for atrial fibrillation. ( Rosei, EA; Salvetti, M, 2010) |
| "Diagnosis of thyrotoxicosis is easy, based on the finding of increased free thyroid hormone concentrations and suppressed TSH levels." | 2.46 | Approach to the patient with amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Martino, E, 2010) |
| " An important drug-drug interaction between amiodarone and vitamin K antagonists is encountered frequently in daily clinical practice." | 2.46 | Dronedarone and vitamin K antagonists: a review of drug-drug interactions. ( Becker, RC; Fiuzat, M; Shirolkar, SC, 2010) |
| "Dronedarone is a multichannel blocker with electrophysiologic effects similar to amiodarone." | 2.46 | A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission. ( Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL, 2010) |
| "Ranolazine is a new antianginal substance which influences the atrial ion channels and leads to a significant reduction of atrial and more specifically ventricular tachyarrhythmias." | 2.46 | [New developments in the antiarrhythmic therapy of atrial fibrillation]. ( Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O, 2010) |
| "Dronedarone is an amiodarone analogue without iodine moiety in its structure, and is similar to amiodarone with regard to its structural and electrophysiological properties." | 2.45 | Dronedarone: a promising alternative for the management of atrial fibrillation. ( Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB, 2009) |
| "Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile." | 2.45 | Dronedarone for atrial fibrillation: a new therapeutic agent. ( Arora, BL; Arora, RR; Bhuriya, R; Patel, DD; Patel, PD; Singh, PP, 2009) |
| "Dronedarone." | 2.44 | Dronedarone: a new treatment for atrial fibrillation. ( Kowey, PR; Laughlin, JC, 2008) |
| "Amiodarone is an iodinated compound, and the possibility that its molecule may be modified with or without elimination of the iodine is being tested." | 2.44 | Amiodarone as paradigm for developing new drugs for atrial fibrillation. ( Singh, BN, 2008) |
| "Dronedarone has a favourable benefit/risk ratio, with the absence of any proarrhythmic effects." | 2.44 | Dronedarone: drondarone, SR 33589, SR 33589B. ( , 2007) |
| "Amiodarone is an effective antiarrhythmic agent that has been in clinical use for about 20 years." | 2.44 | A review of the investigational antiarrhythmic agent dronedarone. ( Rowles, J; Tafreshi, MJ, 2007) |
| " Inconsistent prescribing practices, variable dosage regimens, and a lack of consensus regarding the appropriate use of amiodarone prompted the need for developing practice guidelines." | 2.44 | Amiodarone for atrial fibrillation following cardiac surgery: development of clinical practice guidelines at a university hospital. ( Khanderia, U; Prager, R; Wagner, D; Walker, PC; Woodcock, B, 2008) |
| "Amiodarone is an effective antiarrhythmic agent for preventing and treating atrial and ventricular arrhythmias." | 2.44 | Fatal amiodarone-induced hepatotoxicity: a case report and literature review. ( Chan, AL; Hsieh, HJ; Hsieh, YA; Lin, SJ, 2008) |
| "Amiodarone and early CVN was more effective than nonamiodarone therapies with regard to restoring NSR for patients in whom AF developed after elective CABG." | 2.43 | Selective use of amiodarone and early cardioversion for postoperative atrial fibrillation. ( Holmes, EC; Samuels, FL; Samuels, LE, 2005) |
| "Dronedarone is a noniodinated benzofuran derivative that has been developed to overcome the limiting iodine-associated adverse effects of the commonly used antiarrhythmic drug, amiodarone." | 2.43 | The novel antiarrhythmic drug dronedarone: comparison with amiodarone. ( Karle, CA; Kathofer, S; Thomas, D, 2005) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "Dronedarone has since undergone further extensive evaluation in three pivotal phase III trials." | 2.43 | Dronedarone: an emerging agent with rhythm- and rate-controlling effects. ( Ehrlich, JR; Hohnloser, SH; Wegener, FT, 2006) |
| " Amiodarone effectively controls a wide spectrum of atrial and ventricular antiarrhythmic disorders, but its limiting side effects, such as thyroid dysfunction, pulmonary fibrosis, and dermatologic changes, may limit its long-term use in some patients." | 2.43 | Amiodarone: a multifaceted antiarrhythmic drug. ( Singh, BN, 2006) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "Tedisamil is a complex class 3 agent, blocking multiple channels." | 2.42 | Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. ( Singh, S, 2004) |
| "A wide spectrum of ventricular and supraventricular tachyarrhythmias occurs in the setting of congestive cardiac failure." | 2.41 | Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. ( Singh, BN, 2002) |
| "amiodarone) because of atrial fibrillation or non-sustained VT that may activate the device." | 2.41 | Antiarrhythmic therapy in heart failure. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "Procainamide is effective for stable ventricular tachycardia, and amiodarone is effective in the treatment of shock-refractory ventricular fibrillation." | 2.41 | Intravenous antiarrhythmic agents. ( Dorian, P; Pinter, A, 2001) |
| " Sotalol requires careful patient selection due to the risk of proarrhythmia and although cardiac effects are rare with amiodarone therapy, potentially serious non-cardiac adverse effects can limit the long-term use of this agent." | 2.41 | The role of class III antiarrhythmic agents in maintaining sinus rhythm. ( Brachmann, J, 2000) |
| "Reports of dilated cardiomyopathy associated with Graves' disease and evidence for TSH-receptors in the human myocardium suggest a relationship between these two diseases." | 2.41 | [Hyperthyroidism and heart]. ( Weissel, M, 2001) |
| "Cardiac arrhythmias are common in the perioperative period." | 2.41 | Postoperative arrhythmias and conduction disorders. ( Sloan, SB; Weitz, HH, 2001) |
| "Amiodarone has minimal proarrhythmic risk but has numerous noncardiac toxicities that require frequent monitoring." | 2.41 | A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. ( Cox, CD; Tsikouris, JP, 2001) |
| "Amiodarone is a structural analogue of thyroid hormone and some of its anti-arrhythmic properties and toxicity may be attributable to interactions with nuclear thyroid hormone receptors." | 2.41 | Amiodarone -- waxed and waned and waxed again. ( Doggrell, SA, 2001) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 2.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "Patients with other supraventricular arrhythmias may be treated with adenosine, a calcium channel blocker, or a short-acting beta blocker to disrupt reentrant pathways." | 2.41 | Management of common arrhythmias: Part I. Supraventricular arrhythmias. ( Hebbar, AK; Hueston, WJ, 2002) |
| "Amiodarone was introduced as an antiarrhythmic compound in the early 1970s and was approved in the U." | 2.40 | Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. ( Singh, BN, 1997) |
| "Sotalol has a rapid onset of action, allowing it to be efficacious when used orally shortly after surgery." | 2.40 | Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents. ( Morady, F, 1999) |
| "Amiodarone has a lower incidence of proarrhythmia and heart failure exacerbation compared with class I drugs." | 2.38 | Low-dose amiodarone for atrial fibrillation: time for a prospective study? ( Middlekauff, HR; Saxon, LA; Stevenson, WG; Wiener, I, 1992) |
| "A 19-year-old man with pectus excavatum developed symptomatic persistent atrial fibrillation (AF)." | 1.91 | Adolescent Persistent Atrial Fibrillation Concomitant with Pectus Excavatum. ( Kondo, H; Mitarai, K; Shinohara, T; Shinozaki, K; Takahashi, N; Uchida, N; Wakabayashi, T; Zaizen, H, 2023) |
| "In the patient, the paroxysmal atrial fibrillation was responsible for S-L-S-S sequence." | 1.91 | The short-long-short-short sequence and polymorphic ventricular tachycardias storm. ( Li, J; Liu, Q; Yang, L, 2023) |
| " In patients receiving CF-LVADs, the use of prophylactic amiodarone was associated with a reduction in the incidence of postoperative arrhythmias, which was driven primarily by a reduction in postoperative atrial arrhythmias, without significantly increasing the rate of amiodarone-related adverse events." | 1.91 | Safety and Efficacy of Prophylactic Amiodarone After Left Ventricular Assist Device. ( Graboyes, SDT; Harris, TN; Hollis, IB; Iyer, PS; Kline, TM, 2023) |
| "Amiodarone has superior efficacy relative to other AADs." | 1.91 | Relationship between amiodarone response prior to ablation and 1-year outcomes of catheter ablation for atrial fibrillation. ( Akhtar, T; Berger, R; Brilliant, J; Calkins, H; Marine, J; Milstein, J; Sampognaro, JR; Spragg, D; Yadav, R, 2023) |
| "propafenone." | 1.91 | Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. ( Chang, SH; Chen, SW; Huang, CH; Huang, YC; Huang, YT; Hung, KC; Kuo, CF; Tu, HT; Wang, CL; Wu, VC, 2023) |
| "Amiodarone was stopped subsequently." | 1.91 | Three-dimensional electroanatomical mapping for guidance of pulmonary vein isolation as treatment for persistent atrial fibrillation in a dog. ( Bosmans, T; Duytschaever, M; Hellemans, A; Mampaey, G; Skotarek, M; Smets, P; Stock, E; van Loon, G; Van Steenkiste, G, 2023) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 1.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 1.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "51 ± 38." | 1.62 | Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone. ( Celik, A; Eyuboglu, M, 2021) |
| "Flecainide was used most frequently (26." | 1.62 | Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. ( D'Angelo, RN; Goldstein, L; Kalsekar, I; Khanna, R; Rahman, M; Tung, P; Yadalam, S; Yeh, RW; Zimetbaum, PJ, 2021) |
| "We present a 61-year-old patient with persistent atrial fibrillation who, after a one-month treatment with oral amiodarone at a low dose impregnation of 400 mg/day, develops acute pulmonary toxicity, with radiographic and tomographic resolution after antiarrhythmic suspension and steroid treatment." | 1.56 | [Acute amiodarone pulmonary toxicity with low impregnation dose: case report]. ( Cabrera-Rego, JO; Luzurriaga Navas, JD; Yanes Quintana, AA, 2020) |
| " This study aims to summarize the randomized controlled trials (RCTs) of amiodarone combined with beta blockers to maintain sinus rhythm in AF, and to determine an effective and safe intervention for the prevention of AF recurrence through network meta-analysis (NMA)." | 1.56 | The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis. ( Hu, Y; Jia, Q; Shi, J; Shi, S; Yuan, G, 2020) |
| "Amiodarone is an antiarrhythmic medication with many side effects." | 1.56 | Amiodarone-induced neuromyopathy in a geriatric patient. ( Leung, G; Pearce, P; Samii, L; Stanton, MM, 2020) |
| "Amiodarone was the only independent predictor of long PR interval occurrence (odds ratio 2." | 1.51 | Occurrence of significant long PR intervals in patients implanted for sinus node dysfunction and monitored with SafeR™: The PRECISE study. ( Al Daoud, A; Degand, B; Deutsch, P; Elbaz, N; Elkaim, JP; Godenir, JP; Gorka, H; Khattar, P; Le Franc, P; Lellouche, N; Merlo, S; Moubarak, G; Taieb, J, 2019) |
| "However, late recurrences are more common compared to paroxAF." | 1.51 | Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy. ( Benák, A; Bencsik, G; Herczeg, A; Kohári, M; Makai, A; Pap, R; Sághy, L, 2019) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 1.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| "Amiodarone is an effective medication for AF but has limited clinical utility because of off-target tissue toxicity." | 1.48 | Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation. ( Bhatia, NK; Campbell, PF; Cesar, L; Deppen, JN; García, AJ; Garcia, JR; Kumar, G; Langberg, JJ; Levit, RD; Robinson, B; Schneider, F; Shin, EY; Wang, L; Xu, K, 2018) |
| "Aripiprazole is an atypical antipsychotic drug with a polypharmacological mechanism of action and a favorable tolerability profile." | 1.48 | Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. ( Anastasia, A; D'Urso, G; de Bartolomeis, A; Patti, S; Toscano, E, 2018) |
| "Dronedarone has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs." | 1.46 | Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation. ( Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S, 2017) |
| "Carvedilol is an effective additional therapy for the patients with chronic heart failure already receiving Amiodarone." | 1.46 | THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS. ( Khintibidze, I; Tsetskhladze, E, 2017) |
| " One of the most devastating adverse reactions to this drug is pulmonary toxicity, which can present in a myriad of different ways." | 1.46 | Amiodarone-induced pulmonary toxicity. ( Colby, R; Geyer, H, 2017) |
| "Anti-atrial fibrillatory and proarrhythmic potentials of amiodarone were simultaneously analyzed by using the halothane-anesthetized beagle dogs (n = 4) in order to begin to prepare standard protocol for clarifying both efficacy and adverse effects of anti-atrial fibrillatory drugs." | 1.46 | Anti-atrial Fibrillatory Versus Proarrhythmic Potentials of Amiodarone: A New Protocol for Safety Evaluation In Vivo. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 1.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| "Amiodarone was used in the majority of the patients (160/168)." | 1.43 | Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort. ( Hoffmann, B; Lüker, J; Sehner, S; Servatius, H; Steven, D; Sultan, A; Willems, S, 2016) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 1.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Amiodarone was the most prescribed drug with a definite risk of TdP." | 1.43 | Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. ( Ardoino, I; Biganzoli, EM; Corrao, S; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Rossio, R; Tettamanti, M, 2016) |
| "In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits." | 1.43 | Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. ( Chiba, T; Kondo, N; Takahara, A, 2016) |
| "Dronedarone has failed to make an impact on AAD prescribing." | 1.43 | The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. ( Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E, 2016) |
| "In all, 374 (53." | 1.42 | The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department. ( Clark, D; Cragg, A; Gray, A; Grubb, N; Hamilton, A, 2015) |
| "Dronedarone is an amiodarone-like antiarrhythmic with a modified structure." | 1.42 | Diffuse alveolar damage in a patient receiving dronedarone. ( Ahuja, N; Casto, A; Nguyen, DV; Stack, S, 2015) |
| "Eight patients were hospitalized for bradyarrhythmia." | 1.42 | Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis. ( Cho, I; Hartaigh, Bó; Hwang, ES; Joung, B; Lee, HY; Lee, MH; Mun, HS; Pak, HN; Park, JK; Shin, DG; Uhm, JS, 2015) |
| "Dronedarone is a benzofuran derivative of amiodarone newly approved in 2009 for the treatment of AF." | 1.40 | Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation. ( Kim, J; Lee, EJ, 2014) |
| " However, the use of RAI in euthyroid patients requiring chronic administration of amiodarone (AM) where other antiarrhythmic drugs may lack efficacy is still controversial." | 1.40 | Results of preventive radioiodine therapy in euthyroid patients with history of hyperthyroidism prior to administration of amiodarone with permanent atrial fibrillation--a preliminary study. ( Czarnywojtek, A; Czepczyński, R; Królicki, L; Kwiecińska, B; Miechowicz, I; Płazińska, MT; Ruchała, M; Woliński, K; Zgorzalewicz-Stachowiak, M, 2014) |
| "Amiodarone pulmonary toxicity (APT) is the most serious side effect of amiodarone." | 1.39 | Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. ( Goto, E; Horio, Y; Ichiyasu, H; Kohrogi, H; Kojima, K; Masunaga, A; Sato, N, 2013) |
| "The total AF recurrence rate was 67% and lone AF was significantly more often associated with AF recurrences than non-lone AF (84% vs." | 1.39 | Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study). ( Braun-Dullaeus, RC; Esperer, HD; Genz, C; Kluba, K; Rauwolf, T; Said, SM; Schmeisser, A, 2013) |
| "Amiodarone is an effective treatment for atrial and ventricular arrhythmias, but its use is limited by a toxic adverse-effect profile." | 1.39 | Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy. ( Gonzalez, JE; Krantz, MJ; Sauer, WH, 2013) |
| " Dronaderone is a novel antiarrhythmic that is similar in composition to amiodarone, but is non-iodinated and also has a methane-sulfonyl group, significantly decreasing its incidence of adverse effects as compared to amiodarone." | 1.39 | Dronaderone-induced phototoxicity. ( Elpern, DJ; Ladizinski, B, 2013) |
| "For AF recurrence; duration of AF, left atrial (LA) diameter, maximum LA volume index, mitral A velocity and LA lateral AEMD were significant parameters in univariate-analysis, however LA lateral AEMD was the only significant parameter in multivariate-analysis (OR: 1." | 1.39 | Predictive value of atrial electromechanical delay for atrial fibrillation recurrence. ( Akkaya, M; Ari, H; Ari, S; Aydin, C; Bozat, T; Çetinkaya, S; Emlek, N; Karaağaç, K; Melek, M; Sarigül, OY; Şentürk, M; Yilmaz, M, 2013) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s." | 1.38 | A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012) |
| "Amiodarone was the most commonly prescribed antiarrhythmic agent." | 1.38 | Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. ( Curtis, LH; DeWald, TA; Go, AS; Hernandez, AF; Mi, X; Piccini, JP, 2012) |
| "The average time to recurrence of AF after RFCA was 9." | 1.38 | Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. ( Ban, JE; Choi, JI; Kang, JH; Kim, MN; Kim, S; Kim, YH; Lee, DI; Lim, HE; Park, SW; Park, YM, 2012) |
| "Dronedarone is a chemical derivative of amiodarone (though having a significantly different clinical profile) with effects on multiple ion channels that proved effective in reducing the rate of the combined endpoint of death from any cause and cardiovascular hospitalization in patients with non-permanent AF enrolled in the ATHENA study." | 1.38 | [New antiarrhythmic drugs for the treatment of atrial fibrillation]. ( Botto, GL; Campana, C; Mariconti, B; Pentimalli, F; Russo, G, 2012) |
| "Amiodarone is a highly effective antiarrhythmic drug." | 1.37 | Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema. ( Bolognese, L; Brandini, R; Caremani, M; Fabiani, I; Grotti, S; Salvadori, C; Tacconi, D, 2011) |
| " Although oral long-term use of the drug is frequently complicated by an asymptomatic rise in serum aminotransferase concentrations, acute hepatotoxicity during intravenous loading is much less frequent and potentially fatal." | 1.37 | Acute liver injury after intravenous amiodarone: a case report. ( Aprà, F; Elia, F; Ferrari, G; Riva, A; Verhovez, A, 2011) |
| "Amiodarone was shown to be a significant statistical moderator (p < 0." | 1.37 | Atrial arrhythmias after lung and heart-lung transplant: effects on short-term mortality and the influence of amiodarone. ( Cordova, F; Criner, G; Gaughan, J; Isiadinso, I; Lim, S; Meshkov, AB; Sandhu, P, 2011) |
| "During a 4-week follow-up, AF recurrence was observed in 41 patients (65." | 1.37 | Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion. ( Alcaraz, R; Hornero, F; Rieta, JJ, 2011) |
| " No difference was found in the risk of adverse events between the 2 therapies." | 1.37 | Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. ( Miles, RH; Murdock, DK; Passman, R, 2011) |
| "Dronedarone was used mostly in compliance with PI and risk evaluation and mitigation strategy in the studied population." | 1.37 | Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database. ( Dai, WS; Gao, S; Juhaeri, J; Koren, AT; Schiappacasse, HA, 2011) |
| " Adverse events (AEs) associated with AADs may influence patient compliance and compromise the management of atrial fibrillation (AF)." | 1.37 | One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. ( Jhaveri, M; Kim, MH; Klingman, D; Lin, J; Smith, PJ, 2011) |
| "The strongest factor associated with AF recurrence was hsCRP at 48 h > or =2." | 1.36 | Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. ( Dragomanovits, S; Faviou, E; Kalogeropoulos, AS; Kremastinos, DT; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2010) |
| "When landiolol was administered, enough attention should be paid to the patients whose left ventricular function was low." | 1.36 | [Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?]. ( Abe, T; Fukuda, T; Haruna, T; Inoko, M; Ito, H; Miyamoto, S; Nakane, E; Nohara, R; Sasaki, K; Uehara, K; Ueyama, K, 2010) |
| "We describe the case of a patient with persistent atrial fibrillation who subsequently developed an acute myocardial infarction." | 1.36 | [Acute myocardial infarction following persistent atrial fibrillation. Consequence, common etiology or a case?]. ( Bompani, B; Grassi, L; Magnavacchi, P; Ratti, C, 2010) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 1.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| "Dronedarone will cause a small increase in creatinine concentrations, without a change in glomerular filtration rate (GFR)." | 1.36 | Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ( Dorian, P, 2010) |
| " Rhythm control agents are associated with clinically important adverse events." | 1.36 | Rhythm control agents and adverse events in patients with atrial fibrillation. ( Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010) |
| "Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by the Food and Drug Administration to reduce cardiovascular hospitalization in patients with AF or atrial flutter." | 1.36 | Dronedarone: a review of characteristics and clinical data. ( Baroletti, S; Catella, J; Cheng, JW; Ehle, M, 2010) |
| "Amiodarone is a last resort, mainly because of its numerous adverse effects." | 1.36 | Dronedarone. atrial fibrillation: too many questions about long-term adverse effects. ( , 2010) |
| "Dronedarone is a new antiarrhythmic drug that may offer advantages for rhythm control, given its relative safety (although not in patients with decompensated heart failure), efficacy and tolerability." | 1.36 | Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study. ( Lip, GY; Pamukcu, B, 2010) |
| "Flecainide is an antiarrhythmic drug that blocks sodium channels during phase 0 of cardiac action potential, delaying conduction and reducing contractility." | 1.36 | [Flecainide poisoning]. ( Bobillo, B; Diz Gómez, JC; Doniz Campos, M; Filgueira, P; Illodo Miramontes, G; Otero Amoedo, T; Rey López, F, 2010) |
| "Two hundred forty patients with lone paroxysmal atrial fibrillation were assigned to four groups." | 1.35 | The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study. ( Chen, Y; Du, H; Lan, X; Ling, Z; Liu, Z; She, Q; Su, L; Wu, J; Yin, Y, 2008) |
| "Amiodarone is a highly effective antiarrhythmic agent used in life-threatening ventricular and supraventricular arrhythmias." | 1.35 | Amiodarone induced pneumonitis and hyperthyroidism: case report. ( Ambroziak, U; Bareła, AD; Chazan, R; Grabczak, EM; Opuchlik, A; Potulska, A; Wiwała, J; Zielonka, TM, 2008) |
| "Amiodarone is a class III antiarrhythmic agent with a long half-life which is used to control atrial and ventricular arrhythmias, including atrial flutter and fibrillation." | 1.35 | Hepatotoxicity after intravenous amiodarone. ( Buonocore, S; Cataldi, A; Gonella, D; Odetti, P; Robutti, N; Siri, M, 2008) |
| "Amiodarone does not cause elevation of GSTA1-1 as a marker of subclinical liver injury in haemodynamically stable intensive care unit patients with atrial fibrillation." | 1.35 | No elevation of glutathione S-transferase-a1-1 by amiodarone loading in intensive care unit patients with atrial fibrillation. ( Hilkens, M; Peters, WH; Pickkers, P; van der Hoeven, JG, 2009) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "Paroxysmal atrial fibrillation is considered a frequent complication of acute myocardial infarction and the patients with paroxysmal atrial fibrillation probably should be targeted for earlier and more aggressive treatment." | 1.35 | Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction. ( Chiribiri, A; Di Bella, G; Marte, F; Patanè, S, 2008) |
| "Oral amiodarone 600 mg/day was started to control his arrhythmia, and the patient continued to receive digoxin 0." | 1.34 | Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration. ( DeVore, KJ; Hobbs, RA, 2007) |
| "amiodarone treatment protocol for horses." | 1.34 | Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation. ( Baert, K; Croubels, S; De Backer, P; De Clercq, D; Deprez, P; Tavernier, R; van Loon, G, 2007) |
| "Amiodarone is a highly effective antiarrhythmic drug, albeit notorious for its serious pulmonary toxicity." | 1.33 | Amiodarone-induced acute lung toxicity in an ICU setting. ( Galiatsou, E; Karahaliou, A; Kitsakos, A; Metafratzi, Z; Nakos, G; Skroubis, G; Skroubis, T, 2005) |
| "Average time for recurrence of FEA positive patients (4." | 1.33 | Spectral turbulence analysis of the signal-averaged electrocardiogram of the atrial activation as predictor of recurrence of idiopathic and persistent atrial fibrillation. ( Barbosa, EC; Benchimol Barbosa, PR; de Souza Bomfim, A; Destro, C; Ginefra, P; Helena Cardoso Boghossian, S; Nadal, J, 2006) |
| "Amiodarone or sotalol was used in all postoperative patients for 6 months, except in 8 who had bradycardia." | 1.33 | Ablation of atrial fibrillation using microwave energy--early experience. ( Hamzeh, K; Jamil, H; Kabbani, SS; Murad, G; Sabbagh, A, 2005) |
| "Amiodarone is effective in treating persistent atrial fibrillation compared with other antiarrhythmic drugs." | 1.33 | Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. ( Ashikaga, K; Furukawa, K; Iwasa, A; Kimura, M; Kobayashi, T; Motomura, S; Okumura, K; Owada, S; Sasaki, S, 2006) |
| "We report a case of a patient with paroxysmal atrial fibrillation (PAF) and with a permanent AAIR (bipolar atrial-inhibited adaptive rate) pacemaker who suffered life-threatening episodes of arrhythmias during operation." | 1.33 | Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. ( Borel, CO; Lin, JA; Wang, WB; Wong, CS; Wu, CT; Yang, CP; Yeh, CC, 2006) |
| "Polymorphic ventricular tachycardia (VT) comprises a variety of different subforms." | 1.33 | Amiodarone and polymorphic ventricular tachycardia: to slow down or to accelerate the underlying rhythm? ( Goethals, M; Pollet, P, 2006) |
| "To determine whether retinal electrophysiologic changes can be detected and correlated with funduscopic findings in patients with the long-term use of amiodarone." | 1.32 | Retinal evaluation of patients on chronic amiodarone therapy. ( Blumenkranz, MS; Chun, SH; Marmor, MF; Shaikh, N; Shaikh, S; Spin, JM, 2003) |
| "High recurrence rate is still a major problem associated with ablation of paroxysmal atrial fibrillation (AF)." | 1.32 | Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. ( Chan, P; Chang, MS; Chen, SA; Ding, YA; Hsieh, MH; Huang, JL; Lin, WS; Lin, YK; Tai, CT; Tsai, CF; Tsao, HM; Ueng, KC; Yu, WC, 2003) |
| "The amiodarone was omitted in 17 cases because of its side effects." | 1.32 | [Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium]. ( Borbély, M; Dani, G; Erdej, F; Hajdara, I; Katona, A; Márk, L; Nagy, E; Sziklai, G, 2004) |
| "Amiodarone (200 mg/day) was continuously administered after DC shock to maintain SR." | 1.32 | Simultaneous double external DC shock technique for refractory atrial fibrillation in concomitant heart disease. ( Demircioglu, F; Ersel-Tüzüner, F; Kabukcu, M; Minareci, K; Yanik, E, 2004) |
| "In one patient with amiodarone-induced pneumonitis, the KL-6 level increased from 695 to 2,100 U/ml concurrently with worsening interstitial changes shown by high resolution computed tomography." | 1.31 | [Diagnostic usefulness of KL-6 measurements in patients with pulmonary complications after administration of amiodarone]. ( Endoh, Y; Hanai, R; Kasanuki, H; Nagashima, H; Narimatsu, A; Ohnishi, S; Takizawa, T; Uno, M; Uto, K, 2000) |
| "Amiodarone is a class III antiarrhythmic agent that is effective in treating different types of cardiac dysrhythmias." | 1.31 | Bone marrow granulomas possibly associated with amiodarone. ( McIntyre, WW; Ranelli, PL; Sun, TJ; Yamreudeewong, W, 2000) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 1.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| "The circadian variation of paroxysmal atrial fibrillation (AF) was studied in 67 patients who received a dual-chamber pacemaker 3 months before a planned atrioventricular node ablation." | 1.31 | Circadian variation of paroxysmal atrial fibrillation. PA3 Investigators. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. ( Abdollah, H; Connolly, SJ; Dubuc, M; Gardner, MJ; Gillis, AM; Kerr, CR; Kimber, S; Lacomb, P; Molin, F; Newman, D; Philippon, F; Tang, AS; Yee, R, 2001) |
| " The required dosage of amiodarone was lower in the D + AM group than in the AM group (603 +/- 563 mg versus 1058 +/- 680 mg, p = 0." | 1.31 | Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. ( Anastasiou-Nana, MI; Kontoyannis, DA; Kontoyannis, SA; Nanas, JN; Zaga, AK, 2001) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| "Atrial tachyarrhythmias were induced by right atrial burst pacing." | 1.30 | Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. ( Fries, R; Heisel, A; Jung, J; Ozbek, C; Schieffer, H; Sen, S; Stopp, M, 1997) |
| "Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes." | 1.30 | Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. ( Duytschaever, M; Haerynck, F; Jordaens, L; Tavernier, R, 1998) |
| "Amiodarone is an effective class-III antiarrhythmic agent." | 1.30 | [Spontaneous remission of an amiodarone-induced pulmonary lesion]. ( Müller, M; Schima, W; Weissel, M, 1997) |
| "Early recurrence of atrial fibrillation (AF) has been reported to occur in a significant number of patients after internal cardioversion." | 1.30 | Early recurrence of atrial fibrillation after external cardioversion. ( Chang, MS; Chen, CC; Chen, SA; Ding, YA; Hsieh, MH; Hsu, TL; Lin, YK; Tai, CT; Tsai, CF; Yu, WC, 1999) |
| "Amiodarone was withdrawn and dexametasone treatment was begun." | 1.30 | [Amiodarone induced retrobulbar neuritis. Clinical case]. ( Arriagada, G; Bartolucci, J; Fuentes, R; Ibáñez, P; Torres, J; Verdugo, C, 1999) |
| "In 8 patients paroxysmal atrial fibrillation (AF), in 2 patients chronic AF, in 1 patient atrial flutter, and in 3 patients sinus tachycardia triggered antitachycardia pacing functions (12 patients) or internal defibrillation (2 patients)." | 1.29 | Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators. ( Melichercik, J; Montero, M; Schmitt, C, 1994) |
| "Digoxin was still the most popular drug used for ventricular rate control, and cardioversion was performed in only 6." | 1.29 | Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. ( Lau, CP; Lok, NS, 1995) |
| "Amiodarone is an antiarrhythmic agent very often used in clinical practice in spite of its large array of adverse effects." | 1.29 | [Acute hepatitis caused by intravenous amiodarone]. ( Arcusa Gavalda, R; Goma Masip, F; Paniagua Clusells, J; Pons Masanes, S; Soler Masana, JM, 1996) |
| "Non-sustained ventricular tachycardia occurs in 20% of patients and is the single best predictor of sudden death in adults." | 1.28 | Arrhythmia and hypertrophic cardiomyopathy. ( Keeling, PJ; McKenna, WJ; Shakespeare, CF; Slade, AK, 1992) |
| " The mode of administration and the dosage of the drug should be re-considered." | 1.28 | Acute amiodarone-induced hepatitis. ( Gabriel, P; Kalantzis, N; Mouzas, J; Tiniakos, D; Tiniakos, G; Tsigas, D, 1991) |
| "Amiodarone therapy was associated with maintenance of sinus rhythm, fewer alterations in drug therapy, fewer embolic episodes and fewer attempted direct current cardioversions (during a shorter follow-up period)." | 1.28 | Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. ( Frenneaux, MP; Karatasakis, G; McKenna, WJ; Poloniecki, JD; Robinson, K; Stockins, B, 1990) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Thus, the safety of amiodarone in the WPW syndrome should be established by electrophysiologic studies and induction of AF, because amiodarone is not protective in all patients with WPW." | 1.27 | Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. ( Fromer, MA; Kappenberger, LJ; Shenasa, M; Steinbrunn, W, 1984) |
| "During AF in WPW syndrome, the ventricular rate is related to the duration of the anterograde refractory period of the accessory pathway." | 1.27 | Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome. ( Abdollah, H; Brugada, P; Wellens, HJ, 1983) |
| "Ventricular tachycardia is detected during electrocardiographic monitoring in 20 to 30% of patients; this arrhythmia is a sensitive but non-specific marker of those patients who are at particular risk of sudden death." | 1.27 | Arrhythmia and prognosis in hypertrophic cardiomyopathy. ( McKenna, WJ, 1983) |
| "amiodarone was administered (repeated boluses of 3 mg/kg in 3 min, or 30 min-infusions of 5 to 7." | 1.27 | Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. ( Faniel, R; Schoenfeld, P, 1983) |
| "The authors studied 13 cases of arrhythmia following pneumonectomy in a series of 94 pneumonectomies performed in the Thoracic Surgery Unit." | 1.27 | [Cardiac rhythm disorders after pneumonectomy]. ( Debesse, B; Dumouchel, A; Hubsch, JP; Zukerman, C, 1985) |
| "Amiodarone was used in the treatment of 21 patients with supraventricular or ventricular arrhythmias which were refractory to conventional antiarrhythmic drugs, individually or in combination." | 1.27 | Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. ( Best, JF; Dunn, M; Lynch, L; Rinkenberger, R, 1986) |
| "The mechanisms underlying the cause of sudden death have not been clearly elucidated." | 1.27 | [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences]. ( Kleinebenne, A; McKenna, WJ, 1985) |
| "Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data." | 1.27 | Safety and efficacy of amiodarone. The low-dose perspective. ( Friehling, TD; Kowey, PR; Marinchak, RA; Stohler, JL; Sulpizi, AM, 1988) |
| "Amiodarone was used for recurrent supraventricular tachycardia in four cases and frequent ventricular extra systoles complicating congenital QT prolongation in the remaining case." | 1.27 | Amiodarone-induced torsades de pointes. ( Brown, MA; Lubbe, WF; Norris, RM; Smith, WM, 1986) |
| "Amiodarone i." | 1.26 | [Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias]. ( Bianchi, C; Bonifazi, C; Coppetti, S; Distante, S; Ferrari, O; Ricevuti, A; Rinaldo, R; Rizzi, M; Tavecchi, L; Zampaglione, G; Ziletti, G, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 124 (7.79) | 18.7374 |
| 1990's | 207 (13.00) | 18.2507 |
| 2000's | 606 (38.07) | 29.6817 |
| 2010's | 541 (33.98) | 24.3611 |
| 2020's | 114 (7.16) | 2.80 |
| Authors | Studies |
|---|---|
| Plouvier, B | 1 |
| Beatch, GN | 1 |
| Jung, GL | 1 |
| Zolotoy, A | 1 |
| Sheng, T | 1 |
| Clohs, L | 1 |
| Barrett, TD | 1 |
| Fedida, D | 1 |
| Wang, WQ | 1 |
| Zhu, JJ | 1 |
| Liu, Y | 4 |
| Abraham, S | 1 |
| Lynn, L | 1 |
| Dong, Y | 1 |
| Wall, RA | 1 |
| Walker, MJ | 1 |
| Eyuboglu, M | 2 |
| Celik, A | 1 |
| Yokoyama, S | 1 |
| Tanaka, Y | 3 |
| Hosomi, K | 1 |
| Takada, M | 1 |
| Stecher, C | 1 |
| Everhart, A | 1 |
| Smith, LB | 1 |
| Jena, A | 1 |
| Ross, JS | 1 |
| Desai, NR | 2 |
| Shah, N | 1 |
| Karaca-Mandic, P | 1 |
| Grymonprez, M | 1 |
| Vanspranghe, K | 1 |
| Steurbaut, S | 1 |
| De Backer, TL | 1 |
| Lahousse, L | 1 |
| Lévy, S | 3 |
| Bezabhe, WM | 1 |
| Bereznicki, LR | 1 |
| Radford, J | 1 |
| Salahudeen, MS | 1 |
| Garrahy, E | 1 |
| Wimmer, BC | 1 |
| Bindoff, I | 1 |
| Peterson, GM | 1 |
| Shalen, EF | 1 |
| Heitner, SB | 1 |
| Al-Rashdan, L | 1 |
| Akhavein, R | 1 |
| Elman, MR | 1 |
| Fischer, KL | 1 |
| Lin, LQ | 1 |
| Mannello, M | 1 |
| Nazer, B | 1 |
| Song, HK | 1 |
| Masri, A | 1 |
| Chaturvedi, A | 1 |
| Khoury, F | 1 |
| Vashistha, K | 1 |
| Patel, K | 2 |
| Mareda, P | 1 |
| Veasey, T | 1 |
| Link, C | 1 |
| Raina, A | 1 |
| Khachatryan, A | 1 |
| Merino, JL | 4 |
| de Abajo, FJ | 1 |
| Botto, GL | 4 |
| Kirchhof, P | 3 |
| Breithardt, G | 5 |
| Stambler, B | 1 |
| Abenhaim, L | 1 |
| Grimaldi-Bensouda, L | 1 |
| Sun, YH | 1 |
| Ma, CS | 3 |
| Wu, SL | 1 |
| Johnston, BW | 1 |
| Chean, CS | 1 |
| Duarte, R | 1 |
| Hill, R | 1 |
| Blackwood, B | 1 |
| McAuley, DF | 1 |
| Welters, ID | 1 |
| Vamos, M | 2 |
| Oldgren, J | 1 |
| Nam, GB | 3 |
| Lip, GYH | 1 |
| Calkins, H | 6 |
| Zhu, J | 7 |
| Ueng, KC | 4 |
| Ludwigs, U | 2 |
| Wieloch, M | 7 |
| Stewart, J | 5 |
| Hohnloser, SH | 41 |
| Thind, M | 3 |
| Zareba, W | 2 |
| Atar, D | 3 |
| Crijns, HJGM | 1 |
| Pak, HN | 5 |
| Reiffel, J | 1 |
| Kowey, P | 4 |
| McKindley, DS | 2 |
| Reiffel, JA | 7 |
| Naccarelli, GV | 16 |
| Kowey, PR | 18 |
| Zhang, P | 2 |
| Wang, M | 3 |
| Liu, W | 2 |
| Sun, P | 1 |
| Cai, S | 2 |
| Pan, Y | 1 |
| Zhao, Q | 3 |
| Kohajda, Z | 1 |
| Virág, L | 1 |
| Hornyik, T | 1 |
| Husti, Z | 1 |
| Sztojkov-Ivanov, A | 1 |
| Nagy, N | 1 |
| Horváth, A | 1 |
| Varga, R | 1 |
| Prorok, J | 1 |
| Szlovák, J | 1 |
| Tóth, N | 1 |
| Gazdag, P | 1 |
| Topal, L | 1 |
| Naveed, M | 1 |
| Árpádffy-Lovas, T | 1 |
| Pászti, B | 1 |
| Magyar, T | 1 |
| Koncz, I | 1 |
| Déri, S | 1 |
| Demeter-Haludka, V | 1 |
| Aigner, Z | 1 |
| Ördög, B | 1 |
| Patfalusi, M | 1 |
| Tálosi, L | 1 |
| Tiszlavicz, L | 1 |
| Földesi, I | 1 |
| Jost, N | 1 |
| Baczkó, I | 1 |
| Varró, A | 1 |
| Savchuk, H | 1 |
| Bridevaux, PO | 1 |
| Fournier, J | 1 |
| Gobin, N | 1 |
| Lam, JC | 1 |
| Stevenson, B | 1 |
| Lee, YG | 1 |
| Maurer, J | 1 |
| Patanwala, AE | 1 |
| Radosevich, JJ | 1 |
| Gillmann, HJ | 1 |
| Busche, P | 1 |
| Leffler, A | 1 |
| Stueber, T | 1 |
| Camm, AJ | 15 |
| Blomström-Lundqvist, C | 5 |
| Boriani, G | 12 |
| Goette, A | 8 |
| Piccini, JP | 10 |
| Saksena, S | 2 |
| Amar, D | 1 |
| Zhang, H | 4 |
| Chung, MK | 2 |
| Tan, KS | 1 |
| Desiderio, D | 1 |
| Park, BJ | 1 |
| Pedoto, A | 1 |
| Roistacher, N | 1 |
| Isbell, JM | 1 |
| Molena, D | 1 |
| Milne, GL | 1 |
| Meyers, BF | 1 |
| Fischer, GW | 2 |
| Rusch, VW | 1 |
| Jones, DR | 1 |
| Wybraniec, MT | 2 |
| Maciąg, A | 2 |
| Miśkowiec, D | 2 |
| Ceynowa-Sielawko, B | 2 |
| Balsam, P | 3 |
| Wójcik, M | 2 |
| Wróbel, W | 2 |
| Farkowski, M | 1 |
| Ćwiek-Rębowska, E | 2 |
| Szołkiewicz, M | 2 |
| Ozierański, K | 2 |
| Błaszczyk, R | 2 |
| Bula, K | 2 |
| Dembowski, T | 2 |
| Peller, M | 2 |
| Krzowski, B | 2 |
| Wańha, W | 2 |
| Koziński, M | 2 |
| Kasprzak, JD | 2 |
| Szwed, H | 2 |
| Mizia-Stec, K | 2 |
| Cay, S | 1 |
| Kara, M | 1 |
| Ozcan, F | 1 |
| Ozeke, O | 1 |
| Aksu, T | 1 |
| Aras, D | 1 |
| Topaloglu, S | 1 |
| Topp-Zielińska, A | 1 |
| Farkowski, MM | 1 |
| Um, KJ | 3 |
| McIntyre, WF | 3 |
| Mendoza, PA | 2 |
| Ibrahim, O | 1 |
| Nguyen, ST | 1 |
| Lin, SH | 1 |
| Duceppe, E | 2 |
| Rochwerg, B | 1 |
| Healey, JS | 4 |
| Koziarz, A | 2 |
| Lengyel, AP | 1 |
| Bhatnagar, A | 1 |
| Amit, G | 2 |
| Chu, VA | 2 |
| Whitlock, RP | 4 |
| Belley-Côté, EP | 3 |
| Cacioppo, F | 1 |
| Schwameis, M | 1 |
| Schuetz, N | 1 |
| Oppenauer, J | 1 |
| Schnaubelt, S | 1 |
| Simon, A | 1 |
| Lutnik, M | 1 |
| Gupta, S | 1 |
| Roth, D | 1 |
| Herkner, H | 1 |
| Spiel, AO | 1 |
| Laggner, AN | 1 |
| Domanovits, H | 1 |
| Niederdoeckl, J | 1 |
| Handelsman, Y | 1 |
| Bunch, TJ | 1 |
| Rodbard, HW | 1 |
| Steinberg, BA | 4 |
| Bigot, G | 2 |
| Konigsberg, L | 1 |
| Ma, C | 2 |
| Lin, JL | 2 |
| Bai, R | 3 |
| Sun, Y | 2 |
| Kamal, F | 1 |
| Abd Al Jawad, MN | 1 |
| Gamal, M | 1 |
| Mason, JM | 1 |
| Krenz, JR | 1 |
| Koehl, JL | 1 |
| Fuh, L | 1 |
| Nagurney, JT | 1 |
| Wilcox, SR | 1 |
| Hayes, BD | 1 |
| Nakagawa, J | 1 |
| Kinjo, T | 1 |
| Aiuchi, N | 1 |
| Ueno, K | 1 |
| Tomita, H | 1 |
| Niioka, T | 1 |
| Brandner, S | 1 |
| Zhang, J | 2 |
| Wang, Y | 4 |
| Jiang, H | 4 |
| Tao, D | 1 |
| Zhao, K | 1 |
| Yin, Z | 1 |
| Han, J | 1 |
| Xin, F | 1 |
| Jin, Y | 1 |
| Wang, H | 1 |
| Londoño-Tobón, L | 1 |
| García, CAO | 1 |
| Li, X | 1 |
| Wang, X | 3 |
| Guan, Z | 1 |
| Mitarai, K | 1 |
| Kondo, H | 1 |
| Shinohara, T | 1 |
| Uchida, N | 1 |
| Wakabayashi, T | 1 |
| Shinozaki, K | 1 |
| Zaizen, H | 1 |
| Takahashi, N | 1 |
| Charitakis, E | 1 |
| Tsartsalis, D | 1 |
| Korela, D | 1 |
| Stratinaki, M | 1 |
| Vanky, F | 1 |
| Charitos, EI | 1 |
| Alfredsson, J | 1 |
| Karlsson, LO | 1 |
| Foukarakis, E | 1 |
| Aggeli, C | 1 |
| Tsioufis, C | 1 |
| Walfridsson, H | 1 |
| Dragioti, E | 1 |
| Shurrab, M | 1 |
| Jackevicius, CA | 3 |
| Austin, PC | 1 |
| Tu, K | 1 |
| Qiu, F | 1 |
| Singh, SM | 1 |
| Crystal, E | 7 |
| Caswell, J | 1 |
| Michael, F | 1 |
| Andrade, JG | 3 |
| Ko, DT | 1 |
| Pallisgaard, J | 1 |
| Greve, AM | 1 |
| Lock-Hansen, M | 1 |
| Thune, JJ | 1 |
| Fosboel, EL | 1 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Gislason, GH | 3 |
| Torp-Pedersen, C | 17 |
| Bang, CN | 1 |
| Chen, X | 8 |
| Sartor, C | 3 |
| Zhang, S | 3 |
| Baranchuk, A | 6 |
| Ross-White, A | 3 |
| Fernandez, AL | 3 |
| El-Diasty, M | 3 |
| Liu, Q | 2 |
| Li, J | 3 |
| Yang, L | 2 |
| Graboyes, SDT | 1 |
| Kline, TM | 1 |
| Harris, TN | 1 |
| Iyer, PS | 1 |
| Hollis, IB | 1 |
| Diallo, EH | 1 |
| Brouillard, P | 1 |
| Raymond, JM | 1 |
| Liberman, M | 1 |
| Potter, BJ | 2 |
| Yadav, R | 1 |
| Brilliant, J | 1 |
| Akhtar, T | 1 |
| Milstein, J | 1 |
| Sampognaro, JR | 1 |
| Marine, J | 1 |
| Berger, R | 1 |
| Spragg, D | 1 |
| Lin, SY | 1 |
| Liu, YB | 1 |
| Ho, LT | 1 |
| Peng, YF | 1 |
| Kuo, CH | 1 |
| Tang, SC | 1 |
| Huang, CF | 1 |
| Jeng, JS | 1 |
| Smith, S | 1 |
| Coyle, C | 1 |
| Dhutia, N | 1 |
| Kanagaratnam, P | 1 |
| Linton, NWF | 1 |
| Ken-Opurum, J | 1 |
| Srinivas, SS | 1 |
| Vadagam, P | 1 |
| Faith, L | 1 |
| Park, S | 1 |
| Charland, S | 1 |
| Revel, A | 1 |
| Preblick, R | 1 |
| Wu, VC | 1 |
| Wang, CL | 1 |
| Huang, YC | 1 |
| Tu, HT | 1 |
| Huang, YT | 1 |
| Huang, CH | 2 |
| Chen, SW | 1 |
| Kuo, CF | 1 |
| Hung, KC | 1 |
| Chang, SH | 1 |
| Singh, JP | 2 |
| Turakhia, MP | 4 |
| Fazeli, MS | 1 |
| Kreidieh, B | 1 |
| Crotty, C | 1 |
| Wu, D | 2 |
| Li, Q | 2 |
| Xu, M | 2 |
| Wu, J | 6 |
| Yang, J | 1 |
| Yetmiş, F | 1 |
| Babayigit, E | 1 |
| Görenek, B | 2 |
| Agdamag, AC | 1 |
| Westanmo, A | 1 |
| Gravely, A | 1 |
| Angsubhakorn, N | 1 |
| Chen, LY | 2 |
| Adabag, S | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Smalley, W | 1 |
| Zimmerman, E | 1 |
| Dupont, WD | 1 |
| Hung, AM | 1 |
| Daugherty, JR | 1 |
| Dickson, AL | 1 |
| Murray, KT | 2 |
| Caspersen, E | 1 |
| Guinot, PG | 1 |
| Rozec, B | 1 |
| Oilleau, JF | 1 |
| Fellahi, JL | 2 |
| Gaudard, P | 1 |
| Lorne, E | 2 |
| Mahjoub, Y | 1 |
| Besnier, E | 1 |
| Moussa, MD | 1 |
| Mongardon, N | 2 |
| Hanouz, JL | 1 |
| Briant, AR | 1 |
| Paul, LPS | 1 |
| Tomadesso, C | 1 |
| Parienti, JJ | 2 |
| Descamps, R | 1 |
| Denisenko, A | 1 |
| Fischer, MO | 3 |
| Orso, D | 1 |
| Santangelo, S | 1 |
| Guglielmo, N | 1 |
| Bove, T | 1 |
| Cilenti, F | 1 |
| Cristiani, L | 1 |
| Copetti, R | 1 |
| Beaulieu-Jones, BR | 1 |
| Lin, B | 1 |
| Phillips, AM | 1 |
| Haime, M | 1 |
| Quin, JA | 1 |
| Pundi, K | 1 |
| Fan, J | 2 |
| Kabadi, S | 1 |
| Din, N | 1 |
| Rashkin, J | 1 |
| Sandhu, AT | 1 |
| Hellemans, A | 1 |
| Duytschaever, M | 2 |
| Van Steenkiste, G | 1 |
| van Loon, G | 4 |
| Mampaey, G | 1 |
| Bosmans, T | 1 |
| Stock, E | 1 |
| Skotarek, M | 1 |
| Smets, P | 1 |
| Kaur, P | 1 |
| Kaur, A | 1 |
| Sinha, A | 1 |
| Khaliq, W | 1 |
| Dumic, I | 1 |
| Singh, A | 1 |
| Marazzato, J | 1 |
| Eikermann, M | 1 |
| Di Biase, L | 8 |
| Kumar, N | 1 |
| Iyer, MH | 1 |
| Dalia, A | 1 |
| Bardia, A | 1 |
| Balik, M | 1 |
| Maly, M | 1 |
| Brozek, T | 1 |
| Rulisek, J | 1 |
| Porizka, M | 1 |
| Sachl, R | 1 |
| Otahal, M | 1 |
| Brestovansky, P | 1 |
| Svobodova, E | 1 |
| Flaksa, M | 1 |
| Stach, Z | 1 |
| Horejsek, J | 1 |
| Volny, L | 1 |
| Jurisinova, I | 1 |
| Novotny, A | 1 |
| Trachta, P | 1 |
| Kunstyr, J | 1 |
| Kopecky, P | 1 |
| Tencer, T | 1 |
| Pazout, J | 1 |
| Belohlavek, J | 1 |
| Duska, F | 1 |
| Krajcova, A | 1 |
| Waldauf, P | 1 |
| Coletta, MJ | 1 |
| Lis, G | 1 |
| Clark, P | 1 |
| Dabir, R | 1 |
| Daneshvar, F | 1 |
| Luu, K | 1 |
| Welch, RJ | 1 |
| Yiu, G | 1 |
| Rasmussen, PV | 1 |
| Dalgaard, F | 2 |
| Hilmar Gislason, G | 1 |
| Piccini, J | 1 |
| D'Souza, M | 1 |
| Ruwald, MH | 2 |
| Pallisgaard, JL | 2 |
| Hansen, ML | 2 |
| Pokorney, SD | 2 |
| Holmes, DN | 1 |
| Shrader, P | 1 |
| Thomas, L | 3 |
| Fonarow, GC | 3 |
| Mahaffey, KW | 2 |
| Gersh, BJ | 3 |
| Freeman, JV | 1 |
| Singer, DE | 2 |
| Washam, JB | 2 |
| Peterson, ED | 5 |
| Packer, M | 1 |
| Murphy, RP | 1 |
| Canavan, M | 1 |
| Bai, J | 1 |
| Lu, Y | 2 |
| Kupnovytska, I | 1 |
| Virstiuk, N | 1 |
| Danyliuk, O | 1 |
| Luchko, O | 1 |
| Kocherzhat, O | 1 |
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Bandorski, D | 1 |
| Bogossian, H | 1 |
| Ghofrani, A | 1 |
| Schmitt, J | 3 |
| Höltgen, R | 1 |
| Alegret, JM | 2 |
| Viñolas, X | 2 |
| Tajes, H | 1 |
| Valdovinos, P | 1 |
| Palomares, R | 1 |
| Arias, MA | 2 |
| Bazán, V | 1 |
| Miano, TA | 1 |
| Yang, W | 1 |
| Shashaty, MGS | 1 |
| Zuppa, A | 1 |
| Brown, JR | 1 |
| Hennessy, S | 1 |
| Chiang, JY | 1 |
| Chen, PC | 1 |
| Yang, YH | 1 |
| Chang, CH | 1 |
| Chu, FY | 1 |
| Chen, JJ | 1 |
| Wu, CK | 1 |
| Hwang, JJ | 1 |
| Chiang, FT | 1 |
| Lin, LY | 1 |
| Popova, EP | 1 |
| Bogova, OT | 1 |
| Chandirli, SA | 1 |
| Puzin, SN | 1 |
| Sychev, DA | 1 |
| Fisenko, VP | 1 |
| Tam, DY | 1 |
| Fremes, SE | 1 |
| deSouza, IS | 1 |
| Tadrous, M | 1 |
| Sexton, T | 1 |
| Benabbas, R | 1 |
| Carmelli, G | 1 |
| Sinert, R | 1 |
| Pong, T | 1 |
| Cyr, K | 1 |
| Niesen, J | 1 |
| Aparicio-Valenzuela, J | 1 |
| Carlton, C | 1 |
| Fischbein, MP | 1 |
| Woo, YJ | 1 |
| Boyd, JH | 1 |
| Lee, AM | 1 |
| Matos, JD | 1 |
| McIlvaine, S | 1 |
| Grau-Sepulveda, M | 1 |
| Jawitz, OK | 1 |
| Brennan, JM | 1 |
| Khabbaz, KR | 1 |
| Sellke, FW | 1 |
| Yeh, R | 1 |
| Zimetbaum, P | 5 |
| O'Bryan, LJ | 1 |
| Redfern, OC | 1 |
| Bedford, J | 1 |
| Petrinic, T | 2 |
| Young, JD | 1 |
| Watkinson, PJ | 2 |
| Cabello, I | 1 |
| Jacob, J | 1 |
| Arranz, M | 1 |
| Yuguero, O | 1 |
| Guzman, J | 1 |
| Moreno-Pena, A | 1 |
| Frances, P | 2 |
| Santos, J | 1 |
| Esquerrà, A | 1 |
| Mòdol, JM | 1 |
| Fernando, SL | 1 |
| Jain, A | 2 |
| Weir, C | 1 |
| Boyle, T | 1 |
| Yu, Y | 1 |
| Luo, D | 1 |
| Li, Z | 1 |
| Li, F | 1 |
| Qiao, J | 1 |
| Yu, F | 1 |
| Li, M | 1 |
| Bhatt, DL | 1 |
| Le Heuzey, JY | 7 |
| Lombardi, F | 5 |
| Tamargo, J | 3 |
| Martinez, JM | 1 |
| Naditch-Brûlé, L | 3 |
| Lakušić, N | 1 |
| Slivnjak, V | 1 |
| Ciglenečki, N | 1 |
| Cerovec, D | 1 |
| Huang, R | 1 |
| Lin, J | 5 |
| Gong, K | 1 |
| Chen, L | 2 |
| Fan, L | 1 |
| Zhang, F | 1 |
| Zhang, Y | 4 |
| Xu, Z | 1 |
| Cabrera-Rego, JO | 1 |
| Luzurriaga Navas, JD | 1 |
| Yanes Quintana, AA | 1 |
| Maharshak, I | 1 |
| Paul, M | 1 |
| Steiner, H | 1 |
| Shi, S | 2 |
| Jia, Q | 1 |
| Shi, J | 1 |
| Yuan, G | 1 |
| Hu, Y | 1 |
| Aidonidis, I | 4 |
| Simopoulos, V | 3 |
| Stravela, S | 1 |
| Dipla, K | 2 |
| Stamatiou, R | 1 |
| Hatziefthimiou, A | 3 |
| Molyvdas, PA | 2 |
| Qi, A | 1 |
| Moscona, JC | 1 |
| Reed, J | 1 |
| Le Jemtel, TH | 1 |
| Ren, J | 1 |
| Yang, Y | 3 |
| Wu, S | 1 |
| Wang, J | 1 |
| Shao, X | 1 |
| Norhayati, MN | 1 |
| Shaiful Bahari, I | 1 |
| Zaharah, S | 1 |
| Nik Hazlina, NH | 1 |
| Mohammad Aimanazrul, Z | 1 |
| Irfan, M | 1 |
| Stanton, MM | 1 |
| Samii, L | 1 |
| Leung, G | 1 |
| Pearce, P | 1 |
| Young, ML | 1 |
| Exelbert, EJ | 1 |
| Roth, T | 1 |
| Cohen, L | 1 |
| Cogan, J | 1 |
| Hou, XX | 1 |
| He, L | 2 |
| Du, X | 1 |
| Wang, GH | 1 |
| Dong, JZ | 1 |
| Chiou, WR | 1 |
| Huang, CC | 1 |
| Lin, PL | 1 |
| Chuang, JY | 1 |
| Liu, LY | 1 |
| Su, MI | 1 |
| Liao, FC | 1 |
| Chen, CY | 5 |
| Kuo, JY | 1 |
| Tsai, CT | 1 |
| Wu, YJ | 1 |
| Lee, YH | 1 |
| Portelli, D | 1 |
| Mifsud, S | 1 |
| Abela, A | 1 |
| Fava, S | 1 |
| Littmann, L | 1 |
| Norton, HJ | 1 |
| Bosch, NA | 1 |
| Rucci, JM | 1 |
| Massaro, JM | 1 |
| Winter, MR | 2 |
| Quinn, EK | 1 |
| Chon, KH | 1 |
| McManus, DD | 1 |
| Walkey, AJ | 2 |
| Li, W | 1 |
| Wang, YC | 1 |
| Tiwari, N | 1 |
| Ibrahim, OA | 1 |
| Benz, AP | 1 |
| Dalmia, S | 1 |
| Wang, CN | 1 |
| Alhazzani, W | 1 |
| Conen, D | 2 |
| Devereaux, PJ | 1 |
| Sciria, CT | 1 |
| Zhao, X | 1 |
| Matsouaka, R | 1 |
| Lewis, WR | 1 |
| Takahashi, K | 2 |
| Yamashita, M | 1 |
| Sakaue, T | 1 |
| Enomoto, D | 1 |
| Uemura, S | 1 |
| Okura, T | 1 |
| Ikeda, S | 1 |
| Takemoto, M | 2 |
| Utsunomiya, Y | 1 |
| Hyodo, T | 1 |
| D'Angelo, RN | 1 |
| Rahman, M | 1 |
| Khanna, R | 1 |
| Yeh, RW | 1 |
| Goldstein, L | 1 |
| Yadalam, S | 1 |
| Kalsekar, I | 1 |
| Tung, P | 1 |
| Zimetbaum, PJ | 4 |
| Shantha, G | 1 |
| Chugh, A | 4 |
| Crawford, T | 1 |
| Latchamsetty, R | 1 |
| Ghanbari, H | 1 |
| Ghannam, M | 1 |
| Liang, J | 1 |
| Batul, A | 1 |
| Chung, E | 1 |
| Saeed, M | 1 |
| Cunnane, R | 1 |
| Jongnarangsin, K | 1 |
| Bogun, F | 3 |
| Pelosi, F | 3 |
| Morady, F | 8 |
| Oral, H | 4 |
| Reddy, SA | 1 |
| Nethercott, SL | 1 |
| Khialani, BV | 1 |
| Grace, AA | 1 |
| Martin, CA | 1 |
| Tan, HL | 1 |
| Tang, LWT | 1 |
| Chin, SY | 1 |
| Chan, ECY | 1 |
| Smith, HA | 1 |
| Kanji, S | 2 |
| Tran, DTT | 1 |
| Redpath, C | 1 |
| Ferguson, D | 1 |
| Lenet, T | 1 |
| Sigler, G | 1 |
| Gilbert, S | 1 |
| Maziak, D | 1 |
| Villeneuve, P | 1 |
| Sundaresan, S | 1 |
| Seely, AJE | 1 |
| Sipahi, FN | 1 |
| Sugimura, Y | 1 |
| Boeken, U | 1 |
| Yilmaz, E | 1 |
| Makimoto, H | 1 |
| Lichtenberg, A | 1 |
| Dalyanoĝlu, H | 1 |
| Bosak-Barani, S | 2 |
| Mercer, E | 1 |
| Blaszczyk, A | 1 |
| Drikite, L | 1 |
| Bedford, JP | 1 |
| O'Bryan, L | 1 |
| Rajappan, K | 2 |
| Doidge, J | 1 |
| Harrison, DA | 1 |
| Rowan, KM | 1 |
| Mouncey, PR | 1 |
| Young, D | 1 |
| Corbett, M | 1 |
| Curtis, AB | 5 |
| Zeitler, EP | 1 |
| Malik, A | 1 |
| Bogard, A | 1 |
| Bhattacharyya, N | 1 |
| Moskowitz, A | 1 |
| Chen, KP | 1 |
| Cooper, AZ | 1 |
| Chahin, A | 1 |
| Ghassemi, MM | 1 |
| Celi, LA | 1 |
| Leelathanalerk, A | 1 |
| Dongtai, W | 1 |
| Huckleberry, Y | 1 |
| Kopp, B | 1 |
| Bloom, J | 1 |
| Alpert, J | 1 |
| Cadrin-Tourigny, J | 2 |
| Shohoudi, A | 1 |
| Roy, D | 15 |
| Khairy, P | 4 |
| Saengklub, N | 1 |
| Limprasutr, V | 1 |
| Sawangkoon, S | 1 |
| Hamlin, RL | 1 |
| Kijtawornrat, A | 1 |
| Kettering, K | 1 |
| Gramley, F | 1 |
| Kolokotroni, SM | 1 |
| Toufektzian, L | 1 |
| Harling, L | 1 |
| Billè, A | 1 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Schizas, D | 1 |
| Spartalis, E | 1 |
| Wasserstrum, Y | 1 |
| Raanani, P | 1 |
| Kornowski, R | 1 |
| Iakobishvili, Z | 1 |
| Greenstein, D | 1 |
| Beau, J | 2 |
| Gottlieb, G | 1 |
| Teller, D | 1 |
| Kulik, A | 3 |
| De Vecchis, R | 1 |
| Ariano, C | 1 |
| Giasi, A | 1 |
| Cioppa, C | 1 |
| Feng, J | 2 |
| Rivinius, R | 2 |
| Helmschrott, M | 2 |
| Ruhparwar, A | 2 |
| Darche, FF | 2 |
| Thomas, D | 5 |
| Bruckner, T | 2 |
| Katus, HA | 4 |
| Doesch, AO | 2 |
| Tsetskhladze, E | 1 |
| Khintibidze, I | 1 |
| Göndör, G | 1 |
| Stöllberger, C | 2 |
| Darkner, S | 4 |
| Goetze, JP | 1 |
| Henningsen, K | 1 |
| Pehrson, S | 4 |
| Svendsen, JH | 5 |
| Drigalla, D | 1 |
| Essler, SE | 1 |
| Stone, CK | 1 |
| Khan, MH | 1 |
| Rochlani, Y | 1 |
| Aronow, WS | 1 |
| Gasparini, M | 2 |
| Galimberti, P | 1 |
| Colby, R | 1 |
| Geyer, H | 1 |
| Quintana-Villamandos, B | 1 |
| Gomez de Diego, JJ | 1 |
| Delgado-Martos, MJ | 1 |
| Muñoz-Valverde, D | 1 |
| Soto-Montenegro, ML | 1 |
| Desco, M | 1 |
| Delgado-Baeza, E | 1 |
| Khan, I | 1 |
| Patel, HC | 2 |
| Nanayakkara, S | 1 |
| Raju, H | 1 |
| Voskoboinik, A | 1 |
| Mariani, JA | 1 |
| Huang, X | 1 |
| Chen, Y | 3 |
| Huang, Y | 1 |
| Zhao, H | 2 |
| Liu, S | 1 |
| Shee, V | 1 |
| Xu, D | 1 |
| Peng, J | 3 |
| Lupercio, F | 2 |
| Romero, J | 2 |
| Peltzer, B | 1 |
| Maraboto, C | 1 |
| Briceno, D | 1 |
| Villablanca, P | 1 |
| Ferrick, K | 1 |
| Gross, JN | 1 |
| Kim, S | 2 |
| Fisher, J | 1 |
| Krumerman, A | 1 |
| Mehaffey, JH | 1 |
| Hawkins, RB | 1 |
| Byler, M | 1 |
| Smith, J | 1 |
| Kern, JA | 2 |
| Kron, I | 1 |
| Ailawadi, G | 2 |
| Wanchek, T | 1 |
| Yarboro, LT | 1 |
| Nicot, F | 1 |
| Procopi, N | 1 |
| Nguyen, LS | 1 |
| Pavlovic, D | 1 |
| Fabritz, L | 1 |
| Fong, HK | 1 |
| Abdullah, O | 1 |
| Gautam, S | 1 |
| Wu, C | 2 |
| Tcherny-Lessenot, S | 2 |
| Dai, W | 2 |
| Kechemir, H | 1 |
| Gandhi, S | 1 |
| Lin, S | 1 |
| Juhaeri, J | 3 |
| Mandal, K | 1 |
| Sethi, NJ | 1 |
| Nielsen, EE | 1 |
| Safi, S | 1 |
| Feinberg, J | 1 |
| Gluud, C | 1 |
| Jakobsen, JC | 1 |
| Garcia, JR | 1 |
| Campbell, PF | 1 |
| Kumar, G | 1 |
| Langberg, JJ | 1 |
| Cesar, L | 1 |
| Deppen, JN | 1 |
| Shin, EY | 1 |
| Bhatia, NK | 1 |
| Wang, L | 1 |
| Xu, K | 1 |
| Schneider, F | 1 |
| Robinson, B | 1 |
| García, AJ | 1 |
| Levit, RD | 1 |
| Ehrlich, JR | 7 |
| Brown, M | 1 |
| Nassoiy, S | 1 |
| Chaney, W | 1 |
| Plackett, TP | 1 |
| Blackwell, RH | 1 |
| Luchette, F | 1 |
| Engoren, M | 2 |
| Posluszny, J | 1 |
| Kapelios, CJ | 1 |
| Bonou, MS | 1 |
| Diamantopoulos, P | 1 |
| Angelopoulou, MK | 1 |
| Masoura, C | 1 |
| Barbetseas, J | 1 |
| Viniou, NA | 1 |
| Sayeed, S | 1 |
| Hernandez, AF | 3 |
| D'Urso, G | 1 |
| Anastasia, A | 1 |
| Toscano, E | 1 |
| Patti, S | 1 |
| de Bartolomeis, A | 1 |
| Chen, M | 1 |
| Ji, C | 1 |
| Avendano, R | 1 |
| Diaz, JC | 1 |
| Quispe, R | 1 |
| Golive, A | 1 |
| Natale, A | 6 |
| Garcia, MJ | 1 |
| Krumerman, AK | 1 |
| Münkler, P | 1 |
| Wutzler, A | 1 |
| Attanasio, P | 1 |
| Huemer, M | 1 |
| Parwani, AS | 1 |
| Haverkamp, W | 4 |
| Meyer, C | 1 |
| Boldt, LH | 2 |
| Gu, D | 1 |
| Ge, Q | 1 |
| Haddad, FG | 1 |
| Mulrooney, S | 1 |
| Konecny, T | 1 |
| Brady, PA | 1 |
| Park, JY | 1 |
| Reddy, PK | 1 |
| Ruzek, L | 1 |
| Mach, L | 1 |
| Caples, SM | 1 |
| Somers, VK | 1 |
| Hevas, A | 1 |
| Skoularigis, I | 2 |
| Tsilimingas, N | 1 |
| Lussi, C | 1 |
| Christ, M | 1 |
| Flömer, F | 1 |
| Perrone, MA | 1 |
| Babu Dasari, J | 1 |
| Intorcia, A | 1 |
| Morgagni, R | 1 |
| Sergi, D | 1 |
| Battaini, F | 1 |
| De Lorenzo, A | 1 |
| Bernardini, S | 1 |
| Merra, G | 1 |
| Romeo, F | 1 |
| Taieb, J | 1 |
| Le Franc, P | 1 |
| Khattar, P | 1 |
| Moubarak, G | 1 |
| Gorka, H | 1 |
| Godenir, JP | 1 |
| Deutsch, P | 1 |
| Degand, B | 1 |
| Al Daoud, A | 1 |
| Elkaim, JP | 1 |
| Elbaz, N | 1 |
| Merlo, S | 1 |
| Lellouche, N | 1 |
| Ledingham, D | 1 |
| Cordato, D | 1 |
| Sharma, SP | 1 |
| Turagam, M | 1 |
| Atkins, D | 1 |
| Bommana, S | 1 |
| Jeffrey, C | 1 |
| Newton, D | 1 |
| Nydegger, C | 1 |
| Carroll, H | 1 |
| Gopinathannair, R | 1 |
| Lakkireddy, D | 4 |
| Milojevic, K | 1 |
| Beltramini, A | 1 |
| Nagash, M | 1 |
| Muret, A | 1 |
| Richard, O | 1 |
| Lambert, Y | 1 |
| Kim, IS | 1 |
| Kim, HJ | 1 |
| Yu, HT | 1 |
| Kim, TH | 1 |
| Uhm, JS | 2 |
| Kim, JY | 1 |
| Joung, B | 3 |
| Lee, MH | 3 |
| Dobrev, D | 3 |
| Aguilar, M | 1 |
| Heijman, J | 1 |
| Guichard, JB | 1 |
| Nattel, S | 14 |
| Benák, A | 1 |
| Kohári, M | 1 |
| Herczeg, A | 1 |
| Makai, A | 1 |
| Bencsik, G | 1 |
| Sághy, L | 1 |
| Pap, R | 1 |
| Jamieson, A | 1 |
| Diederichsen, SZ | 2 |
| Johannessen, A | 2 |
| Hansen, J | 3 |
| Tisdale, JE | 5 |
| Jaynes, HA | 1 |
| Watson, MR | 1 |
| Corya, AL | 1 |
| Shen, C | 2 |
| Kesler, KA | 4 |
| Hassan, OF | 1 |
| Weksler, B | 1 |
| Yin, J | 1 |
| Yang, M | 1 |
| Yu, S | 1 |
| Fu, H | 1 |
| Huang, H | 1 |
| Yang, B | 3 |
| He, B | 2 |
| Bao, M | 1 |
| Wu, G | 1 |
| Lu, Z | 1 |
| Liu, H | 1 |
| Liu, X | 7 |
| Dong, L | 2 |
| Huang, C | 1 |
| Hayanga, JA | 1 |
| Buenaventura, P | 1 |
| Abbas, G | 1 |
| Beyranvand, MR | 1 |
| Farrokhi, S | 1 |
| Peyvandi, H | 1 |
| Soltaninejad, K | 1 |
| Shadnia, S | 1 |
| Arnouk, S | 1 |
| Aberle, C | 1 |
| Altshuler, D | 1 |
| Merchan, C | 1 |
| Piper, GL | 1 |
| Papadopoulos, J | 1 |
| Vacheron, CH | 1 |
| Allaouchiche, B | 1 |
| Osman, W | 1 |
| Hanson, M | 1 |
| Sharma, S | 3 |
| Patti, R | 1 |
| Soni, P | 1 |
| Ehrlich, S | 1 |
| Kupfer, Y | 1 |
| Osmanovic, E | 1 |
| Ostojic, M | 1 |
| Avdic, S | 1 |
| Djedovic, S | 1 |
| Delic, A | 1 |
| Kadric, N | 1 |
| Terzic, A | 1 |
| Avdic-Salihovic, A | 1 |
| Lindhardt, TB | 1 |
| Lin, Y | 1 |
| Liang, D | 1 |
| Qi, G | 1 |
| Tian, W | 1 |
| Bockeria, OL | 1 |
| Kanametov, TN | 1 |
| Shvartz, VA | 1 |
| Sokolskaya, MA | 1 |
| Zhuginisov, DS | 1 |
| Sanakoev, MK | 1 |
| Bockeria, LA | 1 |
| Atreya, AR | 1 |
| Priya, A | 1 |
| Pack, QR | 1 |
| Pekow, PS | 1 |
| Stefan, M | 1 |
| Lagu, T | 1 |
| Lotfi, AS | 1 |
| Lindenauer, PK | 1 |
| Frankel, G | 1 |
| Kamrul, R | 1 |
| Kosar, L | 1 |
| Jensen, B | 1 |
| Tagarakis, GI | 1 |
| Daskalopoulou, SS | 2 |
| Daskalopoulos, ME | 1 |
| Lenos, A | 1 |
| Chryssagis, K | 1 |
| Skoularingis, I | 1 |
| Tsilimingas, NB | 1 |
| Arsenault, KA | 1 |
| Yusuf, AM | 1 |
| Morillo, CA | 1 |
| Nair, GM | 1 |
| Van Wagoner, DR | 1 |
| Skiba, MA | 1 |
| Pick, AW | 2 |
| Chaudhuri, K | 1 |
| Bailey, M | 1 |
| Krum, H | 1 |
| Kwa, LJ | 1 |
| Rosenfeldt, FL | 2 |
| Fountzilas, C | 1 |
| George, J | 1 |
| Levine, R | 1 |
| Chen, A | 1 |
| Sauer, W | 1 |
| Nguyen, DT | 1 |
| Joppi, R | 1 |
| Cinconze, E | 1 |
| Mezzalira, L | 1 |
| Pase, D | 1 |
| Poggiani, C | 1 |
| Rossi, E | 1 |
| Pengo, V | 1 |
| Dagres, N | 2 |
| Lewalter, T | 11 |
| Lip, GY | 20 |
| Pison, L | 1 |
| Proclemer, A | 2 |
| Sato, N | 1 |
| Kojima, K | 1 |
| Horio, Y | 1 |
| Goto, E | 1 |
| Masunaga, A | 1 |
| Ichiyasu, H | 1 |
| Kohrogi, H | 1 |
| Mikhaylov, EN | 1 |
| Orshanskaya, VS | 1 |
| Lebedev, AD | 1 |
| Szili-Torok, T | 2 |
| Lebedev, DS | 1 |
| Haraldsdottir, S | 1 |
| Villalona-Calero, MA | 1 |
| Olencki, TE | 1 |
| Kendra, K | 1 |
| Ing, SW | 1 |
| Berg, J | 1 |
| Sauriol, L | 1 |
| Connolly, S | 4 |
| Lindgren, P | 3 |
| Chatterjee, S | 2 |
| Sardar, P | 1 |
| Mukherjee, D | 2 |
| Lichstein, E | 3 |
| Aikat, S | 2 |
| Savelieva, I | 2 |
| Rao, DA | 1 |
| Lakdawala, NK | 1 |
| Miller, AL | 1 |
| Loscalzo, J | 1 |
| Conde, D | 2 |
| Costabel, JP | 1 |
| Alves de Lima, A | 1 |
| Riber, LP | 3 |
| Christensen, TD | 6 |
| Pilegaard, HK | 3 |
| Frommeyer, G | 1 |
| Milberg, P | 1 |
| Uphaus, T | 1 |
| Kaiser, D | 1 |
| Kaese, S | 1 |
| Eckardt, L | 2 |
| Kagal, DR | 1 |
| Lashevsky, I | 1 |
| Tiong, I | 1 |
| Lau, C | 1 |
| Vitali, AC | 1 |
| Newman, D | 4 |
| Said, SM | 3 |
| Esperer, HD | 3 |
| Kluba, K | 2 |
| Genz, C | 2 |
| Rauwolf, T | 1 |
| Schmeisser, A | 2 |
| Braun-Dullaeus, RC | 3 |
| Deftereos, S | 1 |
| Giannopoulos, G | 2 |
| Kossyvakis, C | 1 |
| Efremidis, M | 1 |
| Panagopoulou, V | 1 |
| Raisakis, K | 1 |
| Kaoukis, A | 1 |
| Karageorgiou, S | 1 |
| Bouras, G | 1 |
| Katsivas, A | 1 |
| Pyrgakis, V | 1 |
| Stefanadis, C | 2 |
| Mun, HS | 2 |
| Lin, SF | 1 |
| Chen, PS | 1 |
| Li, T | 1 |
| Wei, X | 1 |
| Watkins, AC | 1 |
| Sanchez, PG | 1 |
| Wu, ZJ | 1 |
| Griffith, BP | 1 |
| Sato, Y | 4 |
| Dohi, K | 1 |
| Kusuki, H | 1 |
| Tanimura, M | 1 |
| Watanabe, K | 2 |
| Sugiura, E | 1 |
| Kumagai, N | 1 |
| Nakamori, S | 1 |
| Nakajima, H | 1 |
| Fujii, E | 1 |
| Nakamura, M | 4 |
| Nobori, T | 1 |
| Ito, M | 1 |
| Connolly, M | 1 |
| Menown, IB | 1 |
| Hussey, S | 1 |
| Cinnamond, N | 1 |
| Damani, L | 1 |
| Orgaz-Molina, J | 1 |
| Girón-Prieto, M | 1 |
| Cotugno, M | 1 |
| Arias-Santiago, S | 1 |
| Jahn, S | 1 |
| Zollner, G | 1 |
| Lackner, C | 1 |
| Stauber, RE | 1 |
| Chen, WS | 1 |
| Gao, BR | 1 |
| Chen, WQ | 1 |
| Li, ZZ | 1 |
| Xu, ZY | 1 |
| Zhang, YH | 1 |
| Yang, K | 1 |
| Guan, XQ | 1 |
| Gonzalez, JE | 1 |
| Sauer, WH | 1 |
| Krantz, MJ | 1 |
| Zhao, Y | 1 |
| He, X | 2 |
| Mathew, JP | 1 |
| Fullerton, DA | 1 |
| Hegland, DD | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Chinushi, M | 2 |
| Verrier, RL | 3 |
| Sobrado, MF | 2 |
| Pagotto, VP | 2 |
| Kanas, AF | 2 |
| Machado, AD | 1 |
| Varone, BB | 1 |
| Sobrado, LF | 1 |
| Nearing, BD | 2 |
| Zeng, D | 3 |
| Belardinelli, L | 8 |
| Li, JG | 1 |
| Yang, TC | 1 |
| Yu, DM | 1 |
| Ren, TH | 1 |
| Park, DS | 1 |
| Morley, GE | 1 |
| Ladizinski, B | 1 |
| Elpern, DJ | 1 |
| Yagishita, A | 2 |
| Hachiya, H | 2 |
| Kawabata, M | 2 |
| Nakamura, T | 1 |
| Sugiyama, K | 1 |
| Sasano, T | 1 |
| Isobe, M | 2 |
| Hirao, K | 2 |
| Pisters, R | 1 |
| Connolly, SJ | 22 |
| Page, RL | 9 |
| Crijns, HJ | 21 |
| Sonoda, K | 2 |
| Watanabe, I | 2 |
| Ohkubo, K | 2 |
| Okumura, Y | 2 |
| Kofune, M | 1 |
| Sasaki, N | 2 |
| Kogawa, R | 2 |
| Mano, H | 1 |
| Nakai, T | 2 |
| Hirayama, A | 2 |
| Lodziński, P | 1 |
| Kiliszek, M | 3 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piątkowski, R | 1 |
| Opolski, G | 8 |
| Galperin, J | 4 |
| Elizari, MV | 5 |
| Bonato, R | 3 |
| Ledesma, R | 3 |
| Vazquez Blanco, M | 2 |
| Lago, M | 3 |
| Spada, P | 1 |
| Sanchez, J | 3 |
| Piasentin, J | 1 |
| Chiale, PA | 5 |
| Capucci, A | 16 |
| Raviele, A | 2 |
| Brignole, M | 2 |
| Calò, L | 3 |
| Calvi, V | 1 |
| De Ponti, R | 1 |
| De Simone, A | 4 |
| Delise, P | 1 |
| Di Biase, M | 1 |
| Lunati, M | 2 |
| Santomauro, M | 1 |
| Senni, M | 1 |
| Stabile, G | 4 |
| Themistoclakis, S | 5 |
| Tritto, M | 1 |
| Volpe, M | 1 |
| Ari, H | 1 |
| Ari, S | 1 |
| Akkaya, M | 1 |
| Aydin, C | 1 |
| Emlek, N | 1 |
| Sarigül, OY | 1 |
| Çetinkaya, S | 1 |
| Bozat, T | 1 |
| Şentürk, M | 1 |
| Karaağaç, K | 1 |
| Melek, M | 1 |
| Yilmaz, M | 1 |
| Karavelioğlu, Y | 1 |
| Karapınar, H | 1 |
| Yüksel, M | 1 |
| Memiç, K | 1 |
| Sarak, T | 1 |
| Kurt, R | 1 |
| Yilmaz, A | 2 |
| Miwa, Y | 1 |
| Minamiguchi, H | 1 |
| Bhandari, AK | 1 |
| Cannom, DS | 2 |
| Ho, IC | 1 |
| Huang, JH | 2 |
| Lin, YK | 5 |
| Hsieh, MH | 4 |
| Chen, SA | 12 |
| Chen, YJ | 3 |
| Teme, T | 1 |
| Goldberger, JJ | 1 |
| Koskinas, KC | 2 |
| Fragakis, N | 3 |
| Katritsis, D | 1 |
| Skeberis, V | 1 |
| Vassilikos, V | 1 |
| Kim, BB | 1 |
| Kim, DM | 1 |
| Choi, DH | 1 |
| Chung, JW | 1 |
| Koh, YY | 1 |
| Chang, KS | 1 |
| Hong, SP | 1 |
| Thammakhoune, J | 1 |
| Koren, A | 3 |
| Caubel, P | 1 |
| Ravens, U | 1 |
| Murin, J | 2 |
| Brette, S | 1 |
| Chiang, CE | 3 |
| O'Neill, J | 1 |
| Steg, PG | 1 |
| Ul Rehman, S | 1 |
| Siddiqui, N | 1 |
| Khan, NS | 1 |
| Sobia, R | 1 |
| Assaly, R | 1 |
| Czarnywojtek, A | 2 |
| Woliński, K | 2 |
| Waśko, R | 1 |
| Florek, E | 1 |
| Zgorzalewicz-Stachowiak, M | 2 |
| Fichna, M | 1 |
| Greberska, W | 1 |
| Guzik, P | 1 |
| Lodyga, M | 1 |
| Kwiecinska, B | 2 |
| Ruchała, M | 2 |
| Włodarczyk, P | 1 |
| Dąbrowski, R | 1 |
| Ponikowski, P | 3 |
| Iannone, P | 1 |
| Haupt, E | 1 |
| Flego, G | 1 |
| Truglio, P | 1 |
| Minardi, M | 1 |
| Clarke, S | 1 |
| Magrini, N | 1 |
| Kim, MH | 4 |
| Jhaveri, M | 2 |
| Caldentey, G | 1 |
| Leduc, H | 1 |
| Talajic, M | 11 |
| Racine, N | 2 |
| White, M | 2 |
| O'Meara, E | 2 |
| Guertin, MC | 1 |
| Rouleau, JL | 2 |
| Ducharme, A | 3 |
| Friberg, L | 1 |
| John Camm, A | 1 |
| Halperin, JL | 8 |
| Radzik, D | 7 |
| Lee, EJ | 1 |
| Kim, J | 2 |
| Beckerman, Z | 1 |
| Azran, A | 1 |
| Cohen, O | 1 |
| Nir, RR | 1 |
| Maessen, JG | 2 |
| Bianco-Peled, H | 1 |
| Bolotin, G | 1 |
| Patel, AJ | 1 |
| Hunt, I | 1 |
| Chung, R | 1 |
| Houghtaling, PL | 1 |
| Tchou, M | 1 |
| Niebauer, MJ | 1 |
| Lindsay, BD | 2 |
| Tchou, PJ | 1 |
| Hellkamp, AS | 3 |
| Lokhnygina, Y | 2 |
| Passman, R | 3 |
| Hankey, GJ | 1 |
| Patel, MR | 1 |
| Becker, RC | 2 |
| Hacke, W | 1 |
| Berkowitz, SD | 1 |
| Nessel, CC | 1 |
| Fox, KA | 1 |
| Califf, RM | 3 |
| Rohrhoff, NJ | 1 |
| McNeill, DB | 1 |
| Boggan, JC | 1 |
| Osawa, H | 2 |
| Muraki, S | 1 |
| Sakurada, T | 2 |
| Kawaharada, N | 1 |
| Sasaki, J | 2 |
| Araki, E | 2 |
| Nakashima, S | 1 |
| Shea, J | 1 |
| Sodhi, G | 1 |
| Najam, F | 1 |
| Solomon, AJ | 5 |
| Feng, XD | 3 |
| Wang, XN | 1 |
| Yuan, XH | 2 |
| Wang, W | 4 |
| Berry, MF | 1 |
| D'Amico, TA | 1 |
| Onaitis, MW | 1 |
| Al-Khatib, SM | 3 |
| Wojdyla, DM | 2 |
| Shaw, LK | 1 |
| Horton, JR | 1 |
| Anstrom, KJ | 1 |
| DeWald, T | 1 |
| Allen-LaPointe, N | 1 |
| Thomas, K | 1 |
| Daubert, JP | 1 |
| Chun, KJ | 1 |
| Byeon, K | 1 |
| Im, SI | 1 |
| Park, KM | 2 |
| Park, SJ | 1 |
| Kim, JS | 2 |
| On, YK | 1 |
| Guo, X | 1 |
| Xu, G | 1 |
| Zhou, X | 1 |
| Li, L | 2 |
| Tang, B | 1 |
| Wyse, DG | 6 |
| Blondeau, L | 1 |
| Levesque, S | 2 |
| Dubuc, M | 6 |
| Thibault, B | 6 |
| Guerra, PG | 2 |
| Macle, L | 1 |
| Rivard, L | 1 |
| Kuck, KH | 5 |
| Wissner, E | 1 |
| Nielsen, JB | 1 |
| Płazińska, MT | 1 |
| Miechowicz, I | 1 |
| Czepczyński, R | 1 |
| Królicki, L | 1 |
| Hamilton, A | 1 |
| Clark, D | 1 |
| Gray, A | 1 |
| Cragg, A | 1 |
| Grubb, N | 1 |
| Huynh, K | 1 |
| Flaker, G | 4 |
| Lopes, RD | 1 |
| Hylek, E | 1 |
| Sullivan, RM | 1 |
| Garcia, D | 1 |
| Hanna, M | 1 |
| Amerena, J | 2 |
| Harjola, VP | 1 |
| Dorian, P | 15 |
| Avezum, A | 2 |
| Keltai, M | 1 |
| Wallentin, L | 1 |
| Granger, CB | 3 |
| Viles-Gonzalez, JF | 1 |
| Liyanage, CR | 1 |
| Kodali, V | 1 |
| Sirsikar, SS | 1 |
| Ranpise, SM | 1 |
| Patil, AS | 1 |
| Deodhar, KY | 1 |
| Hudzik, B | 1 |
| Zubelewicz-Szkodzinska, B | 1 |
| Khan, A | 1 |
| Puttanna, A | 1 |
| Raskauskiene, D | 1 |
| Rosa, GM | 1 |
| Bianco, D | 1 |
| Parodi, A | 1 |
| Valbusa, A | 1 |
| Zawaideh, C | 1 |
| Bizzarri, N | 1 |
| Ferrero, S | 1 |
| Brunelli, C | 1 |
| Loewe, A | 1 |
| Lutz, Y | 1 |
| Wilhelms, M | 1 |
| Sinnecker, D | 1 |
| Barthel, P | 1 |
| Scholz, EP | 1 |
| Dössel, O | 1 |
| Schmidt, G | 1 |
| Seemann, G | 1 |
| Gao, P | 1 |
| Kang, IS | 1 |
| Kim, KJ | 1 |
| Kim, Y | 1 |
| Park, SH | 1 |
| Tesic, D | 1 |
| Kostic, M | 1 |
| Paunovic, D | 1 |
| Jankovic, SM | 1 |
| Mohanty, S | 3 |
| Mohanty, P | 3 |
| Trivedi, C | 3 |
| Santangeli, P | 5 |
| Burkhardt, JD | 4 |
| Gallinghouse, JG | 1 |
| Horton, R | 3 |
| Sanchez, JE | 1 |
| Hranitzky, PM | 1 |
| Zagrodzky, J | 1 |
| Al-Ahmad, A | 1 |
| Pelargonio, G | 4 |
| Reddy, M | 3 |
| Forleo, G | 3 |
| Rossillo, A | 3 |
| Hongo, R | 3 |
| Beheiry, S | 3 |
| Casella, M | 3 |
| Dello Russo, A | 4 |
| Tondo, C | 3 |
| Guerra, F | 3 |
| Aliot, EM | 2 |
| Allen LaPointe, NM | 1 |
| Dai, D | 1 |
| Gecks, T | 1 |
| Prochnau, D | 1 |
| Franz, M | 1 |
| Jung, C | 1 |
| Kühnert, H | 1 |
| Schliemann, S | 1 |
| Figulla, HR | 1 |
| Besli, F | 1 |
| Basar, C | 1 |
| Kecebas, M | 1 |
| Turker, Y | 3 |
| Alonso, A | 1 |
| MacLehose, RF | 1 |
| Lutsey, PL | 1 |
| Konety, S | 1 |
| Ciszowski, K | 1 |
| Biedroń, W | 1 |
| Gomólka, E | 1 |
| Ezekowitz, MD | 8 |
| Ellenbogen, KA | 3 |
| DiMarco, JP | 6 |
| Kaszala, K | 2 |
| Boddy, A | 1 |
| Geba, GP | 1 |
| P, GG | 1 |
| Stiefelhagen, P | 4 |
| Benninger, G | 1 |
| Pittrow, D | 3 |
| Paar, WD | 1 |
| von Stritzky, B | 1 |
| Bosch, RF | 1 |
| Bajer, M | 1 |
| Hahn, J | 1 |
| Brescia, L | 1 |
| Benoit, A | 1 |
| Betea, D | 1 |
| Delvenne, P | 1 |
| Hamoir, E | 1 |
| Beckers, A | 1 |
| Aguilar, C | 1 |
| Mochalina, N | 1 |
| Juhlin, T | 1 |
| Platonov, PG | 1 |
| Svensson, PJ | 1 |
| Stack, S | 1 |
| Nguyen, DV | 1 |
| Casto, A | 1 |
| Ahuja, N | 1 |
| Yan, Y | 1 |
| Shen, H | 1 |
| Ramos-Rúa, L | 1 |
| Álvarez-Fernández, L | 1 |
| Nogueira-Fernández, V | 1 |
| da Silva-Franca, CF | 1 |
| Brañas-Fernández, FM | 1 |
| Pego-Reigosa, R | 1 |
| Cortés-Laíño, JA | 1 |
| Steffel, J | 1 |
| Giugliano, RP | 1 |
| Braunwald, E | 1 |
| Murphy, SA | 1 |
| Heidbuchel, H | 2 |
| Antman, EM | 2 |
| Ruff, CT | 1 |
| Chen, WC | 2 |
| Wu, BR | 1 |
| Cheng, WC | 1 |
| Lin, KH | 1 |
| Hsia, TC | 1 |
| Chen, W | 1 |
| Chen, CH | 1 |
| Muo, CH | 1 |
| Liao, WC | 1 |
| Li, CH | 1 |
| Müssigbrodt, A | 1 |
| John, S | 3 |
| Kosiuk, J | 2 |
| Richter, S | 1 |
| Hindricks, G | 3 |
| Bollmann, A | 4 |
| Alp, A | 1 |
| Akdam, H | 1 |
| Karwatowska-Prokopczuk, E | 1 |
| Olmsted, A | 1 |
| Rosero, S | 1 |
| Qin, D | 2 |
| Leef, G | 2 |
| Alam, MB | 2 |
| Rattan, R | 2 |
| Munir, MB | 2 |
| Patel, D | 3 |
| Khattak, F | 2 |
| Adelstein, E | 2 |
| Jain, SK | 2 |
| Saba, S | 2 |
| Ad, N | 2 |
| Holmes, SD | 1 |
| Shuman, DJ | 1 |
| Pritchard, G | 1 |
| Miller, CE | 1 |
| Mei, YQ | 1 |
| White, RD | 1 |
| Riggs, KW | 1 |
| Ege, EJ | 1 |
| Petroski, GF | 1 |
| Koerber, SM | 1 |
| Evans, SR | 1 |
| Benjamin, EJ | 1 |
| Maimone, S | 1 |
| Filomia, R | 1 |
| Saitta, C | 1 |
| Raimondo, G | 1 |
| Squadrito, G | 1 |
| Kenzaka, T | 1 |
| Doshi, D | 1 |
| Jayawardana, R | 1 |
| Shin, DG | 1 |
| Cho, I | 1 |
| Hartaigh, Bó | 1 |
| Lee, HY | 1 |
| Hwang, ES | 1 |
| Park, JK | 1 |
| Onk, OA | 1 |
| Erkut, B | 1 |
| Melby, SJ | 1 |
| Foppiani, L | 1 |
| Cascio, C | 1 |
| Lo Pinto, G | 1 |
| Ullal, AJ | 1 |
| Than, CT | 1 |
| Schmitt, S | 1 |
| Perino, AC | 1 |
| Kaiser, DW | 1 |
| Heidenreich, PA | 1 |
| Frayne, SM | 1 |
| Phibbs, CS | 1 |
| Lüker, J | 1 |
| Sultan, A | 1 |
| Sehner, S | 1 |
| Hoffmann, B | 1 |
| Servatius, H | 2 |
| Willems, S | 3 |
| Steven, D | 1 |
| Jackson, MW | 1 |
| Taylor, RJ | 1 |
| Sarrias, A | 1 |
| Villuendas, R | 1 |
| Bisbal, F | 1 |
| Pereferrer, D | 1 |
| Rueda, F | 1 |
| Serra, J | 1 |
| García, C | 1 |
| Bayés-Genís, A | 1 |
| Elikowski, W | 1 |
| Małek, M | 1 |
| Skowroński, M | 1 |
| Wróblewski, D | 1 |
| Skrzywanek, P | 1 |
| Zawilska, K | 1 |
| Matassini, MV | 1 |
| Scappini, L | 2 |
| Urbinati, A | 1 |
| Kondo, T | 1 |
| Miake, J | 1 |
| Kato, M | 1 |
| Ogura, K | 1 |
| Iitsuka, K | 1 |
| Yamamoto, K | 1 |
| Franchi, C | 1 |
| Ardoino, I | 1 |
| Rossio, R | 1 |
| Nobili, A | 1 |
| Biganzoli, EM | 1 |
| Marengoni, A | 1 |
| Marcucci, M | 1 |
| Pasina, L | 1 |
| Tettamanti, M | 1 |
| Corrao, S | 1 |
| Mannucci, PM | 2 |
| Shibata, SC | 1 |
| Uchiyama, A | 1 |
| Ohta, N | 1 |
| Fujino, Y | 1 |
| Glover, BM | 1 |
| Koike, H | 1 |
| Fujino, T | 1 |
| Koike, M | 1 |
| Shinohara, M | 1 |
| Kitahara, K | 1 |
| Kinoshita, T | 1 |
| Yuzawa, H | 1 |
| Suzuki, T | 2 |
| Sato, H | 1 |
| Fukunaga, S | 1 |
| Kobayashi, K | 2 |
| Ikeda, T | 2 |
| Zhang, L | 2 |
| Gao, S | 2 |
| Habbab, LM | 1 |
| Chu, FV | 1 |
| Robinson, E | 1 |
| Kaushal, S | 1 |
| Alaboson, J | 1 |
| Belagodu, A | 1 |
| Watkins, C | 1 |
| Walker, B | 1 |
| Webster, G | 1 |
| McCarthy, P | 1 |
| Ho, D | 1 |
| Dixon, DL | 1 |
| Dunn, SP | 1 |
| Kelly, MS | 1 |
| McLlarky, TR | 1 |
| Brown, RE | 1 |
| Maniar, H | 1 |
| Novak, E | 1 |
| Shen, Y | 1 |
| Cheng, X | 1 |
| Ying, M | 1 |
| Schmack, B | 1 |
| Erbel, C | 1 |
| Gleissner, CA | 1 |
| Akhavanpoor, M | 1 |
| Frankenstein, L | 1 |
| Schweizer, PA | 3 |
| Ehlermann, P | 1 |
| Salem, JE | 1 |
| El-Aissaoui, M | 1 |
| Alazard, M | 1 |
| Hulot, JS | 1 |
| Aissaoui, N | 1 |
| Le-Heuzey, JY | 1 |
| Funck-Brentano, C | 1 |
| Faisy, C | 1 |
| Urien, S | 1 |
| Sbrana, F | 1 |
| Genovesi, D | 1 |
| Catapano, GA | 1 |
| Panchetti, L | 1 |
| Bottoni, A | 1 |
| Iervasi, G | 2 |
| Lenarczyk, R | 1 |
| Mitręga, K | 1 |
| Mazurek, M | 1 |
| Janion, M | 2 |
| Drożdż, J | 1 |
| Streb, W | 1 |
| Fuglewicz, A | 2 |
| Sokal, A | 1 |
| Laroche, C | 1 |
| Kalarus, Z | 1 |
| Jais, P | 4 |
| Narducci, ML | 2 |
| Schweikert, R | 2 |
| Neuzil, P | 2 |
| Hao, S | 2 |
| Haissaguerre, M | 6 |
| Chiba, T | 1 |
| Kondo, N | 1 |
| Takahara, A | 1 |
| Mitrić, G | 1 |
| Udy, A | 1 |
| Bandeshe, H | 1 |
| Clement, P | 1 |
| Boots, R | 1 |
| Matsukura, S | 1 |
| Nakamura, Y | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Gillinov, AM | 2 |
| Bagiella, E | 1 |
| Moskowitz, AJ | 1 |
| Raiten, JM | 1 |
| Groh, MA | 1 |
| Bowdish, ME | 1 |
| Kirkwood, KA | 1 |
| Perrault, LP | 1 |
| Parides, MK | 1 |
| Smith, RL | 1 |
| Dussault, G | 1 |
| Hackmann, AE | 1 |
| Jeffries, NO | 1 |
| Miller, MA | 1 |
| Taddei-Peters, WC | 1 |
| Rose, EA | 1 |
| Weisel, RD | 1 |
| Williams, DL | 1 |
| Mangusan, RF | 1 |
| Argenziano, M | 1 |
| Moquete, EG | 1 |
| O'Sullivan, KL | 1 |
| Pellerin, M | 1 |
| Shah, KJ | 1 |
| Gammie, JS | 1 |
| Mayer, ML | 1 |
| Voisine, P | 2 |
| Gelijns, AC | 1 |
| O'Gara, PT | 2 |
| Mack, MJ | 2 |
| Johnson, SM | 1 |
| Brophy, JM | 1 |
| Johannesen, A | 1 |
| Feldt-Rasmussen, U | 1 |
| Tang, RB | 2 |
| Wang, ZL | 1 |
| Yin, YH | 3 |
| Zhang, ZH | 1 |
| Li, ZQ | 1 |
| Cao, J | 2 |
| Cao, KJ | 1 |
| Yang, YZ | 1 |
| Yang, PZ | 1 |
| Sun, YX | 1 |
| Tadros, R | 1 |
| Sun, L | 1 |
| Feng, W | 1 |
| Bonora, A | 1 |
| Turcato, G | 1 |
| Franchi, E | 1 |
| Taioli, G | 1 |
| Dilda, A | 1 |
| Zerman, G | 1 |
| Maccagnani, A | 1 |
| Pistorelli, C | 1 |
| Olivieri, O | 1 |
| Chequel, M | 1 |
| Ollitrault, P | 1 |
| Saloux, E | 1 |
| Desgué, J | 1 |
| Allouche, S | 1 |
| Milliez, P | 1 |
| Alexandre, J | 1 |
| Hayward, C | 1 |
| Di Mario, C | 1 |
| Lyon, AR | 1 |
| Ahsan, SY | 1 |
| Rowland, E | 5 |
| Kaess, BM | 1 |
| Ebinger, JE | 1 |
| Porten, BR | 1 |
| Strauss, CE | 1 |
| Garberich, RF | 1 |
| Han, C | 1 |
| Wahl, SK | 1 |
| Sun, BC | 1 |
| Abdelhadi, RH | 1 |
| Henry, TD | 1 |
| Barea-Mendoza, JA | 1 |
| García-Gigorro, R | 1 |
| Renes-Carreño, E | 1 |
| Sorisky, A | 1 |
| Darabant, SP | 1 |
| Hoffman, I | 1 |
| Van Gelder, IC | 11 |
| Rienstra, M | 3 |
| Olshansky, B | 2 |
| Turco, P | 4 |
| Willey, JZ | 1 |
| Biviano, A | 1 |
| Yang, XJ | 1 |
| Skolnik, N | 2 |
| Escobar, C | 2 |
| Arceluz, M | 1 |
| Montes de Oca, R | 1 |
| Mori, R | 1 |
| López-Sendón, JL | 1 |
| Diemberger, I | 2 |
| Massaro, G | 1 |
| Reggiani, MLB | 1 |
| Lorenzetti, S | 1 |
| Biffi, M | 5 |
| Ziacchi, M | 1 |
| Martignani, C | 2 |
| Kirchhoff, JE | 1 |
| Diness, JG | 1 |
| Abildgaard, L | 1 |
| Sheykhzade, M | 1 |
| Grunnet, M | 2 |
| Jespersen, T | 1 |
| White, CM | 22 |
| Nguyen, E | 1 |
| Hannibal, GB | 1 |
| Chouchoulis, K | 1 |
| Chiladakis, J | 1 |
| Koutsogiannis, N | 1 |
| Davlouros, P | 1 |
| Kaza, M | 1 |
| Alexopoulos, D | 1 |
| Montero-Tinnirello, J | 1 |
| Magaldi, M | 1 |
| Fontanals, J | 1 |
| Masgoret, P | 1 |
| Bravo, JC | 1 |
| Knudsen, A | 1 |
| Hasson Charles, R | 1 |
| Shabsigh, M | 1 |
| Sacchet-Cardozo, F | 1 |
| Iyer, M | 1 |
| Essandoh, M | 1 |
| Pereira, MM | 1 |
| Jung, S | 1 |
| Wooldridge, AA | 1 |
| Tsanaxidis, N | 1 |
| Giamouzis, G | 1 |
| Triposkiadis, F | 1 |
| Su, M | 1 |
| Seki, D | 1 |
| Moheet, AM | 1 |
| Men, EE | 1 |
| Yildirimtürk, O | 1 |
| Tuğcu, A | 1 |
| Aytekin, V | 1 |
| Aytekin, S | 1 |
| Lee, KL | 3 |
| Bourassa, MG | 1 |
| Arnold, JM | 1 |
| Buxton, AE | 1 |
| Lambert, J | 4 |
| O'Hara, G | 1 |
| Pedersen, OD | 1 |
| Singh, BN | 22 |
| Stevenson, LW | 3 |
| Stevenson, WG | 10 |
| Waldo, AL | 6 |
| Zebis, LR | 3 |
| Thomsen, HF | 2 |
| Hjortdal, VE | 3 |
| Gjesdal, K | 1 |
| Kurt, IH | 2 |
| Yigit, T | 1 |
| Karademir, BM | 1 |
| Piga, M | 1 |
| Cocco, MC | 1 |
| Serra, A | 1 |
| Boi, F | 1 |
| Loy, M | 1 |
| Mariotti, S | 1 |
| Balasubramaniam, R | 1 |
| Kistler, PM | 1 |
| Riera, AR | 1 |
| Uchida, AH | 1 |
| Ferreira, C | 1 |
| Ferreira Filho, C | 1 |
| Schapachnik, E | 1 |
| Dubner, S | 1 |
| Moffa, PJ | 1 |
| Kapoor, JR | 1 |
| Maffè, S | 1 |
| Paffoni, P | 1 |
| Perucca, A | 1 |
| Dellavesa, P | 1 |
| Parravicini, U | 1 |
| Nicali, R | 1 |
| Bielli, M | 1 |
| Paino, AM | 1 |
| Signorotti, F | 1 |
| Franchetti Pardo, N | 1 |
| Zenone, F | 1 |
| Zanetta, M | 1 |
| Coletta, AP | 1 |
| Cleland, JG | 5 |
| Cullington, D | 1 |
| Clark, AL | 2 |
| Sleilaty, G | 2 |
| Madi-Jebara, S | 3 |
| Yazigi, A | 3 |
| Haddad, F | 3 |
| Hayeck, G | 1 |
| El Rassi, I | 1 |
| Ashoush, R | 1 |
| Jebara, V | 1 |
| Laughlin, JC | 1 |
| Komatsu, T | 4 |
| Ozawa, M | 3 |
| Tachibana, H | 3 |
| Orii, M | 1 |
| Kunugida, F | 1 |
| Arkun, A | 1 |
| Van Deusen, SK | 1 |
| Grau, T | 1 |
| Birkhahn, RH | 1 |
| Mindel, JS | 1 |
| Davy, JM | 3 |
| Herold, M | 1 |
| Hoglund, C | 1 |
| Timmermans, A | 1 |
| Alings, A | 1 |
| Van Kempen, L | 1 |
| Diaz-Guzman, E | 1 |
| Mireles-Cabodevila, E | 1 |
| Arrossi, A | 1 |
| Kanne, JP | 1 |
| Budev, M | 1 |
| Palardy, M | 1 |
| Tardif, JC | 2 |
| Tétreault, K | 1 |
| Dabouz, F | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Conway, E | 1 |
| Musco, S | 1 |
| Gonzalez, MD | 3 |
| Liu, Z | 3 |
| Ling, Z | 3 |
| Su, L | 5 |
| Lan, X | 3 |
| Du, H | 1 |
| She, Q | 3 |
| Yin, Y | 3 |
| Cao, DJ | 1 |
| Mu, CY | 1 |
| Tong, F | 1 |
| Perrea, DN | 1 |
| Ekmektzoglou, KA | 1 |
| Vlachos, IS | 2 |
| Tsitsilonis, S | 1 |
| Koudouna, E | 1 |
| Stroumpoulis, K | 1 |
| Xanthos, T | 3 |
| Grabczak, EM | 1 |
| Zielonka, TM | 1 |
| Wiwała, J | 1 |
| Bareła, AD | 1 |
| Opuchlik, A | 1 |
| Potulska, A | 1 |
| Ambroziak, U | 1 |
| Chazan, R | 1 |
| Ahmed, S | 2 |
| Links, TP | 1 |
| Wiesfeld, AC | 2 |
| Hillege, HL | 1 |
| Bosker, HA | 1 |
| Lok, DJ | 1 |
| Van Veldhuisen, DJ | 3 |
| Milicevic, G | 1 |
| Gavranovic, Z | 1 |
| Bakula, M | 1 |
| Pazur, V | 1 |
| Frank, B | 1 |
| Walton, J | 1 |
| Attaran, S | 1 |
| Sherwood, R | 1 |
| John, L | 1 |
| El-Gamel, A | 1 |
| Desai, J | 1 |
| Rolf, S | 1 |
| Dietz, R | 2 |
| Stanaitiene, G | 1 |
| Babarskiene, RM | 1 |
| Kułakowski, P | 2 |
| Meinertz, T | 6 |
| Runge, S | 1 |
| Kisters, K | 1 |
| Cziborra, M | 1 |
| Funke, C | 1 |
| Brylak, S | 1 |
| Hausberg, M | 1 |
| e Silva, LP | 1 |
| Luís, F | 1 |
| Cabrera, H | 1 |
| Fazekas, T | 1 |
| Kim, DD | 1 |
| Young, S | 1 |
| Cutfield, R | 1 |
| Fedorov, VV | 1 |
| Burashnikov, A | 5 |
| Di Diego, JM | 3 |
| Sicouri, S | 5 |
| Ferreiro, M | 1 |
| Carlsson, L | 3 |
| Antzelevitch, C | 7 |
| Matrka, L | 1 |
| Steward, D | 1 |
| Falciglia, M | 1 |
| Nikiforov, Y | 1 |
| Nitschmann, S | 2 |
| Roshanali, F | 1 |
| Mandegar, MH | 1 |
| Yousefnia, MA | 1 |
| Alaeddini, F | 1 |
| Saidi, B | 1 |
| Bodalski, R | 1 |
| Maryniak, A | 1 |
| Walczak, F | 1 |
| Szumowski, L | 1 |
| Jedynak, Z | 1 |
| Arya, A | 1 |
| Silberbauer, J | 1 |
| Teichman, SL | 1 |
| Milner, P | 1 |
| Sulke, N | 2 |
| Cataldi, A | 1 |
| Gonella, D | 1 |
| Robutti, N | 1 |
| Siri, M | 1 |
| Buonocore, S | 1 |
| Odetti, P | 1 |
| Singh, SN | 10 |
| Tang, XC | 6 |
| Reda, D | 1 |
| van Eickels, M | 4 |
| Gaudin, C | 5 |
| Verma, A | 1 |
| Doyle, JF | 1 |
| Ho, KM | 1 |
| Bollu, M | 1 |
| Bobba, RK | 1 |
| Arsura, EL | 1 |
| Bellocci, F | 1 |
| Shelton, RJ | 1 |
| Goode, K | 1 |
| Rigby, AS | 1 |
| Houghton, T | 1 |
| Kaye, GC | 2 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Hilkens, M | 1 |
| Pickkers, P | 1 |
| Peters, WH | 1 |
| van der Hoeven, JG | 1 |
| Krishnamoorthy, S | 1 |
| Watson, T | 2 |
| Siu, CW | 1 |
| Lau, CP | 3 |
| Lee, WL | 2 |
| Lam, KF | 1 |
| Tse, HF | 3 |
| Yang, X | 1 |
| Zrenner, B | 2 |
| Tejani, AM | 1 |
| Yih, V | 1 |
| Horner, SM | 2 |
| Floyd, J | 1 |
| Pugliano, M | 1 |
| Costantino, G | 1 |
| Podda, GM | 1 |
| Brachmann, J | 4 |
| Sinha, AM | 1 |
| Schauvliege, S | 1 |
| De Clercq, D | 3 |
| Devisscher, L | 1 |
| Deprez, P | 3 |
| Gasthuys, F | 1 |
| Mahmod, M | 1 |
| Darul, ND | 1 |
| Mokhtar, I | 1 |
| Nor, NM | 1 |
| Anshar, FM | 1 |
| Maskon, O | 1 |
| Price, J | 1 |
| Tee, R | 1 |
| Lam, BK | 2 |
| Hendry, P | 2 |
| Green, MS | 1 |
| Rubens, FD | 2 |
| Dogan, A | 2 |
| Akcay, S | 1 |
| Karabacak, M | 1 |
| Ozaydin, M | 3 |
| Erdogan, D | 2 |
| Yalta, K | 1 |
| Turgut, OO | 1 |
| Yilmaz, MB | 1 |
| Tandogan, I | 1 |
| Patel, C | 1 |
| Yan, GX | 4 |
| Patel, PD | 1 |
| Bhuriya, R | 1 |
| Patel, DD | 1 |
| Arora, BL | 1 |
| Singh, PP | 1 |
| Arora, RR | 1 |
| Catanzaro, JN | 1 |
| Makaryus, J | 1 |
| Vafai, J | 1 |
| Makaryus, AN | 1 |
| Jadonath, R | 1 |
| Beldner, S | 1 |
| Thomas, SP | 2 |
| Wroblewski, HA | 3 |
| Wall, DS | 2 |
| Rieger, KM | 2 |
| Hammoud, ZT | 2 |
| Young, JV | 2 |
| Mihálcz, A | 1 |
| Földesi, C | 1 |
| Kardos, A | 1 |
| Ladunga, K | 1 |
| Naji, F | 2 |
| Suran, D | 1 |
| Kanic, V | 2 |
| Vokac, D | 2 |
| Sabovic, M | 2 |
| Mahitchi, E | 1 |
| Balagué, F | 1 |
| Waldburger, M | 1 |
| Hasselblad, V | 1 |
| Kong, DF | 2 |
| Chan, PS | 1 |
| Nallamothu, BK | 1 |
| Falk, RH | 3 |
| Hamad, B | 1 |
| Kirkpatrick, P | 1 |
| Olesin, AI | 1 |
| Smolin, ZIu | 1 |
| Konovalova, OA | 1 |
| Shabrov, AV | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Duray, GZ | 4 |
| Marziali, A | 1 |
| Cappato, R | 1 |
| Kojuri, J | 1 |
| Mahmoodi, Y | 1 |
| Jannati, M | 1 |
| Shafa, M | 1 |
| Ghazinoor, M | 1 |
| Sharifkazemi, MB | 1 |
| Fabiani, I | 1 |
| Tacconi, D | 1 |
| Grotti, S | 1 |
| Brandini, R | 1 |
| Salvadori, C | 1 |
| Caremani, M | 1 |
| Bolognese, L | 1 |
| Ding, P | 1 |
| Chen, LJ | 1 |
| Deng, XJ | 1 |
| Yuan, YQ | 1 |
| Gómez, JJ | 1 |
| Pomar, MD | 1 |
| Casariego, AV | 1 |
| Rodríguez, IC | 1 |
| Beaulieu, Y | 1 |
| Denault, AY | 1 |
| Couture, P | 1 |
| Carrier, M | 1 |
| Pagé, P | 2 |
| Christiansen, CB | 2 |
| Køber, L | 3 |
| Hundal, M | 1 |
| Garg, RK | 1 |
| Spragg, DD | 1 |
| Marine, JE | 1 |
| Prystowsky, EN | 6 |
| Rizos, I | 2 |
| Rigopoulos, AG | 2 |
| Kalogeropoulos, AS | 2 |
| Tsiodras, S | 3 |
| Dragomanovits, S | 2 |
| Sakadakis, EA | 2 |
| Faviou, E | 1 |
| Kremastinos, DT | 2 |
| Schafer, JA | 1 |
| Kjesbo, NK | 1 |
| Gleason, PP | 1 |
| Cook, GE | 2 |
| Sasich, LD | 2 |
| Sukkari, SR | 2 |
| Onorati, F | 1 |
| Rubino, AS | 1 |
| Mariscalco, G | 1 |
| Serraino, F | 1 |
| Sala, A | 1 |
| Renzulli, A | 1 |
| Gu, S | 1 |
| Su, PX | 1 |
| Yan, J | 1 |
| Zhang, XT | 1 |
| Wang, TY | 1 |
| Kumagai, K | 1 |
| Ranchor, AV | 1 |
| Cooper, JA | 1 |
| Clem, JR | 2 |
| Farver, DK | 1 |
| Fischer, JR | 1 |
| Johnson, TJ | 1 |
| Uehara, K | 2 |
| Ueyama, K | 1 |
| Ito, H | 1 |
| Fukuda, T | 1 |
| Sasaki, K | 1 |
| Abe, T | 1 |
| Nakane, E | 1 |
| Miyamoto, S | 1 |
| Haruna, T | 1 |
| Inoko, M | 1 |
| Nohara, R | 1 |
| Duray, G | 1 |
| Kirch, W | 1 |
| Hohnloser, S | 4 |
| Röther, J | 2 |
| Laufs, U | 1 |
| Flaker, GC | 1 |
| Pogue, J | 1 |
| Yusuf, S | 4 |
| Pfeffer, MA | 1 |
| Goldhaber, SZ | 1 |
| Anand, IS | 1 |
| Hart, R | 1 |
| Camm, J | 1 |
| Crijns, H | 3 |
| Pedrazzini, L | 1 |
| Salette, G | 1 |
| Schwartz, PJ | 2 |
| Weintraub, W | 1 |
| Bolderman, RW | 1 |
| Bruin, P | 1 |
| Hermans, JJ | 1 |
| Boerakker, MJ | 1 |
| Dias, AA | 1 |
| van der Veen, FH | 1 |
| Singh, D | 1 |
| Cingolani, E | 2 |
| Diamond, GA | 1 |
| Kaul, S | 1 |
| De Ferrari, GM | 2 |
| Santini, M | 7 |
| Akbarzadeh, F | 1 |
| Kazemi-Arbat, B | 1 |
| Golmohammadi, A | 1 |
| Pourafkari, L | 1 |
| González Oliva, JC | 1 |
| Saurina i Solé, A | 1 |
| Pou Potau, M | 1 |
| Salas Gama, KR | 1 |
| Ramírez de Arellano Serna, M | 1 |
| Rosei, EA | 1 |
| Salvetti, M | 1 |
| Disertori, M | 2 |
| Barlera, S | 1 |
| Latini, R | 2 |
| Maggioni, AP | 2 |
| Zeni, P | 1 |
| Di Pasquale, G | 3 |
| Cosmi, F | 1 |
| Franzosi, MG | 1 |
| Simonian, SM | 1 |
| Lotfipour, S | 1 |
| Wall, C | 1 |
| Langdorf, MI | 1 |
| Burger, CI | 1 |
| Clase, CM | 1 |
| Gangji, AS | 1 |
| Hirt, MN | 1 |
| Eschenhagen, T | 2 |
| Sahadevan, J | 1 |
| Ratti, C | 1 |
| Grassi, L | 1 |
| Magnavacchi, P | 1 |
| Bompani, B | 1 |
| Kessenich, CR | 1 |
| Higgs, DA | 1 |
| Nagai, T | 1 |
| Satomi, K | 1 |
| Noda, T | 1 |
| Okamura, H | 1 |
| Yamada, Y | 2 |
| Shimizu, W | 1 |
| Suyama, K | 1 |
| Aihara, N | 1 |
| Kamakura, S | 1 |
| Kurita, T | 2 |
| Taylor, CJ | 1 |
| Hodgkinson, J | 1 |
| Hobbs, FD | 1 |
| Lazzara, R | 1 |
| Johnston, SS | 1 |
| Patel, PP | 1 |
| Schulman, KL | 1 |
| Baroletti, S | 1 |
| Catella, J | 1 |
| Ehle, M | 1 |
| Cheng, JW | 1 |
| Bogazzi, F | 2 |
| Bartalena, L | 2 |
| Martino, E | 2 |
| Pires, LM | 1 |
| Leiria, TL | 1 |
| de Lima, GG | 1 |
| Kruse, ML | 1 |
| Nesralla, IA | 1 |
| Kalil, RA | 1 |
| Rostagno, C | 1 |
| La Meir, M | 1 |
| Gelsomino, S | 1 |
| Ghilli, L | 1 |
| Rossi, A | 1 |
| Carone, E | 1 |
| Braconi, L | 1 |
| Rosso, G | 1 |
| Puggelli, F | 1 |
| Mattesini, A | 1 |
| Stefàno, PL | 1 |
| Padeletti, L | 3 |
| Maessen, J | 1 |
| Gensini, GF | 3 |
| Davis, EM | 1 |
| Packard, KA | 2 |
| Hilleman, DE | 6 |
| Gassanov, N | 1 |
| Caglayan, E | 1 |
| Erdmann, E | 1 |
| Er, F | 1 |
| Franz, MR | 1 |
| Coons, JC | 1 |
| Plauger, KM | 1 |
| Seybert, AL | 1 |
| Sokos, GG | 1 |
| D'Ascenzi, F | 1 |
| Iadanza, A | 1 |
| Zacà, V | 1 |
| Pierli, C | 1 |
| Mondillo, S | 1 |
| Ji, Q | 1 |
| Mei, Y | 1 |
| Wusha, D | 1 |
| Cai, J | 1 |
| Xie, S | 1 |
| Stähli, BE | 1 |
| Schwab, S | 1 |
| Wolbrette, D | 1 |
| Gonzalez, M | 1 |
| Samii, S | 4 |
| Banchs, J | 1 |
| Penny-Peterson, E | 3 |
| Naccarelli, G | 1 |
| Mooss, AN | 3 |
| Lomuscio, A | 1 |
| Belletti, S | 1 |
| Battezzati, PM | 1 |
| Mu, Y | 1 |
| Gao, M | 1 |
| Wang, JR | 1 |
| Su, LQ | 1 |
| Hou, YL | 1 |
| Hirschl, MM | 1 |
| Wollmann, C | 1 |
| Globits, S | 1 |
| Conti, A | 1 |
| Del Taglia, B | 1 |
| Mariannini, Y | 1 |
| Pepe, G | 1 |
| Vanni, S | 1 |
| Grifoni, S | 1 |
| Abbate, R | 1 |
| Michelucci, A | 2 |
| Verhovez, A | 1 |
| Elia, F | 1 |
| Riva, A | 1 |
| Ferrari, G | 1 |
| Aprà, F | 1 |
| Deng, M | 1 |
| Sui, XQ | 1 |
| Zhu, SB | 1 |
| Ma, W | 1 |
| Xu, Y | 1 |
| Chen, ZM | 1 |
| Hughes, PJ | 1 |
| Freeman, MK | 1 |
| Cohenour, FV | 1 |
| Price, EM | 1 |
| Shirolkar, SC | 1 |
| Fiuzat, M | 1 |
| Gil Núñez, A | 1 |
| Fink, A | 1 |
| Maund, E | 2 |
| McKenna, C | 2 |
| Sarowar, M | 2 |
| Fox, D | 2 |
| Stevenson, M | 2 |
| Pepper, C | 2 |
| Palmer, S | 2 |
| Woolacott, N | 2 |
| Pamukcu, B | 2 |
| Burris, JM | 1 |
| Subramanian, A | 1 |
| Sansgiry, S | 1 |
| Palacio, CH | 1 |
| Bakaeen, FG | 1 |
| Awad, SS | 1 |
| Raatikainen, MJ | 1 |
| Huikuri, HV | 1 |
| Miyazaki, S | 2 |
| Shah, AJ | 1 |
| Stone, NJ | 1 |
| Oyer, D | 1 |
| Rigolin, VH | 1 |
| Bonow, RO | 1 |
| Wolbrette, DL | 4 |
| Banchs, JE | 2 |
| Gonska, BD | 1 |
| Sohns, C | 1 |
| Zabel, M | 2 |
| Simon, H | 1 |
| Simon Demel, K | 1 |
| Ritscher, G | 1 |
| Turschner, O | 1 |
| Sulimov, VA | 1 |
| Buehler, D | 1 |
| Martland, AM | 1 |
| Wang, YJ | 1 |
| Finsterer, J | 1 |
| Halonen, J | 1 |
| Loponen, P | 1 |
| Järvinen, O | 1 |
| Karjalainen, J | 1 |
| Parviainen, I | 1 |
| Halonen, P | 1 |
| Magga, J | 1 |
| Turpeinen, A | 1 |
| Hippeläinen, M | 1 |
| Hartikainen, J | 1 |
| Hakala, T | 1 |
| Miranda, RI | 1 |
| Simpson, CS | 1 |
| Michael, KA | 1 |
| Abdollah, H | 3 |
| Baranchuk, AM | 1 |
| Redfearn, DP | 1 |
| Isiadinso, I | 1 |
| Meshkov, AB | 1 |
| Gaughan, J | 1 |
| Sandhu, P | 1 |
| Lim, S | 1 |
| Cordova, F | 1 |
| Criner, G | 1 |
| Doniz Campos, M | 1 |
| Illodo Miramontes, G | 1 |
| Bobillo, B | 1 |
| Otero Amoedo, T | 1 |
| Filgueira, P | 1 |
| Rey López, F | 1 |
| Diz Gómez, JC | 1 |
| Wann, LS | 2 |
| January, CT | 1 |
| Lowe, JE | 2 |
| Estes, NA | 2 |
| Slotwiner, DJ | 1 |
| Jackman, WM | 1 |
| Tracy, CM | 1 |
| Fuster, V | 1 |
| Rydén, LE | 1 |
| Olsson, S | 1 |
| Tamargo, JL | 1 |
| Kay, GN | 2 |
| Jacobs, AK | 1 |
| Anderson, JL | 1 |
| Albert, N | 1 |
| Hochman, JS | 1 |
| Buller, CE | 1 |
| Kushner, FG | 1 |
| Creager, MA | 1 |
| Ohman, EM | 2 |
| Ettinger, SM | 1 |
| Guyton, RA | 1 |
| Tarkington, LG | 1 |
| Yancy, CW | 1 |
| Jie, S | 1 |
| Yu, C | 1 |
| Xiaohu, L | 1 |
| Yanning, Q | 1 |
| Zhengnian, D | 1 |
| Xiaoyang, T | 1 |
| Shen, SL | 1 |
| Zhao, YC | 1 |
| Onan, B | 1 |
| Onan, IS | 1 |
| Caynak, B | 2 |
| Korkmaz, AA | 1 |
| Sağbaş, E | 2 |
| Sanisoğlu, I | 2 |
| Oklü, E | 1 |
| Akpınar, B | 2 |
| Freemantle, N | 2 |
| Lafuente-Lafuente, C | 1 |
| Mitchell, S | 1 |
| Eckert, L | 1 |
| Reynolds, M | 5 |
| Mangal, B | 1 |
| Beatch, G | 1 |
| Saliba, W | 1 |
| Wazni, OM | 1 |
| Yalcin, F | 1 |
| Becker, R | 2 |
| Manzano-Fernández, S | 1 |
| Sánchez, M | 1 |
| Moreno-Flores, V | 1 |
| García-Alberola, A | 1 |
| Fayssoil, A | 1 |
| Issi, J | 1 |
| Guerbaa, M | 1 |
| Raynaud, JC | 1 |
| Heroguelle, V | 1 |
| Marinelli, A | 1 |
| Nebojša, M | 1 |
| Dragan, S | 1 |
| Nebojša, A | 1 |
| Tamara, A | 1 |
| Singla, S | 1 |
| Karam, P | 1 |
| Deshmukh, AJ | 1 |
| Mehta, J | 1 |
| Paydak, H | 1 |
| Takeda, T | 1 |
| Shimamoto, T | 1 |
| Marui, A | 1 |
| Saito, N | 1 |
| Minakata, K | 1 |
| Miwa, S | 1 |
| Nakajima, N | 1 |
| Hyon, SH | 1 |
| Sakata, R | 1 |
| Benussi, S | 1 |
| Pawar, PS | 1 |
| Woo, DA | 1 |
| Penugonda, N | 1 |
| Mohmand-Borkowski, A | 1 |
| Burke, JF | 2 |
| Samii, SM | 1 |
| Arias, N | 1 |
| Moreno-Pérez, Ó | 1 |
| Boix, E | 1 |
| Serrano, J | 1 |
| Revert, P | 1 |
| González, VL | 1 |
| Sánchez-Ortiga, R | 1 |
| Picó, AM | 1 |
| Brenner, R | 1 |
| Delacrétaz, E | 2 |
| Bushardt, RL | 1 |
| Jones, KW | 1 |
| Motoki, K | 1 |
| Yasuoka, R | 1 |
| Hirota, T | 1 |
| Akaiwa, Y | 1 |
| Kotake, Y | 1 |
| Iijima, K | 1 |
| Pedretti, S | 1 |
| López-Farré, A | 1 |
| Caballero, R | 1 |
| Delpón, E | 1 |
| Mohsen, A | 1 |
| Zhou, L | 2 |
| von Vital, JM | 1 |
| Karachristos, A | 1 |
| Singhal, A | 1 |
| Thomas, R | 1 |
| Russo, AM | 1 |
| Wong, KC | 1 |
| Sadarmin, PP | 1 |
| De Bono, J | 1 |
| Qureshi, N | 1 |
| Jones, M | 1 |
| Bashir, Y | 2 |
| Betts, TR | 1 |
| Dorantowicz, R | 1 |
| Broncel, M | 1 |
| Tayyar, S | 1 |
| Uysal, BA | 1 |
| Içli, A | 1 |
| Ozkan, E | 1 |
| Varol, E | 1 |
| Arslan, A | 1 |
| Mélon, P | 2 |
| Rutzen-Lopez, H | 1 |
| Khanna, V | 1 |
| Vkhanna, V | 1 |
| Reynolds, MR | 1 |
| Alcaraz, R | 1 |
| Hornero, F | 1 |
| Rieta, JJ | 1 |
| Fernández, PA | 1 |
| Sánchez, RA | 1 |
| Garro, HA | 1 |
| Acunzo, R | 1 |
| Tom, A | 1 |
| Essebag, V | 5 |
| Eisenberg, MJ | 4 |
| Rahme, E | 2 |
| Tu, JV | 2 |
| Humphries, K | 1 |
| Behlouli, H | 2 |
| Pilote, L | 5 |
| Tuan, J | 1 |
| Jeilan, M | 1 |
| Kundu, S | 1 |
| Nicolson, W | 1 |
| Chung, I | 1 |
| Stafford, PJ | 1 |
| Ng, GA | 1 |
| Marzocchi, M | 1 |
| Apostolakis, S | 1 |
| Miles, RH | 1 |
| Murdock, DK | 1 |
| Vodovar, D | 1 |
| Moachon, L | 1 |
| Arnaout, M | 1 |
| Beuzeboc, P | 1 |
| Lokiec, F | 1 |
| Rezai, K | 1 |
| Pène, F | 1 |
| Aikens, TH | 1 |
| Nagarakanti, R | 2 |
| Shapiro, T | 1 |
| Lim, SH | 1 |
| Sinha, SK | 1 |
| Kozlowski, D | 1 |
| Budrejko, S | 1 |
| Mikhailidis, DP | 1 |
| Rysz, J | 1 |
| Raczak, G | 1 |
| Banach, M | 1 |
| Tsadok, MA | 1 |
| Humphries, KH | 2 |
| Joo, J | 1 |
| Mackenzie, C | 1 |
| Syed, J | 1 |
| Pollak, PT | 1 |
| Koren, G | 1 |
| Kesselheim, AS | 1 |
| Linz, D | 1 |
| Schotten, U | 1 |
| Neuberger, HR | 1 |
| Böhm, M | 1 |
| Wirth, K | 1 |
| Kunugita, F | 1 |
| Higuchi, K | 1 |
| Inaba, O | 1 |
| Nodari, S | 1 |
| Triggiani, M | 1 |
| Campia, U | 1 |
| Manerba, A | 1 |
| Milesi, G | 1 |
| Cesana, BM | 1 |
| Gheorghiade, M | 1 |
| Dei Cas, L | 1 |
| Joghetaei, N | 1 |
| Weirich, G | 1 |
| Huber, W | 1 |
| Büchler, P | 1 |
| Estner, H | 1 |
| Martínez-Comendador, J | 1 |
| Castaño, M | 1 |
| Mosquera, I | 1 |
| Plana, JG | 1 |
| Gualis, J | 1 |
| Martín, CE | 1 |
| Mencía, P | 1 |
| Balla, I | 1 |
| Petrela, E | 1 |
| Kondili, A | 1 |
| Schiappacasse, HA | 1 |
| Koren, AT | 1 |
| Dai, WS | 1 |
| Hamid, AK | 1 |
| Richards, AM | 1 |
| Crozier, IG | 1 |
| Lainchbury, JG | 1 |
| Melton, I | 1 |
| Bridgman, PG | 1 |
| Palmer, SC | 1 |
| Frampton, CM | 1 |
| Nicholls, MG | 1 |
| Ulus, T | 1 |
| Nadir, A | 1 |
| Birdane, A | 2 |
| Ata, N | 2 |
| Potpara, TS | 1 |
| Polovina, MM | 1 |
| Licina, MM | 1 |
| Mujovic, NM | 1 |
| Marinkovic, JM | 1 |
| Petrovic, M | 1 |
| Vujisic-Tesic, B | 1 |
| Slee, A | 2 |
| Rosenberg, Y | 3 |
| Rathod, S | 1 |
| Grant, S | 2 |
| Thomas, E | 1 |
| Joyner, C | 1 |
| Alings, M | 1 |
| Blomström, P | 2 |
| Borggrefe, M | 1 |
| Budaj, A | 2 |
| Ching, CK | 1 |
| Commerford, P | 1 |
| Dans, A | 1 |
| Diaz, R | 1 |
| Golitsyn, S | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Kautzner, J | 1 |
| Lanas, F | 1 |
| Lewis, BS | 1 |
| Morillo, C | 1 |
| Narasimhan, C | 1 |
| Paolasso, E | 1 |
| Parkhomenko, A | 1 |
| Peters, NS | 1 |
| Sim, KH | 1 |
| Stiles, MK | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Tomcsányi, J | 3 |
| Vardas, P | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, JR | 1 |
| Baret-Cormel, L | 1 |
| Weinling, E | 1 |
| Staiger, C | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Bukowska, A | 1 |
| Hammwöhner, M | 2 |
| Sixdorf, A | 1 |
| Schild, L | 1 |
| Wiswedel, I | 1 |
| Röhl, FW | 1 |
| Wolke, C | 1 |
| Lendeckel, U | 1 |
| Aderkast, C | 1 |
| Bochmann, S | 1 |
| Chilukoti, RK | 1 |
| Mostertz, J | 1 |
| Bramlage, P | 1 |
| Smith, PJ | 1 |
| Klingman, D | 1 |
| Kumar, S | 2 |
| Sutherland, F | 1 |
| Morton, JB | 1 |
| Lee, G | 1 |
| Morgan, J | 1 |
| Wong, J | 1 |
| Eccleston, DE | 1 |
| Voukelatos, J | 1 |
| Garg, ML | 1 |
| Sparks, PB | 1 |
| Ferruzzi, L | 1 |
| Corti, B | 1 |
| Ruffato, A | 1 |
| Gavelli, G | 1 |
| Mattioli, S | 1 |
| Nuno-Gonzalez, A | 1 |
| Calzado-Villarreal, L | 1 |
| Gutierrez-Pascual, M | 1 |
| Gamo-Villegas, R | 1 |
| Sanz-Robles, H | 1 |
| Sanchez-Gilo, A | 1 |
| Pinedo-Moraleda, F | 1 |
| Lopez-Estebaranz, JL | 1 |
| Souto, SB | 1 |
| Fernandes, H | 1 |
| Matos, MJ | 1 |
| Braga, DC | 1 |
| Pereira, J | 1 |
| Carvalho, D | 1 |
| Shantsila, A | 2 |
| Varounis, C | 1 |
| Iliodromitis, EK | 1 |
| Lekakis, JP | 1 |
| Rallidis, LS | 1 |
| Anastasiou-Nana, M | 3 |
| Cohen, M | 1 |
| Boiangiu, C | 1 |
| Omar, HR | 1 |
| Lubinski, A | 1 |
| Bandman, O | 1 |
| Canafax, D | 1 |
| Ellis, DJ | 1 |
| Milner, PG | 1 |
| Ziola, M | 1 |
| Williamson, DR | 1 |
| Yaghchi, BM | 1 |
| Albert, M | 1 |
| McIntyre, L | 1 |
| Billman, GE | 1 |
| Gögelein, H | 1 |
| Ruetten, H | 1 |
| Wirth, KJ | 2 |
| Rizzo, LF | 1 |
| Bruno, OD | 1 |
| Omae, T | 1 |
| Kanmura, Y | 1 |
| Trigo, P | 1 |
| Karam, N | 1 |
| Marijon, E | 1 |
| Montone, RA | 1 |
| Mollo, R | 1 |
| Nerla, R | 1 |
| Overbeck, P | 2 |
| Diazzi, C | 1 |
| Brigante, G | 1 |
| Rossi, G | 1 |
| Rochira, V | 1 |
| Viswam, D | 1 |
| Nair, SG | 1 |
| Patel, V | 1 |
| Borders, CW | 1 |
| Bennett, S | 1 |
| Mount, C | 1 |
| Claassen, SL | 1 |
| Mullard, A | 1 |
| Modi, S | 1 |
| Foster, W | 1 |
| Todd, DM | 2 |
| Klein, GJ | 3 |
| Kawaguchi, T | 1 |
| Takasugi, N | 1 |
| Kubota, T | 1 |
| Takasugi, M | 1 |
| Kanamori, H | 1 |
| Ushikoshi, H | 1 |
| Hattori, A | 1 |
| Aoyama, T | 1 |
| Kawasaki, M | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Minatoguchi, S | 1 |
| Franklyn, JA | 1 |
| Boelaert, K | 1 |
| Menzorov, MV | 1 |
| Shutov, AM | 1 |
| Serov, VA | 1 |
| Marshall, LL | 1 |
| Tomisti, L | 1 |
| Aghini-Lombardi, F | 1 |
| Opie, LH | 1 |
| Rosenstein, R | 1 |
| Woods, D | 1 |
| Elgazayerly, AN | 1 |
| de Graeff, PA | 1 |
| Leufkens, HG | 1 |
| Shreenivas, AV | 1 |
| Lipshitz, J | 1 |
| Thiele, RH | 1 |
| Williams, J | 2 |
| Moylan, CA | 1 |
| Rao, SV | 1 |
| Bennett-Guerrero, E | 1 |
| Jensen, HK | 1 |
| Hoejsgaard, A | 1 |
| Mi, X | 1 |
| DeWald, TA | 1 |
| Go, AS | 1 |
| Curtis, LH | 1 |
| Gaita, F | 1 |
| Blandino, A | 1 |
| Toso, E | 1 |
| Antenucci, C | 1 |
| Antonicelli, R | 1 |
| Bocconcelli, P | 1 |
| Busacca, P | 1 |
| Ciampani, N | 1 |
| Della Casa, S | 1 |
| Gabrielli, D | 1 |
| Galvani, M | 1 |
| Margheri, M | 1 |
| Melandri, F | 1 |
| Modena, MG | 1 |
| Perna, GP | 1 |
| Pieri, P | 1 |
| Piovaccari, G | 1 |
| Pozzolini, A | 1 |
| Rapezzi, C | 2 |
| Villani, GQ | 3 |
| De Ponti, F | 1 |
| Mugelli, A | 1 |
| Nilsson, J | 2 |
| Åkerborg, Ö | 2 |
| Bégo-Le Bagousse, G | 1 |
| Rosenquist, M | 1 |
| Nadarasa, K | 1 |
| Williams, MJ | 1 |
| Blecher, GE | 1 |
| Stiell, IG | 1 |
| Rowe, BH | 1 |
| Lang, E | 1 |
| Brison, RJ | 1 |
| Perry, JJ | 1 |
| Clement, CM | 1 |
| Borgundvaag, B | 1 |
| Langhan, T | 1 |
| Magee, K | 1 |
| Stenstrom, R | 1 |
| Birnie, D | 1 |
| Wells, GA | 1 |
| Langford, A | 1 |
| Dayer, M | 1 |
| Ghosh, J | 1 |
| Katritsis, DG | 1 |
| Pagourelias, ED | 1 |
| Zografos, T | 1 |
| Geleris, P | 1 |
| Sviridenko, AV | 1 |
| Buniatian, ND | 1 |
| Korsun, LV | 1 |
| Uteshev, DB | 1 |
| Voronkina, MV | 1 |
| Wang, C | 1 |
| Gao, D | 1 |
| Zhang, C | 1 |
| Gao, Y | 1 |
| Willich, T | 1 |
| Yamase, M | 1 |
| Nakazato, Y | 1 |
| Daida, H | 1 |
| Daidoji, H | 1 |
| Arimoto, T | 1 |
| Nitobe, J | 1 |
| Tamura, H | 1 |
| Kutsuzawa, D | 1 |
| Ishigaki, D | 1 |
| Ishino, M | 1 |
| Takahashi, H | 1 |
| Shishido, T | 1 |
| Miyashita, T | 1 |
| Miyamoto, T | 1 |
| Watanabe, T | 2 |
| Kubota, I | 1 |
| Bascle, S | 1 |
| Wiedemann, AK | 1 |
| Boenigk, H | 1 |
| Herold, J | 1 |
| Schmidt, C | 1 |
| Wiedmann, F | 1 |
| Hernández Voth, AR | 1 |
| Catalán, JS | 1 |
| Benavides Mañas, PD | 1 |
| Avila Martínez, RJ | 1 |
| Peñalver Paolini, CL | 1 |
| Díaz de Atauri Rodríguez, MJ | 1 |
| Rosman, J | 1 |
| Hoffmeister, P | 2 |
| Peralta, A | 1 |
| Duncker, D | 1 |
| Oswald, H | 1 |
| Gardiwal, A | 1 |
| Lüsebrink, U | 1 |
| König, T | 1 |
| Schreyer, H | 1 |
| Klein, G | 2 |
| Boyce, BA | 1 |
| Yee, BH | 1 |
| Kang, JH | 1 |
| Lee, DI | 1 |
| Kim, MN | 1 |
| Park, YM | 1 |
| Ban, JE | 1 |
| Choi, JI | 1 |
| Lim, HE | 2 |
| Park, SW | 1 |
| Kim, YH | 3 |
| Sponga, S | 1 |
| Leoni, L | 1 |
| Buja, G | 1 |
| Nalli, C | 1 |
| Gerosa, G | 1 |
| Ahmad, Y | 1 |
| Saklani, P | 1 |
| Skanes, A | 3 |
| Korantzopoulos, P | 1 |
| Kyrlas, K | 1 |
| Goudevenos, JA | 1 |
| Biondi, B | 1 |
| Dusi, V | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Khalil, MA | 1 |
| Al-Agaty, AE | 1 |
| Ali, WG | 1 |
| Abdel Azeem, MS | 1 |
| Gu, J | 2 |
| Tan, H | 1 |
| Jiang, W | 1 |
| Bash, LD | 1 |
| Chazelle, F | 1 |
| Martín, A | 2 |
| Rosenqvist, M | 1 |
| Sanders, P | 3 |
| Scanavacca, M | 4 |
| Bernhardt, AA | 1 |
| Unniachan, S | 1 |
| Phatak, HM | 1 |
| Gitt, AK | 1 |
| Russo, G | 1 |
| Mariconti, B | 1 |
| Pentimalli, F | 1 |
| Campana, C | 1 |
| Duello, KM | 1 |
| Louh, IK | 1 |
| Burger, CD | 1 |
| Lin, L | 1 |
| Salmas, J | 1 |
| Kornej, J | 1 |
| Löbe, S | 1 |
| Stridh, M | 2 |
| Sörnmo, L | 2 |
| Husser, D | 2 |
| Ng, XR | 1 |
| Wee, LY | 1 |
| Chadachan, V | 1 |
| Miquel, J | 1 |
| Adamski, H | 1 |
| Oger, E | 1 |
| Pollard, E | 1 |
| Le Gall, F | 1 |
| Chevrant-Breton, J | 1 |
| Dupuy, A | 1 |
| Salam, AM | 1 |
| Adlan, AM | 1 |
| Immordino, L | 1 |
| Aliot, E | 1 |
| Giri, S | 3 |
| Tsikouris, JP | 4 |
| Dunn, A | 2 |
| Felton, K | 2 |
| Reddy, P | 7 |
| Kluger, J | 16 |
| Madrid, AH | 3 |
| Bueno, MG | 1 |
| Rebollo, JM | 2 |
| Marín, I | 2 |
| Peña, G | 1 |
| Bernal, E | 2 |
| Rodriguez, A | 1 |
| Cano, L | 1 |
| Cano, JM | 1 |
| Cabeza, P | 1 |
| Moro, C | 3 |
| Hennersdorf, MG | 1 |
| Perings, SM | 1 |
| Zühlke, C | 1 |
| Heidland, UE | 1 |
| Perings, C | 2 |
| Heintzen, MP | 1 |
| Strauer, BE | 1 |
| García Alberola, A | 1 |
| Gómez Agüera, A | 1 |
| Sánchez Muñoz, JJ | 1 |
| Martínez Sánchez, J | 1 |
| Llamas Lázaro, C | 1 |
| Valdés Chávarri, M | 1 |
| Mahoney, EM | 1 |
| Thompson, TD | 1 |
| Veledar, E | 1 |
| Weintraub, WS | 1 |
| Tada, H | 2 |
| Hassan, S | 1 |
| Scharf, C | 3 |
| Lai, SW | 1 |
| Greenstein, R | 1 |
| Knight, BP | 1 |
| Strickberger, SA | 3 |
| Khand, AU | 2 |
| Deedwania, PC | 2 |
| Sharp, JC | 1 |
| Whalley, DW | 1 |
| Wong, CK | 1 |
| White, HD | 1 |
| Wilcox, RG | 1 |
| Criger, DA | 1 |
| Topol, EJ | 1 |
| Sharma, H | 1 |
| Sharma, N | 1 |
| Rahbani, P | 1 |
| Zeid, HA | 1 |
| Hayek, G | 1 |
| Domanski, MJ | 2 |
| Schron, EB | 1 |
| Kellen, JC | 2 |
| Greene, HL | 4 |
| Mickel, MC | 1 |
| Dalquist, JE | 1 |
| Corley, SD | 3 |
| Pignalberi, C | 1 |
| Ricci, R | 1 |
| Kapoor, A | 1 |
| Singh, RK | 1 |
| Pandey, CM | 1 |
| Sinha, N | 1 |
| Kilborn, MJ | 2 |
| Rathore, SS | 1 |
| Oetgen, WJ | 1 |
| Shabalin, AV | 1 |
| Shaposhnikova, IuS | 1 |
| Guseva, IA | 1 |
| Kanorskiĭ, SG | 2 |
| Zingilevskiĭ, KB | 1 |
| Agozzino, F | 1 |
| Picca, M | 1 |
| Pelosi, G | 1 |
| Taylor, SE | 1 |
| Hadjis, T | 2 |
| Platt, RW | 3 |
| Chevalier, P | 1 |
| Durand-Dubief, A | 1 |
| Burri, H | 1 |
| Cucherat, M | 1 |
| Kirkorian, G | 1 |
| Touboul, P | 1 |
| Chen, H | 2 |
| Lanza, LA | 1 |
| Visbal, AI | 1 |
| DeValeria, PA | 1 |
| Zinsmeister, AR | 1 |
| Diehl, NN | 1 |
| Trastek, VF | 1 |
| Shinagawa, K | 1 |
| Shiroshita-Takeshita, A | 1 |
| Schram, G | 1 |
| Kogan, A | 1 |
| Ilgaev, N | 1 |
| Sahar, G | 1 |
| Kramer, M | 1 |
| Saute, M | 1 |
| Aravot, D | 1 |
| Berman, M | 1 |
| Vidne, BA | 1 |
| Kanoupakis, EM | 5 |
| Kochiadakis, GE | 12 |
| Manios, EG | 3 |
| Igoumenidis, NE | 11 |
| Mavrakis, HE | 4 |
| Vardas, PE | 14 |
| Kahn, S | 1 |
| Roberts, R | 2 |
| Thorpe, K | 1 |
| Gent, M | 2 |
| Cairns, JA | 1 |
| Healy, EC | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Luck, J | 1 |
| Saxonhouse, SJ | 1 |
| Winkel, E | 1 |
| Kao, W | 1 |
| Bernard, EO | 1 |
| Schmid, ER | 2 |
| Schmidlin, D | 1 |
| Candinas, R | 3 |
| Germann, R | 1 |
| Kosior, D | 2 |
| Szulc, M | 2 |
| Zawadzka, M | 2 |
| Pierścińska, M | 1 |
| Stawicki, S | 1 |
| Rabczenko, D | 3 |
| Torbicki, A | 3 |
| Hirmerová, J | 1 |
| Suchý, D | 1 |
| Mádr, T | 1 |
| Letelier, LM | 1 |
| Udol, K | 1 |
| Ena, J | 1 |
| Weaver, B | 1 |
| Guyatt, GH | 1 |
| Friberg, J | 2 |
| Gadsbøll, N | 2 |
| Zimmer, J | 1 |
| Pezzullo, J | 1 |
| Choucair, W | 1 |
| Southard, J | 1 |
| Kokkinos, P | 1 |
| Karasik, P | 2 |
| Greenberg, MD | 2 |
| Favale, S | 1 |
| Pappone, C | 3 |
| Nacci, F | 1 |
| Fino, F | 1 |
| Resta, F | 1 |
| Dicandia, CD | 1 |
| Levenson, D | 1 |
| Khan, IA | 1 |
| Mehta, NJ | 1 |
| Gowda, RM | 1 |
| Fynn, SP | 1 |
| Hobbs, WJ | 1 |
| Armstrong, KL | 1 |
| Fitzpatrick, AP | 1 |
| Garratt, CJ | 1 |
| Pandozi, C | 2 |
| Gentilucci, G | 2 |
| Castro, A | 4 |
| Lamberti, F | 1 |
| Loricchio, ML | 1 |
| Santini, L | 1 |
| Magris, B | 1 |
| Bulava, A | 1 |
| Peichl, P | 1 |
| Mitchell, AR | 1 |
| Spurrell, PA | 1 |
| Hauser, TH | 2 |
| Pinto, DS | 2 |
| Josephson, ME | 5 |
| Steinbigler, P | 1 |
| Haberl, R | 1 |
| Drucker, MH | 1 |
| Smith, I | 1 |
| Shaikh, S | 1 |
| Shaikh, N | 1 |
| Chun, SH | 2 |
| Spin, JM | 1 |
| Blumenkranz, MS | 1 |
| Marmor, MF | 1 |
| Saltman, AE | 2 |
| Yagdi, T | 1 |
| Nalbantgil, S | 1 |
| Ayik, F | 1 |
| Apaydin, A | 1 |
| Islamoglu, F | 1 |
| Posacioglu, H | 1 |
| Calkavur, T | 1 |
| Atay, Y | 1 |
| Buket, S | 1 |
| Kallergis, EM | 1 |
| Dermitzaki, DN | 1 |
| Kambouraki, DC | 1 |
| Olsson, R | 1 |
| Mangat, I | 2 |
| Cybulski, J | 1 |
| Danielewicz, H | 1 |
| Maciejewicz, J | 1 |
| Kawka-Urbanek, T | 1 |
| Ceremuzyński, L | 1 |
| Cardona, F | 1 |
| Seide, H | 1 |
| Cox, RA | 1 |
| Pérez, CM | 1 |
| Krittayaphong, R | 2 |
| Raungrattanaamporn, O | 1 |
| Bhuripanyo, K | 1 |
| Sriratanasathavorn, C | 2 |
| Pooranawattanakul, S | 1 |
| Punlee, K | 1 |
| Kangkagate, C | 2 |
| Tai, CT | 7 |
| Tsai, CF | 3 |
| Lin, WS | 1 |
| Tsao, HM | 1 |
| Huang, JL | 1 |
| Yu, WC | 5 |
| Chan, P | 1 |
| Ding, YA | 5 |
| Chang, MS | 7 |
| Jonkaitiene, R | 1 |
| Mizariene, V | 1 |
| Guden, M | 1 |
| Ozbek, U | 1 |
| Bayindir, O | 1 |
| De Pasquale, M | 1 |
| De Matteis, C | 1 |
| Canciello, M | 1 |
| Manzo, M | 1 |
| Sabino, L | 1 |
| Alfano, F | 1 |
| Di Mauro, M | 1 |
| Campana, A | 1 |
| De Fabrizio, G | 1 |
| Vitale, DF | 1 |
| Grönefeld, GC | 2 |
| Lilienthal, J | 2 |
| Reda, DJ | 5 |
| Fye, CL | 1 |
| Fletcher, RD | 3 |
| Sharma, SC | 3 |
| Atwood, JE | 4 |
| Jacobson, AK | 3 |
| Lewis, HD | 3 |
| Lopez, B | 4 |
| Scherer, M | 1 |
| Dzemali, O | 1 |
| Aybek, T | 1 |
| Wimmer-Greinecker, G | 1 |
| Moritz, A | 1 |
| Botelho, RJ | 1 |
| Oxorn, D | 1 |
| Leibowitz, AB | 1 |
| Alyan, O | 1 |
| Arda, K | 1 |
| Ozdemir, O | 1 |
| Acu, B | 1 |
| Soylu, M | 1 |
| Demirkan, D | 1 |
| Caron, MF | 5 |
| Kalus, JS | 5 |
| Rose, H | 1 |
| Song, J | 1 |
| Gallagher, R | 5 |
| Molina, RT | 2 |
| Scapín, AO | 2 |
| Blanco, MV | 1 |
| Trappe, HJ | 1 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| MacFadyen, RJ | 1 |
| Palmer, TJ | 1 |
| Hisamuddin, K | 1 |
| Schrickel, J | 1 |
| Bielik, H | 2 |
| Yang, A | 3 |
| Schwab, JO | 3 |
| Shlevkov, N | 1 |
| Schimpf, R | 1 |
| Lüderitz, B | 5 |
| Drissa, H | 1 |
| Essafi, N | 1 |
| Mahjoub, H | 1 |
| Ben Farhat, M | 1 |
| Boujnah, MR | 2 |
| Haouala, H | 1 |
| Kamoun, S | 1 |
| Khalfallah, A | 1 |
| Slimane, ML | 1 |
| Zaouali, RM | 1 |
| Liu, TJ | 1 |
| Hsueh, CW | 1 |
| Lai, HC | 1 |
| Wang, KY | 1 |
| Ting, CT | 1 |
| Lee, JK | 2 |
| Krahn, AD | 3 |
| Yee, R | 4 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Healey, J | 2 |
| Horta Veloso, H | 1 |
| Ferreira Júnior, JA | 1 |
| Braga de Paiva, JM | 1 |
| Faria Honório, J | 1 |
| Junqueira Bellei, NC | 1 |
| Vicenzo de Paola, AA | 1 |
| Tsai, TP | 1 |
| Lin, MC | 1 |
| Chan, KC | 1 |
| Wu, DJ | 1 |
| Lin, CS | 1 |
| Lan, FC | 1 |
| Chen, HY | 1 |
| Guy, D | 1 |
| Wallace, E | 1 |
| Crampton, R | 1 |
| Kijvanit, P | 1 |
| Eipper, V | 1 |
| Ross, DL | 1 |
| Cooper, MJ | 1 |
| Chen, CJ | 2 |
| Guo, GB | 2 |
| Channer, KS | 1 |
| Birchall, A | 1 |
| Steeds, RP | 1 |
| Walters, SJ | 1 |
| Yeo, WW | 1 |
| West, JN | 1 |
| Muthusamy, R | 1 |
| Rhoden, WE | 1 |
| Saeed, BT | 1 |
| Batin, P | 1 |
| Brooksby, WP | 1 |
| Wilson, I | 1 |
| Burke, SW | 1 |
| Lumer, G | 1 |
| Nannini, S | 2 |
| Limón, L | 2 |
| Singh, S | 2 |
| Tereshchenko, SN | 1 |
| Bulanova, NA | 1 |
| Kositsyna, IV | 1 |
| Morozova, MN | 1 |
| Uteshev, IuA | 1 |
| Jebara, VA | 1 |
| Mukhopadhyay, S | 2 |
| Abraham, NZ | 1 |
| Jones, LA | 1 |
| Howard, L | 1 |
| Gajra, A | 1 |
| Melo, J | 1 |
| Voigt, P | 1 |
| Sonmez, B | 1 |
| Ferreira, M | 1 |
| Abecasis, M | 1 |
| Rebocho, M | 1 |
| Timóteo, A | 1 |
| Aguiar, C | 1 |
| Tansal, S | 1 |
| Arbatli, H | 1 |
| Dion, R | 1 |
| Hamilos, MI | 1 |
| Tzerakis, PG | 2 |
| Klapsinos, NC | 1 |
| Zacharis, EA | 1 |
| Argall, J | 1 |
| Crawford, I | 1 |
| VerNooy, RA | 1 |
| Mounsey, JP | 1 |
| Tamariz, LJ | 1 |
| Bass, EB | 1 |
| Epstein, AE | 1 |
| Geller, N | 1 |
| Josephson, RA | 1 |
| Klein, RC | 1 |
| Mickel, M | 1 |
| Mitchell, LB | 2 |
| Nelson, JD | 1 |
| Schron, E | 1 |
| Shemanski, L | 1 |
| Hermida, JS | 2 |
| Tcheng, E | 2 |
| Jarry, G | 2 |
| Moullart, V | 2 |
| Arlot, S | 2 |
| Rey, JL | 2 |
| Delonca, J | 1 |
| Schvartz, C | 2 |
| Andreu Rodríguez, AL | 1 |
| Morillas Blasco, P | 1 |
| García Aldabe, JJ | 1 |
| Bertomeu Martínez, V | 1 |
| Rodríguez Ortega, JA | 1 |
| Chiumello, D | 1 |
| Caspani, ML | 1 |
| Andreoni, P | 1 |
| Rossi, F | 1 |
| Gattinoni, L | 1 |
| Nedostup, AV | 6 |
| Blagova, OV | 2 |
| Bogdanova, EA | 1 |
| Platonova, AA | 1 |
| Coleman, CI | 9 |
| Takata, H | 3 |
| Auer, J | 1 |
| Weber, T | 1 |
| Berent, R | 1 |
| Puschmann, R | 1 |
| Hartl, P | 1 |
| Ng, CK | 1 |
| Schwarz, C | 1 |
| Lehner, E | 1 |
| Strasser, U | 1 |
| Lassnig, E | 1 |
| Lamm, G | 1 |
| Eber, B | 1 |
| Humphrey, C | 2 |
| Lien, WC | 1 |
| Chen, WJ | 1 |
| Sakamoto, M | 1 |
| Kawagoe, J | 1 |
| Goto, K | 1 |
| Baba, H | 1 |
| Noma, M | 1 |
| Origuchi, H | 1 |
| Yoshimura, H | 1 |
| Sese, A | 1 |
| Yamamoto, H | 1 |
| Wang, JZ | 2 |
| Du, RY | 2 |
| Ding, HX | 1 |
| Bai, BJ | 2 |
| Wang, G | 1 |
| Cui, GF | 1 |
| Zhong, ZH | 2 |
| Merckx, KL | 1 |
| Tieleman, RG | 2 |
| Márk, L | 1 |
| Erdej, F | 1 |
| Dani, G | 1 |
| Borbély, M | 1 |
| Sziklai, G | 1 |
| Nagy, E | 2 |
| Hajdara, I | 1 |
| Katona, A | 1 |
| Nogami, A | 1 |
| Naito, S | 1 |
| Kaneko, T | 1 |
| Barbetakis, N | 1 |
| Vassiliadis, M | 1 |
| Slavik, RS | 1 |
| Zed, PJ | 1 |
| Nunes, JP | 1 |
| Silva, JC | 1 |
| Maciel, MJ | 1 |
| Vora, A | 2 |
| Karnad, D | 1 |
| Goyal, V | 1 |
| Naik, A | 1 |
| Gupta, A | 1 |
| Lokhandwala, Y | 1 |
| Kulkarni, H | 1 |
| Boos, C | 1 |
| Ritzema, J | 1 |
| More, RS | 1 |
| Horowitz, S | 1 |
| Karapanos, A | 1 |
| Mouloudi, HK | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| Nicotra, GC | 1 |
| De Simone, C | 1 |
| Kerstein, J | 1 |
| Soodan, A | 1 |
| Qamar, M | 1 |
| Majid, M | 1 |
| Hollander, G | 1 |
| Shani, J | 1 |
| Freestone, B | 3 |
| Kamath, S | 1 |
| Lip, G | 1 |
| Nicolas, X | 1 |
| Granier, H | 1 |
| Grippari, JL | 1 |
| Bergez, C | 1 |
| Laborde, JP | 1 |
| Talarmin, F | 1 |
| Kerr, CR | 2 |
| Steinbuch, M | 1 |
| Wurdeman, RL | 2 |
| Sugimoto, JT | 1 |
| Lenz, TL | 2 |
| Rovang, KS | 1 |
| Arcidi, JM | 1 |
| Mohiuddin, SM | 3 |
| Lemery, R | 2 |
| Soucie, L | 1 |
| Martin, B | 1 |
| Tang, AS | 2 |
| Green, M | 3 |
| Akdemir, R | 1 |
| Gunduz, H | 1 |
| Erbilen, E | 1 |
| Ozer, I | 1 |
| Albayrak, S | 1 |
| Unlu, H | 1 |
| Uyan, C | 1 |
| Marín, IM | 1 |
| Cervantes, CE | 1 |
| Morell, EB | 1 |
| Estévez, JE | 1 |
| Moreno, G | 1 |
| Parajón, JR | 1 |
| Werner, D | 1 |
| Wuttke, H | 1 |
| Fromm, MF | 1 |
| Schaefer, S | 1 |
| Brune, K | 1 |
| Daniel, WG | 1 |
| Werner, U | 1 |
| Bertaglia, E | 1 |
| Bonso, A | 1 |
| Zoppo, F | 1 |
| Verlato, R | 2 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Pascotto, P | 1 |
| Abrahamowicz, M | 2 |
| Mather, JF | 1 |
| Boden, WE | 1 |
| Canivet, JL | 1 |
| Yans, T | 1 |
| Roediger, L | 1 |
| Radermecker, MA | 1 |
| Kabukcu, M | 2 |
| Yanik, E | 2 |
| Demircioglu, F | 2 |
| Gölbasi, I | 1 |
| Ersel, F | 1 |
| Samuels, LE | 1 |
| Holmes, EC | 1 |
| Samuels, FL | 1 |
| Lad, V | 1 |
| Hofmann, R | 3 |
| Steinwender, C | 2 |
| Kammler, J | 2 |
| Kypta, A | 2 |
| Wimmer, G | 2 |
| Leisch, F | 4 |
| Kirkutis, A | 1 |
| Poviliŭnas, A | 1 |
| Griciene, P | 1 |
| Polena, S | 1 |
| Yang, S | 1 |
| Yalamanchi, G | 1 |
| Gintautas, J | 1 |
| Simkó, J | 1 |
| Barta, K | 1 |
| Szabó, Z | 1 |
| Varga, E | 1 |
| Lorincz, I | 1 |
| Rätz Bravo, AE | 1 |
| Drewe, J | 1 |
| Schlienger, RG | 1 |
| Krähenbühl, S | 1 |
| Pargger, H | 1 |
| Ummenhofer, W | 1 |
| Nygård, E | 1 |
| Sørensen, LH | 1 |
| Hviid, LB | 1 |
| Pedersen, FM | 1 |
| Ravn, J | 1 |
| Thomassen, L | 1 |
| Eliasen, K | 1 |
| Krogsgaard, K | 1 |
| Aldershvile, J | 1 |
| Minareci, K | 1 |
| Ersel-Tüzüner, F | 1 |
| Sami, M | 1 |
| Rubin, A | 1 |
| Kostis, J | 1 |
| Shorofsky, S | 1 |
| Rostock, T | 2 |
| Risius, T | 1 |
| Ventura, R | 1 |
| Weiss, C | 1 |
| DiDomenico, RJ | 1 |
| Massad, MG | 1 |
| Geller, C | 1 |
| Klein, HU | 1 |
| Olsson, SB | 2 |
| Horiuchi, D | 1 |
| Nakamura, S | 1 |
| Suzuki, O | 1 |
| Yomogida, K | 1 |
| Okumura, K | 3 |
| Skroubis, G | 1 |
| Skroubis, T | 1 |
| Galiatsou, E | 1 |
| Metafratzi, Z | 1 |
| Karahaliou, A | 1 |
| Kitsakos, A | 1 |
| Nakos, G | 1 |
| Hersi, A | 1 |
| Sander, S | 4 |
| Mikroulis, D | 1 |
| Didilis, V | 1 |
| Konstantinou, F | 1 |
| Tsakiridis, K | 1 |
| Vretzakis, G | 1 |
| Bougioukas, G | 1 |
| Clement, CI | 1 |
| Myers, P | 1 |
| Tan, KP | 1 |
| Perkerson, KA | 1 |
| Gillespie, EL | 5 |
| Kardas, M | 1 |
| Ismaili, A | 1 |
| Sedrakyan, A | 1 |
| Treasure, T | 2 |
| Browne, J | 1 |
| Krumholz, H | 1 |
| Sharpin, C | 1 |
| van der Meulen, J | 1 |
| Kounas, SP | 1 |
| Letsas, KP | 1 |
| Sideris, A | 1 |
| Efraimidis, M | 1 |
| Kardaras, F | 1 |
| Harris, CL | 2 |
| Raisch, DW | 2 |
| Kocheril, AG | 1 |
| Sharma, AD | 1 |
| Cher, D | 1 |
| Stubbs, HA | 1 |
| Block, JE | 1 |
| Cheng, TO | 1 |
| Camanini, C | 1 |
| Valzania, C | 1 |
| Corazza, I | 1 |
| Zannoli, R | 2 |
| Branzi, A | 3 |
| Baert, K | 2 |
| Tavernier, R | 3 |
| Croubels, S | 2 |
| De Backer, P | 2 |
| Benchimol Barbosa, PR | 1 |
| de Souza Bomfim, A | 2 |
| Barbosa, EC | 2 |
| Ginefra, P | 3 |
| Helena Cardoso Boghossian, S | 1 |
| Destro, C | 1 |
| Nadal, J | 1 |
| Kosior, DA | 2 |
| Wozakowska-Kaplon, B | 1 |
| Tuseth, V | 1 |
| Jaatun, HJ | 1 |
| Dickstein, K | 1 |
| Gryskiewicz, KA | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Gundling, F | 1 |
| Tillmann, HL | 1 |
| Schmidt, O | 1 |
| Brennenstuhl, M | 1 |
| Nerlich, A | 1 |
| Schepp, W | 1 |
| Dilaveris, P | 1 |
| Synetos, A | 1 |
| Gialafos, E | 1 |
| Bhatia, GS | 1 |
| Berenfeld, O | 1 |
| Hocini, M | 2 |
| Vaidyanathan, R | 1 |
| Hsu, LF | 2 |
| Garrigue, S | 1 |
| Takahashi, Y | 2 |
| Rotter, M | 2 |
| Sacher, F | 2 |
| Scavée, C | 1 |
| Ploutz-Snyder, R | 1 |
| Jalife, J | 1 |
| Rubinstein, J | 1 |
| Desai, KR | 1 |
| Schlegel, A | 1 |
| Mangin, L | 1 |
| Vinet, A | 1 |
| Glass, L | 1 |
| Shingu, Y | 1 |
| Aoki, H | 1 |
| Oba, J | 1 |
| Takigami, K | 1 |
| Eya, K | 1 |
| Ebuoka, N | 1 |
| Kabbani, SS | 1 |
| Murad, G | 1 |
| Jamil, H | 1 |
| Sabbagh, A | 1 |
| Hamzeh, K | 1 |
| Aasbo, JD | 1 |
| Lawrence, AT | 1 |
| Krishnan, K | 1 |
| Trohman, RG | 2 |
| Abreu Filho, CA | 1 |
| Lisboa, LA | 1 |
| Dallan, LA | 1 |
| Spina, GS | 1 |
| Grinberg, M | 1 |
| Sosa, EA | 2 |
| Ramires, JA | 1 |
| Oliveira, SA | 1 |
| Shukla, G | 1 |
| Chaudhry, GM | 1 |
| Orlov, M | 1 |
| Haffajee, C | 1 |
| Papadopoulos, N | 1 |
| Papanastasiou, S | 1 |
| Kozirakis, M | 1 |
| Maligkos, G | 1 |
| Tsaritsaniotis, E | 1 |
| Katsaris, G | 1 |
| Zapolski, T | 1 |
| Wysokiński, A | 1 |
| Schuetz, P | 1 |
| Eriksson, U | 1 |
| Christ-Crain, M | 1 |
| Zulewski, H | 1 |
| Miller, B | 1 |
| Sticherling, C | 1 |
| Behrens, S | 1 |
| Kamke, W | 1 |
| Stahn, A | 1 |
| Kathofer, S | 1 |
| Karle, CA | 1 |
| Hunter, CB | 1 |
| Maciejewski, S | 1 |
| Krauser, DG | 1 |
| Segal, AZ | 1 |
| Kligfield, P | 1 |
| Veloso, HH | 4 |
| de Paola, AA | 2 |
| Fuh, A | 1 |
| Feldstein, DA | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Kudaiberdieva, G | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Allali, G | 1 |
| Falconnet, C | 1 |
| Wozakowska-Kapłon, B | 1 |
| Jasik, M | 1 |
| Chilov, MN | 1 |
| Moshegov, CN | 1 |
| Booth, F | 1 |
| Wongcharoen, W | 1 |
| Lin, YJ | 1 |
| Chang, SL | 1 |
| Brantman, L | 1 |
| Howie, J | 1 |
| Enseleit, F | 1 |
| Wyss, CA | 1 |
| Duru, F | 1 |
| Noll, G | 1 |
| Ruschitzka, F | 1 |
| Jonsson, A | 1 |
| O'Neill, MD | 1 |
| Bordachar, P | 1 |
| Reuter, S | 1 |
| Roudaut, R | 1 |
| Clémenty, J | 2 |
| Dovie, JM | 1 |
| Gurwood, AS | 1 |
| Good, E | 1 |
| Bates, ER | 1 |
| Lehmann, MH | 1 |
| Vicedomini, G | 2 |
| Augello, G | 2 |
| Agricola, E | 1 |
| Sala, S | 2 |
| Santinelli, V | 2 |
| Paran, Y | 1 |
| Nimrod, A | 1 |
| Goldin, Y | 1 |
| Justo, D | 1 |
| Sato, S | 1 |
| Ishida, T | 1 |
| Yoshikawa, M | 1 |
| Kanazawa, K | 1 |
| Saito, J | 1 |
| Ohtsuka, Y | 1 |
| Suzuki, H | 1 |
| Maruyama, Y | 1 |
| Munakata, M | 1 |
| Nikolidakis, S | 1 |
| Kyriakides, ZS | 1 |
| Barbatis, C | 1 |
| Zareba, KM | 1 |
| Venkatesan, T | 1 |
| Ninan, S | 1 |
| Rancourt, JA | 1 |
| Ashikaga, K | 1 |
| Kobayashi, T | 1 |
| Kimura, M | 2 |
| Owada, S | 1 |
| Sasaki, S | 1 |
| Iwasa, A | 1 |
| Furukawa, K | 1 |
| Motomura, S | 1 |
| Chotinaiwatarakul, C | 1 |
| Phankingthongkum, R | 1 |
| Panchavinnin, P | 1 |
| Tresukosol, D | 1 |
| Jakrapanichakul, D | 1 |
| Kitrattana, B | 1 |
| Vijayalakshmi, K | 1 |
| Whittaker, VJ | 1 |
| Sutton, A | 1 |
| Campbell, P | 1 |
| Wright, RA | 1 |
| Hall, JA | 1 |
| Harcombe, AA | 1 |
| Linker, NJ | 1 |
| Stewart, MJ | 1 |
| Davies, A | 1 |
| de Belder, MA | 1 |
| Jung, W | 1 |
| Meyerfeldt, U | 1 |
| Birkemeyer, R | 1 |
| Huang, CX | 2 |
| Zhao, QY | 1 |
| Liang, JJ | 1 |
| Li, GS | 1 |
| Sugi, K | 1 |
| Chen, DY | 1 |
| Zhu, BP | 1 |
| Michałkiewicz, D | 1 |
| Dziuk, M | 1 |
| Kamiński, G | 1 |
| Olszewski, R | 1 |
| Cholewa, M | 1 |
| Cwetsch, A | 1 |
| Markuszewski, L | 1 |
| Niu, F | 1 |
| Guo, WL | 1 |
| Chen, YX | 1 |
| Jin, CR | 1 |
| Liu, ZM | 1 |
| Zhao, F | 1 |
| Feng, SX | 1 |
| Zhao, P | 1 |
| Ma, H | 1 |
| Neumann, T | 1 |
| Hölschermann, H | 1 |
| Gulizia, M | 2 |
| Mangiameli, S | 2 |
| Chiarandà, G | 2 |
| Spadola, V | 1 |
| Di Giovanni, N | 2 |
| Colletti, A | 2 |
| Bulla, V | 1 |
| Circo, A | 1 |
| Pensabene, O | 2 |
| Vasquez, L | 2 |
| Vaccaro, I | 1 |
| Grammatico, A | 2 |
| Iskandar, SB | 1 |
| Abi-Saleh, B | 1 |
| Keith, RL | 1 |
| Byrd, RP | 1 |
| Roy, TM | 1 |
| Patel, AA | 1 |
| Kenigsberg, DN | 1 |
| Krishnan, SC | 1 |
| Camarero, V | 1 |
| Llata, L | 1 |
| Ruiz, E | 1 |
| Torres, G | 1 |
| Schrickel, JW | 2 |
| Bitzen, A | 2 |
| Jolobe, O | 1 |
| Kashyap, AS | 1 |
| Anand, KP | 1 |
| Kashyap, S | 1 |
| Prochaczek, F | 1 |
| Winiarska, H | 1 |
| Kończakowski, P | 1 |
| Pyka, R | 1 |
| Dziuk, D | 1 |
| Gałecka, J | 1 |
| Kwatra, MM | 1 |
| Lelorier, J | 1 |
| Janko, S | 1 |
| Hoffmann, E | 3 |
| Porsche, R | 1 |
| Brenner, ZR | 1 |
| Budeus, M | 1 |
| Hennersdorf, M | 1 |
| Perings, S | 1 |
| Röhlen, S | 1 |
| Schnitzler, S | 1 |
| Felix, O | 1 |
| Reimert, K | 1 |
| Feindt, P | 1 |
| Gams, E | 1 |
| Lehmann, N | 1 |
| Wieneke, H | 1 |
| Sack, S | 1 |
| Erbel, R | 1 |
| Liu, ZC | 2 |
| Wu, JJ | 2 |
| Dai, Y | 2 |
| Lan, XB | 2 |
| Ling, ZY | 2 |
| Yang, XY | 2 |
| Luo, KL | 2 |
| Schreiber, DH | 1 |
| DeFreest, MS | 1 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Champagne, J | 1 |
| Dalal, D | 1 |
| Liu, D | 2 |
| Luo, K | 1 |
| Woo, K | 1 |
| Dong, J | 2 |
| Shantsila, E | 1 |
| Kum, LC | 1 |
| Chan, WW | 1 |
| Hui, HH | 1 |
| Wong, GW | 1 |
| Ho, SS | 1 |
| Sanderson, JE | 1 |
| Yu, CM | 1 |
| Fung, JW | 1 |
| Yu, YB | 1 |
| Huang, SE | 1 |
| Mesana, TG | 1 |
| Ruel, M | 1 |
| Masters, R | 1 |
| Bedard, P | 1 |
| Agarwal, SC | 1 |
| Pepper, CB | 1 |
| Lin, JA | 1 |
| Borel, CO | 1 |
| Wang, WB | 1 |
| Wong, CS | 1 |
| Yeh, CC | 1 |
| Yang, CP | 1 |
| Wu, CT | 1 |
| Klein, HH | 1 |
| Pisani, CF | 1 |
| Hachul, D | 1 |
| Lara, S | 1 |
| Hardy, C | 1 |
| Darrieux, F | 1 |
| Trombetta, I | 1 |
| Negrão, CE | 1 |
| Sosa, E | 1 |
| Dale, K | 2 |
| Wegener, FT | 2 |
| Bhatt, PR | 1 |
| Ramaesh, K | 1 |
| Liu, T | 1 |
| Li, G | 1 |
| Paul, G | 1 |
| Schwender, T | 1 |
| Xie, PY | 1 |
| Shen, SH | 1 |
| Hagens, VE | 1 |
| Barnes, BJ | 1 |
| Kirkland, EA | 1 |
| Howard, PA | 2 |
| Grauer, DW | 1 |
| Gorton, ME | 1 |
| Kramer, JB | 1 |
| Muehlebach, GF | 1 |
| Reed, WA | 1 |
| Sablayrolles, S | 1 |
| Le Grand, B | 1 |
| Kruchinova, OA | 1 |
| Zingilevskiĭ, K | 1 |
| Kafkas, NV | 1 |
| Patsilinakos, SP | 1 |
| Mertzanos, GA | 1 |
| Papageorgiou, KI | 1 |
| Chaveles, JI | 1 |
| Dagadaki, OK | 1 |
| Kelesidis, KM | 1 |
| Alcalde, RV | 1 |
| Guaragna, JC | 2 |
| Bodanese, LC | 2 |
| Castro, I | 1 |
| Sussenbach, E | 1 |
| Noer, R | 1 |
| Goldani, MA | 1 |
| Feier, F | 1 |
| Petracco, JB | 1 |
| Bagshaw, SM | 1 |
| Galbraith, PD | 1 |
| Sauve, R | 1 |
| Exner, DV | 1 |
| Ghali, WA | 1 |
| Long, D | 1 |
| Hu, F | 1 |
| Yu, R | 1 |
| Tang, R | 1 |
| Fang, D | 1 |
| Hao, P | 1 |
| Lu, C | 1 |
| Dunning, J | 1 |
| Versteegh, M | 1 |
| Nashef, SA | 1 |
| Poole, J | 2 |
| Anderson, J | 2 |
| Mark, DB | 2 |
| Bardy, GH | 2 |
| Xin, LP | 1 |
| Wang, CG | 1 |
| Rejnmark, L | 1 |
| Vestergaard, P | 1 |
| Mosekilde, L | 1 |
| Coceani, M | 2 |
| O'Donnell, MJ | 1 |
| Valens, N | 1 |
| Lansberg, MG | 1 |
| Wijman, CA | 1 |
| Bobbio, A | 1 |
| Caporale, D | 1 |
| Internullo, E | 1 |
| Ampollini, L | 1 |
| Bettati, S | 1 |
| Rossini, E | 2 |
| Carbognani, P | 1 |
| Rusca, M | 1 |
| Pollet, P | 1 |
| Goethals, M | 1 |
| Martínez-Brotóns, AM | 1 |
| Ruiz-Granell, R | 1 |
| Morell, S | 1 |
| Plancha, E | 1 |
| Ferrero, A | 1 |
| Roselló, A | 1 |
| Llácer, A | 1 |
| García-Civera, R | 1 |
| Palanca, V | 1 |
| Quesada, A | 1 |
| Trigo, A | 1 |
| Jiménez, J | 1 |
| Maheshwari, M | 1 |
| Baid, JC | 1 |
| Vijayvergia, A | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Carrió, ML | 2 |
| Fortià, C | 2 |
| Javierre, C | 2 |
| Rodríguez, D | 2 |
| Farrero, E | 2 |
| Castells, E | 2 |
| Ventura, JL | 2 |
| Gugliotta, F | 1 |
| Gulletta, S | 1 |
| Paglino, G | 1 |
| Mazzone, P | 1 |
| Sora, N | 1 |
| Greiss, I | 1 |
| Santagostino, A | 1 |
| LiVolsi, L | 1 |
| Pappone, N | 1 |
| Radinovic, A | 1 |
| Manguso, F | 1 |
| Tsiperfal, A | 1 |
| Hsia, H | 1 |
| Thompson, C | 1 |
| Horiguchi, T | 1 |
| Kondo, R | 1 |
| Shiga, M | 1 |
| Hirose, M | 1 |
| Itou, T | 1 |
| Torigoe, H | 1 |
| Hayashi, N | 1 |
| Ouhira, D | 1 |
| Shiga, T | 2 |
| Jong, GP | 1 |
| Chang, MH | 1 |
| Chang, TC | 1 |
| Chou, P | 1 |
| Fu, CY | 1 |
| Tien, LY | 1 |
| Ma, TC | 1 |
| Henyan, N | 2 |
| Ogawa, H | 1 |
| Wakeyama, T | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Hadano, Y | 1 |
| Miyazaki, Y | 1 |
| Shimizu, A | 1 |
| Matsuzaki, M | 1 |
| Kanna, B | 1 |
| Gopalam, M | 1 |
| Curtiss, FR | 1 |
| Kawabata, VS | 1 |
| Vianna, CB | 1 |
| Moretti, MA | 1 |
| Gonzalez, MM | 1 |
| Ferreira, JF | 2 |
| Timerman, S | 1 |
| Cesar, LA | 2 |
| Sideris, S | 1 |
| Bonios, M | 1 |
| Melexopoulou, C | 1 |
| Exarchos, P | 1 |
| Tsatiris, K | 1 |
| Kogias, J | 1 |
| Fradi, I | 1 |
| Mokaddem, A | 1 |
| Selmi, K | 1 |
| Minhaj, MM | 1 |
| Zvara, DA | 1 |
| Nayyar, P | 1 |
| Maslow, A | 1 |
| Smellie, WS | 1 |
| Coleman, JJ | 1 |
| La Rocca, V | 1 |
| Iuliano, A | 1 |
| Capuano, V | 1 |
| Astarita, C | 1 |
| Di Napoli, T | 1 |
| Messina, V | 1 |
| Baldi, S | 1 |
| Buckley, MS | 1 |
| Nolan, PE | 2 |
| Slack, MK | 2 |
| Copeland, JG | 1 |
| DeVore, KJ | 1 |
| Hobbs, RA | 1 |
| Sheikh, I | 1 |
| Krum, D | 1 |
| Cooley, R | 1 |
| Dhala, A | 1 |
| Blanck, Z | 1 |
| Bhatia, A | 1 |
| Nangia, V | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Lertsburapa, K | 1 |
| Faheem, O | 1 |
| Xu, HK | 1 |
| Zhang, YF | 1 |
| Myers, JN | 1 |
| Mikkelsen, MM | 1 |
| Folkersen, L | 1 |
| Sørensen, HT | 1 |
| Dale, KM | 1 |
| Bassiakou, E | 1 |
| Bassiakos, S | 1 |
| Michalakis, K | 1 |
| Moutzouris, DA | 1 |
| Papadimitriou, L | 2 |
| Macedo, TA | 1 |
| Chammas, MC | 1 |
| Jorge, PT | 1 |
| Souza, LP | 1 |
| Farage, L | 1 |
| Santos, VA | 1 |
| Cerri, GG | 1 |
| Tapio, H | 1 |
| Jari, H | 1 |
| Kimmo, M | 1 |
| Juha, H | 1 |
| Beall, JW | 1 |
| Mahan, EF | 1 |
| Blau, AB | 1 |
| Freudenberger, RS | 1 |
| Johnson, G | 1 |
| Tafreshi, MJ | 1 |
| Rowles, J | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 2 |
| Chandhok, S | 1 |
| Schwartzman, D | 1 |
| Abuladze, GV | 1 |
| Dzhindzholiia, NA | 1 |
| Dzhashi, IA | 1 |
| Narsiia, EV | 1 |
| Gudzhedzhiani, LA | 1 |
| Hill, JN | 1 |
| Rehman, Hu | 1 |
| Hamilos, ME | 1 |
| Marketou, ME | 5 |
| Chlouverakis, GI | 4 |
| Kurnik, D | 1 |
| Loebstein, R | 1 |
| Olchovsky, D | 1 |
| Armon, C | 1 |
| Hang, CL | 1 |
| Chang, HW | 1 |
| Wu, CJ | 1 |
| Fang, CY | 1 |
| Turk, T | 1 |
| Ata, Y | 1 |
| Vural, H | 1 |
| Ozkan, H | 1 |
| Yavuz, S | 1 |
| Ozyazicioglu, A | 1 |
| Metra, M | 1 |
| Spark, P | 1 |
| Lukas, MA | 1 |
| Moullet, C | 1 |
| Scherhag, A | 1 |
| Komajda, M | 1 |
| Remme, W | 1 |
| Di Lenarda, A | 1 |
| Swedberg, K | 1 |
| Poole-Wilson, PA | 1 |
| Iwamoto, J | 1 |
| Inoue, H | 1 |
| Ricart, A | 1 |
| Prapa, V | 1 |
| Papadimitriou, D | 1 |
| Patanè, S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Chiribiri, A | 1 |
| Nikolaou, M | 1 |
| Ikonomidis, I | 1 |
| Lekakis, I | 1 |
| Kremastinos, D | 1 |
| Shavit, E | 1 |
| Sherer, Y | 1 |
| Nogueras, C | 1 |
| Miralles, R | 1 |
| Roig, A | 1 |
| Llorach, I | 1 |
| Cervera, AM | 1 |
| Alves, RJ | 1 |
| Geovanini, GR | 1 |
| Brito, Gd | 1 |
| Miguel, GA | 1 |
| Glauser, VA | 1 |
| Nakiri, K | 1 |
| Khanderia, U | 1 |
| Wagner, D | 1 |
| Walker, PC | 1 |
| Woodcock, B | 1 |
| Prager, R | 1 |
| Batcher, EL | 1 |
| Hershman, JM | 1 |
| Papathanasiou, S | 1 |
| Daccarett, M | 1 |
| Segerson, NM | 1 |
| Weiss, JP | 1 |
| Day, JD | 1 |
| Morrow, JP | 1 |
| Cannon, CP | 1 |
| London, B | 1 |
| Malfatto, G | 1 |
| Zaza, A | 1 |
| Facchini, M | 1 |
| Seiz, W | 1 |
| Torp-Petersen, C | 1 |
| Vasiukov, SS | 1 |
| Fedorova, VI | 1 |
| Gordeev, SA | 1 |
| Argyriou, M | 1 |
| Hountis, P | 1 |
| Antonopoulos, N | 1 |
| Mathioudaki, M | 1 |
| Arlet, JB | 1 |
| Chouchana, L | 1 |
| Capron, L | 1 |
| Kayser, SR | 1 |
| Fink, AH | 1 |
| Chen, YQ | 1 |
| Reinhart, K | 1 |
| Orazi, S | 1 |
| Piccione, G | 1 |
| Lisi, F | 1 |
| Kristiansen, IS | 1 |
| Lee, CH | 1 |
| Park, HG | 1 |
| Kim, HY | 1 |
| Choi, KJ | 1 |
| Chan, AL | 1 |
| Hsieh, HJ | 1 |
| Hsieh, YA | 1 |
| Lin, SJ | 1 |
| Taimur, Z | 1 |
| Hussaini, S | 1 |
| Abildstrom, SZ | 1 |
| Schramm, TK | 1 |
| Folke, F | 1 |
| Sørensen, R | 1 |
| Rasmussen, S | 1 |
| Poulsen, HE | 1 |
| Madsen, M | 1 |
| Slim, AM | 1 |
| Roth, JE | 1 |
| Duffy, B | 1 |
| Boyd, SY | 1 |
| Rubal, BJ | 1 |
| Stewart, JI | 1 |
| Chawla, R | 1 |
| Lloyd, JM | 1 |
| Kane, GC | 1 |
| Di Micoli, A | 1 |
| Zambruni, A | 1 |
| Bracci, E | 1 |
| Benazzi, B | 1 |
| Zappoli, P | 1 |
| Berzigotti, A | 1 |
| Zoli, M | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Zygmunt, AC | 1 |
| Hindle, JV | 1 |
| Ibrahim, A | 1 |
| Ramaraj, R | 1 |
| Liakishev, AA | 1 |
| Peters, RW | 1 |
| Leclercq, JF | 6 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 2 |
| Maisonblanche, P | 1 |
| Coumel, P | 8 |
| Zhivoderov, VM | 1 |
| Zakharov, VN | 2 |
| Doshchitsin, VL | 1 |
| Aksenova, TN | 1 |
| Andriukova, EI | 1 |
| Korkushko, OV | 1 |
| Butenko, AG | 1 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Assayag, P | 1 |
| Rossini, G | 1 |
| Sbarbaro, FG | 1 |
| Mazzoni, M | 1 |
| Arata, G | 1 |
| Martines, G | 1 |
| Heger, JJ | 1 |
| Miles, WM | 1 |
| Zipes, DP | 2 |
| Kappenberger, LJ | 1 |
| Fromer, MA | 1 |
| Steinbrunn, W | 1 |
| Shenasa, M | 1 |
| Koutras, DA | 1 |
| Levis, G | 1 |
| Souvatzoglou, A | 1 |
| Boukis, MA | 1 |
| Moulopoulos, SD | 2 |
| Dick, M | 1 |
| Campbell, RM | 1 |
| Roussane, A | 1 |
| Blanc, P | 1 |
| Virot, P | 1 |
| Doumeix, JJ | 1 |
| Chabanier, A | 1 |
| Bensaid, J | 1 |
| Blanc, G | 1 |
| Pozzi, E | 1 |
| Sada, E | 1 |
| Luisetti, M | 1 |
| De Rose, V | 1 |
| Scelsi, M | 1 |
| Edvardsson, N | 2 |
| McKenna, WJ | 8 |
| Harris, L | 1 |
| Kleinebenne, A | 2 |
| Krikler, DM | 4 |
| Oakley, CM | 2 |
| Goodwin, JF | 1 |
| Graboys, TB | 1 |
| Podrid, PJ | 1 |
| Lown, B | 1 |
| Wellens, HJ | 2 |
| Brugada, P | 2 |
| Rosenbaum, MB | 1 |
| Haedo, A | 1 |
| Lázzari, JO | 2 |
| del Río Ligorit, A | 1 |
| Casasnovas Lenguas, JA | 1 |
| González Carretero, M | 1 |
| Lozano, HC | 1 |
| Ferreira Montero, IJ | 1 |
| Petronelli, FP | 1 |
| Marrozzini, C | 1 |
| Melandri, G | 1 |
| Maresta, A | 1 |
| Magnani, B | 7 |
| Levis, GM | 1 |
| Gronda, M | 1 |
| Occhetta, E | 1 |
| Magnani, A | 1 |
| Rognoni, G | 1 |
| D'Aurelio, M | 1 |
| Prando, MD | 1 |
| Rossi, P | 1 |
| Garabedian, V | 1 |
| Lagarde, O | 1 |
| Guiraudon, C | 1 |
| Frank, F | 1 |
| Fontaine, G | 2 |
| Richart, JC | 1 |
| Coignard, A | 1 |
| Duret, JC | 1 |
| Mardelle, T | 1 |
| Droniou, J | 1 |
| Blandford, RL | 1 |
| Crampton, J | 1 |
| Kudlac, H | 1 |
| Sullivan, M | 1 |
| Barnett, DB | 1 |
| Akhtar, N | 1 |
| Hudson, SA | 1 |
| Sheinman, BD | 1 |
| Evans, T | 1 |
| Critelli, G | 2 |
| Grassi, G | 1 |
| Perticone, F | 2 |
| Coltorti, F | 2 |
| Monda, V | 2 |
| Condorelli, M | 2 |
| Faniel, R | 1 |
| Schoenfeld, P | 2 |
| Lubbe, WF | 2 |
| Mercer, CJ | 1 |
| Roche, AH | 1 |
| Lowe, JB | 1 |
| Marcus, FI | 1 |
| Fontaine, GH | 1 |
| Frank, R | 2 |
| Grosgogeat, Y | 2 |
| Vitolo, E | 2 |
| Tronci, M | 2 |
| Larovere, MT | 2 |
| Rumolo, R | 2 |
| Morabito, A | 1 |
| Keren, A | 1 |
| Tzivoni, D | 1 |
| Gottlieb, S | 1 |
| Benhorin, J | 1 |
| Stern, S | 1 |
| Allaria, B | 1 |
| Romanò, M | 1 |
| Zucco, F | 1 |
| De Gasperi, A | 1 |
| Gallagher, JJ | 1 |
| Varma, MP | 1 |
| Geddes, JS | 1 |
| Pantridge, JF | 1 |
| Moncini, S | 1 |
| Piccone, U | 1 |
| Frustaglia, A | 1 |
| Ricevuti, A | 1 |
| Bianchi, C | 1 |
| Bonifazi, C | 1 |
| Coppetti, S | 1 |
| Ferrari, O | 1 |
| Rinaldo, R | 1 |
| Rizzi, M | 1 |
| Tavecchi, L | 1 |
| Zampaglione, G | 1 |
| Ziletti, G | 1 |
| Distante, S | 1 |
| Piras, L | 2 |
| Frau, G | 2 |
| Terrosu, P | 2 |
| Sannia, L | 3 |
| Dore, L | 2 |
| Carta, G | 1 |
| Ibba, GV | 3 |
| Di Michele, R | 1 |
| Bertoni, PD | 1 |
| Tosetto, C | 1 |
| del Río, A | 1 |
| Ferreira, JI | 1 |
| Ramos, F | 1 |
| Ruiz, C | 1 |
| Bueno, J | 1 |
| Ward, DE | 2 |
| Spurrell, RA | 1 |
| Schmitt, C | 1 |
| Montero, M | 1 |
| Melichercik, J | 1 |
| Ahmad, S | 2 |
| Serrano, CV | 1 |
| Pamplona, D | 1 |
| D'Avila, AL | 1 |
| Amato, RV | 1 |
| Pfeferman, E | 1 |
| Bellotti, G | 1 |
| Konstantinova, TV | 1 |
| Legkonogov, AV | 1 |
| Savchuk, OM | 1 |
| ter Maaten, JC | 1 |
| Strack van Schijndel, RJ | 1 |
| Jukema, GJ | 1 |
| Kerkhof, SC | 1 |
| Williamson, BD | 1 |
| Hummel, J | 1 |
| Niebauer, M | 1 |
| Man, KC | 2 |
| Daoud, E | 1 |
| García Gil, D | 1 |
| Escobar Jiménez, L | 1 |
| Piñero Gálvez, C | 1 |
| Girón González, JA | 1 |
| Hou, ZY | 1 |
| Tu, MS | 1 |
| Lin, SL | 1 |
| Chiang, HT | 1 |
| Woosley, RL | 1 |
| Zarembski, DG | 1 |
| Caruso, AC | 1 |
| Middlekauff, HR | 5 |
| Gornbein, JA | 1 |
| Moro Serrano, C | 1 |
| Hernández Madrid, A | 1 |
| Lage Silveira, J | 1 |
| Vivas Alvarez, E | 1 |
| Kanjhi, M | 1 |
| Lok, NS | 1 |
| Gencel, L | 1 |
| Poquet, F | 1 |
| Gosse, P | 1 |
| Lemétayer, P | 1 |
| Sager, PT | 1 |
| Nademanee, K | 2 |
| McMurray, J | 1 |
| Rankin, A | 1 |
| Andrivet, P | 2 |
| Boubakri, E | 1 |
| Dove, PJ | 1 |
| Mach, V | 2 |
| Vu Ngoc, C | 1 |
| Zehender, M | 4 |
| Just, H | 4 |
| Sung, RJ | 1 |
| Donovan, KD | 1 |
| Power, BM | 1 |
| Hockings, BE | 1 |
| Dobb, GJ | 1 |
| Lee, KY | 1 |
| Pisapia, A | 1 |
| Bine-Scheck, F | 1 |
| Schenowitz, A | 1 |
| Domerego, JJ | 1 |
| Maraud, L | 1 |
| Canler, A | 1 |
| Labban, N | 1 |
| Viart, R | 1 |
| Aubry, P | 1 |
| Beruben, E | 1 |
| Treglia, A | 1 |
| Alfano, C | 1 |
| Terada, Y | 1 |
| Mitsui, T | 1 |
| Yamaguchi, I | 1 |
| Albanesi Filho, FM | 1 |
| Girardi, JM | 1 |
| Castier, MB | 1 |
| Cochrane, AD | 1 |
| Siddins, M | 1 |
| Salamonsen, R | 1 |
| McConaghy, L | 1 |
| Marasco, S | 1 |
| Davis, BB | 1 |
| Klingenheben, T | 1 |
| Faber, TS | 1 |
| Van de Loo, A | 1 |
| Van Mieghem, W | 2 |
| Coolen, L | 1 |
| Malysse, I | 1 |
| Lacquet, LM | 1 |
| Deneffe, GJ | 1 |
| Demedts, MG | 1 |
| Cowan, JC | 2 |
| Manz, M | 1 |
| Wiener, I | 2 |
| Borruat, FX | 1 |
| Regli, F | 1 |
| Unger, J | 2 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 2 |
| Disch, DL | 2 |
| Greenberg, ML | 2 |
| Holzberger, PT | 1 |
| Malenka, DJ | 2 |
| Birkmeyer, JD | 1 |
| Bellandi, F | 1 |
| Cantini, F | 1 |
| Pedone, T | 1 |
| Dabizzi, RP | 1 |
| Palchetti, R | 1 |
| Tarquinii, M | 1 |
| Lolli, C | 1 |
| Foscoli, M | 1 |
| Giofrè, R | 1 |
| Labriola, E | 1 |
| Toschi, GP | 1 |
| Skoularigis, J | 1 |
| Röthlisberger, C | 1 |
| Skudicky, D | 1 |
| Essop, MR | 1 |
| Wisenbaugh, T | 1 |
| Sareli, P | 1 |
| Tisi, G | 1 |
| Baroffio, R | 1 |
| Croce, A | 1 |
| Alves, LE | 1 |
| Rose, EP | 1 |
| Negrini, M | 2 |
| Chapman, MJ | 1 |
| Moran, JL | 1 |
| O'Fathartaigh, MS | 1 |
| Peisach, AR | 1 |
| Cunningham, DN | 1 |
| Follath, F | 1 |
| Frielingsdorf, J | 1 |
| Kerin, NZ | 4 |
| Ansari-Leesar, M | 1 |
| Faitel, K | 4 |
| Narala, C | 1 |
| Frumin, H | 2 |
| Cohen, A | 1 |
| Sanchis, J | 1 |
| Chorro, FJ | 1 |
| López-Merino, V | 1 |
| Burguera, M | 1 |
| Martínez-Mas, ML | 1 |
| Such, L | 1 |
| Gnoc, CV | 1 |
| Naini, M | 1 |
| Di Biasi, P | 1 |
| Scrofani, R | 1 |
| Paje, A | 1 |
| Cappiello, E | 1 |
| Mangini, A | 1 |
| Santoli, C | 1 |
| van 't Hof, AW | 1 |
| Mosterd, A | 1 |
| Suttorp, MJ | 2 |
| Tits, G | 1 |
| Demuynck, K | 1 |
| Lacquet, L | 1 |
| Deneffe, G | 1 |
| Tjandra-Maga, T | 1 |
| Demedts, M | 1 |
| Galve, E | 1 |
| Rius, T | 1 |
| Ballester, R | 1 |
| Artaza, MA | 1 |
| Arnau, JM | 1 |
| García-Dorado, D | 1 |
| Soler-Soler, J | 1 |
| Lee, SH | 4 |
| Chiou, CW | 1 |
| Wen, ZC | 1 |
| Cheng, CC | 1 |
| Frabetti, L | 2 |
| Azzolini, U | 1 |
| Sabbatani, P | 1 |
| Bronzetti, G | 1 |
| Muñoz Ruiz, AI | 1 |
| Calvo Elipe, A | 1 |
| Guerrero Vega, E | 1 |
| Gorgojo Martínez, JJ | 1 |
| Vera López, E | 1 |
| Gilsanz Fernández, C | 1 |
| Spirito, P | 1 |
| Assadi, S | 1 |
| Edoute, Y | 1 |
| Kumar, A | 1 |
| Paniagua Clusells, J | 1 |
| Arcusa Gavalda, R | 1 |
| Goma Masip, F | 1 |
| Pons Masanes, S | 1 |
| Soler Masana, JM | 1 |
| Falcone, RA | 1 |
| Armstrong, WF | 1 |
| Storch, HD | 1 |
| Larbuisson, R | 1 |
| Venneman, I | 1 |
| Stiels, B | 1 |
| Ayers, GM | 2 |
| Rho, TH | 1 |
| Ben-David, J | 1 |
| Besch, HR | 1 |
| Jolobe, OM | 2 |
| Hamilton, MA | 1 |
| Woo, MA | 1 |
| Saxon, LA | 2 |
| Natterson, PD | 1 |
| Steimle, A | 1 |
| Walden, JA | 1 |
| Tillisch, JH | 1 |
| Watanabe, Y | 1 |
| Hara, Y | 1 |
| Tamagawa, M | 1 |
| Nakaya, H | 1 |
| Matiouchine, GV | 1 |
| Shulman, VA | 1 |
| Balog, AI | 1 |
| Bezruk, AP | 1 |
| Golovenkin, SE | 1 |
| Jung, F | 1 |
| Gosselink, AT | 2 |
| van den Berg, MP | 2 |
| de Kam, PJ | 2 |
| van Gilst, WH | 2 |
| Lie, KI | 4 |
| Steinbeck, G | 3 |
| Malaterre, HR | 1 |
| Renou, C | 1 |
| Kallee, K | 1 |
| Gauthier, A | 1 |
| Stanisławska, J | 1 |
| Górecki, A | 1 |
| Swiecicka, G | 1 |
| Kraska, T | 1 |
| Heisel, A | 1 |
| Jung, J | 1 |
| Fries, R | 1 |
| Stopp, M | 1 |
| Sen, S | 1 |
| Schieffer, H | 1 |
| Ozbek, C | 1 |
| Oltrona, L | 1 |
| Broccolino, M | 1 |
| Merlini, PA | 1 |
| Spinola, A | 1 |
| Pezzano, A | 1 |
| Goldstein, I | 1 |
| Topilsky, M | 1 |
| Segev, D | 1 |
| Isakov, A | 1 |
| Heller, I | 1 |
| Winters, SL | 1 |
| Sachs, RG | 1 |
| Curwin, JH | 1 |
| Gonzalez, J | 1 |
| James, PR | 1 |
| Hardman, SM | 1 |
| Leenhardt, A | 1 |
| Thomas, O | 1 |
| Ciampi, A | 1 |
| Cecchi, F | 1 |
| Montereggi, A | 1 |
| Olivotto, I | 1 |
| Marconi, P | 1 |
| Dolara, A | 1 |
| Maron, BJ | 1 |
| Neri, R | 1 |
| Palermo, P | 1 |
| Cesario, AS | 1 |
| Baragli, D | 1 |
| Amici, E | 1 |
| Gambelli, G | 1 |
| López-Mínguez, JR | 1 |
| Merchán Herrera, A | 1 |
| Cimboria Ortega, A | 1 |
| Millán Núñez, V | 1 |
| García-Andoain, JM | 1 |
| Alvarez Suárez-Bárcenas, JM | 1 |
| Martínez de la Concha, L | 1 |
| Fernández de la Concha, J | 1 |
| Alonso Ruiz, F | 1 |
| Daoud, EG | 1 |
| Goyal, R | 1 |
| Deeb, GM | 1 |
| Bolling, SF | 1 |
| Pagani, FD | 1 |
| Bitar, C | 1 |
| Meissner, MD | 1 |
| Bart, BIa | 1 |
| Mamtsev, BN | 1 |
| Larin, VG | 1 |
| Smirnova, OL | 1 |
| Galenko-Iaroshevskiĭ, PA | 1 |
| Kryzhanovskiĭ, SA | 1 |
| Uvarov, AV | 1 |
| Turovaia, AIu | 1 |
| Popov, PB | 1 |
| Khankoeva, AI | 1 |
| Haerynck, F | 1 |
| Jordaens, L | 1 |
| Müller, M | 1 |
| Schima, W | 1 |
| Weissel, M | 2 |
| Escudero, EM | 1 |
| San Mauro, M | 1 |
| Lauglé, C | 1 |
| McCullough, PA | 2 |
| Redle, JD | 2 |
| Zaman, AG | 1 |
| Archbold, A | 1 |
| Alamgir, F | 1 |
| Ulahannan, TJ | 1 |
| Solomou, MC | 2 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 2 |
| Martins, V | 1 |
| Brunini, TM | 1 |
| Linhatti, JL | 1 |
| Brauner, FB | 1 |
| Pires, RC | 1 |
| Feng, AN | 2 |
| Kuo, BI | 1 |
| Drent, M | 1 |
| Cobben, NA | 1 |
| Van Dieijen-Visser, MP | 1 |
| Braat, SH | 1 |
| Wouters, EF | 1 |
| Hutcheson, J | 1 |
| Peters, CA | 1 |
| Diamond, DA | 1 |
| Wang, YX | 2 |
| Zheng, YM | 2 |
| Tan, YH | 2 |
| Sheng, BH | 2 |
| Douchet, MP | 1 |
| Barsotti, P | 1 |
| Schneeberger, M | 1 |
| Bauer, C | 1 |
| Massard, G | 1 |
| Wihlm, JM | 1 |
| Humphries, JO | 1 |
| Bello, D | 1 |
| Massie, BM | 1 |
| Antón Aranda, E | 1 |
| Alkiza Basañez, R | 1 |
| Laplaza Jiménez, Y | 1 |
| Clerico, A | 1 |
| Bonini, R | 1 |
| Nannipieri, M | 1 |
| Manfredi, C | 1 |
| Sabatino, L | 1 |
| Biagini, A | 1 |
| Donato, L | 1 |
| Botto, G | 1 |
| Broffoni, T | 1 |
| Ongari, M | 1 |
| Trisolino, G | 2 |
| Rubino, I | 1 |
| Sanguinetti, M | 1 |
| Simantirakis, EN | 4 |
| Parthenakis, FI | 2 |
| Mezilis, NE | 1 |
| Ellenbogen, K | 1 |
| Fisher, S | 1 |
| Fletcher, R | 1 |
| Ameneiros Lago, E | 1 |
| González Moraleja, J | 1 |
| Carballada Rico, C | 1 |
| Sesma Sánchez, P | 1 |
| Sarubbi, B | 1 |
| Ducceschi, V | 1 |
| D'Andrea, A | 1 |
| Liccardo, B | 1 |
| Santangelo, L | 1 |
| Iacono, A | 1 |
| Toscano, S | 1 |
| Altamura, G | 1 |
| Jesi, AP | 1 |
| Villani, M | 1 |
| Scianaro, MC | 1 |
| Mehdirad, AA | 1 |
| Clem, KL | 1 |
| Love, CJ | 1 |
| Nelson, SD | 1 |
| Schaal, SF | 1 |
| Schreckengost, VE | 1 |
| Cohen, DJ | 1 |
| Love, D | 1 |
| Laham, R | 1 |
| Kaleboubas, MD | 3 |
| Banasiak, W | 1 |
| Telichowski, A | 1 |
| Anker, SD | 1 |
| Kalka, D | 1 |
| Molenda, W | 1 |
| Reczuch, K | 1 |
| Adamus, J | 1 |
| Coats, AJ | 1 |
| Cherednik, IL | 1 |
| Sheĭkh-Zade, IuR | 1 |
| Noble, SL | 1 |
| Replogle, WH | 1 |
| Dickey, SR | 1 |
| Carrel, T | 1 |
| Meyer, B | 1 |
| Turina, M | 1 |
| Khurana, S | 1 |
| Marzan, R | 1 |
| Stewart, JR | 1 |
| Westveer, DC | 1 |
| O'Neill, WW | 1 |
| Bassett, JS | 1 |
| Tepe, NA | 1 |
| Frumin, HI | 1 |
| Merkely, B | 2 |
| Tenczer, J | 1 |
| Papp, L | 1 |
| Karlócai, K | 1 |
| Barry, JJ | 1 |
| Franklin, K | 1 |
| Guarnieri, T | 3 |
| Nolan, S | 1 |
| Gottlieb, SO | 1 |
| Dudek, A | 1 |
| Lowry, DR | 1 |
| Levy, T | 1 |
| Walker, S | 2 |
| Rochelle, J | 1 |
| Paul, V | 1 |
| Tuinenburg, AE | 1 |
| Brügemann, J | 1 |
| Blommaert, D | 1 |
| De Roy, L | 1 |
| Adam, JF | 1 |
| Jamart, J | 1 |
| Mucumbitsi, J | 1 |
| Brosch, S | 1 |
| Johannsen, HS | 1 |
| Kreiss, Y | 1 |
| Sidi, Y | 1 |
| Gur, H | 1 |
| Richerson, M | 1 |
| Freeman-Bosco, L | 2 |
| Chow, MS | 1 |
| Mody, FV | 1 |
| Sarma, JS | 1 |
| Blanc, JJ | 1 |
| Voinov, C | 1 |
| Maarek, M | 1 |
| Susano, R | 1 |
| Caminal, L | 1 |
| Ramos, D | 1 |
| Díaz, B | 1 |
| Shah, DC | 1 |
| Cotter, G | 1 |
| Blatt, A | 1 |
| Kaluski, E | 1 |
| Metzkor-Cotter, E | 1 |
| Koren, M | 1 |
| Litinski, I | 1 |
| Simantov, R | 1 |
| Moshkovitz, Y | 1 |
| Zaidenstein, R | 1 |
| Peleg, E | 1 |
| Vered, Z | 1 |
| Golik, A | 1 |
| Katariya, K | 1 |
| DeMarchena, E | 1 |
| Bolooki, H | 1 |
| Chen, CC | 1 |
| Hsu, TL | 1 |
| Proença, G | 1 |
| Caetano, F | 1 |
| Silvestre, I | 1 |
| Cardoso, P | 1 |
| Segurado, F | 1 |
| Forjaz, A | 1 |
| Aschieri, D | 1 |
| Rosi, A | 1 |
| Piepoli, MF | 2 |
| Kaufmann, R | 1 |
| Bartolucci, J | 1 |
| Ibáñez, P | 1 |
| Verdugo, C | 1 |
| Fuentes, R | 1 |
| Arriagada, G | 1 |
| Torres, J | 1 |
| Kramer, MJ | 1 |
| Ide, B | 1 |
| Drew, BJ | 1 |
| Endoh, Y | 2 |
| Hanai, R | 2 |
| Uto, K | 2 |
| Uno, M | 1 |
| Nagashima, H | 1 |
| Takizawa, T | 1 |
| Narimatsu, A | 1 |
| Ohnishi, S | 2 |
| Kasanuki, H | 3 |
| Peuhkurinen, K | 1 |
| Niemelä, M | 1 |
| Ylitalo, A | 1 |
| Linnaluoto, M | 1 |
| Lilja, M | 1 |
| Juvonen, J | 1 |
| Rankin, AC | 1 |
| Kus, T | 1 |
| Gagné, P | 2 |
| Berkman, M | 1 |
| Stolarz, P | 1 |
| Dawidowska, R | 1 |
| Kołodziej, P | 1 |
| Stopiński, M | 1 |
| Achremczyk, P | 1 |
| Lewandowski, Z | 1 |
| Geelen, P | 1 |
| Reithmann, C | 2 |
| Spitzlberger, G | 1 |
| Dorwarth, U | 2 |
| Gerth, A | 2 |
| Remp, T | 2 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Alpert, MA | 1 |
| Tsatsakis, AM | 1 |
| Joseph, AP | 1 |
| Ward, MR | 1 |
| Dörge, H | 1 |
| Schoendube, FA | 1 |
| Schoberer, M | 1 |
| Stellbrink, C | 1 |
| Voss, M | 1 |
| Messmer, BJ | 1 |
| Nielsen, KD | 1 |
| Møller, S | 1 |
| Yamreudeewong, W | 1 |
| McIntyre, WW | 1 |
| Sun, TJ | 1 |
| Ranelli, PL | 1 |
| Chang, CM | 1 |
| Lu, MJ | 1 |
| Lee, RJ | 1 |
| Cheng, JJ | 1 |
| Hung, CR | 1 |
| DeSimone, KL | 1 |
| Bianconi, L | 3 |
| Dinelli, M | 1 |
| Alboni, P | 2 |
| Pappalardo, A | 1 |
| Richiardi, E | 1 |
| Weinfeld, MS | 1 |
| Drazner, MH | 1 |
| Boutros, NY | 1 |
| Dilly, S | 1 |
| Bevan, DH | 1 |
| Terracciano, C | 1 |
| Cellarier, G | 1 |
| Deharo, JC | 1 |
| Chalvidan, T | 1 |
| Savon, N | 1 |
| Barra, N | 1 |
| Roux, O | 1 |
| Djiane, P | 1 |
| Aggarwal, A | 1 |
| Furmaga, EM | 1 |
| Good, CB | 1 |
| Odeh, M | 1 |
| Seligmann, H | 1 |
| Oliven, A | 1 |
| Toft, AD | 1 |
| Boon, NA | 1 |
| Ahle, GB | 1 |
| Blum, AL | 1 |
| Martinek, J | 1 |
| Oneta, CM | 1 |
| Dorta, G | 1 |
| Paquette, M | 2 |
| Couturier, A | 2 |
| Yang, C | 1 |
| Martínez-Marcos, FJ | 1 |
| García-Garmendia, JL | 1 |
| Ortega-Carpio, A | 1 |
| Fernández-Gómez, JM | 1 |
| Santos, JM | 1 |
| Camacho, C | 1 |
| Cioffi, G | 1 |
| Cemin, C | 1 |
| Russo, TE | 1 |
| Pellegrini, A | 1 |
| Terrasi, F | 1 |
| Ferrario, G | 1 |
| Forney, AJ | 1 |
| Schooff, M | 1 |
| Treggiari-Venzi, MM | 1 |
| Waeber, JL | 1 |
| Perneger, TV | 1 |
| Suter, PM | 1 |
| Adamec, R | 1 |
| Romand, JA | 1 |
| Spindler, B | 1 |
| Kaufmann, C | 1 |
| Cron, TA | 1 |
| Meier, C | 1 |
| Staub, JJ | 1 |
| Oberholzer, M | 1 |
| Osswald, S | 1 |
| Gutknecht, DR | 1 |
| Van Noord, T | 1 |
| Schoonderwoerd, BA | 1 |
| Guillemare, E | 1 |
| Marion, A | 1 |
| Nisato, D | 1 |
| Gautier, P | 1 |
| Pinter, A | 1 |
| Cattaneo, F | 1 |
| Chrysostomakis, SI | 2 |
| Li, YG | 1 |
| Tanaka, T | 1 |
| Ohta, Y | 1 |
| Klein, I | 1 |
| Ojamaa, K | 1 |
| Barbosa, PR | 1 |
| Boghossian, SH | 1 |
| da Rocha, PJ | 1 |
| Filho, FM | 1 |
| Vágó, H | 1 |
| Szabolcs, Z | 1 |
| Moravcsik, E | 1 |
| Gellér, L | 1 |
| Szabó, T | 1 |
| Turbók, E | 1 |
| Matkó, I | 1 |
| Bodor, E | 1 |
| Glatter, K | 1 |
| Chatterjee, K | 1 |
| Modin, G | 1 |
| Cheng, J | 1 |
| Kayser, S | 1 |
| Scheinman, MM | 2 |
| Knobloch, K | 1 |
| Gillis, AM | 1 |
| Lacomb, P | 1 |
| Philippon, F | 1 |
| Kimber, S | 1 |
| Gardner, MJ | 1 |
| Molin, F | 1 |
| Louis, R | 1 |
| Kassab, A | 1 |
| Soyeur, D | 1 |
| Dunn, AB | 2 |
| Wilcox, HA | 1 |
| Bharat, V | 1 |
| Mohanty, B | 1 |
| Harrison, RA | 1 |
| Liratsopulos, G | 1 |
| Maras, D | 1 |
| Bosković, SD | 1 |
| Popović, Z | 1 |
| Nesković, AN | 1 |
| Kovacević, S | 1 |
| Otasević, P | 1 |
| Marinković, J | 1 |
| Vuk, L | 1 |
| Borzanović, M | 1 |
| Nastasić, S | 1 |
| Jovanović, T | 1 |
| Bojić, M | 1 |
| Babić, R | 1 |
| Popović, AD | 1 |
| Nkomo, VT | 1 |
| Shen, WK | 2 |
| Groneberg, DA | 1 |
| Barkhuizen, A | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Neunteufl, T | 1 |
| Priglinger, U | 1 |
| Haumer, M | 1 |
| Gschwandtner, M | 1 |
| Siostrzonek, P | 1 |
| Heinz, G | 1 |
| Hancock, EW | 1 |
| Lazzeri, C | 1 |
| Bagliani, G | 1 |
| Colella, A | 1 |
| Sabini, A | 1 |
| Zipoli, R | 1 |
| Costoli, A | 1 |
| Pieragnoli, P | 1 |
| Franchi, F | 1 |
| Brilakis, ES | 1 |
| Friedman, PA | 1 |
| Tahapary, GJ | 1 |
| Routledge, HC | 1 |
| Nuttall, SL | 1 |
| Kendall, MJ | 1 |
| Kerin, IA | 1 |
| Quinones, L | 1 |
| Stomel, RJ | 1 |
| Lee, TH | 1 |
| Sloan, SB | 1 |
| Weitz, HH | 1 |
| Harahsheh, BS | 1 |
| Sawalha, WA | 1 |
| Kontoyannis, DA | 1 |
| Anastasiou-Nana, MI | 1 |
| Kontoyannis, SA | 1 |
| Zaga, AK | 1 |
| Nanas, JN | 1 |
| Katz, NM | 1 |
| Balser, JR | 1 |
| Gallagher, ME | 1 |
| Morewood, GH | 1 |
| Garcia, JP | 1 |
| Furukawa, S | 1 |
| Jeantet, M | 1 |
| Losay, J | 1 |
| Cassinat, G | 1 |
| Andral, J | 1 |
| Guize, L | 1 |
| de Pouvourville, G | 1 |
| Stamou, SC | 1 |
| Hill, PC | 1 |
| Sample, GA | 1 |
| Snider, E | 1 |
| Pfister, AJ | 1 |
| Lowery, RC | 1 |
| Corso, PJ | 1 |
| Maisel, WH | 1 |
| Rawn, JD | 1 |
| Cox, CD | 1 |
| Dernellis, J | 1 |
| Panaretou, M | 1 |
| Spinler, SA | 1 |
| Doggrell, SA | 1 |
| Tokmakoglu, H | 1 |
| Kandemir, O | 1 |
| Gunaydin, S | 1 |
| Catav, Z | 1 |
| Yorgancioglu, C | 1 |
| Zorlutuna, Y | 1 |
| Skalidis, EI | 1 |
| Kalebubas, MD | 1 |
| Rachwal, W | 1 |
| McHale, C | 1 |
| Bruckman, D | 1 |
| Decena, BF | 1 |
| Russman, P | 1 |
| Eagle, KA | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Haan, CK | 1 |
| Geraci, SA | 1 |
| Menozzi, C | 1 |
| Bongiorni, MG | 1 |
| Ometto, R | 1 |
| Bruna, C | 1 |
| Vincenti, A | 1 |
| Blackman, DJ | 1 |
| Ferguson, JD | 1 |
| Wakaumi, M | 1 |
| Imai, T | 1 |
| Hosaka, F | 1 |
| Matsuda, N | 1 |
| Shoda, M | 1 |
| Sugiura, R | 1 |
| Hagiwara, N | 1 |
| Lardinois, D | 1 |
| Handschin, A | 1 |
| Weder, W | 1 |
| Hebbar, AK | 1 |
| Hueston, WJ | 1 |
| Krahn, A | 1 |
| Skanes, AC | 1 |
| Lumer, GB | 1 |
| Frasure-Smith, N | 1 |
| Sleik, K | 1 |
| Ginger, TJ | 1 |
| Somlói, M | 1 |
| Horváth, L | 1 |
| Lavallée, J | 1 |
| Flammang, D | 1 |
| Slama, R | 3 |
| Donaldson, RM | 1 |
| Kuznetsov, KK | 1 |
| Waleffe, A | 1 |
| Bruninx, P | 1 |
| Kulbertus, HE | 1 |
| Demoulin, JC | 1 |
| Legrand, V | 1 |
| Bracchetti, D | 2 |
| De Garaté, S | 1 |
| Di Ciò, G | 1 |
| Carini, G | 2 |
| Chamberlain, DA | 1 |
| Clark, AN | 1 |
| Aros, F | 1 |
| Valles, V | 1 |
| Alegria, E | 1 |
| Loma-Osorio, A | 1 |
| Malpartida, F | 1 |
| Ghini, V | 1 |
| Greco, R | 1 |
| Musto, B | 1 |
| De Martino, U | 1 |
| Marsico, F | 1 |
| Ferrero, C | 1 |
| Bär, FW | 1 |
| Wesdorp, JC | 1 |
| Dohmen, HJ | 1 |
| Düren, DR | 1 |
| Durrer, D | 1 |
| Kaufmann, G | 1 |
| Herre, JM | 2 |
| Shakespeare, CF | 1 |
| Keeling, PJ | 1 |
| Slade, AK | 1 |
| Fouchard, J | 1 |
| Le, F | 1 |
| Py, A | 1 |
| Guérin, F | 1 |
| Denisiuk, VI | 1 |
| Lipnitskiĭ, TN | 2 |
| Kotsuta, GI | 2 |
| Pilipchuk, VP | 2 |
| Stepaniuk, AV | 1 |
| Osiadlaia, ES | 1 |
| Arstall, MA | 1 |
| Hii, JT | 1 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Lauribe, P | 1 |
| Dolla, E | 1 |
| Kou, W | 1 |
| Kadish, A | 1 |
| Pagannelli, F | 1 |
| Moyal, C | 1 |
| Bremondy, M | 1 |
| Schork, A | 1 |
| Dabrowski, A | 1 |
| Sandler, M | 1 |
| Fomina, IG | 1 |
| Iankin, VV | 1 |
| Chouty, F | 2 |
| Denjoy, I | 1 |
| Müller, B | 1 |
| Villani, R | 1 |
| Zoletti, F | 1 |
| Veniani, M | 1 |
| Locati, F | 1 |
| Nava, S | 1 |
| Labate, FD | 1 |
| Borghi, M | 1 |
| Kato, K | 1 |
| Vietti-Ramus, G | 1 |
| Veglio, F | 3 |
| Marchisio, U | 2 |
| Burzio, P | 2 |
| Georges, JL | 1 |
| Normand, JP | 1 |
| Lenormand, ME | 1 |
| Schwob, J | 1 |
| Hillige, H | 1 |
| Lenzi, T | 1 |
| Binetti, N | 1 |
| Cavazza, M | 1 |
| Fontana, G | 1 |
| Tomaselli, G | 1 |
| Griffith, LS | 1 |
| Brinker, J | 1 |
| Alekseevskaia, MA | 2 |
| Maevskaia, IV | 2 |
| Zykova, TA | 1 |
| Miroliubova, OA | 1 |
| Kyrkalova, NE | 1 |
| Mileĭko, OS | 1 |
| Tkachev, AV | 1 |
| Ramus, GV | 1 |
| Bonino, ML | 2 |
| Tonda, L | 1 |
| Vietti Ramus, G | 1 |
| Bigo, P | 1 |
| Leopaldi, D | 1 |
| Ricco, G | 1 |
| Syrkin, AL | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Gilligan, DM | 1 |
| Missouris, CG | 1 |
| Boyd, MJ | 1 |
| Dammbacher, T | 1 |
| Steiert, K | 1 |
| Jähnchen, E | 1 |
| Fraedrich, G | 1 |
| Strasberg, B | 2 |
| Kalantzis, N | 1 |
| Gabriel, P | 1 |
| Mouzas, J | 1 |
| Tiniakos, D | 1 |
| Tsigas, D | 1 |
| Tiniakos, G | 1 |
| Blackshear, JL | 1 |
| Randle, HW | 1 |
| Politi, G | 1 |
| Romanini, B | 1 |
| Tos, M | 1 |
| Pucci, C | 1 |
| Rescalli, S | 1 |
| Ferro, C | 1 |
| Noc, M | 1 |
| Stajer, D | 1 |
| Horvat, M | 1 |
| McAlister, HF | 1 |
| Luke, RA | 1 |
| Whitlock, RM | 1 |
| Smith, WM | 2 |
| Kushakovskiĭ, MS | 1 |
| Rebrova, GA | 1 |
| Mostow, ND | 1 |
| Vrobel, TR | 1 |
| Noon, D | 1 |
| Rakita, L | 1 |
| Novikov, ID | 1 |
| Bauernfeind, RA | 1 |
| Welch, WJ | 1 |
| Robinson, K | 2 |
| Frenneaux, MP | 1 |
| Stockins, B | 1 |
| Karatasakis, G | 1 |
| Poloniecki, JD | 1 |
| Greenspan, AM | 2 |
| Gligan, LI | 1 |
| Ol', IV | 1 |
| Shmeleva, LA | 1 |
| Gibelli, G | 1 |
| De Ponti, C | 1 |
| Yapa, RS | 1 |
| Green, GJ | 1 |
| Lwakatare, JM | 1 |
| Morris-Jones, S | 1 |
| Knight, EJ | 1 |
| Zukerman, C | 1 |
| Hubsch, JP | 1 |
| Dumouchel, A | 1 |
| Debesse, B | 1 |
| Haines, DE | 1 |
| Lerman, BB | 1 |
| Fisher, JD | 1 |
| Kim, SG | 1 |
| Waspe, LE | 1 |
| Johnston, DR | 1 |
| Kiseleva, LN | 1 |
| Nekrasova, LF | 1 |
| Best, JF | 1 |
| Rinkenberger, R | 1 |
| Lynch, L | 1 |
| Dunn, M | 1 |
| Piwowarska, W | 1 |
| Sniezek-Maciejewska, M | 1 |
| Johnston, A | 1 |
| Mulrow, JP | 1 |
| Holt, DW | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Cantor, J | 1 |
| Mahaim, C | 1 |
| Jorens, PG | 1 |
| van den Heuvel, PA | 1 |
| Ranquin, RE | 1 |
| van den Branden, FA | 1 |
| Parizel, GA | 1 |
| Tuzcu, EM | 1 |
| Gilbo, J | 1 |
| Masterson, M | 1 |
| Maloney, JD | 1 |
| Reĭngardene, DI | 1 |
| Mattioni, TA | 1 |
| Zheutlin, TA | 1 |
| Sarmiento, JJ | 1 |
| Parker, M | 1 |
| Lesch, M | 1 |
| Vorob'ev, LP | 1 |
| Kaziulin, AN | 1 |
| Lewis, R | 1 |
| McClay, J | 1 |
| Bayés de Luna, A | 1 |
| Oter, MC | 1 |
| Guindo, J | 1 |
| Beaufils, P | 1 |
| Bizot, J | 1 |
| Nazarian, SM | 1 |
| Jay, WM | 1 |
| Tsialtas, D | 1 |
| Ghiringhelli, S | 1 |
| Cozzi, E | 1 |
| Glisenti, F | 1 |
| Straneo, U | 1 |
| Chittolini, L | 1 |
| Straneo, G | 1 |
| Vomácka, Z | 1 |
| Válka, L | 1 |
| Gardiner, P | 1 |
| Reid, DS | 1 |
| Newell, DJ | 1 |
| Campbell, RW | 1 |
| Tonet, JL | 1 |
| Bernardeau, C | 1 |
| Lechat, P | 1 |
| Touzet, I | 1 |
| McCarthy, ST | 1 |
| McCarthy, GL | 1 |
| Chadwick, D | 1 |
| Wollner, L | 1 |
| Benbow, LJ | 1 |
| Leach, C | 1 |
| Bailey, RJ | 1 |
| Saoudi, N | 1 |
| Berland, J | 1 |
| Cribier, A | 1 |
| Letac, B | 1 |
| Anastasio, R | 1 |
| Facchin, L | 1 |
| Gualandi, G | 1 |
| Zannini, L | 1 |
| Caturelli, G | 1 |
| Mirchev, V | 1 |
| Sauve, MJ | 1 |
| Blevins, RD | 1 |
| Benaderet, D | 1 |
| Jarandilla, R | 1 |
| Rubenfire, M | 1 |
| Friehling, TD | 1 |
| Marinchak, RA | 1 |
| Sulpizi, AM | 1 |
| Stohler, JL | 1 |
| Feld, GK | 1 |
| Stevenson, W | 1 |
| Weiss, J | 1 |
| Klitzner, T | 1 |
| Cauchie, P | 1 |
| Decaux, G | 1 |
| Peters, KG | 1 |
| Kienzle, MG | 1 |
| Gudim, EV | 1 |
| Castellaccio, M | 1 |
| Scorcu, PP | 1 |
| Gubelli, S | 1 |
| Jacobs, MB | 1 |
| Perelman, MS | 1 |
| Cañas, M | 1 |
| Rosselot, I | 1 |
| Bahamonde, L | 1 |
| Rosselot, E | 1 |
| Lukl, J | 3 |
| Heinc, P | 3 |
| Cernosek, B | 3 |
| Huang, ZD | 1 |
| Deng, HF | 1 |
| Zhang, BX | 1 |
| Schützenberger, W | 1 |
| Gmeiner, R | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Walker, CJ | 1 |
| Casey, TP | 1 |
| Luckett, CR | 1 |
| Henry, WL | 1 |
| Brown, MA | 1 |
| Norris, RM | 1 |
| Liu, PH | 1 |
| Lin, CC | 1 |
| Ko, GC | 1 |
| Wang, DJ | 1 |
| Shieh, SM | 1 |
| Sung, PK | 1 |
| Gold, RL | 1 |
| Haffajee, CI | 1 |
| Charos, G | 1 |
| Sloan, K | 1 |
| Baker, S | 1 |
| Alpert, JS | 1 |
| Rezácová, M | 2 |
| Escoubet, B | 1 |
| Poirier, JM | 1 |
| Maison-Blanche, P | 1 |
| Jaillon, P | 1 |
| Menasche, P | 1 |
| Cheymol, G | 1 |
| Piwnica, A | 1 |
| Lagier, G | 1 |
| Holt, P | 1 |
| Crick, JC | 1 |
| Davies, DW | 1 |
| Curry, P | 1 |
| Clarke, B | 1 |
| Honey, M | 1 |
| Kumana, CR | 1 |
| Tanser, P | 1 |
| Eydt, J | 1 |
| Penn, IM | 1 |
| Barrett, PA | 1 |
| Pannikote, V | 1 |
| Barnaby, PF | 1 |
| Campbell, JB | 1 |
| Lyons, NR | 1 |
| Bencini, PL | 1 |
| Crosti, C | 1 |
| Sala, F | 1 |
| Bertani, E | 1 |
| Nobili, M | 1 |
| Storelli, A | 1 |
| Andriulo, C | 1 |
| Chisena, A | 1 |
| De Giorgi, M | 1 |
| De Giorgio, NA | 1 |
| Gallone, V | 1 |
| Guadalupi, M | 1 |
| Lupis, O | 1 |
| Nadovezza, S | 1 |
| Tarentini, A | 1 |
| Arditti, A | 1 |
| Sclarovsky, S | 1 |
| Lewin, RF | 1 |
| Buimovici, B | 1 |
| Agmon, J | 1 |
| Horowitz, LN | 1 |
| Spielman, SR | 1 |
| Mintz, GS | 1 |
| Morganroth, J | 1 |
| Brown, R | 1 |
| Brady, PM | 1 |
| Kay, HR | 1 |
| Petelenz, T | 1 |
| Jastrzebska, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)[NCT00259428] | Phase 3 | 615 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)[NCT00259376] | Phase 3 | 629 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Assessment of Intra-Operative Atrial Fibrillation Inducibility As a Screening Tool to Prevent Post-Operative Atrial Fibrillation With Prophylaxis Amiodarone[NCT03868150] | Phase 4 | 600 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF.[NCT01140581] | Phase 4 | 402 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Re[NCT01199081] | Phase 4 | 154 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation[NCT04392921] | 80 participants (Anticipated) | Interventional | 2022-03-07 | Recruiting | |||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Association of Postoperative Lactate Levels With Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Graft Surgery[NCT05448521] | 250 participants (Anticipated) | Observational | 2022-08-15 | Recruiting | |||
| Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial[NCT05076019] | 266 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial[NCT05062239] | 100 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | |||
| A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery[NCT05780320] | 242 participants (Anticipated) | Observational | 2022-09-19 | Active, not recruiting | |||
| Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation[NCT05656170] | 0 participants (Actual) | Interventional | 2023-10-01 | Withdrawn (stopped due to Unable to begin study) | |||
| Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery[NCT05543278] | Phase 4 | 242 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: a Prospective, Controlled, Randomized Pilot Study[NCT02889562] | Phase 2/Phase 3 | 56 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences[NCT03162120] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)) | ||
| Ultrasound-assessed Internal Jugular Vein Distensibility to Predict Right Atrial Pressure and Other Hemodynamic Parameters in Patients With Advanced Chronic Heart Failure[NCT03874312] | 200 participants (Anticipated) | Observational | 2017-10-18 | Active, not recruiting | |||
| A Prospective Study Using Intra-Pericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation (POAF) in Patients Undergoing Cardiac Arterial Bypass Grafting and/or Valve Surgery[NCT06063538] | Early Phase 1 | 63 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion[NCT01991119] | 98 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation (ICM REDUCE-AF)[NCT04922281] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-02-28 | Recruiting | ||
| A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors[NCT01151137] | Phase 3 | 3,236 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to The study was stopped because of safety concerns) | ||
| Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation[NCT01173809] | Phase 3 | 176 participants (Anticipated) | Interventional | 2010-10-31 | Completed | ||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation[NCT01522651] | Phase 2 | 134 participants (Actual) | Interventional | 2012-01-24 | Completed | ||
| Anti-Arrhythmic Medication (Amiodarone) Post Surgical Ablation for Atrial Fibrillation - Is it Necessary?[NCT01416935] | 186 participants (Actual) | Interventional | 2011-01-01 | Terminated | |||
| A Prospective Pilot Study of the Combination of CardiaMend and Amiodarone for the Prevention of Postoperative Atrial Fibrillation (POAF) in Patients Undergoing Isolated Cardiac Arterial Bypass Grafting or Isolated Valve Surgery (CAMP POAF)[NCT05681182] | Phase 4 | 30 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Telemedicine Enabling Patients in Self-care Behaviors[NCT04297735] | 60 participants (Actual) | Interventional | 2020-02-26 | Completed | |||
| Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD[NCT00729911] | Phase 4 | 203 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| The Efficacy and Safety of Left Atrial Appendage Closure in Combination With Catheter Ablation in Patients With Atrial Fibrillation[NCT03788941] | 1,200 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction Before and After Ablation of Atrial Fibrillation[NCT05376748] | 34 participants (Anticipated) | Observational | 2022-04-15 | Recruiting | |||
| Trial of New Oral Anticoagulants vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation[NCT03702582] | Phase 3 | 100 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation[NCT02132767] | Phase 3 | 523 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial[NCT00597077] | Phase 4 | 1,376 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO)[NCT00697086] | Phase 3 | 174 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life[NCT00392431] | 220 participants | Interventional | 2003-01-31 | Completed | |||
| Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence Post Ablation: The EDORA Trial[NCT04704050] | Phase 4 | 22 participants (Actual) | Interventional | 2021-05-15 | Terminated (stopped due to Sponsor withdrew funding) | ||
| Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery[NCT00127712] | Phase 4 | 130 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft, A Prospective Double-Blind Randomized Study[NCT00654290] | 240 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| New Causes and Predictors for the Development of Atrial Fibrillation and Its Complications[NCT01863979] | 500 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Prevention of Atrial Fibrillation Following Thoracoabdominal Esophagectomy Surgery[NCT00420017] | Phase 4 | 80 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrill[NCT00489736] | Phase 3 | 504 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence[NCT00376272] | Phase 3 | 1,442 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery[NCT00784316] | Phase 4 | 316 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Evaluating the Efficacy of Circumferential Pulmonary Vein Ablation (CPVA) Versus Segmental Pulmonary Vein Isolation (SPVI) in Paroxysmal Atrial Fibrillation[NCT02106663] | 97 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation[NCT00668759] | Phase 3 | 254 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation[NCT01447862] | Phase 4 | 101 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients[NCT04748991] | Phase 3 | 50 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.[NCT01198275] | Phase 3 | 199 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Rapid Atrial Fibrillation Treatment Strategy[NCT04092621] | Phase 4 | 40 participants (Anticipated) | Interventional | 2019-09-16 | Not yet recruiting | ||
| Long-term Recurrence Rates of Atrial Fibrillation Following New-onset Atrial Fibrillation During ICU Admission[NCT05151523] | 100 participants (Anticipated) | Observational [Patient Registry] | 2022-01-01 | Not yet recruiting | |||
| A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease[NCT03013257] | 240 participants (Actual) | Interventional | 2017-04-25 | Completed | |||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| International Registry on Cardioversion of Atrial Fibrillation[NCT01119716] | 4,658 participants (Actual) | Observational | 2010-05-31 | Completed | |||
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| [NCT00224341] | Phase 4 | 360 participants | Interventional | 2003-11-30 | Recruiting | ||
| Risk Factors That Contribute to the Maintenance of Sinus Rhythm: A Prospective Study to Create a Prediction Model for Atrial Fibrillation Patients to Maintain Sinus Rhythm.[NCT04655443] | 77 participants (Actual) | Observational | 2017-08-29 | Terminated (stopped due to due to COVID-19) | |||
| Atrial Fibrillation Lifestyle Project[NCT03724383] | 80 participants (Anticipated) | Interventional | 2018-09-06 | Recruiting | |||
| Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial[NCT02509754] | Phase 4 | 180 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation[NCT00007605] | Phase 3 | 706 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting[NCT00338715] | Phase 3 | 193 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Catheter Ablation vs. Medical Therapy in Congested Hearts With AF (CATCH-AF in Patients With Impaired LV Function): An Early Ablation Strategy Study Impact on Health Care Utilization[NCT02686749] | Phase 4 | 220 participants (Anticipated) | Interventional | 2016-06-30 | Terminated (stopped due to lack of enrollment) | ||
| Norwegian Randomized Study of Persistent Atrial Fibrillation Treatment: Cryoballoon Versus Radiofrequency Catheter Ablation (NO PERS-AF)[NCT03008811] | 101 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| Effect of Venous Cannulation Technique on the Incidence of Post-operative Atrial Fibrillation in Patients Undergoing Elective Coronary Artery Bypass Grafting. A Pilot Randomized Controlled Trial.[NCT04641611] | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | |||
| Double Sequence External Defibrillation: A Randomized Controlled Trial in Patients With Atrial Fibrillation Refractory to DC Cardioversion[NCT03827915] | 100 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide[NCT03005366] | Phase 4 | 50 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF[NCT00514735] | Phase 3 | 210 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Multi-catheter Cryotherapy Versus Radiofrequency Catheter Ablation for the Treatment of Standard and Resistant Arrhythmias[NCT03816033] | 600 participants (Anticipated) | Interventional | 2018-06-01 | Recruiting | |||
| SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI[NCT01182376] | Phase 3 | 33 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| Circumferential vs Ganglionated Plexi Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Study[NCT00671905] | 150 participants (Anticipated) | Interventional | 2008-05-31 | Completed | |||
| A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.[NCT02614521] | 0 participants (Actual) | Observational | 2017-01-31 | Withdrawn | |||
| A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial[NCT00340314] | Phase 4 | 198 participants | Interventional | 2005-01-31 | Completed | ||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism[NCT02467244] | 120 participants (Actual) | Observational | 2017-02-01 | Completed | |||
| Transcutaneous (Tragus) Vagal Nerve Stimulation (tVNS) for Post-op Atrial Fibrillation (POAF)[NCT04514757] | 266 participants (Anticipated) | Interventional | 2021-09-20 | Recruiting | |||
| Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving an Amniotic Membrane Patch Placed on the Epicardial Surface[NCT02193321] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2014-07-31 | Withdrawn | ||
| Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients[NCT04539158] | 200 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
Efficacy will be measured by the freedom from stroke during the study period. Events relating to stroke will be adjudicated using pre-determined definitions by independent committee members that remain blinded to the patient's treatment arm. (NCT02889562)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Efficacy will be measured by the freedom from thromboembolytic events during the study period. Events relating to thromboembolytic events will be adjudicated using pre-determined definitions by independent committee members that remain blinded to the patient's treatment arm. (NCT02889562)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Time in therapeutic range of INR, if on warfarin, (eg. 2-3), measured as a percentage and defined for each patient using the Rosendaal equation (NCT02889562)
Timeframe: 30 days
| Intervention | percentage (Mean) |
|---|---|
| Warfarin | 56.8 |
This will be measured from the date/time of the end of the subject's surgery until the date/time of the patient's discharge from the hospital. This will be measured in hours, to the nearest tenth of an hour. (NCT02889562)
Timeframe: 30 days
| Intervention | hours (Mean) |
|---|---|
| Apixaban | 167.5 |
| Warfarin | 143.1 |
Units of blood or blood products given after the first dose of anticoagulation. (NCT02889562)
Timeframe: 30 days
| Intervention | total units of blood (Number) |
|---|---|
| Apixaban | 6 |
| Warfarin | 2 |
Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any death | - Cardiovascular death | --- Cardiac arrhythmic death | |
| Dronedarone | 25 | 21 | 13 |
| Placebo | 13 | 10 | 4 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any AE | - Any serious AE | - Any AE leading to death | - Any AE leading to treatment discontinuation | - Any AE leading to hospitalization | |
| Dronedarone | 797 | 113 | 4 | 212 | 95 |
| Placebo | 600 | 77 | 0 | 80 | 71 |
(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| MI or unstable angina pectoris | - MI | Stroke | - Ischemic stroke | Systemic arterial embolism | Episode of heart failure | - Hospitalization due to heart failure | Unplanned hospitalization for cardiovascular cause | |
| Dronedarone | 15 | 3 | 23 | 18 | 1 | 115 | 43 | 113 |
| Placebo | 8 | 2 | 10 | 9 | 0 | 55 | 24 | 59 |
"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |
|---|---|---|
| First co-primary endpoint | Second co-primary endpoint | |
| Dronedarone | 43 | 127 |
| Placebo | 19 | 67 |
"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.003 | 0.005 | 0.008 | 0.022 | 0.026 | 0.026 |
| Placebo | 0.001 | 0.003 | 0.004 | 0.004 | 0.027 | 0.027 |
"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.009 | 0.013 | 0.021 | 0.042 | 0.045 | 0.045 |
| Placebo | 0.002 | 0.003 | 0.007 | 0.013 | 0.038 | 0.038 |
"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.020 | 0.034 | 0.069 | 0.110 | 0.137 | 0.137 |
| Placebo | 0.005 | 0.014 | 0.033 | 0.059 | 0.099 | 0.099 |
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline
| Intervention | Percentage of total recording time (Geometric Mean) |
|---|---|
| Placebo | 12.7 |
| Ranolazine 750 mg | 10.8 |
| Dronedarone 225 mg | 11.6 |
| Ranolazine 750 mg + Dronedarone 225 mg | 11.7 |
| Ranolazine 750 mg + Dronedarone 150 mg | 11.7 |
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline; Week 12
| Intervention | percent change (Geometric Mean) |
|---|---|
| Placebo | -5.9 |
| Ranolazine 750 mg | -23.0 |
| Dronedarone 225 mg | 3.5 |
| Ranolazine 750 mg + Dronedarone 225 mg | -59.1 |
| Ranolazine 750 mg + Dronedarone 150 mg | -45.5 |
AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. (NCT01522651)
Timeframe: Baseline; Week 12
| Intervention | percentage of total recording time (Mean) | |
|---|---|---|
| Baseline | Absolute Change From Baseline in AFB by Week 12 | |
| Dronedarone 225 mg | 19.1 | 5.6 |
| Placebo | 16.8 | 4.6 |
| Ranolazine 750 mg | 17.3 | -3.1 |
| Ranolazine 750 mg + Dronedarone 150 mg | 16.7 | -3.9 |
| Ranolazine 750 mg + Dronedarone 225 mg | 16.8 | -4.7 |
AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time. (NCT01522651)
Timeframe: Week 12
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| ≥ 30% Reduction From Baseline AFB | ≥ 50% Reduction From Baseline AFB | ≥ 70% Reduction From Baseline AFB | |
| Dronedarone 225 mg | 21.7 | 13.0 | 8.7 |
| Placebo | 22.2 | 16.7 | 11.1 |
| Ranolazine 750 mg | 50.0 | 22.2 | 16.7 |
| Ranolazine 750 mg + Dronedarone 150 mg | 54.5 | 54.5 | 27.3 |
| Ranolazine 750 mg + Dronedarone 225 mg | 45.0 | 45.0 | 45.0 |
Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at 60 days after randomization (NCT02132767)
Timeframe: 60 days after randomization
| Intervention | participants (Number) |
|---|---|
| Rate Control | 220 |
| Rhythm Control | 231 |
Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at hospital discharge (NCT02132767)
Timeframe: Hospital discharge
| Intervention | participants (Number) |
|---|---|
| Rate Control | 231 |
| Rhythm Control | 244 |
Compare heart rhythm (patients in sustained, stable non-AF rhythm) between treatment arms at 30 days after randomization (NCT02132767)
Timeframe: 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Rate Control | 220 |
| Rhythm Control | 223 |
Overall length of stay for the index hospitalization (NCT02132767)
Timeframe: Within 60 days post surgery
| Intervention | days (Median) |
|---|---|
| Rate Control | 4.3 |
| Rhythm Control | 4.3 |
Compare length of stay between groups for any cause and AF-related hospitalizations, including ED visits (NCT02132767)
Timeframe: Within 60 days of randomization
| Intervention | days (Median) |
|---|---|
| Rate Control | 2.2 |
| Rhythm Control | 2.1 |
Compare frequency of outpatient visits between groups for any cause and AF-related causes (NCT02132767)
Timeframe: Within 60 days of randomization
| Intervention | hospital stays < 24 hours (Number) |
|---|---|
| Rate Control | 5 |
| Rhythm Control | 4 |
(NCT02132767)
Timeframe: Up to index hospital discharge or 7 days post surgery, whichever came first
| Intervention | days (Median) |
|---|---|
| Rate Control | 1.85 |
| Rhythm Control | 0.95 |
The total number of days in hospital for any hospitalization that occurs within 60 days of randomization to AF treatment strategy. (NCT02132767)
Timeframe: Within 60 days of randomization
| Intervention | days (Median) |
|---|---|
| Rate Control | 5.1 |
| Rhythm Control | 5.0 |
(NCT00127712)
Timeframe: 7 days
| Intervention | Participants (Number) |
|---|---|
| Amiodarone | 9 |
| Control | 22 |
(NCT00127712)
Timeframe: 7 days
| Intervention | participants (Number) |
|---|---|
| Amiodarone | 9 |
| Control | 21 |
(NCT00127712)
Timeframe: Duration of hospitalization
| Intervention | Days (Median) |
|---|---|
| Amiodarone | 7 |
| Control | 8 |
(NCT00127712)
Timeframe: Duration of hospitalization
| Intervention | Hours (Median) |
|---|---|
| Amiodarone | 46 |
| Control | 84 |
(NCT00420017)
Timeframe: 7 days
| Intervention | participants (Number) |
|---|---|
| Amiodarone | 6 |
| Control | 16 |
(NCT00420017)
Timeframe: Duration of hospitalization
| Intervention | days (Median) |
|---|---|
| Amiodarone | 11 |
| Control | 12 |
(NCT00420017)
Timeframe: 7 days
| Intervention | hours (Median) |
|---|---|
| Amiodarone | 68 |
| Control | 77 |
Adverse effects, including cardiovascular (hypotension, bradycardia, prolonged QT interval, ventricular tachycardia), respiratory (ARDS, pneumonia, atelectasis), and other (pericardial effusions, anastomotic leak) (NCT00420017)
Timeframe: 7 days
| Intervention | patients (Number) |
|---|---|
| Amiodarone | 21 |
| Control | 19 |
"The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 83 |
| Amiodarone 600mg/200mg od | 107 |
"The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 61 |
| Amiodarone 600mg/200mg od | 99 |
"The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 184 |
| Amiodarone 600mg/200mg od | 141 |
Sinus Rhythm maintenance means no Atrial Fibrillation recurrence at one-year follow up. Patients with successful electrical cardioversion (DCCV)underwent weekly clinical and electrocardiographic controls for the first three weeks following cardioversion. Subsequently, follow up visits with performance of clinical evaluation, ECG, and a 24-hour Holter monitoring were performed at 1, 3, 6 and 12 months after DCCV. (NCT01198275)
Timeframe: one year
| Intervention | partecipants (Number) |
|---|---|
| n-3 PUFAs | 61 |
| Placebo | 34 |
(NCT01119716)
Timeframe: Baseline (time of admission)
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Congenital Heart Disease | Sick Sinus Syndrome | Sustained Ventricular Tachycardia | Ventricular Fibrillation | |
| Female | 1.6 | 3.5 | 0.5 | 0.4 |
| Male | 1.3 | 2.3 | 1.2 | 0.7 |
| Total | 1.4 | 2.8 | 0.9 | 0.6 |
(NCT01119716)
Timeframe: Baseline (time of admission)
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| 1st Detected Episode | Paroxysmal | Persistent | Permanent | Unknown | |
| Female | 33.6 | 31.9 | 27.6 | 3.6 | 3.3 |
| Male | 29.2 | 27.2 | 36.4 | 4.2 | 3.0 |
| Total | 30.8 | 28.9 | 33.1 | 4.0 | 3.1 |
(NCT01119716)
Timeframe: Baseline (time of admission)
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | Peripheral Vascular Disease | Chronic Renal Failure | Anemia | Sleep Apnea Syndrome | Haemorrhagic Complication | |
| Female | 7.1 | 5.1 | 5.3 | 5.3 | 2.1 | 1.8 |
| Male | 7.8 | 6.3 | 6.7 | 3.6 | 4.8 | 1.2 |
| Total | 7.5 | 5.8 | 6.2 | 4.2 | 3.8 | 1.4 |
(NCT01119716)
Timeframe: up to 60 days from day of treatment (cardioversion)
| Intervention | Participants (Number) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myocardial Infarction | Non-haemorrhagic Stroke | Haemorrhagic Stroke | Peripheral Embolism | Pulmonary Embolism | Transient Ischaemic Attack | Heart Failure | Major Bleeding | Minor Bleeding | Recurrence of Atrial Fibrillation | Recurrence of Atrial Flutter | Asystole for more than 3 seconds | Symptomatic Ventricular Tachycardia | Ventricular Fibrillation | Sick Sinus syndrome | Torsade de pointes | Syncope | Endocarditis | Tamponade | Bradycardia | Hypotension | Other Complication | Death | |
| Female | 2 | 3 | 0 | 2 | 3 | 1 | 10 | 3 | 6 | 63 | 2 | 2 | 1 | 1 | 2 | 1 | 4 | 1 | 0 | 0 | 1 | 18 | 113 |
| Male | 2 | 7 | 1 | 0 | 1 | 0 | 9 | 3 | 12 | 107 | 10 | 2 | 0 | 2 | 1 | 0 | 5 | 0 | 1 | 4 | 4 | 27 | 198 |
| Total | 4 | 10 | 1 | 2 | 4 | 1 | 19 | 6 | 18 | 170 | 12 | 4 | 1 | 3 | 3 | 1 | 9 | 1 | 1 | 4 | 5 | 45 | 311 |
Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered. (NCT01119716)
Timeframe: At time of treatment (up to 1 day from admission)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Electrical Cardioversion | Pharmacological Cardioversion | |
| Female | 55.1 | 44.9 |
| Male | 69.5 | 30.5 |
| Total | 64.2 | 35.8 |
(NCT01119716)
Timeframe: At time of Treatment (up to 1 day from admission)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Electrical Cardioversion | Pharmacological Cardioversion | Combined Electrical/Pharmacological Cardioversion | Rate Control Change | Catheter Ablation | Surgical Therapy | Implantable Cardiac Defibrillator | Pacemaker | No Treatment | |
| Female | 792 | 609 | 69 | 152 | 32 | 0 | 0 | 18 | 342 |
| Male | 1677 | 705 | 120 | 215 | 92 | 1 | 10 | 20 | 550 |
| Total | 2469 | 1314 | 189 | 367 | 124 | 1 | 10 | 38 | 892 |
"A treatment success/failure up to the conclusion of the procedure for each subject in Ablation Management. A subject was considered successfully treated if the following were true:~Medtronic ablation catheters were used to achieve procedure success.~All accessible pulmonary veins were isolated.~At least 50% reduction of complex fractionated atrial electrograms mapped and ablated with Medtronic ablation catheters.~Sinus rhythm was achieved upon leaving the electrophysiology lab (±cardioversion)." (NCT00514735)
Timeframe: Procedure conclusion
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 92.8 |
The primary endpoint for acute safety was a success/failure variable calculated for each subject in Ablation Management at the 7 day post-procedure time point. Any subject with at least one adverse event adjudicated by the Data Safety Monitoring Board as both serious and either probably or definitely procedure and/or device-related occurring within 7 days of the ablation procedure was considered an acute safety failure, regardless of whether the event occurred following the index or retreatment ablation procedure. (NCT00514735)
Timeframe: 7 days
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 12.3 |
"The chronic efficacy endpoint was a treatment success/failure measure for each subject computed at 6 months. Treatment success included:~A 90% reduction in clinically significant atrial fibrillation from baseline to the 6 month time point based on a Holter recording. Clinically significant atrial fibrillation was defined as sustained atrial fibrillation lasting more than 10 minutes.~The subject was off all antiarrhythmic drugs at 6 months (Ablation Management arm only)~The Investigator judged all procedures to be acutely successful (Ablation Management arm only)." (NCT00514735)
Timeframe: 6 months
| Intervention | percentage of participants with success (Number) |
|---|---|
| Ablation Management | 56 |
| Medical Management | 26 |
The primary endpoint for chronic safety was a success/failure variable calculated for each subject at 6 months. Any subject that had at least one adverse event that met designated seriousness and relatedness criteria for the particular treatment group as adjudicated by the Data Safety Monitoring Board was considered a chronic safety failure. Adverse events in Ablation Management that were acute (≤7 days) were not included in the chronic safety primary endpoint. Given the disparity in the length of time at risk between treatment arms,the Chronic Safety endpoint was not statistically powered. (NCT00514735)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Ablation Management | 9 |
| Medical Management | 3 |
The SF-36 questionnaire was administered to subjects at baseline, 1, 3 and 6 month visits. The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based Physical Component Score and Mental Component Score. The possible range for Physical Component Score and Mental Component Score is 0 to 100. The higher score, the better quality of life. (NCT00514735)
Timeframe: 6 months
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Component Score at Baseline | Physical Component Score at 1 Month | Physical Component Score at 3 Months | Physical Component Score at 6 Months | Mental Component Score at Baseline | Mental Component Score at 1 Month | Mental Component Score at 3 Months | Mental Component Score at 6 Months | |
| Ablation Management | 42.54 | 45.61 | 48.30 | 49.12 | 47.19 | 51.53 | 53.42 | 53.45 |
| Medical Management | 42.26 | 43.05 | 43.99 | 44.98 | 47.99 | 48.96 | 48.97 | 50.06 |
The severity of subject's atrial fibrillation related symptoms on a scale from 1 (no symptoms) to 5 (most severe). The symptoms included palpitations, fatigue, shortness of breath, lightheadedness or dizziness, and lack of energy during exertion or exercise. The scores were tabulated at the 1, 3 and 6 month follow-up visits. Scores could range from 5 to 25, indicating a spectrum of subject status from asymptomatic to severely symptomatic. (NCT00514735)
Timeframe: 6 months
| Intervention | AF Symptom Severity Score (Mean) | |||
|---|---|---|---|---|
| Measurement at Baseline | Measurement at 1 Month | Measurement at 3 Months | Measurement at 6 Months | |
| Ablation Management | 12.38 | 8.95 | 7.56 | 7.58 |
| Medical Management | 12.72 | 9.90 | 10.03 | 9.84 |
Left atrial diameter (LAD), as measured by transthoracic echocardiogram (TTE) looking at the longitudinal long axis at baseline and at the 6 month follow-up visit in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | centimeters (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 4.5 | 4.4 |
| Medical Management | 4.6 | 4.6 |
Left ventricular ejection fraction (LVEF), as measured by transthoracic echocardiogram at baseline and 6 months in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | percent (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 54.7 | 58.3 |
| Medical Management | 54.9 | 57.0 |
The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment. (NCT01182376)
Timeframe: baseline, 1 year
| Intervention | percentage of fibrosis (Mean) |
|---|---|
| Placebo | 24.6 |
| Multaq® (Dronedarone) | 16.8 |
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
276 reviews available for amiodarone and Atrial Fibrillation
| Article | Year |
|---|---|
Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
Topics: Administration, Oral; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Mem | 2023 |
Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European perspective.
Topics: Administration, Intravenous; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Count | 2021 |
Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countershock; Hu | 2022 |
Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Network Meta | 2022 |
[Atrial fibrillation on the intensive care unit : The special prognostic importance of the first manifestation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Intensive Ca | 2022 |
Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses.
Topics: Amiodarone; Atrial Fibrillation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertensio | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Effectiveness of intra-operative topical amiodarone for prevention of postcardiac surgery new-onset atrial fibrillation: A review of current evidence.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postoperative Complications | 2022 |
Predictors and impact of postoperative atrial fibrillation following thoracic surgery: a state-of-the-art review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Thoracic Surgery; Thoracic Su | 2023 |
Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Network Meta-An | 2023 |
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; H | 2023 |
Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Dizziness; Drug- | 2023 |
Management of Atrial Arrhythmias After Lung Transplant.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Transplantation; Retrospective | 2023 |
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
[Tachycardia and pulmonary arterial hypertension].
Topics: Amiodarone; Atrial Fibrillation; Electric Countershock; Humans; Pulmonary Arterial Hypertension; Tac | 2020 |
Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bayes Theorem; Electric Countershock; Human | 2020 |
Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Atrial Fibrillation; Calcium Channel Blockers; Criti | 2020 |
Metoprolol for prophylaxis of postoperative atrial fibrillation in cardiac surgery patients: systematic review and meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Metopr | 2020 |
Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Network Meta | 2021 |
Management of arrhythmias in pulmonary hypertension.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Humans; Hypertension, Pulmon | 2021 |
Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2021 |
In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases; Pneumonectomy; | 2017 |
Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2018 |
Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Topics: Age Factors; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; | 2017 |
Atrial fibrillation and cardiac resynchronization therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricul | 2018 |
Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Drug | 2018 |
Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Bias; Calcium Channel Blockers; Comorbidity; | 2018 |
Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; | 2019 |
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Sub | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Counter | 2019 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2013 |
Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2013 |
Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2013 |
Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2013 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relat | 2014 |
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization | 2014 |
The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Half-Lif | 2014 |
Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone | 2014 |
[Amiodarone and the thyroid].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyperthyroidism; Hypothyroidism; Ta | 2014 |
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedar | 2015 |
[Paroxysmal atrial fibrillation within the context of cluster headaches].
Topics: Amiodarone; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Autonomic Nervous System D | 2015 |
New anthyarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines | 2015 |
Systematic Review and Meta-analysis of Atrial Fibrillation Prophylaxis After Lung Surgery.
Topics: Amiodarone; Atrial Fibrillation; Humans; Incidence; Lung; Pneumonectomy; Postoperative Complications | 2016 |
Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Humans; Infusions | 2016 |
Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Humans; Infusions | 2016 |
Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Humans; Infusions | 2016 |
Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Humans; Infusions | 2016 |
Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Monitoring; Evidence-Based Medicine; G | 2016 |
Amiodarone and dronedarone: An update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interacti | 2016 |
Dronedarone: Basic Pharmacology and Clinical Use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2016 |
Preoperative Plasma Aldosterone Levels and Postoperative Atrial Fibrillation Occurrence Following Cardiac Surgery: A Review of Literature and Design of the ALDO-POAF Study (ALDOsterone for Prediction of Post-Operative Atrial Fibrillation).
Topics: Adrenergic beta-Antagonists; Aldosterone; Amiodarone; Atrial Fibrillation; Biomarkers; Cardiac Surgi | 2016 |
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibri | 2016 |
Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled | 2017 |
Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Trial | 2017 |
Atrial fibrillation in heart failure: the chicken or the egg?
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Ca | 2009 |
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Long QT Syndrome | 2008 |
Dronedarone: a new treatment for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dose-Res | 2008 |
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aniso | 2008 |
Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Clinical | 2008 |
Amiodarone as paradigm for developing new drugs for atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2008 |
[Atrial fibrillation in patients with heart failure. Pathophysiological concepts and therapeutic options].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2008 |
[Treatment of atrial fibrillation in every days practice].
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic D | 2008 |
[Restoration and maintenance of sinus rhythm in patients with atrial fibrillation. New pharmacological approaches].
Topics: Action Potentials; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Atria | 2008 |
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Droneda | 2009 |
Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Hospitalization; Humans; Patient Dropouts; | 2009 |
Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Huma | 2009 |
Atrial fibrillation (acute onset).
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2008 |
[Dronedarone: the new antiarrythmic agent?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Conduction System; Heart | 2009 |
Dronedarone: a promising alternative for the management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; He | 2009 |
Dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Ch | 2009 |
Dronedarone for atrial fibrillation: a new therapeutic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medici | 2009 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rat | 2009 |
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Adrenergic Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2010 |
Efficacy and safety of dronedarone: a review of randomized trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Fa | 2010 |
Dronedarone--a new alternative for management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedar | 2010 |
Dronedarone: current evidence and future questions.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topi | 2010 |
[Upstream approach for atrial fibrillation].
Topics: Amiodarone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2010 |
Dronedarone: a safety comparison to amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Creatini | 2010 |
[Current antiarrhythmic drug therapy in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Administration Schedule; | 2010 |
[Clinical profile of the new antiarrhythmic drug dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2010 |
[Clinical pharmacology and electrophysiological properties of dronedarone].
Topics: Adrenergic Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological | 2010 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabi | 2010 |
New antiarrhythmic drugs for treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrill | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Practice Guidelines as Topic; Trea | 2010 |
Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2010 |
Dronedarone: an emerging therapy for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Approval; Heart | 2010 |
Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Emergency Servi | 2010 |
[Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Heart Ventricles; Hum | 2010 |
Approach to the patient with amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Humans; Iodine Radioisoto | 2010 |
Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotens | 2010 |
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Fi | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Dronedar | 2010 |
The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2010 |
Dronedarone: an alternative to amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; D | 2010 |
Dronedarone and vitamin K antagonists: a review of drug-drug interactions.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Drug Therapy, Combi | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2010 |
Dronedarone for atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled | 2010 |
A new agent for atrial fibrillation: electrophysiological properties of dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedaron | 2010 |
A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials | 2010 |
[Dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Catheter Ablation; | 2010 |
[Current role of amiodarone in antiarrhythmic therapy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Comple | 2010 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Aged; Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dron | 2010 |
[Novel targets in the treatment of patients with atrial fibrillation: from elimination of symptoms to improvement of clinical outcomes].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Clinical | 2010 |
Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Disease | 2011 |
Advances in the treatment of atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; b | 2010 |
The pharmaceutical pipeline for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrill | 2011 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Huma | 2011 |
Sinus rhythm restoration and treatment success: insight from recent clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as | 2011 |
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization | 2011 |
Antiarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; | 2011 |
Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedar | 2012 |
[Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases].
Topics: Acenocoumarol; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Algorithms; Amiodarone; Atrial | 2011 |
Dronedarone for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Huma | 2011 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Drug Int | 2011 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; F | 2011 |
[The role of dronedarone in the contemporary atrial fibrillation treatment].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
Prophylaxis of atrial fibrillation after noncardiac thoracic surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2010 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimida | 2011 |
Dronedarone for atrial fibrillation therapy.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Ha | 2011 |
Atrial fibrillation (acute onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2011 |
Update on the management of atrial fibrillation: anticoagulation and medical therapy.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; D | 2011 |
Dronedarone: an overview.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dronedarone; Heart Ra | 2012 |
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Anal | 2012 |
Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Incidence; Ischemic At | 2011 |
The management of patients with atrial fibrillation and dronedarone's place in therapy.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiovascular | 2011 |
[Amiodarone and thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hypothyroidism; Iodine | 2012 |
Management of postoperative atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Inflammatory Agents; Atrial Fibrillation; Cardiac Paci | 2012 |
Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2012 |
Postoperative wide complex tachycardia: an alternative hypothesis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Atrial Fibrillation; Electrocardiog | 2013 |
Thyrotoxicosis.
Topics: Agranulocytosis; Amiodarone; Antithyroid Agents; Atrial Fibrillation; Autoimmune Diseases; Child; Ex | 2012 |
Gastrointestinal bleeding and possible hypothyroidism.
Topics: Aged, 80 and over; Amiodarone; Anemia; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroid | 2012 |
Amiodarone and the thyroid: a 2012 update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypothyroidism; Thyroxine | 2012 |
[Dronedarone: a real innovation or a mere second-best choice? How to find the way among guidelines, regulatory agencies and daily clinical practice].
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans | 2012 |
Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Humans; Randomi | 2012 |
Meta-analysis of amiodarone versus β-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; P | 2012 |
[Therapy of atrial fibrillation in the critically ill].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Comorbidity; Contraindicati | 2012 |
Atrial fibrillation: new drugs, devices, and procedures.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dronedar | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzi | 2012 |
Novel anti-arrhythmic medications in the treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2012 |
Amiodarone-induced hair loss: case report and review of the literature.
Topics: Aged, 80 and over; Alopecia; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male | 2015 |
Mechanisms in endocrinology: Heart failure and thyroid dysfunction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; | 2012 |
Drug safety evaluation of dronedarone in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Labeling; Hospit | 2012 |
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Drone | 2012 |
Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Hear | 2013 |
Prevention of and medical therapy for atrial arrhythmias in heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2002 |
Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, | 2002 |
New insights into the mechanisms and management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Hu | 2002 |
Hybrid therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2002 |
Amiodarone: an emergency medicine perspective.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Humans; Tachycardia, Ven | 2002 |
Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle A | 2003 |
Antiarrhythmic therapy in heart failure.
Topics: Algorithms; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmia | 2002 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Risks and benefits of rate control versus maintenance of sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; D | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Conduction System; Humans; Randomized | 2003 |
Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Surgica | 2003 |
Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as To | 2003 |
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2003 |
Atrial fibrillation in patients after cardiovascular surgery: incidence, risk factors, preventive and therapeutic strategies.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardi | 2003 |
Cost evaluation of rhythm control methods for atrial fibrillation: evidence from CTAF.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Anal | 2003 |
Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Bi | 2003 |
Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Randomized Controlled Trials as Top | 2003 |
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cl | 2004 |
[Chronic heart failure and atrial fibrilation: aspects of management].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmi | 2003 |
Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Middle Aged | 2004 |
Antiarrhythmic drug therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Flecainide; Humans; Phenethyl | 2004 |
Pharmacological rate control of atrial fibrillation.
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diltiazem; Heart Rate; Human | 2004 |
Atrial fibrillation after cardiac surgery: evidence on prophylactic interventions.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2003 |
Intravenous amiodarone for conversion of atrial fibrillation: misled by meta-analysis?
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock | 2004 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Humans; Timolol; Verapa | 2003 |
Atrial fibrillation after electrical shock: a case report and review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electric Countershock; El | 2004 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2003 |
Selective use of amiodarone and early cardioversion for postoperative atrial fibrillation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial | 2005 |
[Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Hum | 2004 |
Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2005 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2004 |
[Pharmacological cardioversion of atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electric Counters | 2005 |
Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Anti-Arrhythmia Agents; Atrial Fibrillation | 2005 |
Management of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Atrial Fibrillation; Heart Rate; Humans; Recurr | 2005 |
Bilateral optic neuropathy due to amiodarone with recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Optic Nerve Diseases; R | 2005 |
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary | 2005 |
Atrial fibrillation post-myocardial infarction: frequency, consequences, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Heart Failure; | 2004 |
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Human | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Use of amiodarone to prevent atrial fibrillation after cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Trial | 2006 |
Atrial arrhythmias after cardiac surgery in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 2006 |
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
Atrial fibrillation (recent onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2005 |
Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Humans; Postoperati | 2006 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Amiodarone-induced thyroid dysfunction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Diagnosis, Differentia | 2006 |
Atrial fibrillation post-cardiac surgery: changing perspectives.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Cardiac Surgical | 2006 |
[Dronedarone--a new therapeutic option for controlling atrial rhythm and ventricular frequency].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Function | 2006 |
The use of intravenous amiodarone for chemical conversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Connecticut; Humans; Infusion Pumps | 2006 |
Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fore | 2006 |
Amiodarone: a multifaceted antiarrhythmic drug.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2006 |
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Tri | 2006 |
Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 2006 |
Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Evidence-Based | 2006 |
Pitfalls of testing and summary of guidance on safety monitoring with amiodarone and digoxin.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Monitoring; Female; Hum | 2007 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation.
Topics: Amiodarone; Atrial Fibrillation; Humans; Incidence; Postoperative Complications; Postoperative Perio | 2007 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation.
Topics: Amiodarone; Atrial Fibrillation; Humans; Incidence; Postoperative Complications; Postoperative Perio | 2007 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation.
Topics: Amiodarone; Atrial Fibrillation; Humans; Incidence; Postoperative Complications; Postoperative Perio | 2007 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation.
Topics: Amiodarone; Atrial Fibrillation; Humans; Incidence; Postoperative Complications; Postoperative Perio | 2007 |
Amiodarone for atrial fibrillation.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiogr | 2007 |
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availab | 2007 |
Prevention of atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Chemoprev | 2007 |
Dronedarone: drondarone, SR 33589, SR 33589B.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedar | 2007 |
A review of the investigational antiarrhythmic agent dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedar | 2007 |
Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2007 |
New antiarrhythmic treatment of atrial fibrillation.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythm | 2007 |
[Pharmacological therapy for atrial fibrillation after cardiac surgery].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anticoagulants; Atrial Fibrillation; Calcium Channel Blocke | 2007 |
Amiodarone for atrial fibrillation following cardiac surgery: development of clinical practice guidelines at a university hospital.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Follow-Up Stud | 2008 |
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Evaluation; Heart Rate; H | 2007 |
Dronedarone: in quest of the ideal antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Clinical Trials, P | 2007 |
Fatal amiodarone-induced hepatotoxicity: a case report and literature review.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2008 |
Approach to management of atrial fibrillation in the Indian scenario.
Topics: Age Factors; Amiodarone; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Anticoagul | 2007 |
Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ajmaline; Amiodarone; Anilides; Aprindine; Atr | 1983 |
Clinical use and pharmacology of amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Autonomic Ne | 1984 |
[Cardioversion of atrial flutter and fibrillation with amiodarone in high doses].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Humans; Male; Mid | 1982 |
Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone.
Topics: Acute Disease; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atria | 1981 |
Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trial | 1994 |
Amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Clinical Trials as Topic; Heart Rate; Humans; Risk Factors | 1995 |
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 1995 |
Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Confounding Factors, Ep | 1995 |
[Amiodarone in the nineties: to whom and what dosage?].
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Clinical Trials | 1995 |
[Atrial fibrillation, restoration of sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications; Defibrillators, Implanta | 1994 |
Cardiology--II: Treatment of heart failure and atrial fibrillation and arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Catheter Ablatio | 1994 |
Low-dose amiodarone should not be the first-line treatment for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; | 1994 |
Comparison of class I and class III action in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trial | 1993 |
Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
Topics: Amiodarone; Atrial Fibrillation; Humans; Tachycardia, Ventricular; Torsades de Pointes | 1994 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Low-dose amiodarone for atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Humans | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Decision Support Techniques; Humans; Markov | 1994 |
[Therapy of atrial fibrillation with class III anti-arrhythmia agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart Atria; Humans; S | 1993 |
[Clinical use of intravenous amiodarone for supraventricular arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Infusions, In | 1995 |
Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electrop | 1996 |
Therapeutic strategies for atrial fibrillation. The value of decision analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; D | 1996 |
[Drug therapy of atrial fibrillation: control of heart rate versus establishing sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Diltiazem; Elect | 1996 |
Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Humans; Infusions, | 1997 |
Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic Disease; Cont | 1997 |
[Pharmacological treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1997 |
[Supraventricular arrhythmia after pneumonectomy. Apropos of 100 cases and review of the literature].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Lung Neoplasms; Male; | 1998 |
Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery B | 1998 |
The current role of amiodarone in patients with congestive heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as To | 1998 |
Atrial fibrillation: what are the effects of drug therapy on the effectiveness and complications of electrical cardioversion?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Digoxin; Electri | 1998 |
Amiodarone in atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock | 1998 |
Treatment of postoperative atrial fibrillation: a nonsurgical perspective.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Ca | 1999 |
Evidence-based analysis of amiodarone efficacy and safety.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden; Humans; Tachycardia, Ventric | 1999 |
Intravenous antiarrhythmic regimens with focus on amiodarone for prophylaxis of atrial fibrillation after open heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery B | 1999 |
Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as To | 1999 |
Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiograp | 1999 |
Systematic review of the management of atrial fibrillation in patients with heart failure.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chronic Dise | 2000 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Thyroid disease and the heart.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Heart Diseases; Humans; Hyperth | 2000 |
Supraventricular tachycardia: implications for the intensivist.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiogra | 2000 |
[Amiodarone-induced thyrotoxicosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Thyrotoxicosis | 2000 |
Intravenous antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Procainamid | 2001 |
Thyroid hormone and the cardiovascular system.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Heart; Heart Diseases | 2001 |
The role of class III antiarrhythmic agents in maintaining sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction Syst | 2000 |
Does prophylaxis against atrial fibrillation after cardiac surgery reduce length of stay or hospital costs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Costs and Cost | 2001 |
[Hyperthyroidism and heart].
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; D | 2001 |
Atrial fibrillation: is rate stabilization a valid clinical strategy?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Protocols; Diltiazem; Heart Rate; | 2001 |
Postoperative arrhythmias and conduction disorders.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
Atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial | 2001 |
A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Drug Interactions | 2001 |
Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cohort Studies; Humans; Hypote | 2002 |
Amiodarone -- waxed and waned and waxed again.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Pres | 2001 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, | 2002 |
Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Artery Bypas | 2002 |
Role of amiodarone in reducing atrial fibrillation after cardiac surgery in adults.
Topics: Adult; Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Double-Blind Method; Drug Evaluation | 2002 |
Management of common arrhythmias: Part I. Supraventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Echocardiography, Tra | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
[Isolated atrial fibrillation. The risk of embolism and its prevention].
Topics: 4-Hydroxycoumarins; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Aspirin; Atrial Fibr | 1992 |
Low-dose amiodarone for atrial fibrillation: time for a prospective study?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Humans; Prospecti | 1992 |
Reversibility of blue-gray cutaneous discoloration from amiodarone.
Topics: Amiodarone; Atrial Fibrillation; Follow-Up Studies; Humans; Male; Middle Aged; Photosensitivity Diso | 1991 |
Amiodarone: value of programmed electrical stimulation and Holter monitoring.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiac Pacing, Artificial; Clin | 1986 |
Amiodarone induced torsades de pointe. Report of three cases and review of literature.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Drug Interactions; Electrocardiography; Fe | 1989 |
[Drug treatment of patients with the chronic form of atrial fibrillation in counterindications for cardioversion (a review)].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anabolic Agents; Atrial Fibrillation; Calcium Channel Block | 1985 |
330 trials available for amiodarone and Atrial Fibrillation
| Article | Year |
|---|---|
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Humans; Kidney; R | 2022 |
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans | 2022 |
Amiodarone with or without N-Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial.
Topics: Acetylcysteine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dou | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Treatm | 2022 |
Efficacy of Intraoperative Low Dose Intravenous Amiodarone in Pharmacologic Cardioversion in Patients with Preoperative Atrial Fibrillation Presenting for Mitral Valve Replacement Surgery Randomized Control Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Glucose; Humans; Mit | 2022 |
Preventive Effect of Berberine on Postoperative Atrial Fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Berberine; Biomarkers; C-Reactive Protein; Humans; Interleukins; Li | 2022 |
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Hospitalizatio | 2023 |
Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Multicenter Studies as Topic; | 2023 |
Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Prospective Studies; S | 2023 |
Screening and Prophylactic Amiodarone Reduces Post-Operative Atrial Fibrillation in At-Risk Patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study.
Topics: Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Middle Aged; Propafe | 2020 |
Prophylaxis for patients at Risk to Eliminate Post-operative Atrial Fibrillation (PREP-AF trial): a protocol for a feasibility randomized controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Studies; Humans; Multicenter St | 2021 |
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans | 2022 |
Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Co | 2018 |
Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Cat | 2017 |
Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Catheters; Electrocardio | 2017 |
Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Drug Therapy, | 2018 |
QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Co | 2019 |
Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation.
Topics: Action Potentials; Acupuncture Points; Acupuncture Therapy; Aged; Amiodarone; Anti-Arrhythmia Agents | 2019 |
Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, | 2019 |
Epicardial Application of Hydrogel with Amiodarone for Prevention of Postoperative Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting.
Topics: Administration, Topical; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Art | 2020 |
Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery.
Topics: Acetanilides; Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2014 |
Prophylaxis against atrial fibrillation after cardiac surgery: beneficial effect of perioperative metoprolol.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgica | 2013 |
Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial.
Topics: Aged; Amiodarone; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone; Drug Costs; Female; Follo | 2013 |
Amiodarone is a cost-neutral way of preventing atrial fibrillation after surgery for lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Denmark; Fe | 2014 |
Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2013 |
Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Atrial Fibrillation; Female; Heart Atria; Heart Rate; Humans; Male; Middle Aged; P | 2013 |
Comparison of pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac valve replacement: a prospective randomized trial.
Topics: Adult; Amiodarone; Anesthesia, General; Atrial Fibrillation; Captopril; Drug Therapy, Combination; E | 2013 |
Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2013 |
Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distri | 2014 |
Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Argentina; Atrial Fibrillation; Bayes T | 2014 |
Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation.
Topics: Acetanilides; Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2014 |
Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (atrial fibrillation and chronic heart failure).
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2014 |
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Inten | 2014 |
Effectiveness of biatrial epicardial application of amiodarone-releasing adhesive hydrogel to prevent postoperative atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiac Surgical Proced | 2014 |
Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Coronary Artery Disea | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Female; Hospi | 2014 |
Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality | 2014 |
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brazil; Cause of Deat | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents | 2014 |
Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE).
Topics: Adrenergic beta-Agonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter A | 2015 |
A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Rela | 2015 |
One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrilla | 2015 |
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; H | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Dru | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Dru | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Dru | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Dru | 2015 |
Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial.
Topics: Ablation Techniques; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Sur | 2016 |
Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation.
Topics: Administration, Topical; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemistry, | 2016 |
Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation: After Coronary Bypass Surgery?
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Coronary Ar | 2015 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Defibrillators, Im | 2016 |
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2016 |
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2016 |
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2016 |
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2016 |
Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Denmark; Double-Bl | 2016 |
[A multicenter prospective controlled study of catheter ablation for patients with persistent atrial fibrillation using domestic 3D cardiac electrophysiological mapping system].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Echocardiography, Three- | 2016 |
Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dru | 2017 |
[The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Coronary Arte | 2008 |
The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial.
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Coronary Artery Bypass; Fem | 2009 |
Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillat | 2008 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Meth | 2008 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Meth | 2008 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Meth | 2008 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Meth | 2008 |
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Humans; Male; Middle | 2008 |
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Dronedaron | 2008 |
[Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Drug Therapy, Com | 2008 |
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Drug Administration S | 2008 |
Does stopping amiodarone after successfully treating atrial fibrillation occurring after cardiac surgery increase the risk of recurrence?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascu | 2008 |
[Impact of electrical shock waveform and paddle positions on efficacy of direct current cardioversion for atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Chi-Square Distribut | 2008 |
Prevention of atrial fibrillation after coronary artery bypass grafting via atrial electromechanical interval and use of amiodarone prophylaxis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Coronary Artery Bypa | 2009 |
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Combi | 2009 |
Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Combined Mod | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2009 |
Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Digoxin; Diltiazem; F | 2009 |
Cardiovascular responses to transvenous electrical cardioversion of atrial fibrillation in anaesthetized horses.
Topics: Amiodarone; Anesthesia, General; Anesthetics, General; Animals; Anti-Arrhythmia Agents; Atrial Fibri | 2009 |
A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Non- | 2009 |
Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Hydrox | 2009 |
[The CONVERT trial].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2009 |
Ability of amiodarone and propranolol alone or in combination to prevent post-coronary bypass atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Double-Blind Method; Drug Ther | 2009 |
[Comparison of amiodarone plus irbesartan regimen versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation post valve replacement and cardioversion].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Female; Humans; | 2009 |
Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery.
Topics: Aged; Amiodarone; Anesthesia; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedur | 2010 |
Low-dose amiodarone for the prevention of atrial fibrillation after coronary artery bypass grafting in patients older than 70 years.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Double-Blind | 2009 |
Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Female; | 2010 |
Cognitive function and anticoagulation control in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Comorbidity; Dementia; Dru | 2010 |
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2010 |
A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Critical Car | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Ele | 2010 |
Biatrial pacing vs. intravenous amiodarone in prevention of atrial fibrillation after coronary artery bypass surgery.
Topics: Aged; Amiodarone; Angiography; Atrial Fibrillation; Coronary Artery Bypass; Echocardiography; Female | 2009 |
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Diuretics; E | 2010 |
Dronedarone in patients with congestive heart failure: insights from ATHENA.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Creatinine; Dronedarone; Female; Hear | 2010 |
Comparison of surgical cut and sew versus radiofrequency pulmonary veins isolation for chronic permanent atrial fibrillation: a randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic Disease; F | 2010 |
Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Biphenyl Co | 2010 |
Efficacy of acupuncture in preventing atrial fibrillation recurrences after electrical cardioversion.
Topics: Acupuncture Therapy; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distr | 2011 |
Management of patients with acute atrial fibrillation in the ED.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2010 |
Left atrial wall tension directly affects the restoration of sinus rhythm after Maze procedure.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Drug Admi | 2011 |
Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2010 |
The effect of amiodarone on cardiac rhythm after cardiopulmonary bypass in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiopulmonary | 2010 |
[A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anesthesia; Atrial Fibrillation; Child; Dilt | 2010 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Topics: Acute Disease; Aged; Amiodarone; Anisoles; Atrial Fibrillation; Double-Blind Method; Female; Follow- | 2011 |
Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male; Middle Ag | 2011 |
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cause of Death; Comb | 2011 |
Post-ATHENA and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2011 |
Local activation times at the high posterior wall of the left atrium during left atrial appendage pacing predict roof line block with high specificity and sensitivity.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Cardiac Pacing, Art | 2011 |
N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive | 2011 |
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Dronedarone; Female; F | 2011 |
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 2011 |
Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Confidence Interva | 2012 |
A randomized trial of budiodarone in paroxysmal atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Asthmatic Agents; Atrial Fibrillation; Dose-Response Relat | 2012 |
Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Double-Blind Method; Female; Humans; Lung | 2012 |
Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation.
Topics: Acetanilides; Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2012 |
Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Dose-Response Relationship, Drug; | 2012 |
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Computer Simulation; Cost Sav | 2012 |
Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Child | 2012 |
RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers.
Topics: Amiodarone; Atrial Fibrillation; Electric Countershock; Humans; Prospective Studies; Registries | 2012 |
A comparison of two individual amiodarone regimens to placebo in open heart surgery patients.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2002 |
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cross-Over Studies | 2002 |
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Hospit | 2002 |
Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Confidence Intervals | 2003 |
Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Blood Pressure; Electric | 2003 |
Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT).
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiac | 2003 |
Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electr | 2003 |
[Role amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Electric Countersh | 2002 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; El | 2003 |
Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2003 |
Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary | 2003 |
Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Calcium Cha | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Female; Human | 2003 |
Effect of right atrial pacing, intravenous amiodarone and beta blockers for suppression of atrial fibrillation after coronary artery bypass surgery: a pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2003 |
A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; | 2003 |
Combined radiofrequency modified maze and mitral valve procedure through a port access approach: early and mid-term results.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Echocardiography, | 2003 |
VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2003 |
Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography, | 2003 |
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Heart Ra | 2003 |
Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II).
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Cardiac Pacing, Artificial; Combined Mo | 2003 |
Conversion of rheumatic atrial fibrillation by amiodarone after percutaneous balloon mitral commissurotomy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization; Combined Modality Therapy; | 2003 |
Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study.
Topics: Adolescent; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agent | 2003 |
Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Humans; Infusions, I | 2004 |
External cardioversion in patients with persistent atrial fibrillation: a reappraisal of the effects of electrode pad position and transthoracic impedance on cardioversion success.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiography, Impedance; Electric Cou | 2003 |
A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Double-Bli | 2004 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Randomized Controlled Trials as Top | 2003 |
Amiodarone for postoperative atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationshi | 2004 |
Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response R | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Indicators of atrial fibrillation risk in cardiac surgery patients on prophylactic amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; | 2004 |
A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgica | 2004 |
An evaluation of postoperative P-wave variables after cardiothoracic surgery.
Topics: Aged; Amiodarone; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Surgical Procedures; Elec | 2004 |
Effect of biventricular pacing therapy in patients with dilated cardiomyopathy with severe congestive heart failure.
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiomyopa | 2004 |
Is amiodarone a safe antiarrhythmic to use in supraventricular tachyarrhythmias after lung cancer surgery?
Topics: Adult; Age Distribution; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Huma | 2004 |
Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study.
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Female; Heart Rate; Hu | 2004 |
Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artif | 2004 |
Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Electric Coun | 2004 |
Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control St | 2004 |
Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary | 2004 |
Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers.
Topics: Aged; Amiodarone; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biphenyl Compounds; | 2004 |
Impact of fluid balance on incidence of atrial fibrillation after cardiothoracic surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Female; Fluid | 2004 |
Effects of late regain of sinus rhythm on pulmonary artery pressure and functional status in patients with mitral valve replacement surgery and atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Doppler; Electric | 2004 |
Cardiac rate normalization in chronic atrial fibrillation: comparison of long-term efficacy of treatment with amiodarone versus AV node ablation and permanent His-bundle pacing.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Car | 2004 |
Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting.
Topics: Aged; Amiodarone; Analgesia, Epidural; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery | 2004 |
Impact of amiodarone on electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Conduction System; Heart Rate | 2005 |
Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Coronary Ar | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therap | 2005 |
Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans | 2005 |
Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Female; | 2005 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Dose-Response Relationship, | 2006 |
Effectiveness of the maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablat | 2005 |
Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, L | 2005 |
Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Electric Counters | 2005 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
One-year outcome of cardioversion of atrial fibrillation in patients with mitral stenosis after percutaneous balloon mitral valvuloplasty.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization; Electric Countersho | 2006 |
A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric C | 2006 |
[Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Admini | 2006 |
Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Cardiac Pacing, Artifici | 2006 |
Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Critical Care | 2006 |
[Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Fem | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combin | 2006 |
[Clinical observation on effect and safety of combined use of wenxin granule and amiodarone for conversion of auricular fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Drugs, Chi | 2006 |
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
Topics: Activities of Daily Living; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Bl | 2006 |
Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; | 2006 |
[Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Drug Therapy, Com | 2006 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Respon | 2007 |
High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Female | 2006 |
Is circumferential pulmonary vein isolation preferable to stepwise segmental pulmonary vein isolation for patients with paroxysmal atrial fibrillation?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ab | 2006 |
[The clinical study of circumferential ablation around orifice of pulmonary vein by radiofrequency energy with chronic atrial fibrillation undergoing rheumatic valvular heart surgery].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic Dis | 2006 |
Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Female; Humans; Male; Midd | 2007 |
[On the possibility of amiodarone use in some cases of persistent atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combina | 2006 |
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; | 2006 |
Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Follow | 2007 |
Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Chronic Disease; C | 2006 |
Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Amiodarone; Analysis of Variance; Atrial Fibrilla | 2007 |
Monophasic versus biphasic waveform shocks for atrial fibrillation cardioversion in patients with concomitant amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Combined Modality | 2007 |
Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiograph | 2007 |
Pulmonary vein isolation and linear lesions in atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Ele | 2006 |
Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
Topics: Adrenergic Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2007 |
[Comparison between therapeutic effects of acupuncture and intravenous injection of amiodarone in the treatment of paroxymal atrial fibrillation and atrial flutter].
Topics: Acupuncture Therapy; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2007 |
Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electric Counter | 2007 |
Practical regimen for amiodarone use in preventing postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2007 |
Practical regimen for amiodarone use in preventing postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2007 |
Practical regimen for amiodarone use in preventing postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2007 |
Practical regimen for amiodarone use in preventing postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2007 |
Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; | 2007 |
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Defibrillator | 2007 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 2007 |
Prognostic predictors of sinus rhythm control by amiodarone and electrical cardioversion in patients undergoing percutaneous transluminal mitral valvuloplasty for rheumatic atrial fibrillation.
Topics: Adult; Amiodarone; Angioplasty, Balloon; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterizatio | 2007 |
Intravenous and oral amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality The | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Is short-term amiodarone use post cardiac surgery a cause of acute respiratory failure?
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Gas Analysis; Ca | 2007 |
Comparative study of intravenous amiodarone and procainamide in the treatment of atrial fibrillation of recent onset.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Digoxi | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Hyper | 2007 |
Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide.
Topics: Action Potentials; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; El | 2007 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitali | 2008 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitali | 2008 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitali | 2008 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitali | 2008 |
[New facts about pathogenesis of atrial fibrillation: correlation between changes in bioelectric brain activity and recurrence of atrial fibrillation paroxysms].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticonvulsants; Atrial Fibrillation; Beta Rhythm; Brain; Clonaz | 2007 |
Impact of amiodarone on the ability of anterior fat pad retention to prevent postcoronary arterial bypass grafting atrial fibrillation incidence: a substudy of the AFIST III (Atrial Fibrillation Suppression Trial III).
Topics: Adipose Tissue; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Connecticut; Coronary | 2008 |
A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; | 2008 |
Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fib | 2008 |
Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibril | 2008 |
[Circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Results of the APAF trial].
Topics: Adolescent; Adult; Aged; Amiodarone; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
Amiodarone versus quinidine in the prophylaxis of atrial fibrillation.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Clinical Trials as Topic; Coronary Disease; Fem | 1981 |
[Short-term therapy of atrial fibrillation with an association of digitalis and amiodarone (author's transl)].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digitalis Glycosides; Drug Therapy, Combi | 1980 |
[Acute atrial fibrillation in the emergency room. Which is the best drug for a rapid sinus rhythm conversion?].
Topics: Acute Disease; Adult; Aged; Amiodarone; Atrial Fibrillation; Emergencies; Female; Humans; Male; Midd | 1994 |
Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study.
Topics: Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Digo | 1995 |
A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachyarrhythmia.
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Female; Follow-Up Studi | 1994 |
[Amiodarone and verapamil/quinidine in treatment of patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Drug; Drug Admin | 1994 |
Low-dose amiodarone should not be the first-line treatment for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; | 1994 |
Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Confidence Intervals; Double-Blind Method; Flecainide; | 1995 |
[Value of cibenzoline in the preventive treatment of recurrent atrial arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 1994 |
[A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Heart Rate; H | 1994 |
A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Digoxin; Female; | 1994 |
Amiodarone and the development of ARDS after lung surgery.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Humans; Incidence; Middle Aged; Pneumonectomy; Postope | 1994 |
[Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Humans; Male; Middle Aged; Pr | 1993 |
The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 1996 |
Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; Dos | 1995 |
Verapamil as prophylactic treatment for atrial fibrillation after lung operations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; Hypotension; Incidence | 1996 |
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 1996 |
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 1996 |
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 1996 |
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 1996 |
The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Fe | 1996 |
Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Bl | 1997 |
Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Clinical Protocols; Feasibility Stu | 1997 |
Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Double-B | 1997 |
[A trial of the long-term use of Sedacorone (amiodarone) under polyclinic conditions for the prevention of paroxysms of atrial fibrillation].
Topics: Aged; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 1997 |
Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Stud | 1998 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Effect of antiarrhythmic therapy with intravenous loading dose of amiodarone: evidence for an altered response in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fib | 1998 |
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Electroca | 1998 |
Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Humans; Infusions, Intrave | 1998 |
Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Departmen
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiogra | 1998 |
Low energy intracardiac cardioversion of persistent atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Cat | 1998 |
Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocard | 1999 |
Efficacy of amiodarone for the termination of persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Confounding Factors, Epidemiologic; D | 1999 |
Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Electrocardiography | 1999 |
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electrocardiography; | 1999 |
Amiodarone for the treatment of persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 1999 |
Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial | 1999 |
Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Double-B | 1999 |
Evaluation of biatrial pacing, right atrial pacing, and no pacing in patients with drug refractory atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Ar | 1999 |
Limited internal shocks for atrial fibrillation refractory to external cardioversion.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease- | 1999 |
Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response R | 1999 |
Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart Ra | 1999 |
Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Coun | 2000 |
Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
[Should sinus rhythm be restored in patients with chronic atrial fibrillation? Preliminary results from the Polish "Hot Cafe" study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chronic Disease; Dicu | 1999 |
Medical cardioversion of atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; | 2000 |
Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Res | 2000 |
Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Res | 2000 |
Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Res | 2000 |
Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Res | 2000 |
A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Topics: Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; | 2000 |
Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Coronary Artery Bypass; Female | 2000 |
Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2000 |
Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Female; Human | 2000 |
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atria | 2000 |
Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Dist | 2000 |
Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Electr | 2000 |
Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Fem | 2000 |
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Inte | 2000 |
Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Failure; Heart Rate; Hu | 2000 |
Is either sotalol or amiodarone more effective than digoxin for converting patients with new-onset atrial fibrillation (AF) to sinus rhythm within 48 hours?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Treatment Outcome | 2000 |
Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbon Diox | 2000 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countersho | 2000 |
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countersho | 2000 |
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countersho | 2000 |
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countersho | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
Efficacy and safety of transvenous atrial cardioversion in patients with mitral valve disease and long-standing atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizati | 2000 |
Diagnostic accuracy of KL-6 as a marker of amiodarone-induced pulmonary toxicity.
Topics: Adult; Aged; Amiodarone; Antigens; Antigens, Neoplasm; Atrial Fibrillation; Biomarkers; C-Reactive P | 2000 |
Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgica | 2001 |
Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypas | 2001 |
Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; APACHE; Atrial Fibrillation; Atrial | 2001 |
Efficacy of low-dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type IA antiarrhythmic drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Resistance; Female; Humans; Male | 2000 |
Early reinitiation of atrial fibrillation following external electrical cardioversion in amiodarone-treated patients.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Combined | 2001 |
Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Female; Humans; Inf | 2001 |
Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery.
Topics: Aged; Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Heart Valves; Human | 2001 |
Prevention of atrial fibrillation after cardiac surgery: the significance of postoperative oral amiodarone.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopulmonary | 2001 |
An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Cost-Ben | 2002 |
Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Digoxin; Drug Thera | 2002 |
Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Electric Counter | 2001 |
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Catheter Ablat | 2002 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Costs and Cost | 2002 |
[Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion].
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Drug Evaluation; Electric Countershock; Female; | 1978 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
Amiodarone dosage in older patients with atrial fibrillation: an open, multi-centre study.
Topics: Aged; Amiodarone; Atrial Fibrillation; Drug Administration Schedule; Electrocardiography; Female; Hu | 1992 |
[Prospective course of therapy arresting attacks of atrial fibrillation in patients with preexcitation syndromes].
Topics: Adult; Aged; Aged, 80 and over; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 1992 |
Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Electrocardiography; Fe | 1992 |
[A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation].
Topics: Amiodarone; Analysis of Variance; Atrial Fibrillation; Delayed-Action Preparations; Disopyramide; Fo | 1992 |
Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans | 1992 |
Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Clinical Protocols; Electric Countershock; Follow- | 1992 |
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography, Ambulatory; | 1992 |
[Amiodarone and its infusion velocity in recent-onset atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; H | 1991 |
Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study.
Topics: Aged; Amiodarone; Analysis of Variance; Arrhythmias, Cardiac; Atrial Fibrillation; Chi-Square Distri | 1991 |
Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm.
Topics: Aged; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; Randomized Control | 1990 |
Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Card | 1990 |
[Comparison of amiodarone and quinidine in the conversion to sinusal rhythm of atrial fibrillation of recent onset].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Echocardiography; Female; Humans; Mal | 1990 |
Amiodarone: value of programmed electrical stimulation and Holter monitoring.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiac Pacing, Artificial; Clin | 1986 |
[Cordaron in the treatment of patients with paroxysmal rhythm disorders].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofur | 1986 |
Interatrial conduction block with retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmias: influence of preventive antiarrhythmic treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; | 1989 |
Amiodarone in the management of atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Humans; Myocardial Infarction | 1986 |
Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report).
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Disopyramide; Female; Humans; Ma | 1986 |
Oral flecainide for prophylaxis of paroxysmal atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; Female; Flecai | 1988 |
Amiodarone in the management of refractory atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Clinical Trials as Topic; Drug Administration Schedule | 1987 |
989 other studies available for amiodarone and Atrial Fibrillation
| Article | Year |
|---|---|
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; | 2007 |
Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; H | 2021 |
Polypharmacy Is Associated With Amiodarone-Induced Hypothyroidism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Drug Interactio | 2021 |
Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Medicare; Physic | 2021 |
Ten-year trends in prescribing of antiarrhythmic drugs in Australian primary care patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Humans; Primary Health Care | 2021 |
Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Coronary Artery Bypass; Humans; Lengt | 2021 |
Incidence of Post-Heart Transplant Chronic Thyroiditis and Its Association With Pretransplant Amiodarone Use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Transplantation; Humans; Incidence; M | 2021 |
International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2022 |
[The Chinese expert recommendations on the clinical use of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; China; Dronedarone; Humans | 2021 |
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.
Topics: Adonis; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; | 2022 |
Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hemorrhage; | 2022 |
In vivo and cellular antiarrhythmic and cardiac electrophysiological effects of desethylamiodarone in dog cardiac preparations.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Heart Atr | 2022 |
[Amiodarone: some toxicity considerations].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart; Humans | 2022 |
Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; | 2022 |
Effectiveness of amiodarone versus digitalis for heart rate control in critically ill patients with new-onset atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Illness; | 2022 |
AIM-AF: A Physician Survey in the United States and Europe.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Physicians; Surveys and Questionnai | 2022 |
Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
Topics: Aged; Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Fe | 2022 |
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Car | 2022 |
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
Topics: Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; | 2022 |
Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Electric Co | 2022 |
Amiodarone versus digoxin for acute rate control of atrial fibrillation in the emergency department.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Emergency Service, Hospital; Heart | 2022 |
Associations among Plasma Concentrations of Edoxaban and M-4, Prothrombin Time, and the SLCO1B1*15 Haplotype in Patients With Nonvalvular Atrial Fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Haplotypes; Humans; Liver-Specific Organic Anion Transporter 1; Pro | 2023 |
Pneumonia and de novo atrial fibrillation in a patient with myotonic dystrophy type 1: A case report.
Topics: Amiodarone; Anti-Bacterial Agents; Atrial Fibrillation; Humans; Myotonic Dystrophy; Oxygen; Pneumoni | 2022 |
New onset atrial fibrillation during orthotopic liver transplantation induced by iced saline injection for transpulmonary thermodilution: a case report.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Output; Humans; Ice; Liver Transplantation; Male; Middle Ag | 2022 |
Adolescent Persistent Atrial Fibrillation Concomitant with Pectus Excavatum.
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Catheter Ablation; Funnel Chest; Heart Atria; Hu | 2023 |
Should we limit antiarrhythmic drug choice in patients with left ventricular hypertrophy?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypertrophy, Left Ventricular | 2023 |
Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Cas | 2023 |
Atrial fibrillation onset before heart failure or vice versa: what is worst? A nationwide register study.
Topics: Amiodarone; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Brain Ischemia; Heart Fail | 2023 |
The short-long-short-short sequence and polymorphic ventricular tachycardias storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Tachycardia, V | 2023 |
The short-long-short-short sequence and polymorphic ventricular tachycardias storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Tachycardia, V | 2023 |
The short-long-short-short sequence and polymorphic ventricular tachycardias storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Tachycardia, V | 2023 |
The short-long-short-short sequence and polymorphic ventricular tachycardias storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Tachycardia, V | 2023 |
Safety and Efficacy of Prophylactic Amiodarone After Left Ventricular Assist Device.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart-Assist Devices; Humans; Retrospective | 2023 |
Relationship between amiodarone response prior to ablation and 1-year outcomes of catheter ablation for atrial fibrillation.
Topics: Ablation Techniques; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Hum | 2023 |
Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; | 2023 |
Evaluation of RETRO-Mapping for electrophysiological features including direction of plane activity during atrial fibrillation using multipolar catheters in humans.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Electrophysiology; Catheter Ablation; Catheters; Heart Atri | 2023 |
A value-based budget impact model for dronedarone compared with other rhythm control strategies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Sotalol | 2023 |
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brain | 2023 |
Effectiveness of pharmacological cardioversion of new-onset atrial fibrillation during thoracic surgery operations: a single-centre experience.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; China; Electric Countershock; Humans; Thora | 2023 |
Intravenous bolus potassium: Appropriate indication in recurrent ventricular fibrillation.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Infusions, Intravenous; Injections, I | 2023 |
Mortality associated with antiarrhythmic medication for atrial fibrillation among patients with left ventricular hypertrophy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypertrophy, Left Ventricular | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; | 2023 |
Postoperative Atrial Fibrillation After Surgical Aortic Valve Replacement: Amiodarone and Warfarin Use.
Topics: Amiodarone; Anticoagulants; Aortic Valve; Atrial Fibrillation; Humans; Postoperative Complications; | 2023 |
Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Femal | 2023 |
Three-dimensional electroanatomical mapping for guidance of pulmonary vein isolation as treatment for persistent atrial fibrillation in a dog.
Topics: Amiodarone; Animals; Atrial Fibrillation; Catheter Ablation; Dog Diseases; Dogs; Heart Atria; Male; | 2023 |
The Price of Keeping the Rhythm: Increased Bleeding Risk in Patients With Atrial Fibrillation Concurrently Prescribed Amiodarone and Factor Xa Inhibitors.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Factor Xa Inhibitors; Humans | 2023 |
Reducing New-Onset Atrial Fibrillation After Coronary Artery Bypass Graft Surgery.
Topics: Administration, Oral; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Co | 2019 |
Man in His 90s With a History of Tachycardia and Abnormal Findings on Slitlamp Examination of the Cornea.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Corneal Opacity; Epithel | 2020 |
Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Denmark; Fe | 2020 |
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications, | 2020 |
Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Embolic Stroke; Humans; Muscul | 2020 |
Skin Discoloration from Amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Pigmentati | 2020 |
In silico study of the effects of anti-arrhythmic drug treatment on sinoatrial node function for patients with atrial fibrillation.
Topics: Acetylcholine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Humans; Isoprote | 2020 |
[HEPATOCELLULAR TOXICITY IN THE BACKGROUND OF AMIODARON-INDUCED THYROID DYSFUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Hum | 2019 |
Utility of Amiodarone Pre-Treatment as a Facilitator of the Acute Success of Electrical Cardioversion in Persistent Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Heart | 2020 |
The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Co | 2020 |
Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Digoxin; Drug Therapy | 2020 |
[Influence of amiodarone on the spectral analysis of heart rate variability in patients with atrial fibrillation elderly and senile age.]
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Humans; Treatment Outcome | 2019 |
Commentary: Amiodarone and anticoagulation in postoperative atrial fibrillation: Less is more?
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Humans; Postoperative Perio | 2021 |
Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Canada; Clinical Deci | 2021 |
Impact of emergency department management of atrial fibrillation with amiodarone on length of stay. A propensity score analysis based on the URGFAICS registry.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Emergency Service, Ho | 2020 |
Mixed drug reaction to amiodarone characterized by sequential immediate, immune complex, and delayed hypersensitivity.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Hypersensitivity; H | 2020 |
Inhibitory Effects of Dronedarone on Small Conductance Calcium Activated Potassium Channels in Patients with Chronic Atrial Fibrillation: Comparison to Amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Dronedarone; Female; Heart | 2020 |
TORSADES DE POINTES IN ELDERLY PATIENT WITH PAROXYSMAL ATRIAL FIBRILLATION TREATED BY SHORT-TERM PARENTERAL AMIODARONE THERAPY.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Ele | 2019 |
[Acute amiodarone pulmonary toxicity with low impregnation dose: case report].
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, | 2020 |
Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substi | 2020 |
The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, | 2020 |
Ranolazine depresses conduction of rapid atrial depolarizations in a beating rabbit heart model.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Rab | 2021 |
Altered Mental Status and Hyponatremia After 20 Hours of Amiodarone Therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Hy | 2020 |
The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Infusions, Intravenous; Mal | 2021 |
Amiodarone-induced neuromyopathy in a geriatric patient.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electromyography; Female | 2020 |
External Cardioversion-Defibrillation with Pushing Down on the Chest Wall to Increase the Success Rate in Obese Patients.
Topics: Adolescent; Aged; Amiodarone; Atrial Fibrillation; Electric Countershock; Female; Humans; Male; Midd | 2020 |
Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; China; Humans; Prospective Studies; R | 2020 |
Frontal plane QRS-T angle in the monitoring of intravenous amiodarone infusion for pharmacological cardioversion of acute atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Electrocardiography; Fem | 2021 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2021 |
Amiodarone-induced type 2 thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Thyrotoxicosis | 2021 |
Risk of intravenous amiodarone in patients with atrial fibrillation and ventricular preexcitation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Pre-Excitation Syndromes | 2021 |
Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2021 |
Amiodarone is associated with increased short-term mortality in elderly atrial fibrillation patients with preserved ejection fraction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Middle Aged; Retrospective St | 2022 |
Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Ca | 2021 |
Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Electrocardiography | 2021 |
Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; | 2021 |
Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Ma | 2021 |
Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial | 2021 |
Treatment of Postoperative New Onset Atrial Fibrillation with Repolarization Delaying Agents after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Dronedarone; H | 2021 |
Management of Amiodarone in the Long-Term Care Setting.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Long-Term Care | 2021 |
Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Critical Care; Databases, Factual; Diltiaz | 2017 |
Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiologists; Critical Illness; Depr | 2017 |
Amiodarone and Beta-Blockers in Patients With Heart Failure and Atrial Fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; | 2017 |
Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Atrial Fibrillation; Disease Models, A | 2017 |
eComment. Amiodarone-induced pulmonary toxicity in patients with atrial fibrillation undergoing lung resection.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Pneumonectomy | 2017 |
Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome.
Topics: Adenine; Aged; Amiodarone; Atrial Fibrillation; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions | 2016 |
Topical amiodarone during cardiac surgery: Does epicardial application of amiodarone prevent postoperative atrial fibrillation?
Topics: Administration, Topical; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2017 |
Topical amiodarone: To be or not to be effective?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postop | 2017 |
Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Female; Follow-Up | 2017 |
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
Pulmonary embolism four days after interruption of therapy with rivaroxaban.
Topics: Administration, Oral; Amiodarone; Atrial Fibrillation; Drug Administration Schedule; Drug Therapy, C | 2017 |
Delayed Onset of Atrial Fibrillation and Ventricular Tachycardia after an Automobile Lightning Strike.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Eme | 2017 |
Amiodarone-induced pulmonary toxicity.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases; M | 2017 |
Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrial Remodeling; Dronedarone; Heart Diseases; Humans; Hy | 2017 |
Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrilla | 2018 |
Amiodarone Protocol Provides Cost-Effective Reduction in Postoperative Atrial Fibrillation.
Topics: Aged; Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Case-Control Studies; Cohort Stu | 2018 |
Intravenous amiodarone-induced acute liver failure in cardiac surgery intensive care unit.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Critical | 2018 |
The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2018 |
Cough as the sole manifestation of pericardial effusion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cough; Echocardiography; | 2018 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Stud | 2018 |
Invited Commentary.
Topics: Amiodarone; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Postoperative Period | 2018 |
Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Carri | 2018 |
Re-gaining confidence in contemporary dronedarone use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2018 |
Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Pathways; | 2018 |
Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Piperid | 2019 |
Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hydroxymethylglutaryl-CoA Reductase | 2018 |
Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antipsychotic Agents; Aripiprazole; Atrial Fibrillation; | 2018 |
Transient new-onset atrial fibrillation during general thoracic operations and its treatment with amiodarone: a retrospective analysis in a single centre.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Esophageal Neoplasms; Female; Humans; Intra | 2019 |
Ventricular Tachycardia (VT) Storm After Cryoballoon-Based Pulmonary Vein Isolation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurgery; Defibrillators, Implantable; H | 2018 |
Ventricular repolarization wave variations during the amiodarone treatment course.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Arrhy | 2018 |
A Shiny Liver!
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induce | 2019 |
Usefulness of Heart Rate Control in Atrial Fibrillation Patients With Obstructive Sleep Apnea.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2018 |
Crazy Paving Pattern.
Topics: Aged, 80 and over; Amiodarone; Anti-Bacterial Agents; Atrial Fibrillation; Dyspnea; Female; Glucocor | 2018 |
Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Femal | 2018 |
Occurrence of significant long PR intervals in patients implanted for sinus node dysfunction and monitored with SafeR™: The PRECISE study.
Topics: Action Potentials; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2019 |
Focal myositis and contracture secondary to amiodarone extravasation from a peripheral cannula.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Catheterization; Electric Countershock; Humans; Injection S | 2019 |
Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Female; | 2019 |
Esmolol Compared with Amiodarone in the Treatment of Recent-Onset Atrial Fibrillation (RAF): An Emergency Medicine External Validity Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; | 2019 |
Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Combined Modality The | 2019 |
Drugs, the Thyroid, and the Heart: A Lethal Cocktail.
Topics: Agranulocytosis; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Carbim | 2019 |
Amiodarone for prevention of atrial fibrillation following esophagectomy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Chemoprevention | 2019 |
Commentary: We can prevent postesophagectomy atrial fibrillation, but should we?
Topics: Amiodarone; Atrial Fibrillation; Esophagectomy; Humans | 2019 |
Commentary: Two ounces of prevention does not equal a pound of cure.
Topics: Amiodarone; Atrial Fibrillation; Esophagectomy; Humans; Socioeconomic Factors | 2019 |
The effects of amiodarone prophylaxis on cardiac dysrhythmia in acute aluminium phosphide poisoning.
Topics: Adolescent; Adult; Aluminum Compounds; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose | 2019 |
Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2019 |
Assessing severe alteration of tissue perfusion during atrial fibrillation using esophageal photoplethysmography.
Topics: Acute Disease; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pre | 2019 |
Pseudo-Ventricular Tachycardia, Pseudo-Atrial Fibrillation, and Pseudo-Atrial Flutter in a Patient With Parkinson Disease: Two's Company, Three's a Crowd.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; El | 2019 |
Amiodarone toxicity and the acute respiratory distress syndrome.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchoalveolar Lavage Fluid; Humans; | 2019 |
Rate and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Denmark; Fe | 2019 |
Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Female; Hum | 2019 |
Happy 50th anniversary of amiodarone (1969-2019).
Topics: Amiodarone; Anniversaries and Special Events; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; V | 2019 |
Use and Outcomes Associated With Perioperative Amiodarone in Cardiac Surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Coron | 2019 |
Rate versus rhythm control in atrial fibrillation.
Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Algorithms; Amiodarone; Anti-Arrhythmia Agents; | 2013 |
Multi-channel blockers for treatment of atrial fibrillation: an effective strategy?
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Femal | 2013 |
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Topics: Acute Kidney Injury; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fi | 2013 |
A dire reaction: rash after amiodarone administration.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Exanthema; Female; Humans; Skin; Stev | 2013 |
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cl | 2013 |
Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; D | 2013 |
Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Atrial Fibrillation; Female; Glucocortico | 2013 |
Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cathe | 2013 |
Case of sorafenib-induced thyroid storm.
Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fib | 2013 |
Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2013 |
Clinical problem-solving. In the thick of it.
Topics: alpha-Galactosidase; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomegaly; Codon, N | 2013 |
Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Decision Making; Heart Rate; Huma | 2013 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2013 |
Amiodarone plus Flecainide combination therapy in patients with Amiodarone refractory paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Fl | 2013 |
Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Atria; Hum | 2013 |
Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disease Mode | 2013 |
Heart failure exacerbation associated with newly developed atrioventricular dyssynchrony after chemical conversion to a sinus rhythm in a patient receiving cardiac resynchronization therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Resynchronization Therapy; Defibril | 2013 |
The dronedarone shared-care clinical model and database: a coordinated paradigm to optimize management of evolving clinical recommendations.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical an | 2013 |
Facial discolouration -- a case study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Face; Humans | 2013 |
Severe toxic hepatitis associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2013 |
Conversion of recent onset atrial fibrillation: which drug is faster?
Topics: Administration, Oral; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; | 2013 |
Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Amb | 2013 |
Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2013 |
Amiodarone-related sinoatrial node dysfunction and its implications in the treatment of atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Female; Heart Rate; Humans; Male; Sinoatrial Node | 2013 |
Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Benzazepines; Cyclic Nucleotide-Gat | 2013 |
Fatal acute liver failure after intravenous amiodarone administration.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Fatal Outcome; Female; Humans; | 2015 |
The funny and not-so-funny effects of dronedarone.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Dronedarone; Electrocardiography; H | 2013 |
Dronaderone-induced phototoxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dermatitis, Phototoxic; Dronedarone; Drug E | 2013 |
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; | 2014 |
Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2013 |
[Unexpected atrial fibrillation when monitoring in operating room. Case of the trimester].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric C | 2014 |
[Appropriateness criteria for the treatment of atrial fibrillation with dronedarone: practical issues. An Italian cardiologists' expert opinion].
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as Topic | 2013 |
Predictive value of atrial electromechanical delay for atrial fibrillation recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Chi-Square Dis | 2013 |
Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein; Female; Humans; I | 2015 |
Amiodarone reduces the amount of ablation during catheter ablation for persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality | 2014 |
Non-standard dose dronedarone in treating atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Rela | 2014 |
Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Proc | 2013 |
Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Dronedarone; Heart Conduc | 2014 |
Amiodarone toxicity showing high liver density on CT scan with normal liver function and plasma amiodarone levels in a long-term amiodarone user.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2014 |
Assessment of dronedarone utilization using US claims databases.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Contraindications; Creatinine; Databases, Factual; Dro | 2014 |
Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2014 |
Multisystem side effects of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Fac | 2015 |
Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Eisenmenger Complex; Humans; Iodine | 2013 |
Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Heart | 2014 |
Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Dronedarone; Evidence-Based Medicin | 2014 |
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atr | 2014 |
Safety of dronedarone in routine clinical care.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Failure; H | 2014 |
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2014 |
Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Hospitalization; Humans; Incid | 2014 |
A novel amiodarone-eluting biological glue for reducing postoperative atrial fibrillation: first animal trial.
Topics: Alginates; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biocompatible Materials | 2014 |
Reply to Patel and Hunt.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Lung Neoplasms; Male | 2015 |
The evidence for routine anti-arrhythmic prophylaxis in patients undergoing pulmonary resection surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Lung Neoplasms; Male | 2015 |
Effects of intravenous amiodarone and ibutilide on action potential duration and atrial conduction kinetics in patients with persistent atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Respon | 2014 |
Editorial: advances in the therapy of atrial fibrillation: incrementally progressive but not without missteps.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug | 2014 |
Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Hyper | 2014 |
An adverse reaction to a medication given to treat an adverse reaction: a teachable moment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Febrile Neutropen | 2014 |
[Therapeutic use of amiodarone against postoperative fibrillation after cardiac surgery].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Dise | 2014 |
Does the addition of atrial pacing to amiodarone reduce the incidence of postoperative atrial fibrillation: a pilot study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiogr | 2014 |
Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Embo | 2014 |
Use of amiodarone after major lung resection.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Middle Age | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor | 2014 |
Why amiodarone failed to lower the rate of recurrence six months after catheter ablation for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Ta | 2014 |
Results of preventive radioiodine therapy in euthyroid patients with history of hyperthyroidism prior to administration of amiodarone with permanent atrial fibrillation--a preliminary study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Rela | 2014 |
The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2015 |
Arrhythmias: Amiodarone fails to lower AF recurrence in AMIO-CAT trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Ta | 2014 |
Efficacy and safety of amiodarone in patients with atrial fibrillation in the era of target-specific anticoagulants.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Female; Humans; Male | 2014 |
Bulk muscles, loose cables.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dietary Supplements; Electrocardiography; H | 2014 |
Amiodarone induced pulmonary toxicity in a case of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Pulmonary Fibros | 2014 |
Amiodarone-related thyroid dysfunction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; Hypothyroidism; Thyr | 2014 |
Amiodarone-induced thyrotoxicosis: type 1 or type 2?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Carbimazole; Gluc | 2014 |
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Dos | 2014 |
The diagnostic utility of chest computed tomography scoring for the assessment of amiodarone-induced pulmonary toxicity.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Sectional Studies; Cryptogenic | 2014 |
Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Disease-Free Surviva | 2015 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Droneda | 2015 |
Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Fatal Outcome; F | 2015 |
Improvement of the myocardial performance index in atrial fibrilation patients treated with amiodarone after cardioversion.
Topics: Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Chronic Disease; Cohort Studies; Combin | 2015 |
Association of amiodarone use with acute pancreatitis in patients with atrial fibrillation: a nested case-control study.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; | 2015 |
Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Caffeine; Drug Overdose; Echocardiog | 2014 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
Effects of dronedarone on ventricular repolarization and repolarization dynamics in patients with preserved left ventricular systolic function.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Ambulator | 2015 |
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Topics: Aged; Amiodarone; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dr | 2015 |
Diffuse alveolar damage in a patient receiving dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dron | 2015 |
Acute severe back pain radiating to the whole body during intravenous administration of amiodarone.
Topics: Acute Pain; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Back Pain; Drug Substitution; H | 2015 |
Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Comorbid | 2015 |
Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion.
Topics: Aged; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; | 2016 |
Edoxaban and amiodarone: interactions on multiple levels.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Pyrid | 2015 |
Vortex Keratopathy: Fabry Related or Amiodarone Induced?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cornea; Corneal Diseases; Diagnosis, Differ | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2016 |
The effect of the amiodarone-warfarin interaction on anticoagulation quality in a single, high-quality anticoagulation center.
Topics: Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Drug Combinations; Female; | 2016 |
Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2016 |
Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzamides; Carcinoma, Hepatocellular | 2015 |
Hepatic computed tomography changes caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induce | 2015 |
Amiodarone-Induced Life-Threatening Refractory Hypotension.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypotension; Male | 2015 |
Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dru | 2015 |
Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2015 |
A possible strike on postoperative atrial fibrillation with the bullet amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Carriers; Female; Humans; Male; Polyet | 2016 |
Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; H | 2016 |
Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; California; Dose-Response Relationshi | 2015 |
Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiograph | 2016 |
New-Onset Heart Failure in a Patient With a Pacemaker: An Unusual Cause.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Atrial Fibrillation; Bisoprolol; Ca | 2016 |
From Atrial Fibrillation to Ventricular Fibrillation and Back.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiopulmonary Resuscitation; Catheter Ablation; Combined M | 2015 |
[Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchiectasis; Drug Therapy, Combina | 2015 |
Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies; Catheter Ab | 2016 |
Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Hospitalizati | 2016 |
Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Female; Humans; Male; | 2016 |
Amiodarone for atrial fibrillation: Friend or foe?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Humans | 2015 |
Obesity Is Associated With the Development of Interstitial Pneumonia Under Long-Term Administration of Amiodarone in Refractory Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2016 |
Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans | 2016 |
Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans | 2016 |
Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans | 2016 |
Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans | 2016 |
Considerations for the success of topical amiodarone to prevent postoperative atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans | 2016 |
Combinatorial release of dexamethasone and amiodarone from a nano-structured parylene-C film to reduce perioperative inflammation and atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cell Survival; Dexamethasone; Drug | 2016 |
Postoperative medication management after surgical ablation: Clarifying the role of amiodarone therapy.
Topics: Ablation Techniques; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Rate; Hu | 2016 |
Prophylactic amiodarone: Use it or not?
Topics: Ablation Techniques; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Rate; Hu | 2016 |
Prophylactic amiodarone reduced the recurrence of atrial arrhythmias.
Topics: Ablation Techniques; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Rate; Hu | 2016 |
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Transplantation; | 2016 |
Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Cr | 2016 |
Dabigatran malabsorption in amiodarone-induced thyrotoxicosis: a clinical report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dabigatran; Echocardiography; Humans; | 2016 |
Polish and European management strategies in patients with atrial fibrillation. Data from the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot).
Topics: Aged; Amiodarone; Anticoagulants; Atrial Fibrillation; Cardiology; Catheter Ablation; Disease Manage | 2016 |
Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Bepri | 2016 |
Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Critical Illness; Fem | 2016 |
Anti-atrial Fibrillatory Versus Proarrhythmic Potentials of Amiodarone: A New Protocol for Safety Evaluation In Vivo.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; | 2017 |
Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Canada; Comorbidity; Coronary Artery Bypas | 2016 |
Is Less More for the Treatment of Atrial Fibrillation after Cardiac Surgery?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Heart | 2016 |
Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Ele | 2016 |
Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2017 |
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Prescriptions; Drug Utili | 2016 |
Rise and fall of dronedarone: the need for new drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2016 |
Design, Challenges, and Implications of Quality Improvement Projects Using the Electronic Medical Record: Case Study: A Protocol to Reduce the Burden of Postoperative Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Proto | 2016 |
Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Heart Rate; Hu | 2016 |
Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Heart Rate; Hu | 2016 |
Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Heart Rate; Hu | 2016 |
Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Heart Rate; Hu | 2016 |
Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Heart Rate; Hu | 2016 |
Letter from Turco Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Letter from Willey and Biviano Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Letter from Kosiuk et al Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Letter from Liu and Yang Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Letter from Skolnik Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Response by Di Biase et al to Letter Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial".
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans | 2016 |
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relatio | 2017 |
Antiarrhythmic effect of the Ca
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Synergism; Guinea Pigs; Heart | 2016 |
Peripheral Phlebitis Related to Amiodarone Infusion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care Nursing; Humans; Phlebitis; P | 2016 |
Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography | 2017 |
Sinusal reversion of supraventricular tachyarrhythmias after propofol administration. A case series.
Topics: Adenosine; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Fema | 2017 |
Short-term treatment with oral amiodarone resulting in bilateral optic neuropathy and permanent blindness.
Topics: Administration, Oral; Aftercare; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blin | 2017 |
Con: Atrial Fibrillation Prophylaxis Is Not Necessary in Patients Undergoing Major Thoracic Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Thoracic Surgery | 2017 |
ECG of the Month.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electric Cou | 2017 |
Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2017 |
[From where come the spot-form shadows in thoracic radiography? Corticoids make them disappear].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation | 2008 |
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Atrial Fibri | 2008 |
[Amiodarone--still a useful antiarrhythmic drug].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Inte | 2008 |
Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Male; | 2008 |
Combination prophylactic therapy for post-operative atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 2008 |
[Effects of pretreatment with amiodarone infusion in patients with persistent atrial fibrillation submitted to external electrical cardioversion: a single center experience].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Data Interpretation, Statistical; Electric | 2008 |
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiotonic Agents; Clinica | 2008 |
Hepatic dysfunction and neurotoxicity in a patient receiving long-term low-dose amiodarone therapy.
Topics: Aged, 80 and over; Amiodarone; Ammonia; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Dr | 2010 |
Amiodarone and optic neuropathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Incidence; Optic Nerve Diseases; Un | 2008 |
Amiodarone pulmonary toxicity after lung transplantation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopulmonary Bypass; Humans; Lung Transp | 2008 |
The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; | 2008 |
I was told to stop taking my daily betablocker (Coreg)before a myocardial perfusion test. I was hospitalized with chest pain and a bout of atrial fibrillation. I have cardiomyopathy and was prescribed amiodarone and warfarin, but I stopped taking them w
Topics: Adrenergic beta-Antagonists; Amiodarone; Anticoagulants; Atrial Fibrillation; Cardiomyopathies; Ches | 2008 |
A formula for the stratified selection of patients with paroxysmal atrial fibrillation in the emergency setting: a retrospective pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Decision Support Tech | 2011 |
Amiodarone induced pneumonitis and hyperthyroidism: case report.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Humans; Hyperthyro | 2008 |
Successful conversion of recent-onset atrial fibrillation by sequential administration of up to three antiarrhythmic drugs.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Admini | 2008 |
The need for adequate rate control points to amiodarone as the drug of choice for treating critically ill patients with acute onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Illness; Humans | 2008 |
[Current pharmacological management of atrial fibrillation management by practice cardiologists - news from congress in Munich].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Cardiology; Congresses as | 2008 |
Amiodarone-tacrolimus interaction in kidney transplantation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dru | 2008 |
Facial hyperpigmentation. amiodarone-induced hyperpigmentation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Facial Derma | 2008 |
[The concise history of atrial fibrillation].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Physiological Pheno | 2007 |
A survey of thyroid function test abnormalities in patients presenting with atrial fibrillation and flutter to a New Zealand district hospital.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2008 |
Does the postrepolarization refractoriness play a role in amiodarone's antiarrhythmic efficacy?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Disease Models, A | 2008 |
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Funct | 2008 |
Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Atrial Fibrillation; Contrast Media; Humans; Iopanoic Acid; Male; Middle Aged; Thyroidec | 2008 |
[Therapeutic aims for atrial fibrillation in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2009 |
[Glass of water or ablation? - episodes of malignant atrial tachyarrhythmias during swimming in a lake in a woman with overt Wolff-Parkinson-White syndrome and benign palpitations for several decades of life].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter | 2008 |
Hepatotoxicity after intravenous amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2008 |
Alternatives to amiodarone: search for the Holy Grail.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Combined Modality Therapy; Dos | 2009 |
Treatment with amiodarone to prevent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans | 2009 |
Treatment with amiodarone to prevent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans | 2009 |
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.
Topics: Acetylcholine; Action Potentials; Adrenergic beta-Agonists; Amiodarone; Animals; Anti-Arrhythmia Age | 2009 |
Trial watch: novel antiarrhythmic agent shows promise in Phase III trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Droned | 2009 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
No elevation of glutathione S-transferase-a1-1 by amiodarone loading in intensive care unit patients with atrial fibrillation.
Topics: Adult; Aged; Alanine Transaminase; Amiodarone; Anti-Arrhythmia Agents; Aspartate Aminotransferases; | 2009 |
Dronedarone for atrial fibrillation--an odyssey.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinic | 2009 |
New pharmacological options for patients with atrial fibrillation: the ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Endpoint Determination; Humans | 2009 |
Why amiodarone is better: another piece of the puzzle.
Topics: Acetylcholine; Action Potentials; Adrenergic beta-Agonists; Amiodarone; Animals; Anti-Arrhythmia Age | 2009 |
[A hypertensive patient with atrial fibrillation has increasing dyspnea. Cardiac or pulmonary etiology?].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dyspnea; Electric Countershock; Femal | 2009 |
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation.
Topics: Amiodarone; Angiotensin II Type 2 Receptor Blockers; Atrial Fibrillation; Catheter Ablation; Drug Th | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; H | 2009 |
Dronedarone in atrial fibrillation.
Topics: Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Dr | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Hospi | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Human | 2009 |
Atrial fibrillation as a complication of dengue hemorrhagic fever: non-self-limiting manifestation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Male; S | 2009 |
Current use of prophylactic strategies for postoperative atrial fibrillation: a survey of Canadian cardiac surgeons.
Topics: Adrenal Cortex Hormones; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical P | 2009 |
The effect of pretreatment with renin-angiotensin-aldosterone system blockers on cardioversion success and acute recurrence of atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Elect | 2009 |
Dual atrioventricular-nodal physiology, elicited by pacing and leading to a reversible cardiomyopathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Arti | 2009 |
Invited commentary.
Topics: Age Factors; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fi | 2009 |
[Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Catheter | 2009 |
[What is your diagnosis. Myopathy due to hypothyroidism aggravated by amiodarone].
Topics: Accidental Falls; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagno | 2009 |
Amiodarone or dronedarone for atrial fibrillation: too early to know the winner?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rat | 2009 |
Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Hosp | 2009 |
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2009 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Co | 2009 |
Dronedarone (Multaq) for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug | 2009 |
[Cardiac symptoms in endocrinologic disorders. Heart illness caused by the thyroid gland].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Arrhythmias, Cardiac; Atrial Fi | 2009 |
[Efficacy of transesophageal pacing for correction of newly diagnosed atrial fibrillation of type I in patients with coronary heart disease].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Co | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema.
Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2011 |
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Drug Synergism | 2010 |
[Selective pituitary resistance to thyroid hormone in a patient treated with amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus, Type 2; Feedback, Physio | 2009 |
Inappropriate biventricular implantable cardioverter defibrillator firing due to cryptogenic double counting.
Topics: Amiodarone; Atrial Fibrillation; Defibrillators, Implantable; Heart Block; Humans; Male; Middle Aged | 2010 |
Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side | 2010 |
Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactiv | 2010 |
Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Middle Aged; Multicent | 2010 |
Results of atrial fibrillation ablation during mitral surgery in patients with poor electro-anatomical substrate.
Topics: Ablation Techniques; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2009 |
[Comparison of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Indirect meta-analysis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2010 |
FDA drug information that never reaches clinicians.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Appr | 2010 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electroc | 2010 |
Dronedarone is superior to placebo the case for optimism.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electroc | 2010 |
[Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2010 |
Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Comp | 2010 |
Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch.
Topics: Action Potentials; Administration, Topical; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibr | 2010 |
[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Bradycardia; Calcium | 2010 |
Case report: drug interaction between tacrolimus and amiodarone with QT prolongation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Diabetic Neph | 2010 |
A perspective on DIONYSOS.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled | 2010 |
[Acute myocardial infarction following persistent atrial fibrillation. Consequence, common etiology or a case?].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Coron | 2010 |
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Dis | 2010 |
Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial | 2010 |
Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose | 2010 |
Understanding amiodarone-induced hypothyroidism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Insufficiency; Atrial Fibrillation; Female; H | 2010 |
Relationship between oral amiodarone and inappropriate therapy from an implantable cardioverter defibrillator.
Topics: Aged; Amiodarone; Atrial Fibrillation; Defibrillators, Implantable; Female; Heart Diseases; Humans; | 2010 |
Rhythm control agents and adverse events in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Female; | 2010 |
The right stuff in the right place-the quest for atrial selective antiarrhythmic agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Delivery Systems; Drug Design | 2010 |
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Co | 2010 |
Dronedarone: a review of characteristics and clinical data.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans | 2010 |
Atrial fibrillation after cardiac surgery: incidence, risk factors, and economic burden.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedu | 2010 |
[Amiodarone-induced liver dysfunctions].
Topics: Alanine Transaminase; Amiodarone; Anti-Arrhythmia Agents; Aspartate Aminotransferases; Atrial Fibril | 2010 |
Amiodarone and dronedarone: the worker bee and the drone?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; | 2010 |
Worsening heart failure in the setting of dronedarone initiation.
Topics: Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Progression; D | 2010 |
Subocclusion of the sinus node artery during coronary angioplasty: arrhythmological considerations.
Topics: Acute Coronary Syndrome; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Atrial | 2010 |
Amiodarone-induced skin hyperpigmentation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Face; Hand; Humans; Hyperpigmentation | 2011 |
Dronedarone: where does it fit in the treatment of atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; D | 2010 |
Role of dronedarone in atrial fibrillation: more questions than answers.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Huma | 2010 |
A 2-year survey of treatment of acute atrial fibrillation in an ED.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2011 |
Acute liver injury after intravenous amiodarone: a case report.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induce | 2011 |
Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection (参麦注射液).
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Combinations; | 2010 |
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2010 |
Optimal timing of electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiog | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Treatment Outcome | 2010 |
Dronedarone. atrial fibrillation: too many questions about long-term adverse effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Euro | 2010 |
The dronedarone odyssey.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug | 2010 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2010 |
A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Dronedar | 2011 |
Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Randomized | 2010 |
Perioperative atrial arrhythmias in noncardiothoracic patients: a review of risk factors and treatment strategies in the veteran population.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Follow-Up Stud | 2010 |
[New antiarrhythmic drugs for treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Design; Electri | 2010 |
Transmitral isthmus conduction alternans.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophysiologic Techn | 2012 |
Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedu | 2010 |
Treatment of atrial fibrillation in 2010 and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Prevalence; Quality of | 2010 |
Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Drug Therap | 2010 |
Are neurological and other side effects truly less frequent in dronedarone compared to amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2010 |
Atrial arrhythmias after lung and heart-lung transplant: effects on short-term mortality and the influence of amiodarone.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2011 |
[Flecainide poisoning].
Topics: Aged; Amiodarone; Atrial Fibrillation; Cholecystectomy; Cholecystitis; Electrocardiography; Emergenc | 2010 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Algorithms; Amiodarone; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Combined Modality Th | 2011 |
[Comparison of the results of irrigated monopolar and bipolar radiofrequency ablation in the surgical treatment of atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ab | 2011 |
Anaphylactic shock due to intravenous amiodarone.
Topics: Amiodarone; Anaphylaxis; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous | 2012 |
Acute disabling low-back pain during intravenous administration of amiodarone: could intravenous to oral switch therapy be a safe strategy?
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, In | 2010 |
Torsade de pointes induced by citalopram and amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Depressive D | 2011 |
Lethal outcome after intravenous administration of amiodarone in patient with atrial fibrillation and ventricular preexcitation.
Topics: Adult; Amiodarone; Atrial Fibrillation; Fatal Outcome; Humans; Infusions, Intravenous; Male; Ventric | 2011 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Fleca | 2011 |
Topical application of a biodegradable disc with amiodarone for atrial fibrillation.
Topics: Absorbable Implants; Administration, Topical; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fi | 2011 |
Invited commentary.
Topics: Absorbable Implants; Administration, Topical; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2011 |
Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient.
Topics: Aged, 80 and over; Amiodarone; Amitriptyline; Anti-Arrhythmia Agents; Antidepressive Agents, Tricycl | 2010 |
Dronedarone for atrial fibrillation: How does it compare with amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans; Pre | 2011 |
Atrial fibrillation: AVRO--were the results a surprise?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Statistics as Topic; Sulfonamides | 2011 |
What's new in...atrial fibrillation. Is dronedarone more effective than amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
[Prophylactic use of amiodarone against postoperative atrial fibrillation after cardiac surgery].
Topics: Aged; Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Female; Heart Valves; Humans; Male; P | 2011 |
Rhythm control should be better for the management of patients with atrial fibrillation and heart failure--rhythm control vs. rate control: which is better in the management of atrial fibrillation? (Rhythm-side).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Female; Heart Fail | 2011 |
Rate control is a better initial treatment for patients with atrial fibrillation and heart failure--rhythm control vs. rate control: which is better in the management of atrial fibrillation? (Rate-side).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Female; Heart Fail | 2011 |
[Treatment of atrial fibrillation: when to use drugs or to perform ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic | 2010 |
Amiodarone causing a glowing liver in a patient with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Liver; Tomography, X- | 2011 |
Acute amiodarone hepatotoxicity after liver transplantation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Hepatocellular; C | 2011 |
The impact of dronedarone on lone atrial fibrillation: perhaps not such a "benign" arrhythmia?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2011 |
[Perspectives and recommendations for the anti-arrhythmic treatment of atrial fibrillation: focus on dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as | 2011 |
Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; E | 2011 |
Intravenous amiodarone facilitates electrical cardioversion in patients with persistent atrial fibrillation pre-treated with oral amiodarone.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relatio | 2011 |
Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Femal | 2011 |
Hospitalization: a relevant endpoint in atrial fibrillation management?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Human | 2011 |
Regional fractionation and dominant frequency in persistent atrial fibrillation: effects of left atrial ablation and evidence of spatial relationship.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophysiologic Techn | 2011 |
Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.
Topics: Acetanilides; Aged; Amiodarone; Atrial Fibrillation; Chi-Square Distribution; Coronary Artery Bypass | 2011 |
Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Docetaxel; Dro | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-A | 2011 |
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; | 2011 |
Falling between the cracks: a case of amiodarone toxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged | 2011 |
The backlash against bioequivalence and the interchangeability of brand-name and generic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drugs, Generic; Female; Humans; Male; Thyro | 2011 |
Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Male; Models, Animal; Potassium; P | 2011 |
Long-term efficacy of amiodarone therapy for the prevention of recurrence of paroxysmal atrial fibrillation. Analysis based on patient characteristics.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response R | 2011 |
Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2011 |
Acute liver failure associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Female; Humans; | 2011 |
Pharmacological treatment of atrial fibrillation: what does it take?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Male; Potassium Channels, Voltage- | 2011 |
Cryoablation of atrial fibrillation in cardiac surgery: outcomes and myocardial injury biomarkers.
Topics: Aged; Amiodarone; Anesthesia; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Biomarker | 2011 |
Thyroxine monotherapy without amiodarone enhances atrial fibrillation recurrences in amiodarone-induced hypothyroidism.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Comb | 2011 |
Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Co | 2011 |
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Chi-S | 2011 |
Native mitral valve causing left ventricular outflow tract obstruction in an adult with Ebstein's anomaly.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Ebstein Ano | 2011 |
The impact of dilated left atrium on rhythm control in patients with newly diagnosed persistent atrial fibrillation: the Belgrade atrial fibrillation project.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as | 2011 |
[The AVRO study].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Pyrrolidines; Randomized | 2011 |
Dronedarone in atrial fibrillation--Jekyll and Hyde?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.
Topics: Acute Coronary Syndrome; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blotting, | 2012 |
One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Ma | 2011 |
Short-term onset of fatal pulmonary toxicity in a patient treated with intravenous amiodarone for post-operative atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Fatal Outcome; Humans; Infusions, Int | 2012 |
An unusual adverse effect of nadroparin injections: Calcinosis cutis.
Topics: Adult; Amiodarone; Anticoagulants; Atrial Fibrillation; Biopsy; Calcinosis; Calcium; Enoxaparin; Hum | 2011 |
Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Humans; Male; Midd | 2011 |
Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Risk Factors; Stroke | 2011 |
Amiodarone-induced T-U fusion.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; El | 2012 |
Dronedarone trial stopped due to excess mortality.
Topics: Amiodarone; Atrial Fibrillation; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Drone | 2011 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Electric Countershock; | 2012 |
Effects of a novel amiodarone-like compound SAR114646A on the pig atrium and susceptibility to ventricular fibrillation in dogs and pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Elec | 2012 |
Letter by Karam and Marijon regarding article, "Atrial fibrillation: outpatient presentation and management".
Topics: Amiodarone; Atrial Fibrillation; Electrocardiography; Humans; Male; Outpatients | 2012 |
Letter by Montone et al regarding article, "Atrial fibrillation: outpatient presentation and management".
Topics: Amiodarone; Atrial Fibrillation; Electrocardiography; Humans; Male; Outpatients | 2012 |
[Atrial fibrillation. PALLAS study: when dronedarone becomes a risk].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Contraindications; Dronedar | 2011 |
Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Cryptogenic Organ | 2012 |
Ultra-short course of low-dose amiodarone-induced post-operative fatal pulmonary toxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Drug-Related Side E | 2011 |
A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Fatal Outcome; Hemorrh | 2012 |
Second chance for dronedarone after recent setback?
Topics: Acetanilides; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cli | 2012 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagula | 2012 |
[Total body water and recurrent atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Body Water; Female; Humans | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2012 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2012 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2012 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2012 |
A rare case of factor V inhibitor in a patient on amiodarone therapy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Coagulation Tests; | 2012 |
CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Arter | 2012 |
Pharmacotherapy in Medicare beneficiaries with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagul | 2012 |
[The PALLAS study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Intervals; Dronedarone; Hu | 2012 |
[Between guidelines and regulatory decisions: the odyssey of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug and Narcotic Control; Evi | 2012 |
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiovascular Disease | 2013 |
Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2012 |
Electrocution-induced atrial fibrillation: a novel cause of a familiar arrhythmia.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Electric Injuries; Elect | 2012 |
[Rhythm---control in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Dro | 2012 |
[Abnormal liver function during therapy with amiodarone in patients with persistent atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2011 |
Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopa | 2012 |
[Supraventricular extrasystole after cardioversion with amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complex | 2012 |
Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2013 |
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Topics: Amiodarone; Animals; Atrial Fibrillation; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relations | 2012 |
A 73-year-old man with interstitial lung disease due to dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Lung; Lung Disea | 2012 |
Possible proarrhythmia with dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Humans; M | 2013 |
Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatinine; Cystat | 2013 |
Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization, P | 2012 |
Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Catheter Ablation; C | 2012 |
Role of an aggressive rhythm control strategy on sinus rhythm maintenance following intra-operative radiofrequency ablation of atrial fibrillation in patients undergoing surgical correction of valvular disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2012 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
Topics: Acetanilides; Amiodarone; Animals; Atrial Fibrillation; Chromatography, High Pressure Liquid; Diseas | 2013 |
[Dronedarone in high-risk patients with atrial fibrillation : PALLAS study].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2012 |
A comparative study between amiodarone and magnesium sulfate as antiarrhythmic agents for prophylaxis against atrial fibrillation following lobectomy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Female; Humans; Infusion | 2013 |
[Update 2012: new European guidelines for atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Germany; Humans; Long-Term Care; Pract | 2012 |
Occasionally, I have atrial fibrillation. I hate it, but I hate taking medications, too. My doctor wants me to go on amiodarone. Can you tell me if it has any side effects? I need to decide which is worse--the problem or the medication?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Injury; Pneumonia; Pulmonary F | 2010 |
[New antiarrhythmic drugs for the treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines | 2012 |
48-Year-old woman with dyspnea, cough, and weight loss.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cough; Diagnosis, Differential; Drug-Relate | 2012 |
Dronedarone: is it time to turn it down?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans; Pat | 2013 |
Effects of dronedarone and amiodarone on atrial fibrillatory rate in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Fem | 2013 |
Acute amiodarone syndrome after a single intravenous amiodarone bolus.
Topics: Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Coagulation Diso | 2012 |
[Febrile maculopapular eruption due to dronedarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dron | 2012 |
Effects of dronedarone started rapidly after amiodarone discontinuation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Dronedarone; Drug Substi | 2013 |
Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critical Care; Electr | 2002 |
[Transient atrial fibrillation induced by adenosine in a patient with atrial tachycardia].
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Hum | 2002 |
Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Cost-Benefit | 2002 |
Effectiveness and safety of low-energy internal cardioversion of long-standing atrial fibrillation after unsuccessful external cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Device R | 2002 |
[Sartan improves anti-arrhythmia therapy after cardioversion. Fewer recurrent fibrillation incidents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Drug Therapy, Combinati | 2002 |
Ischemia versus amiodarone induced polymorphic ventricular tachycardia.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differe | 2002 |
Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization; Combined Modality T | 2002 |
Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Myocardial Infa | 2002 |
[Effect of amiodarone on autonomic status and its efficacy in the treatment of different variants of paroxysmal atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nervous System; Female; Hum | 2002 |
[Comparative effects of amiodarone, diltiazem, and atenolol on results of electrical cardioversion in patients with chronic atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Chronic Disease; Dil | 2002 |
Acute hepatitis complicating intravenous amiodarone treatment.
Topics: Acute Disease; Acute Kidney Injury; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2002 |
Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiac Pacing, Artifici | 2003 |
[Efficacy and safety of low dose amiodarone for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Ma | 2001 |
Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channels, L-Type; Dogs; El | 2003 |
Atrial fibrillation after adult lung transplantation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Transplantation; Postop | 2003 |
Pretreatment of patients with atrial fibrillation who undergo electrical cardioversion.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compo | 2003 |
Atrial fibrillation--rate versus rhythm control.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Heart Rate; Humans; | 2003 |
[Long-term drug interaction of warfarin with amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Drug Interactions; He | 2003 |
Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibr | 2003 |
[Antiarrhythmic drugs in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2002 |
Findings suggest revised atrial fibrillation approach.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2003 |
Relations between monophasic action potential duration and refractoriness after cardioversion of persistent atrial fibrillation: results in wash-out and amiodarone-treated patients.
Topics: Action Potentials; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2003 |
Atrial fibrillation storms.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Circadian Rhythm; Defibrillators, Implantab | 2003 |
[Anticoagulation--control of heart rate--cardioversion. Therpeutic algorithm in ventricular tachycardia].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Combined Modality Therapy; | 2003 |
A simplified amiodarone regimen to prevent postoperative atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopulmonary Bypas | 2003 |
Retinal evaluation of patients on chronic amiodarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electroretinography; Female; Fluoresc | 2003 |
Is it time to choose amiodarone for postoperative atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Postoperative Complications | 2003 |
Acute hepatitis after parenteral amiodarone.
Topics: Acute Disease; Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemica | 2003 |
Restoring sinus rhythm in atrial fibrillation: a Pyrrhic victory?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans | 2003 |
Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophys | 2003 |
[Arrhythmogenic dilated cardiomyopathy].
Topics: Adult; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoagulants; | 2003 |
Drugs to promote sinus rhythm reversion and maintenance in atrial fibrillation--why amiodarone is better.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Electr | 2003 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
Amiodarone for conversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2003 |
New atrial fibrillation and elective surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedure | 2003 |
Disagreement with conclusions.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedure | 2003 |
Differential diagnosis and clinical course of amiodarone-induced thyroid dysfunction.
Topics: Adult; Aged; Amiodarone; Antithyroid Agents; Atrial Fibrillation; Diagnosis, Differential; Female; H | 2003 |
More on amiodarone--meeting the challenges of the combined epidemics of heart failure and atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans | 2003 |
Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Electric Co | 2003 |
Rapidly fatal acute amiodarone hepatitis occurring in the context of multiple organ failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; Chemical and Drug | 2003 |
Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
Topics: Acetyldigoxins; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2003 |
[Multicenter study of atrial fibrillation].
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transe | 2003 |
Acute atrial fibrillation during dengue hemorrhagic fever.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle A | 2003 |
Conduction properties of the crista terminalis in patients with atrial flutter due to amiodarone therapy for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrophysiology; Fe | 2003 |
Unexplained bone marrow granulomas: is amiodarone the culprit? A report of 2 cases.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy, Needle; Bo | 2004 |
New-onset postoperative atrial fibrillation: a riddle wrapped in a mystery inside an enigma.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Arter | 2004 |
Ventral cardiac denervation reduces the incidence of atrial fibrillation after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillat | 2004 |
Introduction--roundtable on atrial fibrillation: update on mechanisms and approaches to treatment.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Iodine Radioisotopes; Male; | 2004 |
[Recent beginning atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Echocardiography, Doppler | 2004 |
A complication of amiodarone infusion.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contrast Media; | 2004 |
[Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Electrocardi | 2004 |
I had atrial fibrillation for a long time. My cardiologist recently tried me on amiodarone, and I am finally in a normal heart rhythm. Are there any side effects from this medication?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2004 |
[Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hea | 2004 |
Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter.
Topics: Age Factors; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atri | 2004 |
Bidirectional ventricular tachycardia resulting from digoxin and amiodarone treatment of rapid atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Synergism; Drug Therapy | 2004 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramid | 2004 |
Limited posterior left atrial linear radiofrequency ablation for patients with chronic atrial fibrillation undergoing rheumatic valvular heart surgery.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Chronic Disease; Female; Heart Atri | 2004 |
Cardioversion threshold, IRAF and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; | 2004 |
[Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2004 |
Unidirectional atrio-atrial conduction after surgical isolation of the posterior part of the left atrium and pulmonary veins for atrial fibrillation: simple postsurgical procedure electrophysiological evaluation.
Topics: Adenosine Triphosphate; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurgery; | 2004 |
Troponin I in atrial fibrillation with no coronary atherosclerosis.
Topics: Aged; Amiodarone; Atrial Fibrillation; Digoxin; Humans; Male; Troponin I | 2004 |
A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock | 2004 |
Acute pancreatitis caused by amiodarone.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Dose- | 2004 |
Is a charge a cost if nobody pays it?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Cost Savings; Hospi | 2004 |
[Should drug-induced gynecomastia be monitored?].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Gynecomastia; Humans; Iatroge | 2004 |
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Contraindications; Female; Fl | 2004 |
Human study of biatrial electrical coupling: determinants of endocardial septal activation and conduction over interatrial connections.
Topics: Adult; Aged; Amiodarone; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cardiac Pac | 2004 |
Effect of amiodarone on the plasma levels of metoprolol.
Topics: Aged; Alleles; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Dru | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Effect of amiodarone dose on the risk of permanent pacemaker insertion.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cohort Stud | 2004 |
Left atrial thrombus formation early after mitral valve replacement.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Output, Low; Echoca | 2004 |
Recurrence of atrial fibrillation and flutter after atrial compartment operation: modified atrial incisions and role of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cryosurgery; Heart Atria; H | 2005 |
Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiograph | 2004 |
Simultaneous double external DC shock technique for refractory atrial fibrillation in concomitant heart disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; Cardiomyopat | 2004 |
Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Cohort Studies; | 2005 |
Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Clinical Tri | 2005 |
Time-frequency analysis of the surface electrocardiogram for monitoring antiarrhythmic drug effects in atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Monitoring; Elec | 2005 |
[Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles].
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Mi | 2005 |
Amiodarone-induced acute lung toxicity in an ICU setting.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Cystectomy; Humans; Lu | 2005 |
The use of prophylactic amiodarone after cardiothoracic surgery reduces the incidence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Incidence; Postoperative Complicati | 2005 |
I had atrial fibrillation for a long time. My cardiologist recently tried me on amiodarone, and I am finally in a normal heart rhythm. Are there any side effects from this medication?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2005 |
Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Cohort S | 2005 |
QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Drug Interacti | 2005 |
This DAFNE is definitely not that DAFNE.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Elec | 2005 |
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterization; Electric Cou | 2005 |
Intravenous amiodarone treatment in horses with chronic atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Horse Diseases; H | 2006 |
Spectral turbulence analysis of the signal-averaged electrocardiogram of the atrial activation as predictor of recurrence of idiopathic and persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electrocardiography; | 2006 |
[Severe intrahepatic cholestasis in a 66-year old male patient with medically treated atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cholestasis, Intrahepatic; Humans; Ma | 2005 |
Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm.
Topics: Aged; Algorithms; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atr | 2005 |
Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Ele | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Quality of Life; Sotalol | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Hum | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyperthyroidism; Hypothyroidism | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Sex Factors; Sotalol; | 2005 |
Effects of antiarrhythmic drug therapy on atrioventricular nodal function during atrial fibrillation in humans.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Computer Simul | 2005 |
[Atrial fibrillation after isolated coronary bypass surgery].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary | 2005 |
Ablation of atrial fibrillation using microwave energy--early experience.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Coronary Ar | 2005 |
Summaries for patients. Potential benefits of amiodarone for patients undergoing open-heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Proarrhythmias and antiarrhythmias: two sides of the same coin.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2005 |
Potential proarrhythmic effect of biventricular pacing: fact or myth?
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2005 |
Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
[Amiodarone-induced thyrotoxicosis: a diagnostic and therapeutic challenge].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Atrial Flutter; Carbima | 2005 |
Pharmacological management of atrial fibrillation following cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2005 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2005 |
Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Time Factors | 2005 |
Clinical questions #5: Maintenance of normal sinus rhythm after cardioversion: is amiodarone better than placebo?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric C | 2005 |
I recently underwent a successful cardioversion to correct a rapid pulse (140 beats per minute) attributed to atrial fibrillation. My cardiologist then prescribed 400 milligrams a day of amiodarone for two weeks, then 200 milligrams a day. What do you thi
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2005 |
[Amiodarone: treatment or cause of atrial fibrillation?].
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyperthyroidism | 2005 |
Amiodarone after unsuccessful direct-current cardioversion of persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Counter | 2005 |
Unilateral amiodarone keratopathy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cataract Extraction; Cor | 2005 |
"Pseudosinus rhythm": what is the mechanism?
Topics: Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Middle Aged; Propafenone; Pulmon | 2005 |
Images in cardiovascular medicine. The blue man: amiodarone-induced skin discoloration.
Topics: Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Pigmentation Disorders; Skin Pigmentatio | 2006 |
Localized sources maintaining atrial fibrillation organized by prior ablation.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Body Surface Potential Mapping; Cathete | 2006 |
Acute onset of halos and glare: bilateral corneal epithelial edema with cystic eruptions--atypical presentation of amiodarone keratopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Corneal Edema; Cysts; Epithelium, Cor | 2006 |
Pulmonary hypertension and predominant right heart failure in thyrotoxicosis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Hypertension, Pulmon | 2006 |
[Amiodarone-induced pneumonitis associated with marked eosinophilia in BALF].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchoalveolar Lavage Fluid; Eosinophils; | 2006 |
Images in cardiology. Blue-grey cutaneous discolouration secondary to amiodarone treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Face; Humans; Male; Pigmentation Diso | 2006 |
Dronedarone: a new antiarrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availab | 2006 |
Amiodarone-induced acute lung toxicity in an ICU setting.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases; Postoperative Compli | 2006 |
Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2006 |
Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrill | 2006 |
Differential densities of muscarinic acetylcholine receptor and I(K,ACh) in canine supraventricular tissues and the effect of amiodarone on cholinergic atrial fibrillation and I(K,ACh).
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillatio | 2006 |
Drug therapy of paroxysmal atrial fibrillation in the elderly over 75 years old.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardi | 2006 |
[Detection of patients at risk for paroxysmal atrial fibrillation (PAF) by signal averaged P wave, standard ECG and echocardiography].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Fema | 2006 |
[Effect of oral cordarone in reversing persistent atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle A | 2006 |
[Atrial remodeling and anti-remodeling therapy in atrial fibrillation].
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2006 |
Amiodarone-induced pulmonary hemorrhage.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Hemorrhage; Humans; Lung Diseas | 2006 |
Amiodarone-induced alveolar hemorrhage.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Hemorrhage; Humans; Lung Diseases; Ma | 2006 |
Drug-induced T wave alternans.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aortic Diseases; Arrhythmias, Cardiac; Atrial Fibrillation; Elec | 2006 |
[Plasmapheresis in amiodarone-induced hyperthyroidism].
Topics: Adrenergic beta-Antagonists; Aged; Agranulocytosis; Amiodarone; Anti-Arrhythmia Agents; Antithyroid | 2006 |
"Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Arter | 2006 |
Inadvertent toxic drug reaction in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Secondary Pr | 2006 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2006 |
Pro-arrhythmic effects of amiodarone and concomitant rate-control medication.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmia | 2006 |
Evaluation of the defibrillation threshold in atrial fibrillation by transoesophageal cardioversion using a biphasic impulse.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2006 |
Prevention of atrial fibrillation following cardiac surgery.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Delirium; Humans; Vasodilator Agents | 2006 |
Prevention of atrial fibrillation following cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; R | 2006 |
Prevention of atrial fibrillation following cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Atrial Fibrillation; Body Mass Index; Cardiac Surgical Proc | 2006 |
Paroxysmal atrial fibrillation precipitated by amiodarone-induced thyrotoxicosis five months after cessation of therapy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Electrocardiography; Humans; Male; Middle | 2006 |
Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction.
Topics: Alanine Transaminase; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Fl | 2006 |
Combined atrial fibrillation ablation with mitral valve surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Ev | 2006 |
Effect of amiodarone treatment on outcome after direct current cardioversion in atrial fibrillation: should we cardiovert atrial fibrillation of longer duration.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric C | 2007 |
Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery.
Topics: Aged; Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Atropine; Bradyc | 2006 |
Unilateral amiodarone keratopathy: occlusive contact lens spares development in the contralateral eye.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contact Lenses; Cornea; Corneal Opaci | 2007 |
Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Potential benefits for the prevention of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Combinations; Humans; Losartan; Perind | 2006 |
Unmasking of the Brugada syndrome phenotype during the acute phase of amiodarone infusion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; | 2006 |
[Dronedarone establishes and maintains control of sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2006 |
Risk-stratified evaluation of amiodarone to prevent atrial fibrillation after cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Cost-Benefit A | 2006 |
[Advantages of restoration and maintenance of sinus rhythm in middle aged patients with atrial fibrillation and chronic heart failure].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Female; Heart Failure; Hum | 2006 |
Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Female; | 2006 |
Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study.
Topics: Adult; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillat | 2007 |
Comment on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Huma | 2006 |
Thyroid replacement therapy and atrial fibrillation in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bra | 2006 |
Amiodarone and polymorphic ventricular tachycardia: to slow down or to accelerate the underlying rhythm?
Topics: Aged; Aged, 80 and over; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Atrial | 2006 |
[Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Protocols; Data Interpretati | 2006 |
[Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia].
Topics: Administration, Oral; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catecholamines | 2006 |
Amiodarone related rare toxicity in a burn patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Burns; Humans; Hyponatremia; Male; Pl | 2007 |
Torsade de pointes induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillat | 2006 |
Selective prophylaxis of atrial fibrillation with amiodarone after cardiac surgery.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Fe | 2006 |
What to treat-the fast or the slow rhythm?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complexes; Catheter Ablati | 2006 |
[A case of drug-induced pneumonitis due to amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; | 2006 |
Atrial fibrillation and rheumatic valvular heart disease: usefulness of very-low-dose amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Valve Diseases; Humans; Quality of Li | 2006 |
[Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cardiomy | 2006 |
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Humans; Losartan | 2007 |
Rhythm versus safety in amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Safety Management; United States | 2006 |
The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Sulfonamides; T | 2007 |
[Chronic atrial fibrillation in adults: direct current cardioversion or medical cardioversion].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Coun | 2006 |
Case 1-2007 morbidly obese patient undergoing cardiac surgery.
Topics: Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizatio | 2007 |
Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; Digoxin; Dr | 2007 |
Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2007 |
Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrill | 2007 |
Use of amiodarone in a patient with a shellfish allergy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Follow-Up Studies; Food Hypersensitiv | 2007 |
Amiodarone therapy for atrial rhythm control: insights gained from a single center experience.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cohort Studies; Fema | 2007 |
[Dynamics of echocardiographic changes and the tactic of optimal therapy in patients with atrial fibrillation with chronical heart failure].
Topics: Adult; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrilla | 2007 |
Amiodarone for atrial fibrillation: comfort for the afflicted and affliction for the comforted.
Topics: Amiodarone; Atrial Fibrillation; Humans; Sinoatrial Node; Survival Rate | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Thyrotoxicosis | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Humans; International Norma | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Parkinson Disease; Parkinson | 2007 |
Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Atrial | 2008 |
Amiodarone-induced epididymitis: a case report and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Epididymitis; Humans; Male; Middle Aged | 2007 |
Hyponatremia induced by amiodarone therapy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyponatremia; Ma | 2007 |
Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diarrhea; Dose-Response Relationsh | 2007 |
Polypharmacy as part of comprehensive geriatric assessment: disclosure of false diagnosis of atrial fibrillation by drug revision.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Artifacts; Aspirin; Atrial Fibrillation; Diagnostic Errors | 2007 |
Prevention of atrial fibrillation with moderate doses of amiodarone in the postoperative period of cardiac surgery is safe and effective in patients with high risk for developing this arrhythmia.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 2007 |
Maintaining sinus rhythm--making treatment better than the disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; | 2007 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
Dual tachycardia in the setting of amiodarone-induced hyperthyroidism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; | 2007 |
Amiodarone and atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Biphenyl Compound | 2007 |
Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Electrocardiography; Humans; L | 2008 |
Acute fatal post-CABG low dose amiodarone lung toxicity.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hyperthyroidism; Propo | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Quality of | 2007 |
[Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality | 2007 |
Is dronedarone effective for the prevention of recurrent atrial fibrillation?
Topics: Amiodarone; Atrial Fibrillation; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blin | 2008 |
Invited commentary on amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery.
Topics: Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Cost-Benefit Analysis; Female; Humans; Male | 2008 |
Atrial fibrillation in a commercial diver.
Topics: Adult; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diving; Electric Injuries; | 2008 |
Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 2008 |
The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Incidence; Infusions, | 2007 |
Amiodarone pneumonitis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchoalveolar Lavage Fluid; Bronchoscopy; | 2008 |
"Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hepatic Encephalopathy; Human | 2009 |
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electrophysiol | 2008 |
Ataxia caused by amiodarone in older people.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Dose-Response Re | 2008 |
[Treatment of supraventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter | 1981 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
[Anti-arrhythmic effectiveness of ethmozine, cordaron and rhythmodan in treating ischemic heart disease].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Cardiac Complexes | 1981 |
[Characteristics of action and efficacy of cordarone in permanent auricular fibrillation and extrasystole in elderly and aged patients].
Topics: Age Factors; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Cardiac Complexes, Premature; Hemod | 1983 |
The use of amiodarone in children.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Bundle-Branch Bl | 1983 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
Control of ventricular rate during atrial fibrillation: ambulatorial experience.
Topics: Aged; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Digoxin | 1981 |
Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation.
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Cardiac Pacing, Artificial; Electro | 1984 |
The correlation of serum amiodarone levels with abnormalities in the metabolism of thyroxine.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Female; Humans; Male; Middle Aged; Thyrotropin; | 1984 |
Advances in the management of cardiac arrhythmias in children.
Topics: Adolescent; Adult; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pa | 1984 |
[Long-term fate of 103 patients with auricular fibrillation lasting for over 15 days treated with cardioversion and preventive therapy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Ele | 1984 |
Interstitial pneumopathy and low-dosage amiodarone.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Biopsy; Humans; Lung; Male; Middle Aged; Pulmonary Fib | 1984 |
Amiodarone in atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Benzofurans; Electric Countersh | 1984 |
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiom | 1984 |
Efficacy of amiodarone for refractory supraventricular tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1983 |
Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome.
Topics: Ajmaline; Amiodarone; Atrial Fibrillation; Benzofurans; Electrophysiology; Heart; Humans; Isoprotere | 1983 |
Ten years of experience with amiodarone.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Chagas Cardiomyopathy; Dose-Resp | 1983 |
[Influence of treatment with amiodarone in response to electric cardioversion in patients with complete arrhythmia caused by auricular fibrillation].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Electric Countersho | 1983 |
[Drug therapy of atrial fibrillation in acute myocardial infarct: comparison of intravenous amiodarone and digoxin].
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Female; Humans; Injections, Intravenous | 1983 |
Arrhythmia and prognosis in hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; | 1983 |
Amiodarone--application and clinical pharmacology in atrial fibrillation and other arrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Electrocardiography | 1984 |
[Malignant ventricular tachyarrythmia due to atrial fibrillation in the Wolff-Parkinson-White syndrome. Section of the Kent bundle apropos of 2 cases].
Topics: Adult; Amiodarone; Atrial Fibrillation; Electrocardiography; Electrophysiology; Heart Conduction Sys | 1981 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Infusions, Parenteral; Male; Middle Aged | 1982 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Myocardial Infarction; Time Factors | 1982 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Arrhythmia, Sinus; Atrial Fibrillation; Benzofurans; Humans; Male | 1982 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Injections, Intravenous; Myocardial Infarction | 1982 |
Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Humans; Male; Tachycardia; | 1982 |
Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy.
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Cardiac Pacing, Artificial; Death, Sudden; Esoph | 1983 |
Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dose-Response Relationshi | 1983 |
Amiodarone in long term management of refractory cardiac tachyarrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Female; Heart Atria | 1981 |
Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Disopyramide; Dose-Response Relationship, Drug; | 1982 |
[Treatment of atrial fibrillation of recent onset by a combination of quinidine and amiodarone].
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Drug Therapy, Combination; Fe | 1982 |
[Closed chest interruption of A-V conduction in the treatment of refractory supraventricular tachyarrhythmias. A clinical contribution].
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Digitalis Glycosides; E | 1982 |
D.C. conversion in patients on amiodarone.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Electric Countershock; Female; Humans; Male; Mi | 1981 |
[Comparison of the effectiveness of amiodarone and quinidine in the prevention of arrhythmia].
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiomyopathies; Female; | 1980 |
[Maintenance of the sinus rhythm after pharmacological cardioversion in the aged].
Topics: Aged; Amiodarone; Atrial Fibrillation; Female; Humans; Hyperthyroidism; Male; Recurrence | 1981 |
[Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Fem | 1981 |
[Treatment of atrial arrythmias with amiodarone. Short-term and long-term results].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Humans; Male; Mid | 1981 |
[Pharmacologic cardioversion with intravenous amiodarone].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Humans; Injections, Intra | 1981 |
[Conversion of recent atrial fibrillation to sinus rhythm. Predictive value of the clinical and echocardiographic parameters].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digitalis Glycosides; Echocardiography; E | 1981 |
Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Ele | 1980 |
Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Child; Drug Administration Sc | 1980 |
[Auricular vagal arrhythmia (author's transl)].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 1980 |
Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators.
Topics: Amiodarone; Atrial Fibrillation; Chemotherapy, Adjuvant; Defibrillators, Implantable; Electrocardiog | 1994 |
Treatment guidelines for hyperthyroidism and hypothyroidism.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Practice Guidelines as Topic; Thyro | 1995 |
[Case of long-term maintenance of sinus rhythm by means of multiple repeated electric defibrillation].
Topics: Adult; Amiodarone; Atrial Fibrillation; Electric Countershock; Electrocardiography; Humans; Male; Pr | 1995 |
[Respiratory insufficiency due to pulmonary toxicity of amiodarone].
Topics: Aged; Amiodarone; Atrial Fibrillation; Dyspnea; Female; Humans; Pulmonary Fibrosis; Respiratory Insu | 1995 |
Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Bradycardia; Catheter Ablation; Electr | 1995 |
Amiodarone and the heart.
Topics: Amiodarone; Atrial Fibrillation; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Heart Fai | 1995 |
[Ablation of the hyperconducting atrioventricular node in a patient with thyrotoxicosis induced by amiodarone].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Catheter Ablation; Female; Humans; Th | 1995 |
Amiodarone: should we use it more than we do?
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Death, Sudden, | 1993 |
Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital.
Topics: Aged; Amiodarone; Atrial Fibrillation; Comorbidity; Digoxin; Electric Countershock; Emergencies; Fem | 1995 |
Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Evaluation Studies as Topic; | 1995 |
Conduction disturbances after open heart operation in a patient receiving amiodarone.
Topics: Amiodarone; Atrial Fibrillation; Female; Heart Block; Heart Valve Prosthesis; Humans; Middle Aged; P | 1994 |
[Influence of atrial fibrillation in the natural history of hypertrophic cardiomyopathy].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrop | 1994 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Antiarrhythmic drugs in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Flecainide; Heart; Humans; Propafe | 1993 |
Pseudotumor cerebri as a complication of amiodarone therapy.
Topics: Amiodarone; Atrial Fibrillation; Fundus Oculi; Humans; Male; Middle Aged; Papilledema; Pseudotumor C | 1993 |
The paradox of treating thyrotoxicosis with amiodarone.
Topics: Amiodarone; Angina Pectoris; Atrial Fibrillation; Humans; Thyroid Gland; Thyrotoxicosis | 1993 |
[The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Follow- | 1993 |
Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery.
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Electric Counter | 1993 |
[Ventricular fibrillation during stress test on a treadmill. Apropos of a case].
Topics: Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Electric Countershock; El | 1993 |
Amiodarone in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans | 1993 |
Intravenous amiodarone for conversion of recent-onset atrial fibrillation to sinus rhythm.
Topics: Amiodarone; Atrial Fibrillation; Humans; Injections, Intravenous; Time Factors | 1993 |
Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Female; Heart Rate; Humans; I | 1993 |
The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Combinations; Electr | 1993 |
Radiofrequency versus pharmacologic modification of the atrioventricular node.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Dogs; Electrophysiology; Flecainide | 1993 |
A clinical study of intravenous cibenzoline in selected patients with recent-onset atrial tachyarrhythmia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Humans; Imidazoles; | 1993 |
Amiodarone for prevention of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans | 1996 |
Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular N | 1996 |
Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Male | 1996 |
[Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 1996 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critic | 1996 |
[Acute hepatitis caused by intravenous amiodarone].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug | 1996 |
Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Blood Flow Vel | 1996 |
Intravenous amiodarone for the conversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; Injections, Intrav | 1996 |
Intravenous amiodarone in treatment of recent-onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Research Design; Time Fact | 1996 |
Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Female; Heart Conduction Sys | 1996 |
Cardioversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countershock; Humans; War | 1996 |
Improving survival for patients with atrial fibrillation and advanced heart failure.
Topics: Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fi | 1996 |
Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbachol; Guin | 1996 |
Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter.
Topics: Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Fun | 1996 |
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Echocardiography; Ele | 1997 |
Akinesia and amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Liver Cirrhosis; Male; Middle Aged; | 1997 |
Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Chronic Disease; Comb | 1997 |
Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1997 |
[Modern therapy of tachycardiac heart arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Flutter; Humans; | 1995 |
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Antithrombin III; Atrial Fibrillation; Biomarkers | 1997 |
Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cough; Dyspnea; Fever; | 1997 |
Reversible high rate atrial fibrillation dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 1997 |
Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Ind | 1997 |
Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hy | 1997 |
Internal cardioversion of chronic atrial fibrillation in patients.
Topics: Acenocoumarol; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chroni | 1997 |
[Ventricular tachycardia in a patient with mid-ventricular hypertrophic myocardiopathy and apical aneurysm].
Topics: Aged; Amiodarone; Atrial Fibrillation; Cardiomegaly; Echocardiography, Transesophageal; Electrocardi | 1997 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-1997. A 65-year-old woman with a dry cough and pulmonary nodules.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cough; Diagnosis, Differential; Diarr | 1997 |
[Cardioprotective effects of the cyclic derivative of gamma-aminobutyric acid T3-146 during reperfusion].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cats; Electr | 1997 |
Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countershock; Female; Fol | 1998 |
[Spontaneous remission of an amiodarone-induced pulmonary lesion].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases, Interstitial; Radiog | 1997 |
Bilateral atrial function after chemical cardioversion of atrial fibrillation with amiodarone: an echo-Doppler study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Blood Flow Velocity; Echoc | 1998 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 1998 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; C | 1998 |
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Postop | 1998 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
[Use of high-dose oral amiodarone for the reversion of atrial fibrillation during the postoperative period of cardiac surgery].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; | 1997 |
Serum lactate dehydrogenase activity: indicator of the development of pneumonitis induced by amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Female; Humans; L-Lactate | 1998 |
Amiodarone induced epididymitis in children.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Death, Sudden, Ca | 1998 |
[Anti-atrial fibrillation effects of cyclovirobuxine-D and its electrophysiological mechanism studied on guinea pig atria].
Topics: Aconitine; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calc | 1996 |
Bronchiolitis obliterans organising pneumonia secondary to amiodarone treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Biopsy, Nee | 1998 |
[Medicine in images. A special "suntan" and bradycardia].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Corneal Diseases; Dermatitis, Photoal | 1998 |
[Further data on amiodarone. Evidence based therapy of cardiac arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Ventricular D | 1998 |
Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheteriz | 1999 |
Effects of cycloprotobuxine-A on atrial fibrillation.
Topics: Acetylcholine; Action Potentials; Alkaloids; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fib | 1997 |
Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
[Antiarrhythmic efficacy of cordarone during neurogenic atrial fibrillation].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cats; Vagus Nerve | 1999 |
Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac surgery: a note of caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures | 1996 |
I have atrial fibrillation and cannot take beta-blockers. What are my alternatives?
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Count | 1999 |
Early proarrhythmia during intravenous amiodarone treatment.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart F | 1999 |
Amiodarone-induced delirium.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Delirium; Humans; Male | 1999 |
Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock | 1999 |
Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; El | 1999 |
[Medication-induced vocal cord paralysis as an uncommon cause of cord paralysis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Follow-Up Studies; Humans; Laryngoscopy; Ma | 1999 |
Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Hospital | 1999 |
Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Cost-Benefit Analys | 1999 |
Amiodarone induced lupus.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Hypertension; Lupus E | 1999 |
The effectiveness and timing of elective pharmacological cardioversion for paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Heart Rate; H | 1999 |
Oral amiodarone reduces incidence of postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopu | 1999 |
Early recurrence of atrial fibrillation after external cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
[Transesophageal echocardiography in electrical cardioversion: Is it possible to predict conversion to sinus rhythm?].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; El | 1999 |
Amiodarone in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Fe | 1999 |
[Atrial fibrillation treated with amidarone].
Topics: Amiodarone; Atrial Fibrillation; Heart Valve Prosthesis Implantation; Humans; Hyperthyroidism; Male; | 1999 |
[Amiodarone induced retrobulbar neuritis. Clinical case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Optic Neuritis; Tachyca | 1999 |
What is the most common arrhythmia following cardiac revascularization?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Electrocardiography | 1999 |
[Diagnostic usefulness of KL-6 measurements in patients with pulmonary complications after administration of amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antigens; Antigens, Neoplasm; Atrial Fibrillation; Biomark | 2000 |
[Apropos of amiodarone: both best and worst].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyperthyroidism; Risk Factors | 2000 |
Hybrid therapy for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Humans | 2000 |
Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; F | 2000 |
[Paroxysmal atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2000 |
Bone marrow granulomas possibly associated with amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bone Marrow; Bone Marrow Diseases; Granulom | 2000 |
Is a single oral dose of amiodarone safe and effective in converting new-onset atrial fibrillation (AF) to sinus rhythm?
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart; Humans | 2000 |
Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artif | 2000 |
Amiodarone-induced bone marrow granulomas.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Bone Marrow Diseases; Female; | 2000 |
[Hospital management of atrial fibrillation. Epidemiologic data and therapeutic strategy. Report of 100 consecutive patients].
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digoxin; Drug Approval; Dru | 2000 |
Propafenone-induced ataxia: report of three cases.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Brain; Fem | 2000 |
Cushing's syndrome in an 81-year-old patient treated with budesonide and amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibril | 2000 |
Post-discharge recurrences of new-onset atrial fibrillation following cardiac surgery: impact of low-dose amiodarone and beta-blocker prophylaxis.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2000 |
Clinical trials for conversion of recent onset atrial fibrillation must consider the role of digoxin.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Humans | 2000 |
Of pills and pillows: pseudopigmentation in a patient taking amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bedding and Linens; Coloring Agents; Diagno | 2000 |
Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Counter | 2000 |
Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cell Separation; Dronedarone; Guan | 2000 |
Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Papillary; Cardiomyopathy, | 2000 |
The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 2001 |
[Atrial fibrillation after open-heart surgery--incidence, prevention and treatment].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2000 |
Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Therapy, Combina | 2001 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Circadian variation of paroxysmal atrial fibrillation. PA3 Investigators. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Circadian Rhythm; Cross-Over Studies; Femal | 2001 |
[How I treat...persistent atrial fibrillation, by internal cardioversion, in a patient with exreme obesity].
Topics: Alcoholism; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Body Mass Index | 2001 |
Bleeding complication during coumarin therapy due to amiodarone and azithromycin.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Azithromycin; Coumarins; Drug Interactions; Fatal O | 2000 |
Atrial fibrillation control and cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Electric Countershock; Humans; T | 2001 |
Amiodarone-induced long QT and polymorphic ventricular tachycardia.
Topics: Action Potentials; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cathe | 2001 |
Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Heart Rate; Humans; Randomized C | 2001 |
Comparison of class III antiarrhythmic drugs versus digoxin for the reversion of new-onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Time Factors; Tre | 2001 |
Neutropenia during treatment with amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Neutropenia | 2001 |
Bradycardia with a changing P-R interval.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Electrocardiography; Fem | 2001 |
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
Topics: Aged; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Electric Countershock; Electrocardiography, | 2001 |
Oral amiodarone and atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artif | 2001 |
Oral amiodarone and atrial fibrillation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2001 |
Oral amiodarone and atrial fibrillation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2001 |
[Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2001 |
Ask the doctor. A few months ago, I was diagnosed with atrial fibrillation. My doctor put me on blood thinners for a few weeks and then performed electrical cardioversion. Naturally, I was asleep during the procedure, but I understand that they shocked me
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock; Huma | 2001 |
Amiodarone before electrical cardioversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans | 2001 |
Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Hemodynamics; Humans | 2001 |
Intravenous amiodarone and off-pump coronary artery bypass graft procedures: a new role for intraoperative antiarrhythmic therapy?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Humans; Injections, | 2001 |
Amiodarone for atrial fibrillation during off-pump coronary artery bypass graft surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Female; Human | 2001 |
[Paroxysmal atrial fibrillation in community medicine: management intentions and cost estimates].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2001 |
C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation.
Topics: Acute-Phase Reaction; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Prot | 2001 |
Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans.
Topics: Acute Disease; Adenosine; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Fun | 2002 |
Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Coronary | 2002 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Dose of amiodarone in atrial fibrillation - neither guidelines nor clinical practice reflect available evidence.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Practice Guidelines as Topic; Pract | 2002 |
Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; A | 2002 |
Acute amiodarone-induced pulmonary toxicity after lung operation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases; Pneum | 2002 |
Amiodarone: pearl or peril?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Propafenone; | 2002 |
Amiodarone-induced giant T wave alternans hastens proarrhythmic response.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Ele | 2002 |
[The atrial arrhythmia syndrome of vagal origin].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Drug Resistance | 1978 |
The treatment of supraventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhyt | 1979 |
[Study of the effectiveness of cordaron in different types of arrhythmia].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiac Complexes, Prematu | 1977 |
Effects of amiodarone studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Benzofurans; Cardia | 1978 |
[The place of amiodarone in 1979 in the therapeutic arsenal of a cardiac intensive care unit].
Topics: Amiodarone; Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; | 1979 |
[Comparative study with computerized analysis of the effects of amiodarone and atenolol on the R-R intervals in patients with stabilized atrial fibrillation].
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Benzofurans; Electrocardiography; Heart Rate; Humans; Pro | 1978 |
Atrial fibrillation complicating Wolff-Parkinson-White syndrome treated with amiodarone.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Humans; Male; Wolff-Parkins | 1977 |
[Automatic analysis with a computer of the effects of intravenous amiodarone on median heart rate and R-R intervals in patients with stabilized atrial fibrillation].
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Heart Rate; Humans; Injections, I | 1977 |
[Treatment of atrial flutter and fibrillation with amiodarone and digitalis].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Digoxin; Female; Humans; | 1977 |
[Treatment of auricular flutter and fibrillation with amiodarone and digitalis].
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Digitalis Glycosides; Humans | 1977 |
Effect of amiodarone in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Benzofurans; Electrocardi | 1976 |
[Drug therapy of tachycardial arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digitalis Glycosides; Drug Therapy, Combina | 1976 |
A proposed trial of amiodarone for atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Humans | 1992 |
Arrhythmia and hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Digoxin; Elec | 1992 |
[Clinical effectiveness of cordarone in combination with other anti-arrhythmia agents in refractory atrial fibrillation and adverse effects of the drugs].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combina | 1992 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
[Should the patients with atrial fibrillation receive long-term anti-arrhythmia treatment after successful cardioversion?].
Topics: Amiodarone; Atrial Fibrillation; Combined Modality Therapy; Contraindications; Electric Countershock | 1992 |
A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion.
Topics: Administration, Oral; Amiodarone; Atrial Fibrillation; Combined Modality Therapy; Dose-Response Rela | 1992 |
Flecainide in quinidine-resistant atrial fibrillation.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiograph | 1992 |
[The use of high-dose amiodarone for cardioversion in patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Evaluation; Heart Rate; Humans | 1992 |
Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Dose-Response Re | 1992 |
Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease.
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans; Male; Middle Aged; Thyrotoxi | 1992 |
Evolving strategies for the management of atrial fibrillation. The role of amiodarone.
Topics: Amiodarone; Atrial Fibrillation; Heart Rate; Humans | 1992 |
The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cerebrovascular Disorders; Chr | 1991 |
[A method of choosing maintenance anti-arrhythmia therapy after sinus rhythm restoration in patients with a permanent form of atrial fibrillation].
Topics: Amiodarone; Atrial Fibrillation; Coronary Disease; Electric Countershock; Heart Rate; Humans; Method | 1991 |
[Kordaron and functional disorders of the thyroid gland].
Topics: Adult; Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Thyroid Function Tests; Thyroid G | 1991 |
[The acute treatment of supraventricular tachycardia with endovenous amiodarone].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relat | 1991 |
[Atrial fibrillation. Restoration of the sinus rhythm in patients with a persistent form of atrial fibrillation].
Topics: Adult; Age Factors; Aged; Amiodarone; Atrial Fibrillation; Contraindications; Drug Evaluation; Elect | 1991 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, A | 1991 |
Intravenous amiodarone for conversion of atrial fibrillation to sinus rhythm.
Topics: Amiodarone; Atrial Fibrillation; Humans; Infusions, Intravenous; Time Factors | 1991 |
Acute amiodarone-induced hepatitis.
Topics: Adult; Amiodarone; Atrial Fibrillation; Biopsy; Chemical and Drug Induced Liver Injury; Humans; Live | 1991 |
[Postoperative hyperkinetic arrhythmias treated with amiodarone].
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Evaluation; Electrocardiography; Humans; | 1990 |
[Experience with long-term outpatient use of cordarone in the prevention of paroxysms of atrial fibrillation (flutter)].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Humans; Middle Aged; Time Factors | 1990 |
Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Ev | 1990 |
Invited letter concerning: amiodarone and quinidine for postoperative atrial arrhythmias.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Humans; Quinidine | 1990 |
[A comparison of the efficacy of quinidine and kordaron as agents to stabilize the recovered sinus rhythm in patients with the permanent form of atrial fibrillation].
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Electric Countershock; He | 1990 |
New hope in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Quinidine; Sotalol | 1990 |
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Child; Cinea | 1990 |
Hypertrophic cardiomyopathy and atrial fibrillation: a change of perspective.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Survival Rate | 1990 |
[Experience with the treatment of atrial fibrillation with cordarone and digoxin].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Digoxin; Dose-Response Relations | 1990 |
Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy.
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Cerebrovascular Disorders; Female; Huma | 1990 |
Fatal fulminating liver failure possibly related to amiodarone treatment.
Topics: Amiodarone; Atrial Fibrillation; Female; Hepatic Encephalopathy; Humans; Middle Aged | 1990 |
[Cardiac rhythm disorders after pneumonectomy].
Topics: Adenocarcinoma; Adult; Aged; Aging; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Carcinoma | 1985 |
Repetitive supraventricular tachycardia: clinical manifestations and response to therapy with amiodarone.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dose-Response Relationshi | 1986 |
Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; | 1986 |
Clinical value of cordarone as an antiarrhythmic agent.
Topics: Adolescent; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, P | 1987 |
The digoxin-amiodarone interaction.
Topics: Aged; Amiodarone; Atrial Fibrillation; Biological Availability; Digoxin; Drug Interactions; Female; | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
Elevation of serum cholesterol and triglycerides as a complication of amiodarone therapy.
Topics: Amiodarone; Atrial Fibrillation; Cholesterol; Humans; Male; Middle Aged; Triglycerides | 1989 |
[Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Pr | 1985 |
[What is your diagnosis?].
Topics: Amiodarone; Atrial Fibrillation; Digitalis Glycosides; Electrocardiography; Humans; Male; Middle Age | 1989 |
The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans; Ma | 1989 |
[Pigmentation of the skin after long-term treatment with amiodarone].
Topics: Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Time Factors; Xeroderma Pigmentosum | 1989 |
Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac | 1989 |
Clinical pharmacology of chronic atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Calcium Channel Blockers; Digoxi | 1988 |
[Cardioversion after a loading dose of amiodarone].
Topics: Amiodarone; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Humans | 1989 |
Bilateral optic neuropathy associated with amiodarone therapy.
Topics: Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Ophthalmoscopy; Optic Atrophy; Optic Ner | 1988 |
[Pharmacological cardioversion of paroxysmal atrial fibrillation: 3 methods compared].
Topics: Aged; Amiodarone; Atrial Fibrillation; Deslanoside; Drug Evaluation; Drug Therapy, Combination; Elec | 1987 |
Our experience with amiodarone administration to patients with paroxysmal atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Coronary Disease; Female; Humans; Male; Middle Aged | 1988 |
Amiodarone for the conversion of established atrial fibrillation and flutter.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Humans | 1986 |
Comparison between the efficacy of amiodarone and quinidine in the treatment of atrial cardiac arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Female; | 1986 |
Amiodarone as a treatment for atrial fibrillation refractory to digoxin therapy.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Female; Humans; Male | 1986 |
[Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect].
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Alcoholic; Drug Therapy, Combination; Electrocardio | 1988 |
[Usefulness of pretreatment of patients with atrial fibrillation who are candidates for electric cardioversion].
Topics: Adult; Aged; Amiodarone; Arrhythmia, Sinus; Atrial Fibrillation; Electric Countershock; Female; Huma | 1988 |
[Prevention of supraventricular tachyarrhythmia and tachycardia with kordaron].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Evaluation; Ele | 1988 |
Long-term results of amiodarone therapy.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Follow-Up Studies; Heart Arrest; Humans; Middle Aged; | 1987 |
Safety and efficacy of amiodarone. The low-dose perspective.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; E | 1988 |
Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome.
Topics: Adult; Amiodarone; Atrial Fibrillation; Child; Electrophysiology; Female; Heart Atria; Heart Conduct | 1988 |
Treatment of atrial fibrillation associated with hyperthyroidism by amiodarone and methimazole.
Topics: Aged; Amiodarone; Atrial Fibrillation; Drug Therapy, Combination; Female; Humans; Hyperthyroidism; M | 1988 |
Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Electrocardiography; Hear | 1988 |
[Use of kordaron and Kinilentin in the permanent form of atrial fibrillation].
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; | 1987 |
[Amiodarone in the pharmacologic conversion of arrhythmia caused by atrial fibrillation. Intravenous therapy versus treatment per os].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Female; Human | 1987 |
[Pharmacologic cardioversion with propafenone of stable atrial fibrillation of recent onset].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Injections, Intra | 1987 |
Serum creatinine increase associated with amiodarone therapy.
Topics: Aged; Amiodarone; Atrial Fibrillation; Creatinine; Humans; Kidney; Male | 1987 |
A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bepridil; Chron | 1987 |
[Electric cardioversion in the postoperative period after mitral valve surgery].
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Electric Countershock; Female; Heart Valve Disea | 1986 |
[The effect of the size of the maintenance dose of amiodarone on success and side-effects in the treatment of atrial fibrillation].
Topics: Amiodarone; Atrial Fibrillation; Female; Humans; Male; Middle Aged | 1987 |
[Postoperative therapeutic effect of amiodarone on the conversion of chronic atrial fibrillation in rheumatic heart disease].
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Heart Valve Diseases; Heart Valve P | 1987 |
Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report.
Topics: Amiodarone; Atrial Fibrillation; Female; Heart Conduction System; Heart Rate; Humans; Middle Aged; W | 1987 |
Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Female; Heart Atria; Heart Va | 1987 |
Amiodarone-induced torsades de pointes.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dru | 1986 |
Electrophysiologic effects of amiodarone in tachyarrhythmias.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Female; Heart; Humans; Mal | 1985 |
Amiodarone for refractory atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Chronic Disease; Drug Evaluation; Female; | 1986 |
[Use of amiodarone in the treatment of atrial fibrillation resistant to digoxin. II. Ability of amiodarone to maintain sinus rhythm for a long period of time].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Drug Resistance; Female; Heart R | 1986 |
Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventr | 1985 |
[Use of amiodarone in the treatment of atrial fibrillation resistant to digoxin. I. Ability of amiodarone to convert atrial fibrillation to sinus rhythm and its short-term maintenance].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Drug Resistance; Female; Heart R | 1985 |
Intravenous amiodarone in the acute termination of supraventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Benzofurans; Cardia | 1985 |
Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Combined Modality Therapy; Exer | 1985 |
Life-threatening ventricular arrhythmias provoked by amiodarone treatment.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Digoxin; Electrocardiograp | 1985 |
Amiodarone in pregnancy.
Topics: Adult; Amiodarone; Atrial Fibrillation; Benzofurans; Electrocardiography; Female; Fetal Blood; Human | 1985 |
Toxic epidermal necrolysis and amiodarone treatment.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Male; Stevens-Johnson Syndrome | 1985 |
[Intravenous amiodarone in the therapy of paroxysmal supraventricular tachycardias].
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Human | 1985 |
Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Benzofurans; El | 1985 |
Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Drug Resistance; Female; Humans; Male; Mi | 1985 |
[Effectiveness of electric cardioversion after premedication with amiodarone].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Electric Countershock; Female; | 1985 |